

NATIONAL QUALITY FORUM

+ + + + +

MEASURE APPLICATION PARTNERSHIP
MEDICAID ADULT TASK FORCE

+ + + + +

TUESDAY
MAY 24, 2016

+ + + + +

The Task Force met at the National Quality Forum, 9th Floor Conference Room, 1030 15th Street, N.W., Washington, D.C., at 9:00 a.m., Harold Pincus, Chair, presiding.

MEMBERS PRESENT:

HAROLD PINCUS, MD, Chair

GEORGE ANDREWS, MD, MBA, CPE, FACP, FACC, FCCP,
Humana, Inc.

DIANE CALMUS, JD, National Rural Health
Association

KATHLEEN DUNN, RN, MPH, NH Department of Health
and Human Services*

SUE KENDIG, JD, MSN, WHNP-BC, FAANP, American
Association of Nurse Practitioners

CYNTHIA PELLEGRINI, March of Dimes

GRANT PICARILLO, America's Health Insurance
Plans

MARISSA SCHLAIFER, RPh, MS, CVS Health

MICHAEL SHA, MD, FACP, Indiana University School
of Medicine

SUBJECT MATTER EXPERTS PRESENT:

KIM ELLIOTT, PhD, Health Services Advisory Group
ANN MARIE SULLIVAN, MD, New York State Office of
Mental Health

FEDERAL GOVERNMENT MEMBERS PRESENT (NON-VOTING):

DAVID HUNT, Office of the National Coordinator
for Health Information Technology
LISA PATTON, PhD, Substance Abuse and Mental
Health Services Administration

NQF STAFF:

MARCIA WILSON, PhD, MBA, Senior Vice President,
Quality Management
SHACONNA GORHAM, MS, PMP, Senior Project Manager
DEBJANI MUKHERJEE, MPH, Senior Director
YETUNDE ALEXANDRA OGUNGBEMI, Project Analyst

ALSO PRESENT:

CHARLES GALLIA, PhD, Oregon Health Authority
MARSHA LILLIE-BLANTON, DrPH, Centers for
Medicaid and Medicare Services
JUNQING LIU, PhD, MSW, National Committee for
Quality Assurance
JULIA LOGAN, MD, PhD, California Department of
Health Care Services
KAREN MATSUOKA, PhD, Centers for Medicaid and
Medicare Services
GIGI RANEY, LCSW, Centers for Medicare and
Medicaid

* present by teleconference

CONTENTS

Welcome, Introductions, and Review of Meeting Objectives	4
Overview of Meeting Materials and Key Points from Staff Review of Core Set	19
Updates from CMS	49
Overarching Policy Considerations -- Community Linkage, Care Coordination Alignment	58
State Perspectives Panel	109
Opportunity for Public Comment	182
Measure-Specific Recommendations on Strengthening the Adult Core Set	183
Opportunity for Public Comment	294
Continue Measure-Specific Recommendations on Strengthening the Adult Core Set	295
Prioritizing Remaining Measure Gap Areas	314
Opportunity for Public Comment	324
Adjourn	

1 P-R-O-C-E-E-D-I-N-G-S

2 9:03 a.m.

3 CHAIR PINCUS: So why don't we get
4 started. Everybody's gotten their coffee. I'm
5 Harold Pincus. I'm Professor and Vice Chair of
6 Psychiatry at Columbia University Department of
7 Psychiatry and also Director of Quality and
8 Outcomes Research at New York Presbyterian
9 Hospital, and I wanted to welcome everybody to
10 the Adult Medicaid Task Force.

11 We have a fairly ambitious agenda, and
12 we're going to sort of get right into it. Why
13 don't we start off by doing introductions? So
14 Shaconna, do we want to introduce the NQF staff
15 that are going to be participating?

16 MS. GORHAM: Hi, my name is Shaconna
17 Gorham and I'm the Senior Project Manager for the
18 Medicaid Adult and Child Task Forces.

19 MS. MUKHERJEE: Hi, I'm Debjani
20 Mukherjee. I'm the Senior Director for the
21 Medicaid Adult and Child Task Force.

22 DR. WILSON: Hi, I'm Marcia Wilson.

1 I'm Senior Vice President for Quality
2 Measurement, and are you ready for me to do the
3 disclosures and the introductions of the rest of
4 the -- or do you have any other remarks, Harold?

5 CHAIR PINCUS: No. I think, just as
6 I mentioned, we have an ambitious agenda. We
7 had, I think, a very good call in April where we
8 went over some of the preliminary issues that we
9 wanted people to do some homework beforehand in
10 terms of thinking about some of the issues that
11 we talked about that are sort of broader policy
12 issues, including issues around alignment gaps,
13 and also for people to identify potential
14 measures that are potential candidates to be
15 added to the Adult Core Set. And we had a number
16 of people making suggestions and were pleased
17 with that.

18 And so that's really it. Marsha, do
19 you want to introduce yourself, also?

20 DR. WILSON: Microphone, please.

21 DR. LILLIE-BLANTON: I'm Marsha
22 Lillie-Blanton, and I am Senior Advisor -- Senior

1 Policy Advisor with CMS now. Some of you may
2 know me from my prior life where I served as the
3 Director of the Division of Quality and Health
4 Outcomes and the Chief Quality Officer.

5 Karen Matsuoka is coming. She's on
6 the train trying to get here. So she is our new
7 Chief Quality Officer.

8 I still have other roles. I'm largely
9 working with our nationwide CAHPS survey data, as
10 well as with the Medicaid Managed Care rollout.
11 But I'll continue to support Karen and be a part
12 of this effort to the extent I can.

13 So I want to thank all of you for
14 joining us. I want to welcome you to today's
15 meeting. And, you know, I'm looking forward to
16 the discussion. Your input has been vital to our
17 work, and we very much appreciate the guidance
18 and direction you all provide to us.

19 CHAIR PINCUS: Great.

20 DR. LILLIE-BLANTON: Oh, can I say one
21 more thing?

22 CHAIR PINCUS: Sure.

1 DR. LILLIE-BLANTON: I'm not sure -- we
2 have an opportunity to introduce people? Okay.

3 MS. MUKHERJEE: And I was just going
4 to say we also have some other CMS colleagues in
5 the room, and we wanted them to have an
6 opportunity to introduce themselves.

7 DR. FOX: Good morning. I'm Renee
8 Fox. I'm the Medical and Health Policy Advisor
9 for the Division of Quality and Health Outcomes,
10 and I'm a pediatrician. I joined in September,
11 and I'm the staff person primarily on this
12 endeavor.

13 MS. RANEY: Good morning. I'm Gigi
14 Raney, and I'm a Health Insurance Specialist and
15 I was a Project Officer on the Adult Quality
16 Grants.

17 MS. THOMAS: Hi, good morning. I'm
18 Megan Thomas. I'm a Technical Director in the
19 Division of Quality and Health Outcomes, and I'm
20 the team lead for performance measurement work.

21 MS. PERAULT: I'm Kimberly Perault.
22 I'm a Social Science Researcher within the

1 Division of Quality and Health Outcomes.

2 MS. CHAN: Hi, good morning. My name
3 is Sophia Chan. I work on the IDIQ with NQF, and
4 I'm also a Research Analyst working on quality
5 improvement in payment programs.

6 DR. WILSON: Great, thank you,
7 everyone. And now we'll turn back to the
8 Committee. Again, my name is Marcia Wilson, and
9 we're going to combine the Committee
10 introductions with a few remaining disclosures.
11 I think most of you did a disclosure of interest
12 when you had your webinar, but there's a couple
13 of people that still need to do their disclosure
14 today.

15 So I'll read briefly the disclosure
16 script for their benefit. I think you've heard
17 this before, which is we're going to combine the
18 introductions and the disclosures. The
19 disclosures are actually from organizational
20 representatives, and you do come representing
21 your organization and those interests. And the
22 only thing that you need to disclose is if you

1 have an interest of \$10,000 or more in an entity
2 that is related to the work of this Committee.

3 So let's go ahead and do our
4 introductions, and, if you did not have a chance
5 to disclose on the webinar, I'll ask you to do so
6 today. And I think we have -- do we have one
7 Committee person on the phone who's joined us?
8 So we'll go around the room first, and then we'll
9 turn to the person on the phone. And, Harold, if
10 you'd like to start with the introductions.

11 CHAIR PINCUS: So, well, I introduced
12 myself. I'm from Columbia. I don't have any
13 additional disclosures since April.

14 DR. WILSON: Great, thank you. And,
15 Marissa, if -- and we might ask you -- and I will
16 tell you this is a little bit we're covering this
17 housekeeping. You'll hear this all day long.
18 Microphones, push the button on the -- you should
19 get a red circle. Only three mikes can be on.
20 The tendency is to leave the mike back here and
21 sit back in your chair. You can move the mikes,
22 and, because we do a transcript and a recording

1 and we do have people on the phone, we encourage
2 you to speak out, use your outside voice and use
3 the microphones.

4 So Marissa?

5 MEMBER SCHLAIFER: Hi, I'm Marissa
6 Schlaifer. I represent the Academy of Managed
7 Care Pharmacy but am employed by CVS Health, and
8 I have nothing to disclose.

9 MEMBER PICARILLO: Good morning,
10 everybody. I'm Grant Picarillo, representing
11 America's Health Insurance Plan, sitting in for
12 Aparna Higgins today. I have nothing further to
13 disclose.

14 DR. WILSON: Thank you. And at the
15 end of this table?

16 DR. SULLIVAN: Ann Sullivan,
17 Commission of New York State Office of Mental
18 Health. I'm here as a mental health expert.

19 MEMBER SHA: Michael Sha representing
20 the American College of Physicians. I'm an
21 internist geriatrician at Indiana University,
22 Indianapolis VA.

1 DR. ELLIOT: Kim Elliot, and I have
2 nothing to disclose. I work for Health Services
3 Advisory Group, an external quality review
4 organization working with Medicaid programs. And
5 prior to that, I worked for about 15 years for
6 the Medicaid program in Arizona.

7 MEMBER ANDREWS: Good morning. George
8 Andrews. I'm a cardiologist, and I represent
9 Humana. I'm Humana's Corporate Chief of Quality,
10 and I have nothing to disclose.

11 MEMBER PELLEGRINI: Good morning. I'm
12 Cindy Pellegrini. I'm with the March of Dimes,
13 and I have no further disclosures.

14 DR. LOGAN: Good morning. My name is
15 Julia Logan. I am not on a task force. I'll be
16 presenting on behalf of the California Department
17 of Healthcare Services.

18 MEMBER CALMUS: Diane Calmus. I'm
19 with the National Rural Health Association, and I
20 have nothing to disclose.

21 DR. WILSON: Thank you. And I think
22 that is all for the disclosures, except for we

1 have one Committee person on the phone. Could
2 you please introduce yourself and let us know
3 which organization you're with? Kathleen, are
4 you on the phone?

5 OPERATOR: Kathleen has not joined
6 yet.

7 DR. WILSON: Okay, thank you,
8 operator. And so we'll have Kathleen make an
9 introduction just as soon as she joins us by
10 phone. Thank you so much. And, Debjani, back to
11 you.

12 MS. MUKHERJEE: Thank you. I'm just
13 going to go over a quick few housekeeping items.
14 Please keep your cell phones on vibrate or
15 silent. We know you're very busy and you have
16 obligations. If you do need to take a call, you
17 can take it in the area where you checked in.
18 There's some chairs out there.

19 Please use your tent cards if you want
20 to speak. Also, microphones, please turn on your
21 microphone and make sure the microphone is red or
22 we'll replace your microphone. We do get

1 transcripts and recordings, and we use that to
2 accurately reflect the deliberations of the
3 Committee when we write the report, so that's
4 very important.

5 Throughout the day, we'll have public
6 commenting periods. We'll go around the room
7 first, then we'll ask the audience, then people
8 on the phone, and, finally, we'll look at the web
9 chat to see if anybody has commented using the
10 web chat.

11 As you know, breakfast and lunch are
12 provided for workgroup members and participating
13 NQF staff. Members of the public are welcome to
14 beverages, and we can help them find restaurants
15 in the area.

16 We will be using voting tools
17 throughout the day. When you vote, please point
18 and click in the direction of the voting -- in
19 Sheila's direction. Thank you.

20 And just as a reminder, organizational
21 and subject matter experts are asked to vote and
22 federal representatives are encouraged to

1 participate throughout the day in all our
2 discussions but are requested to abstain from
3 voting. And that is all the housekeeping. And
4 any questions?

5 And the restrooms, very important, if
6 you walk down where you came in past the
7 elevators, it's the hallway to the right.

8 CHAIR PINCUS: So let's just go over
9 a little bit of what we hope to get done today,
10 and tomorrow for that matter. So one of the
11 things we want to do is we want to hear from
12 states about their experiences in participating
13 in the reporting program for the Adult Core Set.
14 And this is a very important component of the
15 meeting today because we really want to see where
16 there are problems, where there are issues, in
17 terms of the ability to report, how states make
18 use of the information, what areas they perceive
19 as gaps in terms of their own priorities.

20 And then based on this information and
21 some of the other information that NQF staff will
22 be going over, we want to think about where are

1 the gaps and how might those gaps be filled in
2 terms of considering other recommendations for
3 either adding or deleting measures. And then
4 think about then on a longer-term basis how we
5 might inform CMS about strengthening the measure
6 set, both in terms of the process of proceeding
7 with adding measures but also in terms of
8 thinking about issues such as alignment and other
9 kind of overarching policy issues that might be
10 considered. And, you know, we want people to
11 feel completely free to, you know, bring up any
12 issues that they want during the process.

13 Next slide. Yes, who controls the
14 slides? Well, anyway, you know, basically, the
15 next slide talks about the overall charge, which
16 actually conforms very closely to what we just
17 said our meeting objectives are. You know, as I
18 said before, the kind of things that -- the
19 overall charge to our task force, you know, for
20 those of you that are newly participating, is
21 that we're supposed to be reviewing states'
22 experiences to refine the measure gaps that we

1 have identified before based upon what we've
2 learned about states' experiences and also the
3 sort of evolution of measure development over
4 time, as well as the needs of the Medicaid
5 program as a whole, to consider what might be
6 done going forward and to actually give specific
7 recommendations for which we'll be voting with
8 regard to removal of measures from the set, as
9 well as the addition of measures.

10 And as many of you know, the members
11 of the task force represent a broad array of
12 stakeholders in the process, as well as specific
13 sources of expertise on particular areas that are
14 relevant to the Medicaid program.

15 Next slide, please. So this is a
16 little bit about the time frame. So today is
17 just us, the Adult Task Force. Tomorrow we'll be
18 joined with members of the Child Task Force, and
19 Foster Gesten and I will be co-chairing that.
20 And then on Thursday is going to be a meeting of
21 the Child Task Force. And tomorrow we're going
22 to be talking about both general policy issues

1 but also issues that kind of cross both adult and
2 child, particularly maternal and child health
3 kinds of issues.

4 This also gives a picture of the time
5 frame in terms of how we operate. So once we
6 finish our meetings, staff will put together a
7 report and we'll have an opportunity to review
8 that report. And then that needs to be submitted
9 by August in a final version. And then CMS will
10 review that report and make their decision --
11 because they don't have to do what we say -- and
12 will make their decisions and put that out by the
13 end of the year.

14 Okay. Next slide. So just to say a
15 little bit about, I thought we had a very
16 productive meeting by phone. And what we did at
17 the last meeting by phone in August was we sort
18 of went through what's the latest version of the
19 Adult and Child Core Sets, looked at what had
20 been suggested before in terms of gap areas. And
21 we also wanted to inform our discussions by
22 looking at what else is going on sort of in the

1 quality measure field, in particular pointing out
2 the recent report from the Institute -- now the
3 National Academy of Medicine, their report called
4 Vital Signs, in which they tried to get at the
5 issue that I think has been plaguing many people
6 in the field around the tremendous proliferation
7 of measures and how do we try to get at the most
8 important and parsimonious set of measures that
9 can be most useful and instructive without
10 spending, you know, as much money doing the
11 measurement as doing the care.

12 And so that's part of what we wanted
13 to do is to get at really key areas and to think
14 about how we harmonize measures so that there's
15 not a lot of duplication of effort in gathering
16 the data and also align them so that there's some
17 clear understanding of like why things are done -
18 - are measured for which purposes. So we aligned
19 the measurement with the purposes and the use of
20 the measures.

21 And we also get into some discussions
22 around how we define alignment and what we mean

1 by alignment. It doesn't necessarily mean that
2 we use the same measure in every program, but it
3 means that there's some rationale for the
4 selection of measures. And all things being
5 equal, if we're trying to measure the same
6 concept, to do it in the same way.

7 And then we discuss some of the sort
8 of operational road blocks in trying to achieve
9 alignment, some of the little bitty details that
10 sometimes bedevil us in terms of being able to
11 use similar concepts in similar settings -- in
12 different settings.

13 So, Shaconna, you're going to go over
14 some of the key points. So in the interim, since
15 April, staff have gone over the current Core Set,
16 looked at measures that have been placed, that
17 have come up for endorsement as part of the NQF
18 Consensus Development Process, looked at some of
19 the gaps that have been previously identified,
20 and have begun to think about and make
21 suggestions around how we might consider some
22 refinement of the Core Set.

1 MS. GORHAM: Thank you, Harold. So
2 just as an overview -- you can go to the next
3 slide, please, Alexandra -- just to reiterate
4 CMS's three-part goal for the Adult Core Set, one
5 is to increase the number of states reporting
6 Core Set measures. Two, increase the number of
7 measures reported by each state; and, three,
8 increase number of states using Core Set measures
9 to drive quality improvement.

10 Next slide, please. CMS uses the Core
11 Set data to obtain a snapshot of the quality
12 across Medicaid. The Core Set data are presented
13 in several populations, including the annual
14 adult health quality reports, the annual child
15 health quality reports, the chart pack and other
16 analysis. Lastly, the Core Set data is used to
17 inform policy and program decisions.

18 The Medicaid adult population -- as we
19 went over in the April web meeting and that
20 you're very familiar with, I won't go over all of
21 these bullets -- but just to say that Medicaid
22 provides coverage for approximately 44 million

1 adults, and two out of three adult women on
2 Medicaid are in their reproductive years.

3 Next slide. So in the 20 states that
4 have not expanded Medicaid, eligibility levels
5 are 42 percent for parents and zero for other
6 adults, leaving many poor adults in a coverage
7 gap since they earn too much to qualify for
8 Medicaid but not enough for tax credit subsidies
9 to purchase marketplace coverage, which begins at
10 100 percent. And our sources are located at the
11 bottom of the screen, but -- although they're
12 like really small, you can't really see that.

13 But next slide, please. So ACA
14 required the Secretary of Health and Human
15 Services to establish an adult healthcare quality
16 measurement program to standardize the
17 measurement of healthcare quality across state
18 Medicaid programs and facilitate the use of the
19 measures for quality improvement. This year will
20 be MAP's fourth set of annual recommendations to
21 HHS, and, again, the states are voluntarily
22 submitting data to CMS and they do so on an

1 annual basis.

2 Next slide. Before you you have the
3 measures recommended in 2015. There were nine
4 measures recommended to CMS in 2015, and they are
5 listed on your screen.

6 Next slide. In front of you, you have
7 the two measures that were actually added to the
8 Core Set. So in 2016, the Adult Core Set was
9 updated with the two measures that MAP
10 recommended. One, Measure 1932, diabetes
11 screening for people with schizophrenia or
12 bipolar disorder who are using anti-psychotic
13 medications. The other is the use of opioids
14 with multiple providers or at high dosage in
15 persons with cancer, opioid high dosage. That is
16 not NQF endorsed; however, that measure will be
17 submitted to a project coming up soon. So these
18 updates correspond well to MAP's suggested course
19 of action.

20 CHAIR PINCUS: Shaconna, could you go
21 back one just to see which ones weren't added.

22 MS. GORHAM: So the contraceptive

1 measures -- there were two contraceptive
2 measures, and those were not added. There were
3 two other opioid measures that were not added.
4 The medication management for people with asthma
5 was not added, and then there was one more. The
6 cardiovascular health screening for people with
7 schizophrenia or bipolar disorder was not added
8 and the controlling high blood pressure for
9 people with serious mental illness.

10 And so we knew that when we
11 recommended nine measures that was a bit
12 ambitious. CMS tends to make incremental changes
13 to the Core Sets to kind of reduce the burden for
14 the states, so two measures, historically, have
15 been about how many they add, if they add any.

16 CHAIR PINCUS: And it's worth pointing
17 out that there's -- oh.

18 MEMBER SHA: And I think also just to
19 clarify my understanding -- since I'm new to the
20 task force -- I believe the last report
21 recommended removing the timely transmission of
22 records, but that was not -- that removal was not

1 implemented with the current measures. Is that
2 correct?

3 DR. LILLIE-BLANTON: So, first, it
4 probably would be helpful to let you know the
5 process we used as we reviewed the
6 recommendations. We actually got input from
7 multiple stakeholders. We got input from
8 stakeholders within CMS, we got input from our
9 Quality Technical Advisory Group, and we also got
10 input from our Adult Quality Grantees. So across
11 that different spectrum of stakeholders, we tried
12 to assess their view of changes in the
13 recommendations.

14 In terms of the transmission -- the
15 timely transmission, we are sensitive to the fact
16 and we're sensitive to the fact that very few
17 states can report on that measure. But there
18 were several factors that weighed into our
19 decision not to retire it at this point. It
20 doesn't mean that at some point we won't,
21 particularly if you all choose to make that
22 recommendation to us again. But the factors that

1 we considered were the fact that, one, it is now
2 a part of the Inpatient Psychiatric Reporting
3 Program for Medicare, so it is a required measure
4 for Medicare reporting just for inpatient psych
5 patients. And though I'm not as familiar with
6 all the details, I think there will be some
7 financial incentives or at least some payment
8 penalties ultimately. I think the first couple
9 of years -- it's a new measure, but the first
10 couple of years it's just kind of a reporting
11 requirement and then, ultimately, it will be
12 subject to some penalties if it's not reported.
13 So in the spirit of alignment and because there
14 is some recognition in the Medicare program of
15 the importance of that measure, we thought it
16 would be premature for us to retire it at this
17 point.

18 The other factor that weighed heavily
19 was we heard at least from two states -- we heard
20 from one state that had lots of problems with it
21 but two states which were actively, actively
22 working, and I can tell you -- I'm willing to say

1 the two states. It was Pennsylvania and Georgia
2 who felt that they were very close to reporting
3 on that measure. So they are both Adult Quality
4 Grantees, so they are states that had some
5 financial resources to support trying to collect
6 and report that data. And we do know that states
7 that don't have that infrastructure or resources
8 are challenged.

9 But we heard from those states that
10 they thought it was important. But we also heard
11 -- there was at least one other state,
12 Washington, that felt very strongly that this was
13 a problem measure. So we were trying to balance
14 what we knew was going into the reporting program
15 for Medicare with what we heard from our states
16 and decided not to retire it, though we are still
17 seriously looking at this measure. I mean, for
18 us to have -- you know, we know the measure has
19 value and is important in terms of continuity of
20 care, in terms of information and transition from
21 one care setting to another. Oh, and one more
22 thing that we know is happening is that our

1 Medicare rule, which has added requirements for
2 care coordination. And one of it is trying to
3 make sure that there is better care coordination
4 from different settings of care, whether it's
5 from a managed care organization to a hospital or
6 a hospital to a skilled nursing facility or other
7 long-term care facility. So we thought that,
8 between all those different avenues trying to
9 improve care coordination, and that being our
10 only measure currently in the data set -- though
11 we do think there are other measures in the data
12 set that kind of help us understand care
13 coordination, so that's something else I think
14 this body can help us with. But we do know this
15 measure is problematic, and there was a lot of
16 discussion last time about this measure and I
17 presume there will be discussion this time again.

18 So I just wanted to give you that
19 history so you understand why we didn't retire
20 it. I think the others are pretty obvious, so, I
21 mean, if you want more information I can give you
22 but that's the only one I think --

1 CHAIR PINCUS: Well, I think one of
2 the things that came up is just that it's -- you
3 know, it's not a claims-based measure, it's
4 difficult to collect the data in a systematic and
5 consistent way, so that was one of the reasons it
6 came up in the discussion we had last time.

7 The other thing that's worth pointing
8 out is that, you know, sometimes we will make
9 recommendations of several measures within a kind
10 of particular domain, and it's understandable
11 that not all of them will be picked up, that CMS
12 has to be quite selective, you know, in terms of
13 the burden of reporting and so forth. So that,
14 you know, choosing one -- for example, one of the
15 sort of segmentation measures of looking at the
16 care of chronic diseases in the severely mentally
17 ill population, there were several of them that
18 were there and they chose one, and there were
19 several measures for opioid use and they chose
20 one.

21 DR. LILLIE-BLANTON: Right.

22 MS. GORHAM: Okay. So we went over

1 the two measures that were added there. The
2 addition of these two measures allows CMS and
3 states to expand the measurement of quality of
4 care and Medicaid for two population groups:
5 adults with substance use disorders and/or mental
6 health disorders.

7 Next slide. So before you you have
8 the 2016 Core Set measures.

9 DR. SULLIVAN: Question. What happens
10 with the recommendation, the list of
11 recommendations that CMS doesn't pick up? Do
12 they kind of -- do they have to be re-recommended
13 or do they stay somewhere? I'm just curious.
14 When they took two out of the ones we
15 recommended. What happens with the others in
16 terms of CMS's view?

17 DR. LILLIE-BLANTON: I can tell you
18 the past is that -- well, this has only happened
19 two years, right? So, for the past two years. I
20 think what would be advisable, if MAP feels we
21 need to reconsider a past recommendation, is that
22 you would need to re-make that recommendation. I

1 mean, I think the climate changes, the issues
2 change, the clinical evidence changes -- so our
3 pattern has not been to reach back to, let's say,
4 the first year's set of recommendations and look
5 at them. So it's not as if we keep a whole set
6 of recommendations in a store and kind of go back
7 and pick them up and look at them again. So I
8 think our --

9 MS. GORHAM: And so from NQF's
10 perspective, what we've done -- we're doing
11 voting a little different this year. We've
12 upgraded. So last year we raised our hands when
13 we wanted to vote. This year we actually have
14 electronic voting. And what we've done, you all
15 will discuss measures that were recommended
16 either by task force members or staff picked, but
17 we've also given you the options, we've listed
18 the recommendations from last year that were not
19 picked up, and so you all can place a motion if
20 you want to vote on those again.

21 So you have the -- this is the updated
22 Core Set for 2016 and it includes the measures

1 that were added to the Core Set by CMS. And you
2 will see those measures, they have an asterisk on
3 them. Alexandra, can you advance the slide?
4 Yes. So probably my old eyes can't see, but
5 there are two measures up there, one at the
6 bottom and there's one midway. Thank you.

7 Next slide. Okay. So what we did was
8 kind of look at the 2014 reporting to give you an
9 overview of just what the states did, the uptake
10 for the states. And CMS provided us with one
11 pagers, as well as snapshots. The snapshots were
12 provided for those states who've reported 26
13 measures or more. And the one pagers were one
14 pagers with information for measures that did not
15 receive at least 26 states reporting on that
16 measure. And they allowed us to see the states'
17 uptake, kind of the patterns for technical
18 assistance where the states asked for assistance,
19 and so forth.

20 Next slide. Okay. So there is room
21 for improvement, but, overall, the Adult Core Set
22 participation is strong. You'll see over the

1 next couple of slides that the most frequently
2 reported measures were focused on postpartum care
3 visits, diabetes care management, women's
4 preventive healthcare, and the detailed TA
5 requests that came in from CMS.

6 And you also -- I know you all receive
7 a slew of information and files from us, and so
8 in that -- all of the files and information you
9 sent -- was a handout with all of the TA requests
10 and the states that asked for the request and so
11 forth. Okay.

12 So this chart compares the number of
13 states reporting in 2013 and 2014. The bold red
14 line divides the measures that were reported on
15 by 26 or more states. And, there, for the
16 purposes for illustration, we kind of bucketed
17 the measures in high, medium, and low, and you'll
18 see that over the next couple of slides.

19 CHAIR PINCUS: Maybe say something
20 about why the red line is there because there's -
21 -

22 MS. GORHAM: So the red line divides

1 the measures that were reported on by at least 26
2 states or more, and those are publicly-reported
3 measures. Twenty-five or more. Thank you.

4 Okay. Next slide. So I have it on
5 the slide correctly, that's good. So those with
6 at least 25 states reporting are the ten measures
7 that are listed on this slide.

8 And just to draw your attention to
9 four of the measures that showed the most growth,
10 at least six or more states reported these
11 measures in 2014 than in 2013. And that would be
12 the Adult Body Mass Index. Ten more states
13 reported it in 2014 than in 2013. The chlamydia
14 screening for women, seven more states reported
15 it in 2014. The initiation and engagement of
16 alcohol and other drug dependencies, seven more
17 states reported it in 2014 versus 2013. And then
18 the antidepressant medication management, six
19 more states reported that measure in 2014 than in
20 2013.

21 Next slide. This chart represents
22 measures with 12 to 24 states reporting. The

1 number of states reporting these measures
2 increased or held steady from 2013 to 2014 with
3 the exception of PC-01. The number of states
4 reporting PC-01 decreased from 13 states in 2013
5 to 11 states in 2014.

6 Next slide. So the measures showed on
7 this slide had the least amount of uptake and the
8 fewest states reporting. HIV viral load
9 suppression, it's important to note that this
10 measure was collected for the first time in FY
11 2014. The PC-03, five fewer states reported in
12 2014 compared to 2013. And the care transition,
13 timely transmission of transition records, which
14 Marsha just spoke on, remained the same. The
15 screening for clinical depression and follow-up
16 remained the same, as well.

17 Next slide. Okay. So, again, I spoke
18 about the handout in your file deck, if you will.
19 For the reasons given for technical assistance,
20 measures with the most TA requests ranged from
21 five to eight requests for various reasons.
22 Reasons are included in the handout submitted, so

1 non-measure-specific requests were also high.

2 The measures receiving the most TA requests are
3 listed on the screen, but non-measure-specific
4 requests included reasons such as reporting of
5 age stratification, requests from CARTS
6 templates, clarification on reporting period and
7 population for inclusion in Core Set measures,
8 questions about time line for release of Core Set
9 specifications, reporting the deadline, and
10 availability of public benchmarks. Again, they
11 were -- all of these reasons and all of the
12 measures with the states were in that handout
13 that you received.

14 Next slide. Any questions?

15 MEMBER ANDREWS: I do have one
16 question. The fact that a state is not reporting
17 on certain measures, is that an indication of the
18 fact that that measure has not been applied or
19 acted upon or is it because of other reasons?

20 DR. LILLIE-BLANTON: So I would say
21 that there are many reasons a state doesn't
22 report on a measure, but it doesn't mean that the

1 state is not collecting that data and using it
2 internally. It just could be that it's using it
3 for one care delivery setting, so it could be
4 it's using it only in its managed care setting.
5 But it is conceivable that if a state is not
6 reporting the data that they are not collecting
7 it, particularly measures which are hybrid
8 measures. We find that those are measures that -
9 - you know, measures that require medical record
10 review are really problematic for states. And so
11 if they're not a primarily managed care state and
12 they have access to an entity to help them with
13 the medical records review, they often will not
14 collect and report on that data.

15 So I think there are various reasons,
16 but I just don't think we'd want to assume that
17 it's not being collected and reported on. And I
18 don't know, we have a few states here, too, so I
19 don't know if any of the states want to add to
20 that, either California or Oregon or --

21 DR. LOGAN: Yes. So Marsha is exactly
22 right. There are so many different reasons why

1 states don't report. A lot of times it's
2 capacity. You know, obtaining the measures and
3 running the measures takes a lot of time and
4 manpower, and we just don't have the capacity to
5 run all the measures. As Marsha said, we're not
6 able to get into the chart review process, so for
7 those measures that include fee-for-service and
8 managed care populations, we can't do that.

9 Another reason would probably be
10 because the data is not available in our data
11 warehouse, it's available in the Department of
12 Public Health or some other data repository that
13 we don't have access to.

14 MEMBER ANDREWS: I do have another
15 question. I'm sorry.

16 CHAIR PINCUS: Let's hear from Oregon.

17 DR. GALLIA: Oh, yes. So my name is
18 Charles Gallia, and I'm from Oregon. And I'm
19 actually going to spend some time talking about
20 some of the reasons for -- from not just Oregon's
21 perspective but from Alaska and West Virginia.
22 And I'll provide some detailed explanations about

1 what precipitates reporting or not.

2 CHAIR PINCUS: George?

3 MEMBER ANDREWS: Yes. The other
4 question I have relates to the added measure of
5 diabetes for schizophrenia and bipolar disorder.
6 And my question relates to the fact that we do
7 have a problem in terms of care coordination
8 between behavioral and medical. So for a state
9 to be reporting on a measure that is very
10 important, somebody has to do that diabetes
11 evaluation.

12 And so my question is do we have an
13 expectation as to whether behavioral or medical
14 is supposed to be doing that; and, if so, how is
15 the information on the expectation related to the
16 medical or the behavioral?

17 DR. MATSUOKA: Well, I think your
18 question points to a very important issue, which
19 is, you know, at a very high level, what is the
20 purpose of these core measures and what are we
21 trying to get out of it? I would just say,
22 speaking for myself, you know, being somewhat new

1 still to CMS, one of the interesting things that
2 I'm hoping to get out of the core measures is
3 comparative information across states on these
4 very kinds of issues.

5 So, for example, in our Health Homes
6 Initiative, many states are looking at this very
7 issue of behavioral health integration within
8 primary care settings. So we know that many
9 states are looking at the issue. They all might
10 be measuring it in very different ways. They
11 might be enacting the delivery reforms in many
12 different ways, but I think the hope is that,
13 over time, that activity will bubble up and roll
14 up to improvement on a state level measure.
15 Regardless -- you know, we can talk about whether
16 it's behavioral health providers that should be
17 reporting the measure or the primary care
18 provider reporting the measure, but, either way,
19 over time we should see improvement on that
20 measure. And I think the hope is that we can
21 start to see, comparatively, which states are
22 doing better than others and then dive deeper

1 into what it is that the states that are doing
2 well are doing and then start to spread those
3 lessons learned.

4 And so I think it points to and it
5 gets back to a very high-level issue, which I
6 think we should all try to keep in mind as we're
7 thinking about measures and voting on measures
8 for the next year is, you know, how are these
9 measures actually being used? What does it mean
10 by it's the states that are really the life blood
11 of this program? It's a voluntary program. It
12 takes a lot of effort and resources for them to
13 report the measures. How do we make sure that
14 the measures that we're selecting really tie back
15 into the very important initiatives, the many of
16 them that are already happening at the state
17 level, and how do we make sure that the measures
18 that we select help us to help them with quality
19 improvement for those initiatives?

20 So I don't know that that necessarily
21 directly addresses your question. It's just all
22 of which to say you're raising very important

1 issues that I think we should all just keep in
2 mind as the day progresses.

3 CHAIR PINCUS: Cindy, is this on this
4 issue or a different one? Okay. Because I want
5 to make a comment on it after you.

6 MEMBER PELLEGRINI: Sure. So I'm
7 hoping that perhaps our colleagues from the
8 states who are here, our guests -- thank you for
9 being here -- can talk a little bit in your
10 presentations about this idea of claims data
11 versus other types of data and how do we, over
12 time, move away from using claims data which is
13 really the most basic, the most fundamental, the
14 least granular kind of data.

15 About three weeks ago, I participated
16 in the perinatal measures panel meeting here and
17 what we saw on a number of things -- first of
18 all, you see that a lot of the perinatal measures
19 are the ones least reported because they are most
20 challenging. Or you end up with measures like
21 postpartum visit or prenatal care visits, which
22 actually don't tell you anything about the

1 quality of care, they only tell you about the
2 quantity of care and the fact that an opportunity
3 was presented for delivering quality care but you
4 don't know if it actually happened. And we're
5 never going to get that kind of granular data
6 about what kinds of issues, for example, were
7 covered in a preventive care visit from claims
8 data.

9 So what do we need to do, what do we
10 need to do to help the states and other users
11 move in the direction of being able to use EHRs
12 or somehow making chart review more efficient or
13 easier or less expensive?

14 CHAIR PINCUS: I think what people are
15 talking about are some of the limitations in
16 process measures and most of which is derived
17 from claims, which give you some information
18 about, as you said, quantity of care. And even
19 here, it's a little bit about quality, at least
20 whether or not, for this important sub-
21 population, there was, in fact, some kind of
22 assessment of a critical potential side effect.

1 Whether something was done about that, once
2 identified, is a whole other issue. And how that
3 actually gets done in terms of who's responsible
4 for it -- whether it's behavioral health or
5 primary care -- is not specified in the measure,
6 simply that it happened.

7 We actually have a grant from the
8 Commonwealth Fund to develop an agenda for
9 measurement at the interface of behavioral health
10 and general medical care, and we're actually in
11 the process of doing that. We've done -- we've,
12 you know, published a couple of articles
13 reviewing all the measures that are out there.
14 We're in the process of convening a Delphi panel
15 to come up with some recommendations about
16 priorities in that area.

17 But I think it's one of the challenges
18 is to come up with something that gets beyond
19 process but still is not so ambitious in terms of
20 the expectations of data availability that it
21 just isn't going to get done. So that's one of
22 the kind of sort of windows of ambitiousness to

1 kind of get in there.

2 I do want to say that one of the
3 strategies, though, that we've looked at has been
4 this whole sort of notion of segmentation or
5 thinking of people with severe mental illness as
6 kind of a disparities population. You know, they
7 obviously have disparities in terms of outcomes.
8 They die, you know, almost two decades sooner
9 than people in the general population, oftentimes
10 from a variety of a general medical co-
11 morbidities. And in fact, actually, despite
12 having severe mental illness, the direct
13 healthcare costs are actually greater on the
14 general healthcare side than they are on the
15 behavioral healthcare side so that there's a lot
16 of reasons to kind of look at this and to think
17 about are there ways by which we can kind of
18 segment that population and compare the
19 performance on existing measures that are
20 relevant to the general population. That's one
21 thing that we're looking at, and this is an
22 example of that.

1 But as you point out, it doesn't say
2 how it actually gets done and who's responsible
3 for it and what do they do about it once it's
4 found. And I think that that's, you know,
5 getting at other -- you know, getting at that,
6 one of the measures that was suggested last time
7 was for the same population segment to look at
8 people with co-morbidities of severe mental
9 illness and hypertension, looking at control of
10 hypertension. Again, that's a more complicated
11 thing because it requires that you actually have
12 access to data about whether -- you know, whether
13 people actually have, you know, a reduced blood
14 pressure and, you know, how do you get that and
15 how do you time it so that it's relevant to the
16 assessment of change over time. So that adds to a
17 much more complicated way of doing it.

18 As we move towards a more integrated
19 data systems, in terms of electronic data
20 systems, that may become something that can be
21 done. But right now we're not there yet,
22 certainly across all the states.

1 I had a question I just wanted to ask
2 our colleagues from CMS. And just to clarify --
3 so for states that have both fee-for-service and
4 managed care, are they expected to report a
5 combined result or separate or one or the other?
6 How does that work?

7 DR. LILLIE-BLANTON: They're asked to
8 report combined data. Now, what we get from them
9 varies. But, usually, in our tables -- the
10 detailed tables in the report -- it will say
11 whether or not the state did report a combined,
12 whether they reported only for their managed
13 care, whether they reported a combined rate. So
14 we ask, but we get --

15 CHAIR PINCUS: Do they also provide
16 information about the proportion of the
17 population that's represented?

18 DR. LILLIE-BLANTON: It varies, but we
19 certainly ask them to. And in our new system,
20 one of the things we haven't talked about is that
21 this year we transitioned to Macro, which is a
22 new system for collecting and reporting --

1 collecting the data which has the capacity to
2 provide -- or we ask additional detail from
3 states and we ask it with specific questions. So
4 we are now specifically asking in the report that
5 comes out next year, we will have information on
6 the proportion of the population that they
7 reported on for that measure. But still, in the
8 past, in some cases we got that information
9 because we would ask, but, you know, if it wasn't
10 a specific question sometimes you wouldn't get
11 that information, a state wouldn't respond to
12 that question.

13 CHAIR PINCUS: Other questions? Oh,
14 Ann?

15 DR. SULLIVAN: Just to echo what you
16 were saying, Harold, I think that the value of
17 this kind of measure in terms of when you look at
18 it, if you do have a low rate of this for
19 schizophrenia, then whose responsibility is it?
20 And that forces your system to kind of start
21 thinking about whether or not behavioral health
22 should be following it or primary care and how do

1 they work together, and I think that's one of the
2 beauties of some of these measures is they push
3 down into the way your systems are actually
4 designed to do things.

5 And I think the other beauty of it is
6 it can point out the disparity, which is I think
7 what you said, that this could -- you could do a
8 broad measure on diabetes and you'd look pretty
9 good because you wouldn't be capturing that small
10 group of some of the disparities, one of which
11 could be schizophrenia. So that's why it's
12 important, I think, to push these up so that you
13 can see it because, you know, you could look very
14 good but not be touching this population really
15 at all very much.

16 So I think it's a very valuable
17 measure, but it does point out the weaknesses, I
18 think, in a big way, in our systems. And that's
19 one of the values of these kinds of measures.

20 CHAIR PINCUS: Other questions? So,
21 Karen, you're going to be presenting from CMS's
22 point of view?

1 DR. MATSUOKA: Sure. So really -- and
2 I apologize for my delay. I had some
3 transportation issues this morning. And really,
4 you know, you're going to get a much more --

5 CHAIR PINCUS: That seems to be the
6 norm in Washington nowadays.

7 DR. MATSUOKA: Is it? Okay. You're
8 going to get a much more full-blown CMS update.
9 There's a lot of activity underway, as you all
10 know. And you're going to get that full-blown
11 update tomorrow when we have the Adult and the
12 Child Task Forces together.

13 So I'm just going to have a very
14 abbreviated update today for this particular
15 session because I wanted to flag a couple of
16 things that I think might be pertinent for you or
17 that we would hope that you take into
18 consideration as you're voting on measures for
19 the Adult Core Set for this year.

20 So we've touched a little bit already
21 on the resource and capacity issues at the state
22 level. We've talked a little bit about how this

1 is a voluntary program. Given where we are in
2 the funding streams that have supported this
3 program to date, that becomes all the more
4 important this year moving forward.

5 As you all know, we had a \$100 million
6 investment through CHIPRA to support -- through
7 the child's demonstration grants -- supporting
8 states on developing infrastructure to be able to
9 report the measures in the Child Core Set. We
10 also had a \$58 million investment over two years
11 to states to help them report on the Adult Core
12 Set measures. As of fiscal year '15, that
13 funding has ended.

14 So I know that one of the things that
15 we've asked you to consider all along has been
16 the value of the measure given the burden of the
17 measure it is to report from the state's point of
18 view. This is just a quick update to let you
19 know that, now more than ever, that becomes a
20 much bigger consideration moving forward, given
21 that a lot of this kind of comparative analysis
22 is not possible if we don't have enough states

1 reporting on particular measures so that we can
2 start to compare across at least 25 states. So
3 just something to keep in mind as you're thinking
4 ahead.

5 And I think also we've started to
6 touch on this a little bit. You know, data
7 infrastructure at the state level is always
8 continually developing, and I think we are trying
9 to keep that in mind as we think through what the
10 best appropriate measures might be for our Core
11 Set measures. But given the state of
12 infrastructure as it is now -- and I think you're
13 going to hear a lot more about the issue of
14 alignment throughout the day -- I think thinking
15 through that alignment piece is going to be very
16 critical. But also not just in terms of not
17 duplicating reporting burden for the states but
18 also in thinking through this very question of
19 what is it that we want these measures to do at
20 the state level?

21 If they're not necessarily meant to
22 replace what's happening at the clinic level, at

1 the plan level, with the Medicaid managed care
2 rule, we're going to have a quality reporting
3 system. And within the next few years, states
4 will have a lot more information at the plan
5 level for Medicaid managed care.

6 So we have the CMS core measures. So
7 separate from the Medicaid core measures, there's
8 the CCSQ core measures that have been developed
9 in conjunction with AHIP and on the child side
10 with AAP. If all of those are feeding into
11 measurement at the provider level and then the
12 Medicaid managed care rule is feeding into
13 measurement at the plan level, what does that
14 mean for what we want to know at the state level?
15 Is it necessarily the same measures but rolled up
16 to the state level, or is it something else to
17 get to the kinds of things that Ann mentioned?

18 So just a couple of -- you know, given
19 where we are in the landscape of things, funding
20 considerations, new regulations, new programs
21 that are being implemented all the time at the
22 state level, what really is it that we want the

1 state-level measures to do. And how do we make
2 sure that the ones that we pick are going to be
3 the ones that have the biggest value add to our
4 state partners and also at the federal level as
5 we're trying to look across the states to provide
6 quality improvement assistance.

7 So more to come tomorrow but, for
8 today, those are just some of the considerations
9 that we thought might be helpful as you're
10 thinking through measures for next year.

11 CHAIR PINCUS: I think it's a really
12 good point because one of the things we think
13 about as we go through this day is, you know, to
14 my mind, one of the prime criteria that we want
15 to use -- at least what I think about when I vote
16 about adding more measures -- is what is going to
17 drive change? What will sort of push, you know,
18 how -- sort of the whole fit-for-use, fit-for-
19 purpose kind of thing, how does a measure sort of
20 start a ball rolling that can actually result in
21 improved outcomes in care, particularly for the
22 Medicaid populations that are, you know,

1 generally so needy.

2 So that's the way at least I think
3 about it. And even though it's not a perfect
4 measure, if it sort of gets the ball rolling,
5 sort of helps to identify where there's problems
6 and the states can then look, okay, we're finding
7 big variation here, let's try to understand
8 what's going on for the high performers, what's
9 going on with the low performers, how do we sort
10 of make use of that information. To my mind,
11 that can be of great value, you know, as an
12 initial step. Thank you.

13 Any comments, questions?

14 DR. ELLIOT: When I think about it a
15 lot from the Medicaid perspective -- I've
16 probably been away too long -- but one of the
17 challenges and I think something that really is
18 an inhibitor, I guess, is that when we do
19 everything by aggregator, by the state-level
20 population, it's really --

21 CHAIR PINCUS: Speak up a little bit.
22 Get a little bit closer.

1 DR. ELLIOT: -- it's really not
2 focusing us on the sub-populations or the
3 stratifications. And we're talking here a lot
4 about behavioral health measures, and simple
5 things like access to care for behavioral health
6 -- and when I say access to care it's not
7 necessarily to the physical health side, it's
8 just as much to a behavioral health provider and
9 how we measure that. And there aren't equal and
10 related measures on the behavioral health side as
11 there are on the physical health side, so I don't
12 know that, even with the measure sets we're
13 looking at today, we're getting to that level
14 where it really is going to make a huge
15 difference in the quality of care provided. When
16 we're looking at access to care and including the
17 behavioral health numbers into a PCP visit,
18 that's wonderful, but if you're not getting
19 access on the behavioral health side through a
20 behavioral health professional you may still not
21 see that quality improvement in care.

22 CHAIR PINCUS: I think you've

1 identified an important gap that we can talk
2 about more, yes. In terms of access, you know,
3 about a year ago, we published a paper in JAMA
4 Psychiatry showing that 40 percent of
5 psychiatrists nationwide take no insurance, and a
6 majority do not accept Medicaid.

7 Diane?

8 MEMBER CALMUS: I just would kind of
9 bring up two related issues. I think, you know,
10 looking at how these measures align is really
11 important, particularly as we move more towards
12 the population health side of things and making
13 sure that we're kind of looking forward and
14 saying, as we move to a system that is more
15 population health-based, are these the measures
16 that we need to be looking at to kind of make
17 that transition and not only help in reporting
18 whether it's happening but also in helping
19 realign the providers that are providing the care
20 to say is this what we need to be looking at for
21 population health.

22 And, similarly, I think aligning with

1 other systems that are trying to make that change
2 is really important, so looking at what the ACOs
3 are doing and how these can align with an ACO.

4 So an ACO that's working with the Medicare
5 population, can we utilize that same
6 infrastructure that's already in place and make
7 it very simple for them to say, you know, we also
8 want to work with this managed care population as
9 they move towards population health. And so
10 really just making sure that we're not
11 continually reinventing the wheel with all of the
12 metrics and making it harder for those who are
13 already kind of one step ahead on looking towards
14 population health, to say we also want to work on
15 this different population.

16 CHAIR PINCUS: Other comments,
17 questions? What Debjani is going to be talking
18 about is issues around the homework that all of
19 you had and some of the broader sort of policy
20 issues that we talked about earlier in April on
21 the conference call and some of the work that's
22 been done since then in terms of integrating that

1 information.

2 MS. MUKHERJEE: Thank you, Harold. So
3 next slide, please. So where all this discussion
4 started was we did some work around the IOM Vital
5 Signs report and looking at some of the themes
6 and then looking across our Core Sets, both adult
7 and child. But today I'll speak to the adult,
8 and then tomorrow I'll do a more in-depth
9 presentation of these policy themes, and then
10 we'll combine both adult and child themes
11 together.

12 Some of the issues that resonated
13 across not only the IOM report but our Core Sets
14 was alignment coordination, community linkage.
15 So they all kind of tie into each other without
16 appropriate care coordination, you might not have
17 alignment. And then once you do a community,
18 especially for behavioral health, if you don't
19 have community linkages of clinical services with
20 supports in other community-related social
21 service supports, you still won't get the outcome
22 that you hope to.

1 Next slide, please. So we had done a
2 SWOT analysis, and in the next slide I'll provide
3 a quick overview of some of the strengths and
4 weaknesses. Some of the strengths were that
5 there were a lot of measures in the quality
6 domain covering screening, immunization,
7 diabetes, asthma, behavioral health, perinatal.
8 And some of the weaknesses are things that we
9 always hear: not enough outcome measures, not
10 enough granularity of data.

11 Some opportunities, such as the
12 meeting today, to revisit gaps and to talk about
13 where we can go from here, also to look at some
14 of the AHRQ CMS PQMP measures. And some of the
15 threats are the usual suspects of burden,
16 resource, data infrastructure, just the capacity
17 to do all this work and bring it together.

18 Next slide, please. So some of the
19 resonant themes were healthy people, engaged
20 people, and patient and family-centered care, and
21 that gets to some of the linkage issues across
22 healthcare services and supports. Care

1 coordination was a big one. Access to care was
2 something that we saw, as well as resource, data
3 collection and reporting, having the
4 infrastructure resource to do that, as well as
5 measurement, alignment, and data burden, and how
6 can we lower the data burden by aligning across
7 different programs and things.

8 Next slide. So that gets us to one of
9 our first big topics today: alignment. And when
10 we're talking about alignment, we're talking
11 about the concept of alignment; alignment of
12 measurement, which necessarily does not mean
13 aligning the exact measure; aligning across
14 multiple programs; standardizing definitions so
15 that you can align easily; and then aligning
16 across different pairs also.

17 Next slide. So this is just a very
18 quick recap of the definition of alignment, and
19 this first one was taken from the MAP
20 Coordinating Committee report. They defined it
21 as same or related measures, and the goal is to
22 reduce duplicative data collection, enhance

1 comparability and transparency of healthcare
2 information. However, there is a caveat that
3 when alignment is not possible and there's a
4 compelling reason, multiple and/or similarly
5 narrowly-focused measures should be allowed.

6 And next slide, please. The next
7 definition is a more technical definition of
8 alignment, but, at the same time, it talks about
9 the use of similar standardized performance
10 measures across and within public and private
11 sector efforts. So it seems like the same words
12 are used in every definition, except you don't
13 know if they're talking about the concept, the
14 exact measure across programs, points of
15 implementation.

16 So we had some questions -- next
17 slide, please. So we had some questions for
18 homework, and they were around what do we mean by
19 alignment, how do we operationalize the concept
20 of alignment, is it the same concept being
21 measured the same way, same concept being
22 measured across different programs.

1 And next slide, please. Over the next
2 couple of slides, what I will do is present some
3 of the themes, and these were all collated from
4 the responses that we received.

5 CHAIR PINCUS: Debjani, just one
6 question. In an earlier slide, it said alignment
7 is not the same as harmonization. Can you say
8 something about the difference?

9 MS. MUKHERJEE: Sure. So one is a
10 more conceptual concept, and the other is more
11 specificity. So you can align conceptually and
12 say we're both looking at HBA1C levels. But to
13 harmonize means you have to have the same value
14 ranges. It's like we always talk -- at least
15 from my experience in the guideline world -- you
16 could align easily conceptually saying I want to
17 look at blood pressure control, but, then once
18 you get to the harmonization, that's when nuances
19 of the patient population, exclusions come in,
20 the ranges become important as far as
21 considerations go.

22 So I think they're terms that are used

1 frequently together, except there's that fine
2 definition of how exactly are you implementing
3 these measures. And I think, for our discussion
4 today, alignment is what we're looking at, and
5 the three things that the IOM report talked about
6 was parsimony, alignment, and harmonization, so
7 there were like three separate buckets. And for
8 today, we picked up alignment and, hopefully,
9 parsimony as part of the discussion, as well.

10 So some of the themes -- the way the
11 responses themed out was benefits and challenges
12 of alignment. Some of the alignment benefits was
13 comparability across states, across pairs, just
14 looking at the quality arena, simplifying
15 reporting and reporting burden, lowering that,
16 facilitating any kind of comparison, and also
17 aligning across levels of measurement to make
18 sure people are measuring what they think and
19 they say they are measuring, as well as across
20 programs and payment models. And especially if
21 you're looking at a more population health
22 perspective and you want to aggregate the data,

1 alignment becomes a bigger issue.

2 Some of the challenges were voluntary
3 nature of reporting, aligning with commercial and
4 private pairs, as well as innovation and
5 variation. And that's something that no matter
6 how much we want to prevent changes, if it's for
7 innovation, if it's evidence-based then it's just
8 necessary. And in some areas there's a lot of
9 evidence and evidence evolution, and, because of
10 that, there's a lot of variation, and that causes
11 a challenge.

12 Next slide, please. So the next set
13 of slides, couple of slides, talks about how to
14 operationalize this concept of alignment. And,
15 interestingly, mandate came up: measure mandate,
16 methodology mandate, as a way to standardize how
17 it's being implemented. Now, this was a wish
18 list, and I'm just reporting what I saw, but I
19 thought that was very interesting, given that
20 it's a voluntary program.

21 Balancing goal of measurement and
22 implementation flexibility. So at the same time

1 mandate was put forth, also the flexibility and
2 having the flexibility to measure what is
3 feasible and possible, given the resource,
4 limitations was put forth.

5 Some of the temporal considerations,
6 if you're looking across age ranges within a core
7 set and/or if you're looking across the child
8 through Adult Core Sets, that also gets to some
9 of the care coordination issues. And then this
10 example was given where comparability versus
11 actual comparability. It's saying I'm measuring
12 something yes/no versus I'm measuring and this is
13 a range that I'm looking at, and that is an
14 interesting fine distinction that might not be
15 apparent when you're looking at data.

16 Next slide, please. And this is just
17 one of --

18 CHAIR PINCUS: Let me just say the way
19 I think about alignment and distinction from
20 harmonization is that I think about alignment
21 across programs. So basically that if a program
22 is measuring something around a particular

1 domain, that it ought not -- unless there's a
2 good reason, it ought to be doing it in the same
3 way as another program. Whether it's Medicaid
4 managed care or Medicaid fee-for-service or
5 between Medicaid and Medicare, if the same
6 concept is being approached in terms of
7 performance in diabetes care, they ought to be
8 measuring similar things so providers, payers,
9 and so forth don't have to go through all kinds
10 of gymnastics around trying to do something
11 that's somewhat different.

12 On the other hand, there's a balance
13 because the Medicare program may want to have
14 more measures that address sort of elderly and
15 frail people to be able to capture that. So it
16 doesn't mean that every measure has to be used.
17 It should be responsive to the population. But
18 when they are looking at a similar concept, they
19 ought to be doing it in a similar way.

20 Harmonization has to do with the
21 harmonization, as you said, of the measure
22 operationalization, that they're being

1 operationalized in the same way. But I think
2 that that's an important point. There can be
3 reasons why, for the Medicaid program, why there
4 may be some areas where there may not be
5 alignment because of our particular issues in
6 Medicaid that need to be addressed in a
7 particular way, and it may not be the same for a
8 commercial program or for the Medicare program.

9 MS. MUKHERJEE: And at the end of the
10 next couple of slides, we'll pause to get any
11 other ideas and thoughts, anything that was
12 missed or not submitted from the group here.

13 So one of the interesting quotes was
14 measures are only as good as their design, and
15 that gets to sort of the design issues that
16 affect either operationalizing it, harmonizing
17 it, aligning it across programs, whatever we're
18 looking at. And some of the measure components
19 that were addressed were exclusions, risk
20 adjustment, the modeling used for risk
21 adjustment, the transient nature of the Medicaid
22 population, who's following it, who's falling

1 out, and how long are they in this program,
2 resource issues, as well as data issues again.

3 And at this point, I was just going to
4 pause to see if there are any others that were
5 missed or should be added to this list for
6 consideration. Okay. We'll also have some
7 questions at the end.

8 Next slide, please. So the next set
9 of questions got to the feasibility of data
10 collection and maybe moving beyond claims data
11 and what's feasible and what can be done as far
12 as stratifying the data by different sub-
13 populations.

14 Next slide, please. And we realize
15 that claims data is rather basic and not as
16 granular as sort of chart data, but one of the
17 biggest themes was that claims data being the
18 limit of feasibility, especially due to the
19 voluntary nature of reporting, as well as some
20 resource limitations. Also, alignment came up
21 under feasibility and sort of the purpose of
22 measurement, the comprehensiveness. Also as far

1 as alignment goes, full alignment versus partial
2 alignment and maybe annotation of that,
3 streamlining data acquisition and data
4 collection. And analysis came up as something
5 that would facilitate data collection and sort of
6 make it more feasible, as well as identifying and
7 developing outcomes measures, so including more
8 outcomes and patient-reported outcomes in the
9 data collection to get at more granularity of
10 data.

11 Next slide, please. And some other
12 themes that came up was the ability to track
13 system and population-level health improvements
14 and get data at the patient level but be able to
15 make some assumptions about population-level
16 improvements, interoperability of EHRs, EMRs,
17 measure design and exclusions, and the quote was
18 to simplify measure constructs, which is
19 interesting given that we have more complex
20 measures coming up, more composites and such.
21 Survey data was another one, looking at
22 functional status, HCVS-type surveys, patient-

1 reported outcomes.

2 Also, it was noted that we should try
3 to maximize provider-reporting systems, such as
4 MDS Nursing Home Compare, to get as much data as
5 we can from them. And then, finally, for data
6 stratification, the NQF SDS project trial period,
7 to follow the data stratification results from
8 that, was another suggestion.

9 Next slide, please. And there was a
10 special section which was for factors influencing
11 state participation in reporting, and some of the
12 themes was clarity of measure specifications, the
13 feasibility of data collection, and with that,
14 it's also data completeness and sort of being
15 able to follow the data longitudinally. The
16 budgetary environment, the perceived importance
17 of a measure, as well as the political will.

18 And at this point, we are pausing for
19 just a little bit of discussion and sort of the
20 question is which barriers of the ones mentioned
21 can be reduced by HHS and/or this MAP through
22 recommendations, and sort of what is the gestalt

1 of the thought of this group in means and ways to
2 go about doing that.

3 CHAIR PINCUS: Comments, questions?

4 MEMBER DUNN: Good morning. This is
5 Katie Dunn.

6 CHAIR PINCUS: Katie. Okay.

7 MEMBER DUNN: Yes, good morning. My
8 apologies for my technical issues, but I'm all
9 set now. To the question that was just asked
10 around feasibility --

11 CHAIR PINCUS: Katie, can you also
12 introduce yourself?

13 MEMBER DUNN: Oh, I'm sorry. Yes, of
14 course. Good morning, everyone. My name is
15 Katie Dunn. I am the Associate Commissioner and
16 Medicaid Director for the State of New Hampshire.
17 And for the purposes of this meeting, I'm
18 representing the National Association of Medicaid
19 Directors.

20 CHAIR PINCUS: Thanks. So your
21 question?

22 MEMBER DUNN: And I'm sorry that I'm

1 not able to be with you all. It's a long story,
2 but I'm happy to be with you at least through
3 technology. What I was going to offer for a
4 comment on the feasibility of data collection is
5 that most of the Medicaid directors have found
6 that, from a fee-for-service perspective, we seem
7 to be able to do a better job at the data
8 collections establishing the methodology, the
9 population, the numerator, the denominator. So
10 alignment, harmonization, isn't an issue.

11 Where we're running into trouble,
12 though, is through the managed care
13 organizations. There seems to be still this idea
14 of one-size-fits-all and that Medicaid so far has
15 not risen to the front of the pack in terms of
16 who's driving how an MCO sets up their data
17 collection systems and what they view as
18 important versus what we view as important.

19 CHAIR PINCUS: Okay. George?

20 MEMBER ANDREWS: Yes. In reference to
21 this slide, I was wondering to what degree, I
22 don't know if we do know or don't know, to what

1 degree is a state's reporting based on the
2 performance on the particular measure? If I'm
3 doing so well, do I report it, versus if I'm
4 willing struggling, do I not report it? In which
5 case, it puts us in a situation where the
6 information we're trying to identify to help
7 other states in terms of what's working for them
8 and why, you don't really get to see that
9 information or be able to ask the questions.

10 DR. LILLIE-BLANTON: So, actually,
11 that's the issue that we have found in a few
12 states. I can't say it generally, but I think
13 it's an issue that occurs more in managed care
14 than in fee-for-service, to follow-up on Kathy's
15 comment. We have found in some states the
16 tracking of the information is occurring more
17 routinely in managed care than in fee-for-
18 service. And part of it is, I mean, fee-for-
19 service providers tend not to focus on the
20 findings because they can't really identify and
21 attribute a finding to them. But in the managed
22 care setting, oftentimes the data are reported in

1 what we call external quality review reports by
2 managed care plans, and there is the ability to
3 look and track performance.

4 And so, certainly, some managed care
5 plans will feel that, because their performance
6 is above average or in the 90th percentile that
7 there's no reason to continue to report the
8 measure. I can't say that we have found that to
9 occur with the state reporting of the data, but,
10 certainly, I think, you know, you have managed
11 care plans who feel if I've got to trade off,
12 then perhaps I should stop reporting.

13 And then the one measure for example
14 we know we're doing decently on is the well child
15 visits. This is a child measure, not the adult
16 measure, but the well child visits for children
17 in the third, fourth, and fifth year of life. I
18 mean, that's a measure that we are almost getting
19 at the 80th percentile, getting the well child
20 visits at that age.

21 And so there have been some
22 discussion, and we've heard that there's some

1 consideration of whether that's a measure. But I
2 don't think it happens a lot in fee-for-service.
3 Not to say that it can't and certainly not to say
4 that the state reporting on that wouldn't make
5 some decisions, but it just has not occurred to
6 us or has not been brought to our attention that
7 it's occurring in the fee-for-service world.

8 MEMBER DUNN: So this is Katie.
9 That's really interesting because at least in the
10 New Hampshire and a couple of other states, we've
11 been looking at the fee-for-service claims data.
12 Now, granted, most states don't have the
13 infrastructure for the hybrid measures that
14 require a chart review, which is really where
15 your EQRO is such valuable tool. But we've been
16 looking at using just the administrative data
17 about performance on some of the big issues that
18 tend to be policy questions that arise in
19 individual state legislatures such as emergency
20 department utilization for ambulatory sensitive
21 conditions, as an example.

22 I can't recall to what extent an

1 assessment was done in terms of the states'
2 ability to do two things. One is to actually
3 collect the data. But then to the previous, the
4 gentleman who spoke before the last speaker, the
5 next evolution of having these measures is what
6 do you do with them?

7 And so I know a number of states have
8 started talking about so if you do see these
9 positive results, how are the best practices
10 being captured and shared? How are states using
11 that information to say, okay, we invested extra
12 dollars, for example, in well child visits for
13 third, fourth, and fifth graders. That's doing
14 well right now. That extra investment we made in
15 focus we're going to move to a different area,
16 maybe neonatal abstinence syndrome issues. And
17 it's kind of the next evolution in maturity in
18 data collection and using the actual results.
19 And I think you're right. I don't know of many
20 states that have been able to transition to that
21 place yet.

22 CHAIR PINCUS: Other comments,

1 questions? Marsha?

2 DR. LILLIE-BLANTON: So I actually
3 think, following up on Katie's last comment, that
4 what could be added to this list, factors
5 influencing state participation in reporting, is
6 the use of the measure to drive change because,
7 as she said, when states can see the value of the
8 data in helping them to improve their
9 performance, whether it's in reducing ED use or
10 improving health that then results in less use of
11 other high-cost services, then I do think that
12 the state becomes motivated. So I think I would
13 add to that list, to the other.

14 CHAIR PINCUS: So that raises a
15 question for me and actually several of these
16 comments raise a question because I think of sort
17 of different measures in three categories. One
18 are measures that are really more for sort of
19 analytic purposes and descriptive purposes where
20 the validity of the measure is uncertain in terms
21 of its relationship to outcomes but where one
22 might be using the measure to explore variation

1 and to understand what's going on. And it's
2 unclear what the appropriate benchmark is but to
3 look at where you think there's a lot of
4 variation, and you try to look at, okay, what are
5 the high-performers, so-called high-performers
6 doing versus what the low-performers are doing.
7 Is the difference really one of artifact in terms
8 of how the data is collected? Have the people
9 doing -- have the high-performers learned some
10 secret sauce about how to do better, or is it
11 really just a selective kind of thing in terms of
12 the kind of patients that they're seeing, and
13 what is that secret sauce that they've learned?

14 The second bucket is one for
15 improvement where you don't need to necessarily -
16 - you have a pretty good set of information that
17 higher is better or that there's a difference,
18 and you're using it to actually move change and
19 perform. But it's usually local small steps of
20 change that you're doing. It's not necessarily
21 something that you would hold somebody
22 accountable for because there are some flaws in

1 the measure. It may not be risk-adjusted
2 sufficiently.

3 And then there's accountability
4 purposes, which is for public reporting or for
5 value-based purchasing where you have to have a
6 considerable degree of confidence with regard to
7 the reliability and validity of the measure.

8 One of the issues around this program
9 is that it's kind of in between, and it has
10 aspects that are related to all three of those
11 categories. And I wonder if you could say --
12 Karen or Marsha could say a little bit more about
13 how you see it fitting in because, in some cases,
14 it's kind of an experimental program, and we're
15 trying to get states to actually use it and do
16 things with it. On the other hand, it is a
17 reporting program, so that it is -- there's some
18 skin in the game.

19 DR. MATSUOKA: Yes. So I think, and
20 this comes back to the earlier comment about so
21 what is it that we want these measures to do,
22 what is the purpose of this? And I think you're

1 right that, in practice, we have been using it in
2 all of these ways and maybe not as deliberately
3 as we need to be.

4 I'll say that, for the accountability
5 piece, I think we've tried very hard not to make
6 this a shaming process, but it really is about
7 transparency, and we can't help all states
8 improve if we don't know where you are. And part
9 of knowing how to help you is to know where you
10 are relative to the high-performers and what the
11 high-performers are doing. So I think that's the
12 spirit of this.

13 So I think out of the three different
14 things that you mentioned, I'd say accountability
15 is the one that we, I think, emphasize the least.
16 Certainly, when we report the measures, you see
17 the bar graphs, and you can see the comparative
18 information, but it's never meant to be about --
19 for example, payment is never associated to
20 performance on these measures.

21 I would say where we're really trying
22 to improve is on the improvement use of the

1 measure. And here's where I think, in addition
2 to collecting the measures, reporting on the
3 measures, we do have a series of things called
4 infinity groups. You'll hear tomorrow from two
5 of our initiatives, Maternal Infant Health
6 Initiative and the Oral Health Initiative, where
7 they're actually taking some of these core
8 measures, either ones that have been adopted or
9 ones during development, and really working with
10 a handful of states to drive improvement at the
11 state level. And I think, you know, to Harold's
12 point, we're still in the very early stages of
13 this. We just launched one around psychotropic
14 medication use among kids. I think that is going
15 to be one that is maybe, hopefully, more useful
16 when it comes to helping with the analytic
17 function as well as the improvement function,
18 because I think that's a measure where it's a
19 little bit easier to tell whether the number
20 being higher is a better number or worse. And I
21 think that's the kind of measure where we can
22 also start to see improvement relatively quickly

1 at a state level, as opposed to, say, obesity
2 rates.

3 So I think some of it we're trying.
4 I think we are trying to perfect the way that we
5 use these measures. You'll hear a little bit
6 either later today or maybe when the child group
7 comes together about the PQMP initiative where
8 we're deliberately trying to get at varying
9 levels of measurement, to your point.

10 So if what we're saying is that our
11 core measures serve this very important analytic
12 purpose of seeing where the variations are, how
13 do we start to align measurement that's happening
14 at the provider level, say at the ACO level, to
15 roll up to a plan level, say Medicaid or
16 Medicare? And then how does that roll up to the
17 state level so that we don't have to have a state
18 level measure doing all three functions? We can
19 start to say more deliberately the state level
20 measures are really meant to serve as analytic
21 function, whereas the provider level measures are
22 really meant to serve more the improvement

1 function.

2 We haven't made any decisions yet, but
3 these are various different initiatives that are
4 underway to help us to address those questions.
5 But, Harold, I think you're exactly right that we
6 haven't necessarily been very deliberate about
7 saying exactly what we want the measures to do,
8 and, as a result of that, I think we've been
9 using them in a lot of varying ways to varying
10 success.

11 But I think this space of, how do you
12 use these measures to drive improvement to
13 quality at the state level is certainly where
14 we're headed. That's where we want to go. So
15 then the question becomes, how do we do that in a
16 way that's going to help the states the most?
17 And, of course, all that comes back to what is it
18 that the state level measures are meant to do
19 relative to all the other levels of measurement
20 that we're already doing?

21 CHAIR PINCUS: Other comments,
22 questions? So one thing that we may want to come

1 back to is if it's not being used for
2 accountability, how important is NQF endorsement?

3 DR. MATSUOKA: I think it's
4 a very important question.

5 CHAIR PINCUS: So it's something we
6 want to get back to. Other comments, questions?
7 Oh, Cindy?

8 MEMBER PELLEGRINI: So I spend most of
9 my time in the world of government affairs, and I
10 tend to look at some of these issues through that
11 lens then. I think one of the challenges here is
12 that we haven't spent a lot of time, I think,
13 trying to make measures understandable or useful
14 to policymakers. And I think what ends up
15 happening is that the middle three bullets on
16 this list are all intertwined, that if these were
17 perceived as more important by policymakers, the
18 budgetary environment would improve and that then
19 feasibility would improve because there would be
20 more resources available to do things like chart
21 review or some of the more challenging aspects.

22 Having said that, kind of everything

1 about quality measures and quality measurement
2 makes it difficult to communicate them to
3 policymakers, right? Especially elected
4 officials and state legislatures and things like
5 that. This is complicated. This is all about
6 shades of gray; it's not about black and white.
7 It is -- you have to have a lot of knowledge, I
8 think, as a layperson, before you even start to
9 understand what this is really about.

10 Progress is not quick. It's not easy;
11 it's not dramatic. It's like, hey, we improved
12 five percent on this measure, yay. That's not
13 press release material, right?

14 So really making this compelling to
15 policymakers is very difficult. We have tried in
16 a couple of places. We're actually promoting a
17 bill on perinatal quality measurement on Capitol
18 Hill right now, and my colleague at the back of
19 the room, Brittany Hernandez, is doing heroic
20 work on this, but it is a major uphill slog.

21 So I think, collectively, we need to
22 think a little bit more about how do we make this

1 more compelling to policymakers and, by
2 extension, to the public so that there will be
3 the support, because then the other thing that
4 we've spent some time talking about at March of
5 Dimes is I'm concerned that this is not right now
6 a sustainable system, that having tens or
7 hundreds of millions of dollars in exclusively
8 federal funding is just not a viable long-term
9 plan. So we need to be looking at the state, at
10 the federal level, with private payers, with
11 others, to say how are we going to incrementally
12 restructure the system over time to actually
13 provide the funding streams, provide the sort of
14 feedback loops and so on that we can make this
15 compelling, usable, and actually use it to drive
16 change for the foreseeable future?

17 CHAIR PINCUS: Thank you. Diane?

18 MEMBER CALMUS: Well, I think kind of
19 building on that, we do have to look at, I think,
20 also the cost of all of this data collection.
21 Access, obviously, in rural areas is a huge
22 issue, and Medicaid is a huge piece of that

1 puzzle, as the residents in rural areas do tend
2 to be poorer, older, sicker than their urban
3 counterparts.

4 And so making sure that the focus is
5 on what is actually making a measurable
6 improvement for that population if we are going
7 to be asking these Medicaid agencies to be taking
8 funding and diverting it away from patient care
9 and making sure that any measures are actually
10 kind of moving that. And that's why I brought up
11 population health previously, that we're kind of
12 looking at the big picture. Access, again, is a
13 huge issue, and we need to make sure that each
14 measure is improving access and not taking away
15 from it.

16 CHAIR PINCUS: Thank you. Marissa,
17 then Kim, and then back to Debjani.

18 MEMBER SCHLAIFER: I think, to follow
19 on some of the things that have been said, and
20 I'm not sure where -- I think, in my view, this
21 kind of falls to perceived importance and
22 political will but probably could fall different

1 places.

2 As we look at getting more and more
3 states participating, I know in the past there's
4 been some philosophy of let the states have
5 choice to -- states are more likely to
6 participate given the ability to choose which
7 measures they want to use. I think, as you
8 talked about, looking at measures as a way to
9 start the ball rolling or rock down the hill or
10 whatever it was, I think in today's world, with
11 more and more Medicaid going from fee-for-service
12 to managed care and with national health plans
13 and national PBMs that serve many different
14 health plans, that awareness that the more
15 alignment we can get across measures, we can use
16 these measures not just to report out but
17 actually to partner with health plans and the
18 PBMs that work with them and other national
19 organizations that work with them to really push
20 the ball down the hill. But to do that, we need
21 more alignment across measures and more states
22 participating using the same measures.

1 DR. ELLIOT: Two things, actually. I
2 think one of the changes in the final managed
3 care regs that I think is going to really put a
4 little bit of a shift in, right now the rules did
5 not require that the states report all measures,
6 that they did. The final managed care regs in
7 the EQR reports does require reporting of all
8 measures. So that's a big shift, so you'll see a
9 lot more of what's actually being measured that
10 the states may or may not be reporting right now.

11 But when it comes to sustainability,
12 when we start focusing these measures more on
13 outcomes versus the process, and you see the
14 improvements in care, and you see the reductions
15 in some of the more costly types of care like
16 inpatient and ED, you're building your case for
17 sustainability simply through financial savings,
18 it not even the better outcomes in care and
19 functional status perhaps of the individuals
20 you're serving. But that also helps build the
21 political will when you can really make a case
22 that the outcomes of the constituents that have

1 been served by Medicaid are really improving and
2 it's also reducing cost of care, that is a huge
3 political message that our politicians typically,
4 at least in the state that I come from, do pay
5 attention to.

6 So I think there is sustainability,
7 but you have to make that shift away from process
8 towards real outcomes and show where those costs
9 interlock or intercede.

10 CHAIR PINCUS: Thank you. So,
11 Debjani, do you want to continue on some of the
12 other issues?

13 MS. MUKHERJEE: Sure. So next slide,
14 please. So in this slide, we go over some of the
15 considerations as far as stratification came, and
16 that was to assess disparities and disparities in
17 care. But there was a caution that we not
18 penalize safety net providers by stratifying too
19 much and who might not be as big.

20 Important stratification parameters,
21 looking at geography and individuals with
22 multiple chronic conditions, individuals with

1 specific conditions such as persistent mental
2 illness, also children with complex medical
3 needs, as well as the NQF project.

4 Next slide, please. And with that,
5 the questions change sort of perspective from
6 alignment and feasibility of data collection,
7 data stratification, to care coordination and
8 care coordination of Medicaid adults, basically
9 chronic health condition management, as well as
10 maybe care coordination for individuals with
11 disability, physical and mental and
12 developmental, and their care coordination.

13 And with that, we had some questions
14 for the group. How can care coordination be
15 optimized for the Medicaid adult population?
16 What are some essential elements of care
17 coordination for this population? And can the
18 core set be used to capture -- can the measures
19 be stretched to capture care coordination?

20 And just to let you know, the next
21 section just forays from care coordination into
22 linkage and models of linking community with

1 medical and behavioral and how to sort of build,
2 sort of moving from alignment down to sort of
3 more specific parts of alignment.

4 Comments, discussions?

5 CHAIR PINCUS: You want to wait until
6 the end?

7 MS. MUKHERJEE: Oh, okay. Next slide,
8 please. So for the next slide, what we did was
9 one of the elements highlighted by the Vital
10 Signs report was community engagement and the
11 interrelatedness of community engagement with
12 health and well-being and getting to the overall
13 public population health of individuals.

14 Next slide. And by linkage, we mean
15 linking community resources with clinical
16 resources, clinical providers with social service
17 providers, activating patient and not only being
18 patient-centric but patient empowered where they
19 feel like they have a voice, referral follow-ups
20 and not only providing a referral but actually
21 following up to see was care provided or followed
22 up with? And then addressing availability,

1 affordability, and accessibility of resources in
2 the community.

3 And then with that, we had some
4 questions about how can community linkage be
5 optimized for -- next slide, please -- optimized
6 for the Medicaid adult population, and how can
7 current measures be stretched to capture that?

8 Next slide, please. The next slide.
9 And so -- no, the one before. So what we did was
10 provide some diagrams of what linkage would
11 actually look like. I know it's kind of small,
12 but it has the health system; it has the
13 community; it has community partners; it has
14 productive relationships and activated community
15 with the patient. And sort of it gets from the
16 individual level getting care, being able to
17 self-manage themselves. It gets to the public
18 policy, as like the big blue bubble and creating
19 supportive environments to where, at the end of
20 the day, at the bottom it gets to population
21 health outcomes and functional clinical outcomes.

22 And I just wanted to, since we are

1 talking about community linkage and all the
2 different types of linkage, have some sort of a
3 diagram up there to sort of refer back to.

4 So discussion?

5 CHAIR PINCUS: Okay. Why don't we
6 open it up for discussion? Care coordination and
7 community linkage and stratification. So,
8 actually, I had a comment. If you can go back to
9 the stratification slide, I had actually two
10 comments. One was the concern about penalizing
11 safety net providers, and it goes back to the
12 issue before about sort of what's the purpose and
13 use of these measures.

14 In a sense, if they're not sort of
15 accountability, per se, there's really not sort
16 of penalties being applied. You're trying to
17 avoid -- so, in some ways, stratification, in
18 that sense, can be illuminated to understand
19 where there are disparities and to understand
20 where sort of new investments need to be made.

21 Going back to, I think, Ann's comments
22 earlier that you could look overall for the

1 population, and it could look like you're
2 performing quite well, but there are key groups,
3 whether it's a severe mental illness or whether
4 it's a certain socioeconomic or minority groups
5 where you're not performing as well. For the
6 purposes of this program, I'm somewhat less
7 concerned about sort of penalizing but actually
8 illuminating the problems for particular
9 populations and identifying the need for more
10 resources or different types of strategies to be
11 applied.

12 The second comment I wanted to make
13 had to do with sort of the coordination and
14 community linkages, particularly for people with
15 severe and persistent mental illnesses. And two
16 points within that. One is that I think that's a
17 particular issue there in terms of thinking about
18 community linkages. Obviously, issues around
19 connection, issues around sort of housing
20 stability being a big one, and to what extent
21 individuals are assessed for stability in
22 housing, to what extent they're assessing

1 services and actually are getting stable housing
2 is something to think about, because that's a key
3 issue, especially with the sort of Housing First
4 movement that has fairly well-developed sort of
5 evidence-based approaches around providing that
6 housing first, even before you're providing
7 health and mental health types of services as
8 being a more effective way to go. And that may
9 be something to think about in terms of going
10 forward. But also, to some degree, also linking
11 to criminal justice as another sort of partner in
12 the community and particularly as sort of jails
13 and prisons have become sort of some of the main
14 places where people are accessing services with
15 severe mental illness.

16 And then, finally, there's an
17 interesting program being developed in New York
18 City around, that's being developed by the
19 Mayor's wife. It's a whole range of different
20 programs under the auspice of what's termed
21 Thrive New York City, some of which are
22 particularly focused on linking social services

1 with behavioral health services. And in this
2 case, there's one component called Care to
3 Community or Connections to Care that are
4 specifically in providing resources to community-
5 based social service organizations to link them
6 up with behavioral health organizations by
7 providing certain evidence-based services there
8 and care management services.

9 Now, that would be very hard to
10 collect information about the impact of that
11 under -- you know, if a state or a city wanted to
12 build that kind of program, I'm not sure where it
13 would show up as an improvement in Medicaid. And
14 to think about how one could somehow, if those
15 innovations are being put in place, how one could
16 capture the fact that that actually was affecting
17 performance of Medicaid. And so it's worth
18 thinking about some of these new innovative
19 programs in terms of community linkage, to be
20 able to use that as a way to demonstrate ways by
21 which innovations can actually improve outcomes
22 for Medicaid populations.

1 So Julia and Ann?

2 DR. LOGAN: To your point about
3 disparities, for the Adult Medicaid Quality
4 Grant, our state was able to look at several
5 measures, to stratify several measures, and we
6 were very surprised by what we found with each
7 measure, that there were certain disparities that
8 we didn't expect. And so I think that's very
9 valuable information because it helps you to look
10 at the measure and the outcomes in a completely
11 different way.

12 There are several problems and
13 difficulties with doing the stratifications. In
14 Medi-Cal and Medicaid data in California we don't
15 require that people, when they fill out their
16 enrollment forms, that they specify what race or
17 ethnicity they are, so a lot of times there are
18 gaps in that data. So there are problems with
19 that, but, overall, I think it's a really
20 important thing to look at.

21 DR. WILSON: Julia, could I just ask
22 you how did you stratify it? Because I know the

1 data, getting the right variables, but how did
2 you stratify? What did you use?

3 DR. LOGAN: You mean what did we
4 stratify by?

5 DR. WILSON: Yes.

6 DR. LOGAN: So certain things: race,
7 ethnicity, age, male or female, rural status, SSI
8 status. I think that was about it, from what I
9 can recall.

10 CHAIR PINCUS: Ann?

11 DR. SULLIVAN: Yes, much of what I was
12 going to say you said, Harold. I just want to
13 make the point that we're all struggling with
14 measures. And once you begin to move into these
15 measures of linkages to community-based
16 organizations, I think it gets increasingly
17 complicated how you do it. It's critical,
18 though, because we all know that that big pie
19 chart that shows how much of your healthcare is
20 determined by our provider system is small and
21 how much is determined by everything else is very
22 big.

1 So I think it's a real question as to
2 how you look at this issue of community linkages
3 and how you might measure it. And I mean, I
4 think we probably have to begin the way we've
5 done. For example, is your housing stable? And
6 if your housing isn't stable -- first, you've got
7 to ask the question just like you kind of do for
8 diabetes. And the second question is, if it's
9 not stable, did you get referred to somebody?
10 And the last question is did you finally get
11 yourself into housing that's stable?

12 How you measure all that is very
13 difficult because that doesn't appear, by and
14 large, easily in anybody's medical record to
15 date. There might be places that do that kind of
16 thing but probably not too many.

17 So I think that it's a real shift to
18 start having providers think about these issues,
19 and it's a big movement to get the medical
20 community to think that they have some
21 responsibility for these things down the pipe.
22 In New York State, with a lot of the money that

1 came in with our CMS innovation, the district
2 money, the major push is this, and, yet, the
3 reality is that very few of the measures of
4 outcome for that district are going to connect to
5 this. So I think it's still this difficulty of
6 measuring it.

7 So I think we have to really put our
8 heads together to try to see if anybody has kind
9 of measured these things and what might be
10 something useful because the reality is, even
11 when that's a big part of what we would like to
12 see happen in New York, I know that in the
13 outcome measures, it's not there. So, I mean,
14 there's still the traditional other kinds of
15 measures.

16 So it's fascinating but very, very
17 tough to think about how you really make that
18 movement into the community linkage.

19 CHAIR PINCUS: Thanks. So we have
20 Katie and then Michael and then George.

21 MEMBER DUNN: Thank you. Just picking
22 up on what the last speaker said, the community

1 linkages, what we're finding in many of the rural
2 states is that you can ask the questions, but
3 then there's a very strong possibility there
4 might not be the resources to actually respond to
5 the need. And I think that dampens states'
6 willingness to ask the question because once you
7 know that there's a need, if you can't help
8 support that person, it's not a very positive
9 feeling. It definitely can provide information
10 to policymakers on what is needed out in the
11 local communities, but I think that's really
12 important if we're going to ask the question.

13 I also think there's challenges with
14 the smaller -- many of our non-medical community
15 entities across this country started off as
16 little grassroots organizations that, at one
17 time, might have just received, for example, a
18 small community action program funding. And they
19 would need a tremendous amount of support. It's
20 not just putting in a new software program that
21 will capture this type of community linkage type
22 information and be able to get to outcomes.

1 There's a whole infrastructure there that we've
2 seen some states do, but it's a pretty heavy
3 investment if states are going to go down that
4 road.

5 Another comment is around care
6 coordination and how that gets back to what you
7 were saying, which is we have -- we found that,
8 depending on which providers we're working with,
9 whether it's a primary care doc, a community
10 mental health center, a federally-qualified
11 health center, a developmental disabilities area
12 agency-type structure, everybody has got a
13 different definition of what care coordination
14 means. And in many instances, because of the
15 federal flow of funds, there is an unwillingness
16 to go outside of the framework of what those
17 funds do and don't allow you to do. And at the
18 Medicaid director level, we've been talking about
19 how, even though some of our key federal
20 agencies, SAMHSA, CMS Medicare, CMS Medicaid, et
21 cetera, are underneath HHS, there's still some
22 issues with the silos of funding.

1 And the last comment I'd like to make
2 around safety net providers, it's interesting
3 that not every state, at least we've talked about
4 this at managing level, most people, when they
5 think of safety net providers, generally go right
6 to the health centers. And we're not all
7 dependent upon -- not dependent. The case mix
8 at, for example, federally-qualified health
9 centers, if you look across the country, it's not
10 the same. In New Hampshire, for example, most of
11 our clients, our Medicaid beneficiaries, are not
12 seen at federally-qualified health centers.

13 And a couple of the states have done
14 some studies, and, yes, it does definitely
15 illuminate issues. It also illuminates success
16 stories. And the messaging about that has been
17 really difficult. Particularly working with
18 health centers, you want to put the information
19 out there, whether it's positive or negative, but
20 there's a tremendous amount of sensitivity on how
21 that message goes out. Thank you.

22 CHAIR PINCUS: Michael? Is your mic

1 on.

2 MEMBER SHA: I would echo Katie's
3 point about the lack of a precise definition of
4 what care coordination is. From a provider
5 standpoint, we oftentimes talk about transitions
6 of care, and I know the Society of Hospital
7 Medicine and the American Medical Directors
8 Association have done a lot of work regarding
9 transitions of care, but I think part of my
10 concerns regarding care coordination is really
11 how it's perhaps best measured because, with the
12 development of meaningful use, the development of
13 Accountable Care Organizations, particularly for
14 the dual eligibles, I think the processes may be
15 already getting beyond our ability to sort of
16 capture this.

17 But perhaps, if we are going to really
18 make an effort of capturing it, the easiest way
19 perhaps, from a CMS standpoint, is to code it and
20 pay for it. I guess that's what I would probably
21 offer.

22 CHAIR PINCUS: Thanks. George?

1 MEMBER ANDREWS: I agree with a lot of
2 what's been said. I think comments relating to
3 capturing sociodemographic information and how
4 that drives patient compliance and working with
5 their provider who is trying to deliver the best
6 care to them. I think the community resources
7 are critical, and I think, just like you
8 mentioned, Harold, I think linking those
9 resources encourages and touches on population
10 health.

11 But as I look at the expanded chronic
12 care model, I think that the -- under the section
13 of informed, activated patient, that, to me,
14 requires further expansion and additional
15 elements incorporated, particularly engaged. You
16 can have an informed, activated patient, but if
17 they're not engaged you are not going to get the
18 collaboration with their provider, their
19 caregiver, or, for that matter, community
20 resources.

21 I think to get to the final end goal
22 of improved health outcomes, you need two pieces

1 of the puzzle, the deliverer of care and the
2 receiver of care, to really agree on that common
3 goal. Physicians are very often extremely
4 frustrated by the fact that they're trying to
5 improve, whether it be diabetes, whether it be
6 cardiac management of their patients, and they
7 can't because the patient is not quite there.
8 And I don't have the solution, but I do think
9 that some way of thinking about -- if our end
10 goal is improved population health, we need, as a
11 society, as policymakers, et cetera, to think
12 about how can we get the individual, who we would
13 like to help and want to be engaged, to be on
14 board? How do we do that? How do we
15 incentivize? What do we have to do within the
16 limits of our ethical and other obligations in
17 terms of trying to help that patient?

18 CHAIR PINCUS: Kim?

19 DR. ELLIOT: I think a firm or more
20 definitive definition for care coordination would
21 really be beneficial. What I see in Medicaid
22 programs depends on the population served and the

1 type of program that they have. But, oftentimes,
2 care coordination is wrapped up into case
3 management, and it interweaves, and it's not
4 really firmly defined. So sometimes it's a
5 service, and sometimes it's an administrative
6 activity, and it really matters when you're
7 really trying to define what it is and what it
8 should look like and, more importantly, what the
9 outcome is.

10 So I'm also thinking that, from an
11 outcomes perspective, and I know I go back to
12 outcomes a lot, but that really is what it's all
13 about is what really happens to an individual
14 patient or member that's served by Medicaid. But
15 if you look at simple things, like follow-up
16 after discharge within a certain number of days,
17 that could be a case management care coordination
18 issue. But looking at what happened, did it
19 result in an improved outcome because they had
20 that follow-up after discharge? So linking back
21 some outcome from that service and showing how,
22 again, a fiscal impact, a quality impact for that

1 individual served, those are the things that
2 ultimately matter. So it's not just measuring
3 whether they had that follow-up but really what
4 was the outcome of that follow-up.

5 CHAIR PINCUS: Thank you. I think
6 we've had a pretty robust discussion on these
7 issues. We're going to take a break now for 15
8 minutes? Ten? Okay. Ten minutes. We'll
9 reconvene at 11:10, and we'll also fix the
10 slides, and we'll come back and we'll hear from
11 the states. So thank you.

12 (Whereupon, the above-entitled matter
13 went off the record at 10:57 a.m. and resumed at
14 11:13 a.m.)

15 CHAIR PINCUS: So we're going to be
16 hearing from two states, California and Oregon.
17 And the kind of questions that we've asked them
18 to talk about are dealing with some of these
19 issues around what they feel are the most
20 significant challenges they face in participating
21 in the program, their thoughts about potential
22 changes to the core set, and to think about how

1 some of the feedback from the states can actually
2 influence our thinking about how we review the
3 materials that we're going to look at this
4 afternoon.

5 We also want to know a little bit more
6 about how the states are using the measures, and
7 we talked a little bit about that earlier, and
8 also to hear more about some of the successes
9 they've had in actually being able to measure
10 quality both within the program but also outside
11 the program.

12 So first we're going to hear from
13 Julia Logan, who is the Chief Quality Officer for
14 the California State Medicaid Program.

15 So Julia?

16 DR. LOGAN: So thank you so much.
17 It's really a privilege and an honor to be here
18 today. It's kind of like being at the Oscars of
19 quality improvement or something like that.

20 So I'm really excited to share
21 California's experience. And as Harold
22 mentioned, we have a long list of things that we

1 should be talking about.

2 Also, as he mentioned, I work at the
3 California Department of Healthcare Services,
4 which is the state's Medicaid program, and we
5 call it Medi-Cal. So if you hear me saying Medi-
6 Cal, that's what I mean.

7 So I wanted to give you a brief
8 overview of what I'll be talking about today.
9 I'll give you a little bit of an idea of our
10 demographics in California and how we aim for
11 alignment in California and some of our successes
12 and some of our challenges in that area. I'll
13 also be touching on Medi-Cal 2020, which is our
14 1115 waiver, especially as it relates to care
15 coordination and community integration and
16 quality measurement.

17 I'll also be discussing how we drive
18 quality at Medi-Cal, what our statewide
19 mechanisms are for measure reporting, and how
20 California decides which measures to report and
21 then reporting and measurement challenges of the
22 CMS core set. And, finally, I'll be talking

1 about areas that California has identified that
2 need high-quality measures that we don't already
3 have high-quality measures in.

4 So a little bit about our
5 demographics. Medi-Cal provides healthcare
6 services to 3.1 million beneficiaries through two
7 distinct healthcare delivery systems: our managed
8 care program and our traditional fee-for-service
9 program. Medi-Cal managed care has grown
10 tremendously over the past three years. In 2013,
11 it served about six million members, and that
12 number has grown to more than ten million members
13 in the past three years.

14 Managed care provides healthcare
15 services to children, pregnant women, seniors and
16 persons with disabilities. We contract with 23
17 full-scope Medi-Cal managed care health plans and
18 three specialty health plans.

19 We serve a very diverse population.
20 As of September 2015, 46 percent of our
21 beneficiaries are Hispanic, 22 percent are white,
22 13 percent are Asian and Pacific Island, and 8

1 percent are African-American. So that speaks to
2 what I was talking about earlier about the
3 importance of stratification.

4 California has a really strong
5 commitment to improving health outcomes and to
6 aligning across -- sorry -- across payers. In
7 2012, our governor, Governor Jerry Brown, signed
8 an executive order to establish the Let's Get
9 Healthy California Task Force. This set out to
10 make California the healthiest state in the
11 nation by 2022, so that's kind of bold and
12 audacious.

13 This task force outlined three key
14 health indicators focused around three distinct
15 areas that you can see on this slide. Healthy
16 beginnings, living well, so preventing and
17 managing chronic disease and end of life, with
18 three core issues addressed: redesigning the
19 healthcare system, creating healthy communities,
20 and lowering the cost of care.

21 The Let's Get Healthy California work
22 and its key themes lead the foundation for

1 several other key groups and initiatives. Medi-
2 Cal 2020, our 1115 waiver which I'll talk about a
3 little bit more later, a statewide workgroup on
4 overuse and misuse, so really implementing
5 choosing wisely; a statewide workgroup on high-
6 cost pharmaceuticals. The catalyst for this was
7 the release of the new hep C medications. And a
8 measure alignment with the three large purchasers
9 in California: the Department of Healthcare
10 Services, Covered California which is our health
11 benefits exchange, and CalPERS, which is our
12 California public employees retirement system
13 which manages the benefits for more than 1.6
14 million public employees and their families.

15 This work has definitely has many
16 challenges. The populations of these three large
17 payers are very different. There's the different
18 focus of control for each of these. Covered
19 California has the ability to influence health
20 plan contracts but not specifically influence
21 provider behavior, so that's a big difference.
22 And there are also different priorities among the

1 three payers.

2 Medi-Cal 2020 is the state's renewed
3 1115 waiver which was approved on December 30th,
4 2015. California received approval for four
5 major initiatives: the Public Hospital Redesign
6 and Incentives in Medi-Cal program, which I'll
7 call PRIME; Whole Person Care pilots which I'll
8 discuss in the next slide; the Global Payment
9 Program which allows for payment of uncompensated
10 care and alternative care models; our Dental
11 Transformation Initiative which provides direct
12 incentives to dental providers to provide
13 preventive services for children.

14 The waiver establishes a foundation to
15 support the transition to value-based purchasing.
16 And another really interesting thing is it
17 provides opportunities to test innovative
18 measures, particularly in the PRIME program. So
19 I wanted to explain a little bit more about PRIME
20 because it relates most closely to measurement
21 and metrics.

22 PRIME is a pay-for-performance, P4P,

1 incentive program for all of the designated
2 public hospitals in California, of which there
3 are 21, and all the district hospitals of which
4 there are about 40. It was organized into three
5 domains of care, which are the first outpatient
6 delivery system transformation and prevention and
7 the second is targeted high-risk or high-cost
8 populations and the third is resource utilization
9 efficiency.

10 An example of -- there are multiple
11 projects per domain, and each project contains a
12 set of quality measures that the hospital must
13 improve on. And examples of projects include
14 obesity prevention, the Million Hearts
15 Initiative, cancer prevention, and there's a
16 perinatal project, post-incarceration project,
17 antibiotic stewardship, and high-cost imaging.
18 So there are about 20 projects in total.

19 All totaled, the PRIME program
20 contains about 75 metrics, 80 percent of which
21 are NQF endorsed and 20 percent we're calling
22 innovative metrics. Innovative metrics are used

1 only in incidences in which a project's current
2 set of standard metrics doesn't adequately assess
3 successful transformation.

4 So examples of these innovative
5 metrics include patient safety. That's one of
6 our projects. One of the metrics is abnormal
7 results follow-up and another is ensuring
8 adherence to prescription medications. We also
9 have an opioid project within PRIME which
10 addresses chronic non-malignant pain, and
11 examples of innovative metrics in this project
12 are checking the prescription drug monitoring
13 programs, screening for depression in people with
14 chronic non-malignant pain, and having a pain
15 agreement in patients with chronic opioid use.

16 So through our federal waiver and
17 through partnership with CMS, we definitely
18 couldn't do this without CMS for sure, the
19 Department of Healthcare Services is able to
20 administer four groundbreaking programs within
21 the last few years with the aim to improve and
22 transform care in California. The Whole Person

1 Care Pilot, as you can see, is a voluntary
2 county-based initiative, which focus on
3 coordination of health, behavioral health, and
4 social services for Medi-Cal beneficiaries who
5 are high utilizers. So this speaks to what we
6 were talking about previously.

7 Health Homes Program is another CMS
8 program. It's led by managed care plans in
9 counties scheduled for implementation, so there
10 are about six of our 58 counties scheduled right
11 now. It supports the development of a network of
12 providers to integrate and coordinate primary,
13 acute, and behavioral healthcare for high-risk
14 high-utilizers of care. And as I said, it's led
15 by the managed care plans.

16 Our Coordinated Care Initiative is a
17 pilot program in seven counties, and it promotes
18 the coordinated care for dual eligibles by
19 combining a beneficiary's Medi-Cal and Medicare
20 benefits into one healthcare plan. And then
21 PRIME I already spoke about.

22 And so there are several common themes

1 within these key programs that kind of run
2 through what we were talking about today. So
3 improving care coordination, integration of care
4 and of services in and out of the healthcare
5 system, and high-utilizers of care.

6 Okay. So there are multiple ways that
7 quality is driven at Medi-Cal. We have the PRIME
8 program and other major initiatives that I just
9 spoke about but also, through our performance
10 expectations with our 23 managed healthcare
11 plans.

12 The managed care plans are
13 contractually required to perform in at least the
14 25th percentile, so a low bar, admittedly, for
15 all metrics in the External Accountability Set,
16 which is a set of metrics that we require them to
17 report on every year. They're required to
18 participate annually in a performance improvement
19 plan around one of our four clinical priority
20 areas, as outlined in our quality strategy.
21 These priority areas are hypertension -- for this
22 year -- are hypertension, postpartum care,

1 childhood immunizations, and diabetes management.

2 They're also required to be part of a
3 PDSA cycle in areas that they're performing below
4 the 25th percentile. So we require them to do
5 small tests of change and then to scale up in
6 those specific areas.

7 And then we also have other areas
8 where we have ongoing QI projects and
9 initiatives. We're working on immunizations,
10 including prenatal immunizations, especially the
11 use of Tdap because of our high rates of
12 pertussis in babies; opioid overuse and misuse,
13 which is a U.S. problem specifically; obesity
14 prevention, we have a USDA grant to address this.
15 We have a CMMI grant to explore incentives to
16 quit smoking. We're working on the Million
17 Hearts Initiative, which was one of the affinity
18 groups with CMS. And because Medi-Cal pays for
19 half the births in California, so about 250,000
20 births a year, we have a big stake in achieving
21 the triple aim in that area, as well.

22 I thought it would be important to

1 describe what mechanisms there are to report on
2 measures in California. First, we have a
3 program-wide reporting of both fee-for-service
4 and managed care through the Adult Medicaid
5 Quality Grant. While the grant is over, sadly,
6 but DHCS intends to report the core set of
7 measures they reported in 2015 on a continuing
8 basis.

9 One challenge that we face -- well,
10 I'll talk about more of the challenges, but one
11 specific challenge I wanted to address right now
12 is validation of the measures. So while we
13 report them internally and run the measures
14 internally, we're not 100 percent sure that the
15 measures are actually reliable and accurate. So
16 one thing that we're doing is we're using our
17 EQRO organization to validate some specific
18 measures.

19 A second way of reporting is required
20 reporting for the managed care plans through the
21 External Accountability Set. So as I mentioned,
22 it's a set of quality measures that closely

1 mirrors the Adult Core Set but not specifically
2 that supports our quality strategy. And every
3 two years, we review the External Accountability
4 Set by an internal quality improvement committee.
5 We review the Adult Core Set and look for measure
6 gaps both in the core set and our own set, and
7 then we look for areas that are no longer
8 relevant, maybe the measure has changed, or where
9 performance is good enough to take that measure
10 off. And then we also try to align with other
11 measures and initiatives in California. And we
12 prefer the measures are NQF endorsed, and it's
13 also helpful for the measures to be NCQA or HEDIS
14 because of the ease of having baselines, or
15 benchmarks rather.

16 There are also several measures, all
17 pediatric at this point, that our state
18 legislature has mandated for us to report, as
19 well.

20 But lastly, I wanted to mention that
21 our department is considering an internal
22 accountability set. So what this would do is

1 this would allow the managed care plans to focus
2 only on hybrid measures and allow our department
3 to report on administrative measures only because
4 right now managed care plans report both on
5 administrative and hybrid, and so it would take
6 the burden off of them for that and would allow
7 us to report on more measures.

8 Okay. So I wanted to briefly show you
9 the Medi-Cal managed care Adult External
10 Accountability set. So this is our list of
11 measures for the managed care plans, and I
12 highlighted all the measures that are consistent
13 with the Adult Core Set. So it's all-cost re-
14 admissions, annual monitoring for patients on
15 persistent medications, cervical cancer
16 screening, two of the diabetes measures:
17 hemoglobin A1C testing and then poor control of
18 diabetes. We also have several other diabetes
19 measures that we've debated about taking off, but
20 our managed care plans actually really like these
21 measures and they say it's not an additional
22 burden for them to do that and we're not

1 improving in them, so we think it might be
2 important to keep it on. Controlling high blood
3 pressure is the core set measure and then
4 postpartum care, of course.

5 So, obviously, you can see, just by
6 looking briefly at it, that there are certain
7 gaps in our External Accountability Set that
8 we've identified. The first is behavioral
9 health, and this is obviously a big issue in
10 terms of high-utilizers and care coordination;
11 opioid management, we have extremely high rates
12 in rural counties and high rates of opioid
13 overdose. And we have the highest rates of
14 overdose that we've ever had, so it's a really
15 big issue for us. And palliative care and
16 advanced care planning.

17 Our state recently passed SP104, which
18 is the implementation of a community-based
19 palliative care program within our Medi-Cal
20 program, and we need to implement that within the
21 next six months, so it's important for us to find
22 a way to measure the implementation of that

1 palliative care program.

2 We did look at the core set for these
3 specific three areas: behavioral health, opioid
4 management, and advanced care planning. There's
5 no core set measure, of course, for end-of-life
6 care or advanced care planning. We did review
7 the NCQA advanced care planning measure, but it's
8 not for the Medicaid population. It's for the
9 Medicare population, so the measure would have to
10 be modified. And we did hear that Oregon has
11 been using this measure and changed it to age
12 over 18, but apparently that caused some
13 confusion, so maybe we can hear more about that
14 offline.

15 And then the second one, opioid
16 management, we did look at the core set measure,
17 but there was a big concern that the N's would be
18 too small because of the issue of having so many
19 prescribers and pharmacy and that that wouldn't
20 really get to the heart of the issue and really
21 not focused on primary prevention and also the
22 issue of it not being NQF endorsed. But I do

1 hear that it may be getting NQF endorsement
2 shortly.

3 And then the third, for behavioral
4 health, we looked at several of the core set
5 measures. And for the antidepressant medication
6 management measure, there was a concern for
7 overuse of medication and using medications that
8 may not be warranted or clinically appropriate
9 for mild to moderate depression.

10 Other behavioral health metrics also
11 require data from mental health providers, and we
12 learned from our work in the Adult Medicaid
13 Quality Grant that this is very challenging to
14 get data that's not in our data set.

15 Okay. So I just wanted to talk about
16 the Adult Medicaid Quality Grant and our
17 experiences with it. We were so thankful to CMS
18 for the opportunity to participate in this grant.
19 It really allowed us to test and evaluate the
20 core set of measures and offered a huge
21 opportunity into driving quality improvement and
22 even using the language of quality improvement

1 within our department.

2 In 2015, we reported on 16 of the 26
3 measures. Eleven were based on administrative
4 data and four were mixed with managed care plan
5 reporting, so hybrid and administrative, and one
6 was based purely on hybrid data from our managed
7 care plans.

8 Over the course of the grant, we were
9 able to report on three different measures that
10 required access to other data elements: the HIV
11 viral load suppression measure, the early
12 elective delivery measure, and antenatal
13 steroids. We had to enter into contracts with
14 external stakeholders to receive this data, and
15 contracting within our state is very complicated
16 and time-consuming and often is fraught with many
17 delays. So we had a lot of trouble actually
18 getting this data, and it was late, and so we're
19 not going to be continuing with those contracts.

20 Okay. So I wanted to talk about some
21 of the lessons that we learned within the Adult
22 Medicaid Quality Grant on reporting and measuring

1 within the CMS core set. So the issue of dually
2 eligible is very challenging for us. We only
3 have a portion of the claim, so we don't have
4 Medicare claims. So measurement is not an
5 accurate reflection of performance of our Medi-
6 Cal beneficiaries who may be dually eligible.

7 Another issue is our encounter data.
8 So encounter data is the data that we get from
9 managed care plans. It's separate from the
10 claims data that we get on the fee-for-service
11 side.

12 The quality of encounter data coming
13 from the plans can be very variable. There are
14 reliability issues. There are timeliness issues.
15 So we have started, as a result of this grant,
16 we've started an encounter data improvement
17 project, so we're working on the quality of the
18 data.

19 One big issue is also missing lab
20 data. We learned through this grant that some of
21 our plans were just not sending lab data at all,
22 so we're trying to work through those kinks, as

1 well.

2 Another issue that I mentioned before
3 is that clinical data is not available in our
4 data warehouse. So some of the measures that
5 require clinical data we cannot continue to
6 report on.

7 Lack of provider data is also
8 important to us and also a challenge. Provider
9 data associated with NPI numbers really play an
10 essential role in a number of the measures. As
11 an example, provider taxonomy is required for
12 numerator services in follow-up after
13 hospitalization for mental illness. This data,
14 however, hasn't been incorporated into our data
15 warehouse. Additionally, state-level databases
16 haven't adopted the NPI as an identifier for
17 healthcare providers or health facilities. So
18 we're lacking a lot of that data.

19 Look-back is required for cervical
20 cancer screening, and that's also challenging for
21 us because we have such a quickly-enlarging
22 enrollment that we don't have that look-back

1 available. So we'd be missing much information
2 in that area, as well.

3 Let's see. PQI measures are also very
4 challenging for us. Dually eligible are under-
5 represented in our hospital data because, as I
6 mentioned before, Medicare is the primary payer.
7 And some of our members have limited-scope
8 benefits, so they're not eligible for preventive
9 services and not really good candidates for the
10 prevention quality indicator set.

11 And then the CAHPS survey is also
12 challenging. We're only able to report it or ask
13 our plans to report it every three years, so we
14 can't follow things over time very well. We also
15 have a very low response rate, maybe about 15
16 percent overall. And we've also found, as I'm
17 sure other people documented very well, that
18 there are a lot of cultural issues, and, because
19 of our very diverse population, we found that
20 different people in different cultures respond to
21 the CAHPS survey in very different ways and we
22 may not get reliable information.

1 Okay. So I wanted to talk about areas
2 in need of high-quality and practical measures.
3 I was in a meeting yesterday at the National
4 Academy of Medicine on end-of-life care, and
5 measurement came up again and again, people
6 saying the only way to see change is to measure
7 it. And I understand that, and I think that's
8 important. But as Harold mentioned before, we
9 can't flood the world with so many more measures.
10 So it's definitely a balancing act of having too
11 many measures. That being said, we can always
12 have a wish list, and there are more areas where
13 we could really use some high-quality measures.

14 As I mentioned, we're testing some
15 measures in each of these areas: promoting
16 outpatient safety, controlling the opioid
17 epidemic, implementing choosing wisely,
18 implementing behavioral health, and implementing
19 palliative care services, and ensuring access
20 through our PRIME waiver program. And we'll be
21 able to see how the measures fared over the next
22 few years, so, hopefully, we'll be able to report

1 back in that area.

2 And I leave you with this slide. We
3 have a Medi-Cal website called Welltopia, and
4 it's our area, our website for wellness. And I
5 end on it because I think it reminds us all that
6 we focus so much on healthcare and improving
7 healthcare measures and process measures and
8 outcome measures, but it's really important to
9 ask are we really improving the health of those
10 people we serve and are we really contributing to
11 the well-being and quality of life of those
12 people we serve?

13 So thank you so much. I really
14 appreciate your time.

15 CHAIR PINCUS: Thank you. Before we
16 get into discussion, why don't we hear from
17 Charles about the situation in Oregon?

18 DR. GALLIA: So I'm going to introduce
19 myself as not only from the state of Oregon but a
20 principal investigator in our three-state CHIPRA
21 demonstration project. So some of the things
22 that you're going to hear about are informed from

1 that perspective, and I know that this is
2 principally focused in on the adult side, but
3 there's relevant lessons that pertain to both,
4 and that's how I created this presentation.

5 The other thing is that, typically,
6 someone would give you a little background about
7 me and tell you that I know what I'm talking
8 about. You're just going to have to take my word
9 for it.

10 So as I mentioned, part of the
11 perspective that I have is working initially on
12 the CHIPRA demonstration grant, and this is one
13 of the projects. I was in Alaska and I was doing
14 some ice climbing, and I wanted to show you what
15 perspective does. This was one viewpoint, and
16 this is another. And you can see that it does
17 make a dramatic impact on how you see things. As
18 to perspective, how close or how far you are away
19 can make a dramatic difference. And so what I'm
20 going to try to do a little bit is describe some
21 of my empathy for the national perspective, the
22 experience that I gained from some of the multi-

1 state perspectives so I can address what the
2 contrast effects are between different states,
3 and then some of the experience that's occurred
4 just within Oregon alone.

5 I start again with the CHIPRA
6 demonstration grant because it presented at least
7 one of the key concepts that I thought where we
8 were headed and on which the adult work was
9 built. One of the key components of it is a
10 little phrase that I lifted exactly from the
11 public law that says that CMS, and AHRQ
12 subsequently, was supposed to develop a measure
13 set that, when taken together, can be used to
14 estimate the overall quality of healthcare for
15 children, including those with special healthcare
16 needs. And part of the reason I say that is
17 because there's some unfinished work that needs
18 to be done there.

19 What happened, though, is that in the
20 adult grant this was taken up as one of the areas
21 of focus. So the stratification that was
22 expected on the children's side has actually

1 occurred on the adult side.

2 One of the other experiences I had was
3 the joy of going through one of the review
4 sessions, one of the first review sessions before
5 NQF assumed responsibility for doing the work you
6 have, and it was on the subcommittee, the
7 National Advisory Council, at AHRQ. And it was
8 work that was being done by measurement
9 developers in the Centers of Excellence, and they
10 would put forward and invest a considerable
11 amount of time to making changes to this core
12 set, and you're faced with the same kind of
13 perspective today. You have a core set of
14 measures. There are lots of great ones that are
15 out there to think about. But really, more
16 fundamentally, what you might be able to do is
17 make an incremental change here or there.

18 So we added a few, we dropped a few,
19 and mostly there were ones that just simply were,
20 on face value, not working or there was
21 substantive alternatives that proved at least as
22 worthwhile. Again, I'm looking at, this is the

1 CHIPRA measures, and I dropped in the wrong slide
2 here, but I highlighted a couple of examples of
3 the contrasts that occur when just using this
4 administrative data.

5 If you look at the first two yellow
6 highlighted numbers, and, again, this is just the
7 pediatric set, you'll see Oregon produced from
8 administrative data that we have 0.4 percent of
9 our population being overweight or obese. And on
10 face validity, it's not true. West Virginia did
11 a combination hybrid, so, while we were able to
12 produce the measure and report on it, it's
13 obvious that it's not valid, but, yet, the
14 specifications permit that as a choice for states
15 to produce. So even though it didn't have the
16 face validity, we still included it, partially to
17 inform the process to say this is something you
18 need to check.

19 The other thing is that, within
20 Oregon, we saw this dramatic change in
21 developmental screening. There's some parallel
22 measures that we did in depression screening in

1 the adults and what we call SBIR measures through
2 the coordinated care organizations. So we saw a
3 rapid increase in this number going from about 18
4 percent to 42 percent. And part of the reason
5 that I'm highlighting that is to show or at least
6 to bring to your attention that measures have
7 life cycles. Marsha, you mentioned the high
8 levels of performance on well-child visits.
9 There's other measures that have been around for
10 a long time, and the performance levels at those
11 upper ends, the differences between the top tier
12 and the bottom tier are pretty small. But when
13 you first introduce any kind of measure in a
14 system, it goes up dramatically. And then,
15 eventually, they taper.

16 But when you're doing reviews of
17 measures here, typically you're looking at a
18 benchmark performance level or a subject matter
19 that's precipitated by media, press, or some
20 other system level novelty that says this is
21 something we need to pay attention to, and then
22 the measure follows.

1 So one of the ways that we identify
2 problems areas or ways we can improve is we do
3 look at the top-performing comparative
4 information. That's one of the added values that
5 sending this information to the federal level has
6 provided states is that who is the top performer
7 and how can we figure out what it is that they're
8 doing that we could emulate? So the comparative
9 information is extremely valuable.

10 So I'm going to just, this is going to
11 be kind of a data dump, so bear with me. Nearly
12 all the state Medicaid CHIP measures require some
13 kind of modification, even with the technical
14 assistance provided by the feds on the adult set
15 and the child set, even the medical home set that
16 exist, because they were designed for a single
17 managed care system, not multiple systems and not
18 levels of aggregation.

19 And if you actually follow the
20 specifications, some of the ways that states are
21 reporting them is not consistent with NCQA or
22 even the technical specifications because of some

1 of the continuous enrollment criteria.

2 And we stratify almost any measure in
3 Oregon, unlike your state. But I actually heard
4 that you had some of the same issues. The
5 numbers become really very small very quickly,
6 and then you're faced with a choice is this a
7 population that we choose to ignore because
8 there's an insufficient N, or do we continue to
9 report the measure and monitor it over time or
10 develop other ways? So this concern also impacts
11 our ability to trend changes or improvements over
12 time, as well.

13 And then just as a word of advice or
14 a request, actually, it would be great to find
15 out what's in the works at a state level. So
16 states can develop their own quality strategies
17 instead of being essentially reactive to what's
18 being proposed to plan ahead, so we can do the
19 infrastructure investments that are necessary,
20 prompt our organizations, the managed care
21 organizations that we work with, and the provider
22 communities to get feedback on the prioritization

1 that they would have particular areas.

2 And then this is going to sound a
3 little bit like some of the hospitals that I
4 heard talk that say, well, you know, you have to
5 cut us some slack because our patients are
6 sicker, and so here's a state saying but this is
7 the Medicaid population. But there really truly
8 are some distinctions that are important to
9 consider. And when measures are produced, they
10 have impacts on the results, and they may not be
11 capturing the true population characteristics
12 that are sought. And the states' primary
13 responsibility, no matter where they are, is the
14 population health, and a part of it is delivered
15 through the managed care organizations or fee-
16 for-service systems or the Medicaid, but it's
17 really the population health. And when people
18 move within the state, that means that they're no
19 longer potentially in a measure, but it doesn't
20 mean that the value of the care that they
21 received at one point in time isn't as important
22 or is not as comprehensive.

1 So the way that we segment measures
2 isn't consistent with the population
3 characteristics of Medicaid. We don't have the
4 same level of stability in terms of insurance
5 coverage, opportunities for enrollment change are
6 not consistent at states. They have open
7 enrollment continuously in some states, not in
8 others. And those updated information doesn't
9 kind of back into the claims systems that many
10 states have.

11 And I would also caution, I had a
12 little bit of a reaction, claims aren't all that
13 bad. Encounter data isn't all that bad. And
14 part of it, it is one method of obtaining
15 information. The other part of it is that it
16 gives the state the ability to check at a
17 practice or provider level that doesn't exist if
18 you don't have it that way. Turning in a measure
19 is turning in a measure, but I can dis-aggregate
20 the information through claims and MMIS. I can
21 find out who the specific provider was at an
22 individual level if I need to validate that

1 information, and it's part of the agreement that
2 we have with our providers. So it's not all that
3 bad. It is a payer system that's been washed,
4 but it has its weaknesses. But it has some
5 strengths, as well.

6 And part of the reason that I bring
7 that up is related to the program eligibility
8 groups that are there. Being able to segment
9 population and knowing that their needs may be
10 different, the help in the Adult Quality Grant to
11 how it's considered disability as stratification
12 based on, essentially, a basis of eligibility was
13 something that I hadn't considered. I was
14 looking for ways to use claims data to help
15 identify disabilities. But using a programmatic
16 eligibility criteria simplified the process, and
17 I knew that other states would be doing something
18 similar. So that allowed us to make some of the
19 comparative information that's there.

20 And then, as I mentioned, the mobility
21 of the population in Medicaid makes some of the
22 claims reporting information and just that you

1 would, we see about a 30-percent drop between our
2 total population and then those that are
3 qualifying for some of the measures when we use
4 continuous enrollment criteria. I'm sure that
5 we're not unique in that regard either.

6 Administrative dis-enrollments occur more
7 frequently in some states than they do others,
8 and, no matter how hard you try to characterize
9 that missing population, it's really difficult.

10 Some of the age segmentation that we
11 have is rooted actually in policies as funding.
12 The CHIPRA program is one of the few federal
13 programs that actually has required measures now.
14 The CHIP measures, the well-child visits and
15 EPSDT, those are actually required as a condition
16 of the federal financial participation. But that
17 program is going away, and so the leveraging that
18 exists -- well, I mean, it's on the horizon
19 maybe.

20 Okay. But encouraging states to
21 participate is really going to be a heavy lift,
22 and when I heard, it actually produced anxiety

1 when I saw the words mandate and then eliminating
2 voluntary components. That was really tough for
3 me to hear because one of the things that I
4 learned in both the previous grant and this one
5 was the minute that we start requiring measures
6 is that's when they become marginalized. They're
7 not in the forefront. What happens is they are a
8 reporting requirement and not an area for people
9 to rally around or to develop energy that's
10 positive. We are in the production measurement
11 mode, and that isn't the kind of environment that
12 facilitates quality improvement.

13 So I mentioned the stratification by
14 population, the population characteristics, and
15 kind of the summary of the issues that I think
16 that I would ask my colleagues at the federal
17 level to take heed of. And I know they're
18 working on it. They're not the only one in the
19 game.

20 And then the characteristics of
21 measures in general, I want to talk about those.
22 The ones that are more general, they're easier to

1 produce, they cover more population, but they're
2 also less actionable. So assistive care with the
3 ambulatory care measures and some of the others
4 that are there, they pertain to some other
5 populations, they give us the ability to do
6 stratification that we couldn't otherwise, but
7 they aren't really the kind of granular-level
8 kinds of measures that are important.

9 When we ran the measures past clinics
10 to say which of these make sense to you, which
11 ones would you use on a daily basis, the news
12 isn't all that good. We published an article on
13 it. It's about 20 percent of the primary care
14 docs thought that our set, between the
15 combination of both of the measures were relevant
16 to their day-to-day actions or work. So I think
17 there's some work that needs to be done about
18 using some generative or some base level
19 information from providers that serve not only
20 Medicaid but other lines of business.

21 One of the things that we found was
22 that the most compelling focal point for people,

1 practices, was using the CAHPS survey, clinician
2 and groups version, not the health plan one, so
3 we could provide practice-level feedback in
4 concert with our managed care organizations to
5 identify areas for improvement. Most of those
6 were process-oriented, I'd have to say. And that
7 might be just to those who like to focus in on
8 health outcomes. But really where the system-
9 level changes occur is on the ground, and it's
10 supported by those managed care organizations.
11 And being able to express or identify across
12 payers and develop meaningful feedback mechanisms
13 to the practices was probably the biggest
14 facilitating course we've had in years. And part
15 of that was a result of the Adult Medicaid
16 Quality Grant, and we're trying to convert that
17 work into a behavioral health setting, which
18 we're finding this a little bit challenging
19 because of the differences in organizational
20 culture and the differences in how the steps are
21 even set up. So the whole process is largely
22 different. There's a lot of work that has to be

1 done around the area of patients experience of
2 care in the behavioral health setting that we
3 don't have.

4 And then, in the interest of time and
5 getting to lunch, I want to make a point, and
6 that is that I didn't use the word "burden." And
7 when I mentioned this before, it was at the SNAC.
8 Actually, it was Marsha who said, well, that's
9 because you're Oregon. And we have an audience,
10 a receptive audience, for the information. We
11 have the political will and support that exists
12 because they want to know what's going on. And
13 they want to know specific areas where we don't
14 know what's going on, and so that creates an
15 environment where we're encouraged to explore and
16 analyze.

17 The other states that I work with
18 don't have that capability. They respond to,
19 essentially, the directives and restrictions that
20 are within the existing infrastructure, and
21 thinking outside the box is really not one of the
22 things that the states are supported to do. But

1 when we provide information effectively back to
2 providers and to the states in ways that are
3 usable, the perception of burden disappears. So
4 it surfaces when the value versus the effort is
5 not perceived, and that, in part, is based on not
6 just generating the information but the
7 interpretation, analysis, and use. So the
8 feedback that we've provided to our practices and
9 the managed care organizations was really
10 critical in whether or not they thought that this
11 was worthwhile.

12 And then it's also trending, too, over
13 time. Not just one year's worth of results but
14 the ability to look back over a period and figure
15 out how sensitive their efforts were or how
16 sensitive the measures were to their efforts. So
17 that feedback loop was also essential in getting
18 information and support for continuing the effort
19 set measurement.

20 And that's the other outcome of the
21 Adult Quality Grant that we found is that, while
22 they didn't, at first it was, you know, do we

1 really have to do this and aren't there other
2 systems? It's like are you really going to look
3 at it? But then when we provided routine
4 feedback to the organizations that we were
5 working with, we found that they actually demand
6 it now, as opposed to being resistant. So the
7 concept of burden is relative to the value that's
8 perceived.

9 I'm not going to have time to go
10 through these next things. One of the things
11 that we're doing in Oregon was to create an
12 equity disparities index. And the reason why I'm
13 just jumping to this framework, because I think
14 it's relevant not only to, well, it's relevant to
15 the topic that you're covering. And we started
16 with a framework, and the first thing that we
17 look at in assessing disparities is about the
18 availability of healthcare insurance overall. So
19 it's even before you hit the Medicaid program.
20 Are you getting coverage? Is there equity in
21 that area?

22 And then the next one is seeking care.

1 So, George, to your point earlier about what's
2 the precipitating event that prompts somebody to
3 go seek care, is it the same between different
4 cultures and organizations? And so that's where
5 -- so we used a select number of measures and
6 dropped them in there. And then after they have
7 coverage, after they have care, are they seeking
8 access to coverage? Is it available 24/7? Is
9 there a patient-centered medical home? And then
10 once they are in those settings with quality of
11 care within those venues.

12 And then the real disparities part
13 comes into where there are measures where you
14 know that there are disparities that exist. And
15 then, finally, it's like having one primary
16 outcome measure, either self-reported health
17 status or improvements in self-reported health
18 status or assessments of the managed care
19 organizations, we use an endpoint primarily
20 through CAHPS as the best judge of where they are
21 is the person saying it themselves.

22 So I'm not sure how I'm going to -- I

1 mean, I'm at my time limit.

2 CHAIR PINCUS: How much longer do you
3 have?

4 DR. GALLIA: Well, let's see. I think
5 this is -- probably three-quarters of the way.
6 Okay.

7 CHAIR PINCUS: See if you can finish
8 up in five minutes so we have some time for
9 discussion.

10 DR. GALLIA: Sure. So when we were
11 producing this health equity index, we
12 anticipated the issues. I just know they're
13 there, and we had small numbers. We knew that
14 there were going to be missing data, and we had
15 to talk about whether they were describing
16 relative versus absolute differences in health
17 outcomes, and we had to think about how we were
18 going to implement or use the improvement areas.
19 And then we also had some other criteria, that it
20 had to be statistically sound and usable for
21 different areas, in addition to race and
22 ethnicity. We wanted it to be applicable to

1 gender, disability, special healthcare needs or
2 people with chronic conditions.

3 And this is just to give you one
4 example. So just imagine, I mean, I can't
5 imagine doing this at a federal level. So we
6 have 16 coordinated care organizations in Oregon,
7 and this is one measure. And we had to figure
8 out, well, how do you incentivize differences
9 between these programs? There's obvious
10 difference in performance, and there's obvious
11 differences that exist between race and ethnicity
12 groups. So what do we do? You know, what is the
13 key crux of how do you facilitate improvement?
14 Do you hit a benchmark?

15 If we use a national or average
16 benchmark, there's some populations who are going
17 to be doing better than others. If we use the
18 best-performing group, are we giving preference
19 to a population that may have inherent benefits
20 that they're experiencing that the other
21 populations may not be? So even having all of
22 this data actually didn't help us identify an

1 index, and that was just one measure, one
2 measure.

3 And so I'm trying to convey it's a
4 challenge. It's a challenge to not produce the
5 measure because it's there. We can even stratify
6 it by race and ethnicity, but how do you convert
7 this into something that's actionable?

8 One of the things we did use and I
9 wanted to give credit to the NQF. We prioritized
10 those measures that were in this NQF report that
11 are sensitive to healthcare disparities, and that
12 helped us to use those.

13 One of the things that I was going to
14 suggest that -- I'm going to skip past this -- is
15 that when you consider measures, think about the
16 added value that they have. So if there is, if
17 there's layering that can occur between a state
18 managed care and a practice level, those should
19 be given priority over ones that only have one
20 system level reflection. The same thing if you
21 know that a particular measure is designed or is
22 sensitive to disparities reduction, that should

1 be given greater emphasis, as well. So weighting
2 those somehow, even if it's unconsciously, should
3 be given some kind of priority.

4 One of the other things we had to do
5 was that the CAHPS survey, which is one measure,
6 one listed measure, has so much rich information
7 that is really being grossly underutilized. One
8 of the things we did was modify it a little bit
9 in the three states and then continue to do it
10 because when we do just managed care at a managed
11 care level, translating that back down to a
12 practice is really challenging. It's like, well,
13 I don't know if my data is in there, I don't know
14 if that even hit my practice. And if you have a
15 response rate of 15 percent, you're not even
16 going to be able to walk in the door and talk
17 about it.

18 So what we did is a couple of things.
19 We emphasized across payer, so when we report
20 back we don't report back just on Medicaid, we do
21 all payers. And we included people with chronic
22 conditions and children with special healthcare

1 needs.

2 One of the other important things that
3 we do is we added questions that are related to
4 shared decision-making. So it's an area of the
5 experience of care that's also not captured
6 routinely at a national level. So if you're
7 going to facilitate change, you're going to
8 address the issue of concern about whether or not
9 a patient is compliant or responds to their
10 medications.

11 Having shared decision-making not only
12 for adults but for children is extremely
13 important. So we added that to the survey and
14 made it so that it's adaptable for both the state
15 and the practice level.

16 I'm just going to move to the last, my
17 last points. When we started with -- why did we
18 select measures? We do them principally for
19 three reasons: they're required, we were asked to
20 do it or requested, or we perceived that there's
21 an area of anticipated need. In other words,
22 there's enough other prevailing information that

1 we say, like, we need to do something in this
2 area. And if we can, so it's taking the
3 initiative. And that's not always possible in
4 every state. Actually, I don't know many states
5 that can do that.

6 So as I said, having something
7 required means that it's going to be treated that
8 way. But being asked, engaged, having supportive
9 stakeholders for particular areas is really going
10 to make, it's going to facilitate using the
11 measure.

12 Data collection challenges are going
13 to exist no matter what systems we have. I mean,
14 and they're always in flux. And as the evolution
15 of the eMeasures comes to play, that's going to
16 have its own problems. So there was a question
17 about the accuracy of each level of information.
18 There's always going to be gaps. I mean, I think
19 it's not a reach to say that we're never going to
20 have a single perfect system of measuring
21 healthcare quality across the country using a
22 single data source or a few sets of measures.

1 It's an aspiration. But I think it's important
2 to understand that you can do areas of focus and
3 substitute measures over time. So you have to
4 develop a system, a framework, that's organic,
5 and it anticipates some of the information
6 technology changes that are forthcoming. And
7 knowing that don't bank it all on one measure. I
8 think going back to some fundamentals with the
9 thinking about what really comprehensively, when
10 you take all these measures together, reflects
11 the healthcare of adults, Medicaid, duals, those
12 with chronic conditions, race and ethnicity, most
13 effectively. That parsimonious set, you can test
14 that. You can know that. And that's where I
15 think the framework got to start.

16 And that's it.

17 CHAIR PINCUS: Well, thank you. A lot
18 of issues brought up, a lot of possibilities for
19 discussion. So why don't we open it up for
20 discussion and comment by the task force? People
21 feel overwhelmed with the information? Michael?

22 MEMBER SHA: I would like to thank

1 both of you for presenting your perspectives. I
2 think this issue of asking states to supply
3 measure results is a very difficult task.

4 I think the question I would have for
5 Julia is the measure regarding controlling blood
6 pressure, which is, I think, the external review
7 set, it requires knowing the patient's blood
8 pressure. So we've talked a lot about using
9 claims data. How did California manage to
10 capture the blood pressure values?

11 CHAIR PINCUS: And can I sort of add
12 to that, as well, in terms of thinking about it.
13 A number of the "innovative" measures that you
14 described go well beyond claims, and that's an
15 example of one. Talk a little bit about how
16 you're capturing the data in those.

17 DR. LOGAN: Yes. Great questions. So
18 that External Accountability Set is the one that
19 we hold the managed care plans to, and so they're
20 able to go and do a chart review into their data
21 set. Certain healthcare organizations, like
22 Kaiser, actually, they have that in their data

1 already, so they pretty much don't have to do any
2 hybrid measures. They present all of their data
3 to us administratively. So that's definitely a
4 model to look to in the future.

5 And the innovative metrics are done
6 with our public hospitals in California, and so
7 they'll be able to do the chart review more
8 easily even than the managed care plans would,
9 theoretically.

10 But, yes, the controlling blood
11 pressure measure is one that we're actually
12 really proud of because we made some measurable
13 change and we know change is small and
14 incremental, but we did make some change. So
15 we're proud of it.

16 DR. SULLIVAN: Just staying with that,
17 did you use that measure, did you stratify -- I
18 mean, did you look to see if, for example,
19 patients with schizophrenia had their blood
20 pressure controlled? Would that be difficult for
21 you to do now with already doing the blood
22 pressure control? Would that make it easier, or

1 is it something you've thought about doing?

2 DR. LOGAN: Yes. So the managed care
3 plans right now are not obligated or required to
4 report stratified data, and they've actually said
5 that that would be an insurmountable challenge to
6 them. And so that blood pressure data is
7 provided by the plans, and so they wouldn't be
8 able to do that fine look at people with
9 schizophrenia.

10 DR. SULLIVAN: Do you understand why
11 that would be such a challenge?

12 DR. LOGAN: I think partly because the
13 enrollment data that they get does not
14 necessarily have race and ethnicity. So what
15 they do, because they do do some disparities
16 analysis as part of their required PDSA cycles
17 and performance improvement plans, but what they
18 do is they look at primary language and they
19 extrapolate from there any sort of disparity.

20 DR. SULLIVAN: Maybe by diagnosis,
21 right? I mean, if you were taking a sub-
22 population with a disability, like schizophrenia,

1 it should have that possibly.

2 CHAIR PINCUS: Yes, they did it by,
3 you know, if people had a claim for schizophrenia
4 over the same course, they could pull it out --

5 DR. LOGAN: Right. Although the way
6 they do their measuring is through a sample, a
7 sample of 411 members. So --

8 CHAIR PINCUS: So the N's would get
9 small.

10 DR. LOGAN: The N's would get really
11 small.

12 DR. SULLIVAN: Unless you sampled for
13 that.

14 DR. LOGAN: Unless you, yes, over-
15 sample or sample specifically for that, but we
16 don't require that right now.

17 CHAIR PINCUS: So is the case, just to
18 go back to my sort of add-on question, for the
19 innovative measures that you described, those
20 were all being done on a sample?

21 DR. LOGAN: They actually have the
22 choice of either doing the full population or

1 sample.

2 CHAIR PINCUS: Other comments or
3 questions? I had a question for Charles. It's
4 actually several questions. One is your
5 disparities framework that you described, is it
6 essential that you go through all of those levels
7 or can you pull out different stages of it, so to
8 speak?

9 And also back to your point about some
10 of the problems that you sort of raised about how
11 actionable some of these things are, what do you
12 mean by actionable? You know, going back to what
13 we described earlier, some things are useful for
14 analytic purposes, some things are useful for
15 improvement purposes, some measures are useful
16 for accountability purposes. And so how are you
17 thinking about actionable?

18 DR. GALLIA: So the index and the
19 framework, in order for it to be a comprehensive
20 assessment, what we did in identifying those
21 areas was those were trigger points where there
22 were disparities, and they're cumulative. So if

1 you're not assessing disparities in coverage,
2 then the subsequent population or each one of
3 those are layered. And so it's important to take
4 them at a total framework.

5 In terms of actionability, states'
6 policies can impact who has coverage and who
7 doesn't, whether or not outreach efforts and
8 enrollment processes are simple or complex,
9 whether they're passive or active. Those are
10 decisions that can influence whether or not
11 people have continuous coverage or not.

12 And then so that's actionable. We
13 even have pilots --

14 CHAIR PINCUS: So you don't have to do
15 the whole thing. Different components of it
16 could be actionable for different purposes.

17 DR. GALLIA: Right. And, in fact, we
18 have a PCORI grant that, with our, a select
19 number of FQHCs that we're using just like a
20 smoking cessation alert that would come up on a
21 screen that says this person's insurance or
22 child's insurance is due to expire. And so it's

1 a prompt to the provider, as well as to the front
2 office, to say that they need to conclude the
3 administrative paperwork so they don't have a
4 break in coverage.

5 So there's an opportunity to engage
6 practices, clinics, and groups in making sure
7 that continuity exists. So that's another
8 example of actionability that's found, and you
9 can go through each one of those and make the
10 same kind of connection. That's what I mean.

11 CHAIR PINCUS: Okay. Because I was
12 worried you were painting too pessimistic a
13 picture, but my sense is that, actually, a lot of
14 the things you mentioned are, in fact,
15 actionable.

16 DR. GALLIA: Oh, yes, they are, they
17 are. No, they are. It requires getting past
18 some of the administrative barriers, it requires
19 getting past some of the administrative barriers,
20 having a team of people and colleagues that are
21 willing to work on a project. So it's possible
22 to address them all, yes.

1 CHAIR PINCUS: Other comments,
2 questions? Oh, Katie?

3 MEMBER DUNN: Yes, thank you.
4 Reflecting back on some of the questions and one
5 in particular about any points of feedback from
6 the states need to influence the decision process
7 about specific measures and what both speakers
8 said. And, by the way, thank you. They were
9 really excellent presentations.

10 I think Charles mentioned at the
11 beginning, you know, whose interest should CMS
12 and the states try to speak to so that the work
13 that's being done from a quality measurement
14 perspective is considered important? And I think
15 one of the things states struggle with is is it
16 possible to develop a set of measures and a
17 reporting tool that can be used by all the
18 potential audience members. I mean, I think it's
19 one thing, at a state level, to write multiple
20 versions of, say, a PowerPoint presentation
21 because one day you're going out to the public
22 and the next day you're going to policymakers and

1 another day you're going to the governor's
2 office. But when it comes to this sort of
3 effort, which is time-consuming and resource-
4 intensive, how do we balance those needs that
5 gets to the task force work of if that's an
6 important part of whether a state is able to
7 execute all the measures as to the expectations
8 of CMS, then who really is our audience? We may
9 not be able to answer that today, but I do think
10 it needs to be kept in the back of our minds.

11 CHAIR PINCUS: Either of you want to
12 comment on that?

13 DR. LOGAN: Well, Katie, this is
14 Julia. Like you were talking about, the
15 PowerPoints change based on your audience, I
16 think the audience changes, you know, who is your
17 audience for reporting the measures, I think that
18 changes. It can be the lay public, it could be
19 members, it could be advocates and stakeholders,
20 CMS, ourselves. So sometimes that can be very
21 challenging.

22 And to your point about this all being

1 so resource-intensive, and I think Charles is
2 going to strangle me if I say this, but about the
3 mandate, whether or not the core set should be
4 mandated or continue to be voluntary, I'm not
5 sure that it's still up on the table or if it
6 ever was up on the table for whether we have
7 input on this, but, from our state perspective,
8 we would actually prefer it to be a required core
9 set because it is so resource-intensive and
10 because we do have many different audiences who
11 ask us for this data anyway. But if we're
12 required to do it by CMS, our state legislature
13 would probably be much more likely to provide us
14 funds to do the work that we need to do.

15 CHAIR PINCUS: Charles?

16 DR. GALLIA: I understand. I'd agree
17 with you if I thought you were right. No, but I
18 really do -- I think when I mentioned the burden
19 idea, the measure is -- implementing and
20 reporting the measure isn't the endpoint. And so
21 when the calculus of the core set, what truly
22 needs to be in a core set, I think it's incumbent

1 upon the states and CMS to calculate what the
2 potential costs are across a system of
3 implementing it and moving the measure towards a
4 desired objective. In other words, how much
5 effort is it going to take to move this measure
6 and what will be the net benefits? I mean,
7 really think about it in terms of implementation,
8 not just the production part. But I mean working
9 with practices and facilitating some of the
10 changes that are going to be essential in order
11 to have them on the ground.

12 Producing a measure and sending it to
13 a report is just one facet of it. We have to
14 make the commitment all the way through to making
15 improvements, and it's not just on one measure at
16 a time. We should be really mindful about, if
17 they're going to be required, that there's the
18 organizational commitment, as well as the
19 resources, to be able to address it because,
20 otherwise, we're going to set up a system of
21 helplessness, and I don't think that's an
22 effective way to implement quality measures.

1 CHAIR PINCUS: I think that is a good
2 point, that we should always anticipate not just
3 the cost of reporting but the cost of doing
4 something about it and also the opportunity costs
5 of doing something about A and not doing
6 something about B because I think that's also
7 critical.

8 Other comments, questions? Marsha?
9 Oh, oh, Kim?

10 DR. ELLIOT: I was just going to say
11 that I agree with everything that was said. It's
12 really important to really understand those
13 factors. But also, when you're looking at what's
14 actionable and really looking at the measure set
15 and looking at what other organizations are doing
16 from a community and stakeholder perspective, and
17 I know, Julia, you touched on that a little bit,
18 that's really one of the keys to successes is
19 whether you can align all of those community
20 organizations, the Medicaid program, and any
21 other area that's working on it. And that's
22 where you're going to start to see your biggest

1 successes and your ability to really measure the
2 outcomes and the personal effect of those
3 different areas that you're focusing on. So I
4 think it's great that you're doing that.

5 CHAIR PINCUS: Marsha?

6 DR. LILLIE-BLANTON: So I wanted to
7 return to Katie's question because I think it is
8 the right question to ask and then we have to try
9 to answer it, and that is whose interest are we
10 trying to serve? And I think it's really easy
11 for us to fragment interests, but I view the
12 partnership at the federal and state level being
13 a similar interest or a common interest. And,
14 ultimately, the main interest we're trying to
15 address is that of the beneficiary, the enrollee.
16 I mean, what we want is to improve the health of
17 the beneficiaries we serve. And so trying to
18 identify the measures that best help us do that,
19 that help us drive improvement, while still
20 controlling costs and managing those costs, I
21 think is ultimately what we're trying to do.

22 CHAIR PINCUS: Charles?

1 DR. GALLIA: I wanted to, actually --
2 you set the framework for that a while ago, and I
3 say "you." There was a relationship that was
4 created between, a unique relationship between
5 the states and CMS through these two grants, and
6 that was because it was learning. It was a
7 learning opportunity, and it was like what you
8 do, a learning collaborative, but at a national
9 level in many ways. And shared decision-making,
10 the people we could talk frankly about where
11 there were weaknesses and strengths without
12 having to fear any kind of repercussions, and the
13 states learned from one another because of the
14 table that was created by CMS. And I have to
15 applaud Marsha for helping facilitate that
16 setting and continue to do so. It's been
17 probably one of the biggest resources that I've
18 used within our own state because I can say that
19 providers in managed care organizations have the
20 opportunity to influence this larger system
21 because they're listening and that dialogue has
22 really made it important to facilitate change.

1 So thank you.

2 CHAIR PINCUS: Other comments,
3 questions? So I had a question to pose to both
4 of you and maybe also to Karen and Marsha. But
5 what would it take for the states to actually be
6 able to access, for quality measurement purposes,
7 clinical data through EHRs?

8 DR. LOGAN: Did you say what would it
9 take or how long?

10 CHAIR PINCUS: No, what would it take.

11 DR. LOGAN: Oh, okay.

12 CHAIR PINCUS: We'll get to the how
13 long afterwards.

14 DR. LOGAN: Oh, boy. My microphone is
15 still on, so I guess I'm obligated to answer. I
16 think it would, you know, I think you were
17 talking about that you have to really, you really
18 need to get alignment in each state. There's a
19 lot of health information exchanges, but they're
20 really lacking. I think that's one thing that's
21 really important.

22 There's a few things that are

1 happening in our state where there's sharing
2 across EHR systems, like health systems who have
3 Epic can share back and forth but they're still
4 not sharing with the state. That's one thing
5 that we're trying to do with our PRIME program is
6 have the hospitals share their clinical data with
7 us in kind of a two-way exchange, and so we're
8 testing that model.

9 But I've heard from several people
10 that are very knowledgeable in our state that, to
11 answer my question, I guess, about how long, but
12 it would be ten years or so before that really,
13 that exchange really happens. There's so many
14 steps that needs to happen.

15 DR. GALLIA: Did you say how long
16 would it take to see clinical level --

17 CHAIR PINCUS: Not how long. What
18 would it take? What structures and processes
19 would need to be put in place?

20 DR. GALLIA: One of the articles that
21 we produced out of the CHIPRA quality
22 demonstration grant was a comparison of the

1 clinical-level data and administrative data.

2 CHAIR PINCUS: Could you get closer to
3 the mic?

4 DR. GALLIA: So one of the things that
5 we did was a comparison of the clinic-level data
6 and the administrative data. So we can do it,
7 but it's a handoff. It's still a manual system,
8 it's not automatic. So it's not populated. But
9 we're moving towards establishing eMeasure
10 specifications within the state so they're more
11 real-time. It's still not what I would consider
12 clinic-level data in that, you know, it's a
13 snapshot. It's usually handed through different
14 systems, but it's close. And we can do that
15 essentially now.

16 CHAIR PINCUS: Because, I mean, what
17 I was saying, it doesn't necessarily require that
18 the state get all the data, but it could be done
19 in a federated way where it's collected through
20 the EA charge and then it's reported to the
21 state. You know, again, it's sort of one of
22 those perfect is the enemy of the good kind of

1 things where it may not necessarily need to cover
2 the whole population but could cover a
3 substantial portion of the population so that you
4 get a reasonable picture.

5 DR. GALLIA: Articulating that outcome
6 makes some providers and organizations extremely
7 nervous and particularly in the behavioral health
8 arena. The idea of not having more individual-
9 level controls about sharing information and
10 being able to do it --

11 CHAIR PINCUS: Yes, but it could be
12 totally de-identified data.

13 DR. GALLIA: But even so, it's still,
14 it just creates a lot of angst. And that's one
15 of the things in implementing our adult quality
16 grant in the behavioral health home. We had to
17 work through with practices and organizations
18 about sharing information, what was okay and what
19 wasn't and how to do it. I'm not disparaging the
20 notion. I just mean there's certain subjects and
21 topics that are going to create a lot more
22 anxiety, and that's one.

1 CHAIR PINCUS: I'm sort of pressing
2 the issue, but I'd be interested in hearing from
3 you guys. But why couldn't sort of each health
4 system be responsible for reporting data on, you
5 know, they would presumably have this information
6 in their electronic systems of, you know,
7 Medicaid participants, and they would also have
8 data on hypertension, on their blood pressure,
9 and report sort of aggregate information in a de-
10 identified way from their healthcare system.

11 DR. MATSUOKA: I would say it's
12 possible, and I've seen some states farther along
13 on this than others. I came from Maryland where
14 we had all of the hospitals sharing data with
15 each other but then also aggregating data up at
16 the state level.

17 And, of course, the meaningful use,
18 health IT funded dollars. You know, every state
19 has some participants, and states are essentially
20 sitting on a lot of data but haven't necessarily
21 built up the data infrastructure to do work with
22 it. And we've tried to put out informational

1 bulletins around how you can use 9010 match
2 dollars to build that out.

3 So I think there are ways to do it,
4 but it's very challenging. And I think the
5 states that have gone along the farthest have, to
6 Charles's point, identified the sort of business
7 case, whether it's the clinical business case or
8 the payment reform business case first, and then
9 the will was there to develop the data
10 infrastructure support, the delivery reform that
11 will make the business case for the people who
12 are supplying the data.

13 So I think there's an infrastructure
14 issue but then also making sure that the
15 infrastructure is linked always back to delivery
16 reform and payment reform is going to be
17 critical. So it's challenging. It's very
18 challenging. There are ways to get there.

19 The other, not low-hanging fruit but
20 something that I was very curious to hear Julia
21 talk about was data sitting in other federal
22 areas where, potentially, you know, the HIV viral

1 load measure is something that I think about all
2 the time because that's a HRSA measure. I think
3 about where health IT adoption rates have been
4 relatively healthy. That's at the FQHCs. I know
5 that HRSA and CDC has HIV linkage to care
6 initiatives that are state-wide in four states,
7 and it was curious to me to see -- and Maryland
8 was one of them -- it was curious for me to see
9 that none of the four states in those grants are
10 the four states that reported on the viral load
11 measure.

12 So I think, even at the federal level,
13 there are things that we might be able to do to
14 unlock data to get at some more of these outcome
15 measures so not necessarily getting to the HR
16 data.

17 CHAIR PINCUS: One of the technical
18 questions that I'm not sure who to address it to
19 is, you know, the issue of the stability of the
20 Medicaid population has come up several times.
21 How has the relative degree of stability changed
22 with Medicaid expansion? Has it gotten worse or

1 better?

2 DR. LILLIE-BLANTON: I would say that,
3 at least in those states that have expanded which
4 we're now at, we're about 31 states that have
5 expanded, the stability has improved because
6 those individuals, first of all, the range of
7 coverage is greater and the opportunities for
8 coverage are greater, so that even if someone no
9 longer qualifies under Medicaid, they can move
10 into the marketplace and there are opportunities
11 for someone, you know, for example if they're a
12 pregnant woman, there are some opportunities for
13 them to stay with their provider if they choose
14 to.

15 So I think we're moving in the right
16 direction in terms of stability of coverage. I
17 do think we're still challenged in those states
18 that have not expanded but in the others we are.

19 Interesting, too, I also wanted to
20 mention that, while there is a lot of concern
21 about stability of coverage, the few studies that
22 have been done, Urban Institute has done a few of
those studies, and it's not as bad as people

1 think. I mean, you know, it's somewhere between
2 9 to 11 months stability of coverage. But it's
3 still, you know, I think for those states that
4 haven't expanded coverage, it's still an issue.

5 DR. LOGAN: Yes. To add to that, we
6 recently looked at how long people are staying in
7 their managed care plans. And as I mentioned
8 earlier, about 90 percent of our members are in
9 managed care plans and about 70 percent of our
10 members stay in a managed care plan over a year-
11 long period. And they have the ability to change
12 every month. I know that's not in and out of
13 coverage, but that's at least stability within
14 managed care plans, which is important for our
15 plan to need to keep track of these measures.

16 CHAIR PINCUS: Other comments,
17 questions? Katie, do you have anything further?
18 Oh, Kim.

19 MEMBER DUNN: No, I'm all set. Thank
20 you.

21 DR. ELLIOT: When I was at the
22 Medicaid program, I was also responsible for the

1 EHR incentive program, so I did spend a lot of
2 time looking at the linkages and how we could
3 better utilize the EHR data going into the HIE,
4 and one of the biggest things that was really
5 important to work on and focus on was the ability
6 in the agreements that are made between providers
7 in the exchange and the health plans in the
8 exchange and even the state in the exchange was
9 just allowing the use of the data that's put in
10 for quality improvement purposes, and that kind
11 of takes some of the risk away of what you're
12 going to be using that data for, from a
13 government perspective.

14 And the other thing that really was a
15 complicating factor is that, even though all of
16 this money has been out there for incentives to
17 put EHRs in place, there's still a huge gap. And
18 the ability to use that data is still somewhat
19 limited because it's only a small fragment of
20 providers that are still reporting it, which
21 creates additional challenges and barriers.

22 And then the third thing I would say

1 about that is it's also looking at the measure
2 specifications and how that data in the exchange
3 is considered. Is it considered administrative
4 data? Is it considered chart data? And what's
5 acceptable from the owners of that measure set to
6 be able to use and how you would use that data
7 coming out of that. But it definitely, in the
8 next maybe ten years, should become a very viable
9 source of information because more and more
10 providers will, of course, be using EHRs and
11 those that aren't may be retiring.

12 CHAIR PINCUS: Thanks. So now it's
13 time to hear from any public comment.

14 OPERATOR: If you'd like to make a
15 public comment at this time, please press star 1
16 on your telephone keypad. Again, that's star 1
17 to make a public comment. And there are no
18 public comments.

19 CHAIR PINCUS: Anybody in the room
20 wish to make a public comment? So why don't we
21 break for lunch and come back at 1:00? Thank
22 you.

1 (Whereupon, the above-entitled matter
2 went off the record at 12:37 p.m. and resumed at
3 1:10 p.m.)

4 CHAIR PINCUS: So the main focus this
5 afternoon is going to be discussion of individual
6 measures and voting as well. We're going to be
7 going through a measure by measure review. We're
8 going to be asking - a number of people have made
9 recommendations for measures that should be
10 considered.

11 We'll also consider measures that,
12 because of low levels of reporting, or because
13 they're not functioning well, that we want to,
14 you know, potentially recommend removing from the
15 measure set.

16 And again, for the majority of them,
17 they really don't - we don't need to have a
18 detailed discussion of each and every measure for
19 the ones that are pretty much functioning well.
20 So Shaconna, do you want to begin to walk us
21 through this?

22 MS. GORHAM: Sure, so as Harold said,

1 we'll do a measure by measure review, and really,
2 the majority of the measures appear to be
3 functioning well, so we're only going to look at
4 the measures of - that had low levels of
5 reporting, if you will, what we can learn about
6 the measures that are a good fit for the program
7 based on the relatively few states that reported
8 on those measures. Next slide.

9 So I wanted to start by giving you
10 just how NQF chose - how we chose some of the
11 measures, the staff picks, and some of the
12 measures that you will be voting on. So the
13 measure selection criteria are developed to
14 assist MAP with identifying the characteristics
15 that are associated with an ideal measure set, so
16 either for public reporting or payment programs.

17 So these are consistent across all of
18 the MAP work groups, as well as the task forces.
19 They are not absolute rules, but they are meant
20 to provide general guidance on making the measure
21 selection decisions.

22 The central focus should be on the

1 selection of high quality measures that address
2 the National Quality Strategy, competing
3 priorities often needed to be weighted against
4 one another, and these measure selection criteria
5 can be used as a reference point when evaluating
6 the relative strengths and weakness of a program
7 measure set.

8 So in addition to using the measure
9 selection criteria, some other factors that will
10 influence your choice of measures, as discussed
11 and you heard a little earlier, we also like, we
12 favor endorsed measures when possible because of
13 the confidence in their scientific properties.

14 The ability to use administrative data
15 captures a reasonable broad segment of the
16 Medicaid population. Could the measures catalyze
17 quality improvement actions in an area with low
18 performance or recognize disparity, measures
19 designated for use at the health plan or
20 population level, and whether those measures are
21 aligned with other programs such as HEDIS, Joint
22 Commission's, Meaningful Use, and such.

1 So I'll just kind of briefly read the
2 seven points. So the program measure sets
3 adequately address each of the National Quality
4 Strategy three aims. The program measure set is
5 responsive to specific program goals and
6 requirement. Program measure set includes an
7 appropriate mix of measure types.

8 Program measure set enables the
9 measurement of person and family centered care
10 and services. The program measure set includes
11 consideration for healthcare disparities and
12 cultural competency, and the program measure set
13 promotes parsimony and alignment, so those are
14 the seven things that we really look at. Next
15 slide?

16 So potential reasons for removal from
17 the core set, so staff looked at reasons listed
18 on this slide while considering the measures
19 currently in the core set, specifically for
20 considering measures for potential removal, so
21 measures with consistently high levels of
22 performance, multiple years of very low numbers

1 of states reporting, change in clinical evidence,
2 or measures that do not provide actionable
3 information. Next slide?

4 So these are the decision categories,
5 and you actually have a handout in front of you
6 at each place. We wanted you all to have that.
7 We have three decision categories, support for
8 immediate use, conditional support, and do not
9 support.

10 MAP uses decision criteria, and again,
11 these are the same across all of the work in all
12 of the task forces. The decisions are used to
13 provide consistency and clear direction to HHS,
14 and then in addition to the decision category,
15 there is usually a statement providing the
16 rationale behind the decision.

17 So for this particular review, the two
18 categories that you would most likely use are
19 support, which would be used in the case of
20 measures that are ready for immediate use and
21 address and identify a gap, and then the
22 conditional support category is appropriate for

1 measures that are either still going through the
2 NQF endorsement process and are pending
3 endorsement, or there is something that needs to
4 be changed or addressed by either the measure
5 steward or working with CMS to confirm the
6 feasibility before it would garner a full
7 support. MAP can express this condition as open
8 ended.

9 So here's how to think about it.
10 Support will be a green light, so we're signaling
11 that CMS should move forward or we recommend that
12 CMS move forward with the measure. Conditional
13 support would be a yellow light, so we're
14 signaling to CMS that we like the measure, but
15 maybe we need to hold up for a little while
16 because maybe NQF endorsement is needed and so
17 forth. Next slide. Okay, so you saw this - yes?

18 MEMBER PELLEGRINI: Just a quick
19 process question. We usually meet in December,
20 right, to make recommendations for the next year?
21 Is that -

22 CHAIR PINCUS: That's for the overall

1 MAP.

2 MEMBER PELLEGRINI: Right.

3 CHAIR PINCUS: This is on a different
4 time frame.

5 MEMBER PELLEGRINI: Okay, thank you.
6 Sorry, I'm getting my committees mixed up.

7 MS. GORHAM: Okay, so you saw this
8 slide earlier, and this represents the four
9 measures with zero to five states reporting. So
10 we want to dive a little deeper into the measures
11 just to see just some things about the measure
12 and whether or not you all wish to consider
13 removal or the measures are fine. So we'll go to
14 the next measure, I mean, I'm sorry, the next
15 slide.

16 And so we'll look at HIV viral load
17 suppression. This was adapted into the Adult
18 Core Set. So stratified and reported for two age
19 groups, 18 and 64, and 65 and older. There were
20 six TA requests submitted by four states. So
21 those topics included use of the SNOMED codes,
22 the numerator definition, clarification on

1 measurement period, continuous enrollment
2 criteria, and allowable gaps in adoption of HVL
3 for fiscal year 2014 reporting.

4 We also have reasons for not reporting
5 the measure. They include 30 states reported
6 reasons for not reporting the measure. The most
7 common reason was that data were not available
8 because of the requirement for medical record
9 review.

10 So the number of states reporting the
11 HIV viral load suppression measure in 2014 was
12 three. The measure was not a part of the core
13 set in FY 2013. In FY 2014, two states reported
14 the measure using the Adult Core Set
15 specifications which are based on HRSA's 2014
16 specifications, so this is to give you a little
17 bit more information about the measure. Okay,
18 next slide?

19 The PC-03 measure is a part of a set
20 of five nationally implemented measures that
21 address perinatal care. The measure was
22 originally specified for reporting at the

1 hospital level. No TA requests were submitted
2 for this measure. But reasons for not reporting
3 the measure, 31 states reported reasons for not
4 reporting the measure. The most common reason
5 was the data were not available due to
6 requirement for medical record review.

7 So the number of states reporting the
8 PC-03 measure decreased from five states in FY
9 2013 to three states in FY 2014. Six states
10 reported the measure at least once during the two
11 years. Okay, next slide?

12 So care transition, transition record
13 transmitted to health care professionals, the
14 number of states reporting the care transition
15 timely transmission of transition record measure
16 remain unchanged from four states reporting in
17 2013 to 2014. Six states reported the measure at
18 least once during the two years.

19 The measure was originally specified
20 for reporting at the inpatient provider level.
21 Two TA requests submitted by one state. Topics
22 include calculation of denominator, chart review

1 process, and exclusion criteria.

2 Reasons for not reporting the measure,
3 30 states reported reasons for not reporting the
4 measure. The most common reason was that data
5 were not available because medical record review
6 and data linkage are required.

7 So among states reporting the measure
8 using the 2014 Adult Core Set specifications,
9 median rate for ages 18 to 64 was 59.4, and the
10 median rate for ages 65 and older was 40.5. Next
11 slide?

12 Measure 0418, screening for clinical
13 depression and follow-up plan. The number of
14 states reporting the screening for clinical
15 depression and follow-up plan measure remain
16 unchanged with five states reporting in 2013 and
17 2014. Seven states reported the measure at least
18 once during the two years.

19 In the fiscal year 2014, four states
20 reported the measure using the Adult Core Set
21 specifications which were based on CMS's 2014
22 specifications. Two states used the Adult Core

1 Set specifications for both years. The measure
2 was originally specified for reporting at the
3 provider level, and this measure is aligned with
4 PQRS, CMS QIP, Home Health Core Set, and MSSP.

5 Reasons for not reporting the measure,
6 29 states reported reasons for not reporting the
7 measure. The most common reason was that data
8 was not easily accessible. Next slide?

9 Okay, so those, I just wanted to give
10 you more information about those measures so that
11 you had a broader picture. But based on staff
12 review, none of the measures currently being
13 reported were identified for potential removal.
14 We thought that more experience and data points
15 were needed, but I will turn it over to Harold
16 for discussion.

17 CHAIR PINCUS: So these are the
18 measures selected because, you know, primarily on
19 the basis of - for discussion, primarily on the
20 basis of the fact that states were not reporting
21 it, and it sounds like in each case, it was
22 because of the difficulty in getting data from

1 the medical record.

2 And so the question is do we think we
3 should remove these measures because of that
4 barrier, or should they be retained to see if
5 states over time are able to begin to develop
6 methodologies for reporting that? So we'll take
7 nominations from the floor for any of these
8 measures that might be nominated to be removed.
9 Cindy?

10 MEMBER PELLEGRINI: I just have a
11 question here. It seems to me like data not
12 available is a vague statement, and so I was
13 wondering if CMS can help us understand. Does
14 that kind of mean the same thing from one measure
15 to another, whether it's this group or others, or
16 is that really kind of four different issues that
17 we're putting in the same category?

18 DR. LILLIE-BLANTON: I would think
19 it's multiple issues. So for example, early
20 elected deliveries, it's about data that is
21 needed from vital records as well as from a
22 hospital reporting system, whereas of course,

1 care transition is about data not available for
2 information that's largely at a hospital.

3 So the key thing about all of these
4 measures is that they're not strictly - I would -
5 I mean, I'd have to - I'm not looking carefully
6 at them, but none of them are claims measures.

7 CHAIR PINCUS: Right.

8 DR. LILLIE-BLANTON: So the data's got
9 to come from a source other than claims.

10 MEMBER PELLEGRINI: So this is a case
11 of most likely multiple systems that are needed
12 to be communicating with each other that just
13 can't for one reason or another, but it's not
14 like the same two systems over and over, okay.

15 CHAIR PINCUS: Well, it is in the
16 sense that it's the medical record, you know,
17 requires that somebody actually, you know, you
18 have to hire somebody to go through the medical
19 record and find the data, and so that's - and
20 it's a limitation that's at the state level to
21 get that reporting.

22 One question I would have is are any

1 of the other measures that were more frequently
2 reported also require that kind of effort?
3 Because it seems to me that controlled
4 hypertension would also require that, and I'm not
5 sure how many states are reporting that measure,
6 and how do they do it?

7 MEMBER ANDREWS: Just a question on
8 that. Isn't that - there are codes, I believe,
9 for controlled hypertension or controlled blood
10 pressure that can be used by the provider at the
11 submission of the claim that can indicate that
12 blood pressure is under control.

13 CHAIR PINCUS: Is that how it's
14 reported?

15 MEMBER ANDREWS: That's how we try to
16 collect it if providers usually work with that.

17 CHAIR PINCUS: Julia, maybe you could
18 help us with that?

19 DR. LOGAN: So the difference with the
20 hypertension measure is that, well, it's a very
21 high priority for many, many states. It's also -
22 it is clinical data, but it's clinical data

1 through, you know, a traditional medical EMR, not
2 through a mental health EMR or a hospital where
3 it's more difficult to obtain. So it's clinical
4 data, but easier to obtain.

5 MEMBER CALMUS: So this is kind of a
6 follow up to what Karen was talking about
7 earlier, as well as kind of Cindy's question. Of
8 these measures, it seems that there's a crossover
9 in other places where they're being required.
10 Have we seen it kind of reach the critical mass
11 in those other areas?

12 The viral load I wasn't as familiar
13 with, but with the care transition, I know that's
14 a big focus on the Medicare side. So I guess my
15 question is I don't know how well entrenched it
16 is on the Medicare side quite yet. I know it's
17 something that's really being pushed as a part of
18 MIPS.

19 So the question is does it just need
20 to reach a critical mass in another area before
21 they're like, "Oh, we're already recording this
22 data," and that infrastructure is there on the

1 provider side to get that information?

2 DR. MATSUOKA: I think that will
3 definitely help, but then there becomes the issue
4 of the aggregation issue as well, so all of those
5 are going to be collected at the provider level,
6 the ECL level, or whatever the level is, and then
7 how does that roll up to a state level measure?

8 So it will be a two-step issue, but I
9 think you're right, that I think that's what the
10 CCSQ, AHIP, AAP effort is trying to do is trying
11 to get alignment around a core set of measures at
12 the provider level, critical mass around that,
13 and then figure out how that can roll up to
14 higher levels of aggregation.

15 MEMBER ANDREWS: Yeah, I'm curious to
16 understand the staff's recommendation when more
17 experience and data points are needed. I mean,
18 the basic issue here is the fact that you need
19 the medical record to retrieve that information
20 which increases the burden on the system, on the
21 providers, etcetera. So what exactly additional
22 data points are needed, that the staff thought is

1 needed before these measures should be removed?

2 MS. MUKHERJEE: I think the thinking
3 was that some of these measures have not been
4 around a long time, so states might not have had
5 the opportunity to implement and gather all of
6 the data, or maybe proxy data, or even try to
7 implement it.

8 And so to give them a year and then be
9 like, okay, four states only submitted data, and
10 these core sets on top of that are fairly new, so
11 to give them some time. Like if this was year
12 eight and they hadn't submitted data and there
13 were still four states only, it's reached a
14 tipping point where you can say, "Okay, you've
15 had eight years."

16 "Whether you're building
17 infrastructure, or you're getting sort of your
18 providers on board, or making it a priority,
19 you've had enough time to hit all of the policy,
20 the infrastructure, the burden, you know, all of
21 the sort of steps that might be used as sort of
22 rationale."

1 But being that these measures, at
2 least some of them, have not been around for long
3 at all, I think on the staff side, it's difficult
4 for us to just look at the data we get and be
5 like, "Okay, this should be up for removal,"
6 because we would be doing a disservice to the
7 state not giving them the opportunity to try and
8 then not be able to do that, so data points not
9 in specific data points, but data - longitudinal
10 data, and maybe proxy data.

11 CHAIR PINCUS: Ann?

12 DR. SULLIVAN: I just have a question.
13 If these - there are some states that are
14 reporting. Do we - I mean, is it promulgated how
15 they do it to the other states? Do they have to
16 ask for technical assistance or do we kind of say
17 to them, you know, "These are possibilities?"

18 I mean, do you give - if you're going
19 to leave them there for a while to give them -
20 spread the information about how maybe some
21 states are doing it to some of the other states?
22 I mean, does that happen or - I mean, does that

1 happen like on a regular basis or just if I ask
2 from the state?

3 DR. MATSUOKA: So, it depends. So
4 definitely any state that chooses to ask for
5 technical assistance, we provide it to them, and
6 then in some of these affinity groups and health
7 initiatives that you'll be hearing about
8 tomorrow, we do provide concerted technical
9 assistance around how to report the measure, and
10 then through some of these prior grants, that was
11 a big focus of the grant program is technical
12 assistance around reporting the measure.

13 So I think the answer is for selected
14 measure - any states that asks for assistance, we
15 provide, but the concerted sort of proactive
16 outreach to states typically happens around some
17 kind of focus area, whether it's an affinity
18 group, like we have the antipsychotic for kids
19 affinity group that's just kicked off.

20 A core piece of the work that we do
21 with those states is going to be around, "If you
22 want to measure this - or if you want to report

1 on this measure, here is some help in how to do
2 that," and we do the same thing for the maternal
3 and infant health developmental measures that
4 you'll be hearing about tomorrow, as well as the
5 sealant measure for oral health.

6 DR. SULLIVAN: I just think it might
7 be a little early to kind of not see if states
8 will figure out a way to do this, partly because
9 many of the things we're thinking of in terms of
10 outcomes, at least until medical records get a
11 lot more robust, are going to require something
12 like this.

13 So I think to just start to let them
14 go just because they're not claims basically, or
15 very easy, might not be the best move. I mean,
16 on the other hand, I agree if it goes for a while
17 and nobody picks them up, it might be best to
18 just let them go, but I'd give them a little more
19 time.

20 MEMBER DUNN: Hi, this is Katie,
21 excuse me, this is Katie. One of the things, or
22 a couple of thoughts that came to mind is

1 understanding that these measures represent
2 important issues.

3 You know, our - have any of these
4 measures been mapped to perhaps other measures
5 that the states are using to monitor the outcome
6 that we're trying to assess through these
7 measures, and if so, is there more value in going
8 with the measures that we know they can do, or
9 are these so important that they absolutely have
10 to be assessed at a population level, which is
11 where we're looking at this, not on - not on an
12 individual level, nor at an individual program or
13 funding source level?

14 And I think I agree with, I think it
15 was Ann who said, if you really want to build
16 capacity here, I think that there is work that is
17 going to need to be done to make that happen, but
18 I would start by looking at if these are really
19 important issues, explaining why they need to be
20 monitored, how to go about it, and make sure that
21 there aren't other measures that perhaps the
22 states are saying, "These make more sense to me."

1 CHAIR PINCUS: Kim?

2 DR. ELLIOT: From a state perspective,
3 you really do have to weigh where you put your
4 resources if you're going to do chart review. So
5 when I look at some of the measures, when I look
6 at the prenatal one, for example, that one there,
7 if a baby was born premature, we're already going
8 to do a quality of care investigation and make
9 sure that all of the care and service delivery
10 was appropriate, and our health plans, of course,
11 would as well, so that wouldn't necessarily rise
12 unless we saw a lot of issues with the care and
13 service delivery to the level of population
14 performance measure or even performance
15 improvement project. So we weigh things and
16 balance them that way because there's such a
17 limited resource to go out and do the chart
18 reviews.

19 And for one like the viral load, we're
20 looking at population size and adverse outcomes
21 in determining whether there's an issue before we
22 put it on as a continual performance measure in a

1 contract with a managed care organization.

2 CHAIR PINCUS: Cindy?

3 MEMBER PELLEGRINI: So I'm really
4 fixating on this idea that some of this data is
5 available in other data sets. I'm thinking about
6 the perinatal measures that are on some of these
7 lists.

8 You know, antenatal corticosteroids,
9 that information is in the 2003 birth
10 certificate, which I know the birth certificate
11 data has some issues, and there is some lag time
12 in it, but it's there. It just would need to be
13 crosswalked, right, and matched against patient
14 records.

15 Similarly, early elective deliveries
16 are being reported as part of the hospital IQR or
17 the Medicare IQR. So do you all get many
18 inquiries about how to use these data sets
19 together, or are states just kind of not even
20 there yet thinking about it?

21 DR. MATSUOKA: Marsha can talk more
22 about the experience that we've had with data

1 linkage. We have provided some outreach to
2 states on how to do data linkage. It turns out
3 to be less, I think, of a technological barrier
4 and more of a, I think, a cultural barrier of a
5 willingness to share -

6 CHAIR PINCUS: You need to get closer.
7 You can bring the mic closer to you.

8 DR. MATSUOKA: So we do help states
9 with data linkage, and we look specifically at
10 vitals and claims for exactly this issue. And I
11 think states have run into what seems like a
12 fairly straightforward fix. It turns out to be
13 fairly complicated in practice and for a number
14 of different reasons.

15 Some technological, but actually in
16 our experience, it turns out to be much more
17 cultural, political, little p political in terms
18 of how do you draw up the data use agreement so
19 that, you know, both the data giver and the data
20 receiver are comfortable with it, you know,
21 things of that nature beyond just the technology
22 aspects of data linkage and making sure it's done

1 in a valid, reliable way.

2 So the short answer is yes, we are
3 working with states to do this, and I want to say
4 it's - how many states? So we're making some
5 headway, and efforts continue, but it's not, you
6 know, all pervasive.

7 CHAIR PINCUS: Charles?

8 DR. GALLIA: So I wanted to talk about
9 the measures and I'm going to speculate a little
10 bit by the uptake based on some of the decision
11 making that we did internally about whether or
12 not to pursue some of the measures. One of them
13 was this one, and part of it is we're going to
14 have to explain it to somebody.

15 And it's really easy to explain
16 depression screening or even the PQIs, as
17 complicated as they are, because just the way
18 that their topic is labeled. This one is more
19 complicated and that means that you have to have
20 somebody -

21 CHAIR PINCUS: When you say this one,
22 which one?

1 DR. GALLIA: The HIV, the viral load.
2 Combining the data set component isn't really, I
3 mean, we did the early elective delivery and we
4 did use the C-section, and we combined with vital
5 records.

6 Combining data sets isn't too
7 complicated, but it requires a staff that's
8 dedicated to that, that can execute it, and
9 follow it through, and do the project management
10 that's necessary on both sides, public health
11 usually, so those partnerships.

12 Even though we have some automatic
13 data feeds between the two systems, it still
14 requires a fixed step to do a specific project.
15 That means that it has to have some authorization
16 at some level. So if it's exploratory, then it's
17 unlikely to go forward, but if it's something
18 that's maybe required, then it might be more
19 likely to happen.

20 So my point bottom line is sometimes
21 the title itself can be an impediment about
22 whether or not a state even considers looking at

1 the details behind what it is and what it means.

2 CHAIR PINCUS: So coming back to the
3 central question, is there anybody that would
4 make a motion to remove one of these measures?
5 It sounds like no. Okay, so we're not going to
6 be recommending removing one of these measures,
7 but I think there is a note of caution that's
8 been expressed that we should not let this go on
9 for too long, that it is one -

10 The issue, I think, that Kim raised,
11 is, you know, there is a certain - and, you know,
12 in some ways reinforced by Charles, there is a
13 certain level of resources that is required to
14 sort of, to reach, to be able to gather the data
15 for these measures, and that, you know, in some
16 ways, it's that the states are voting with their
17 feet, but in some ways it also may be waiting for
18 some technological advance or capacity advance
19 for them to be able to do that.

20 And so we're, you know, so we're
21 holding off on suggesting removal, seeing if that
22 hypothesis that might be true, that it's an

1 advance that will be able to reach a kind of
2 critical mass to be able to capture these kind of
3 data. Does that seem like a summary of the
4 discussion? Karen?

5 DR. MATSUOKA: So I'm curious, so I
6 mentioned earlier that the HIV viral load measure
7 that we use is a HRSA measure, and that HRSA is
8 ahead of the game in terms of the number of
9 community health centers that have the capacity
10 to generate this data, and to a similar extent,
11 our public health partners who administer the
12 Ryan White Program have this data, and so just
13 like we do for the CLABSI measure.

14 Is there a desire or is there enough
15 overlap with regard to the Medicaid populations
16 that are served and will be in these other data
17 sets to say, maybe not retire the measure, but is
18 it okay that we use the data source being HRSA,
19 you know, what we get out of the HRSA data set or
20 out of the Ryan White data set? Is that another
21 way to look at it if we can parse it out state by
22 state?

1 Is that another way to get at viral
2 load, not in a perfect way, and we won't
3 necessarily be able to parse it out by Medicaid
4 and non-Medicaid, but similar to what we've done
5 with some other of the measures like the CLABSI,
6 is that something that would be desirable and
7 helpful at the state level to be able to see that
8 kind of comparative information?

9 CHAIR PINCUS: I mean, just from my
10 perspective, just thinking about that, I think
11 that it depends to what purpose you're going to
12 use it. So that, you know, looking at overall
13 population, it's kind of like a dipstick into the
14 population of getting it from the people that use
15 FQHCs.

16 But the real question is if you did it
17 that way, is it something that states will
18 actually use in a more generalized way to improve
19 their processes? And I don't know the answer to
20 that. Kim?

21 DR. ELLIOT: Well, we did look at
22 linking with vital statistics, and some states

1 have had good success. What we found with
2 linking with some of these data sources is that
3 they were more than willing to have us, as a
4 Medicaid program, dump all of our data into their
5 system. They weren't really willing to share
6 just the very couple of pieces of information
7 that we needed to be able to do some of the
8 measurement on the prenatal side.

9 But linking with other data sources
10 such as Ryan White and some of the others would
11 be an excellent way, but an easier way probably
12 would be just to try and collect the data
13 directly from the labs. The labs do generate
14 that information to health plans and they could
15 put in their requirements and scope of the
16 contract to get the -

17 CHAIR PINCUS: Yeah, I mean, it sounds
18 doable.

19 DR. ELLIOT: Yeah, it's doable.

20 CHAIR PINCUS: So, but I think it
21 still stands that we're not going to be
22 recommending the removal of any of these

1 measures. Okay, so why don't we move onto
2 measures that have been proposed? Oh, yes,
3 actually we should introduce Sue, and David, and
4 Lisa, who have joined us. Do you guys want to
5 introduce yourselves?

6 MR. HUNT: Sorry, I was running late
7 this morning. I'm David Hunt. I'm with the
8 Office of the National Coordinator for Health IT,
9 and you can kind of think of me as the new
10 downscale version of Kevin Larsen.

11 DR. PATTON: Lisa Patton from SAMHSA.
12 I'm the division director for evaluation,
13 quality, and analysis within the Center for
14 Behavioral Health Statistics and Quality. I'm
15 glad to be here.

16 MEMBER KENDIG: Hi, I'm Sue Kendig,
17 and I am a women's health nurse practitioner and
18 attorney from St. Louis. I'm here representing
19 the American Academy of Nurse Practitioners.
20 Thank you.

21 CHAIR PINCUS: Welcome, and thanks, so

22 -

1 MS. MUKHERJEE: Do you mind disclosing
2 your DOI?

3 DR. WILSON: Yes, so it's just what
4 they did on the webinar. It's a verbal
5 disclosure of any conflicts of interest that you
6 might have.

7 Thank you.

8 CHAIR PINCUS: Okay, so, Shaconna,
9 should we move onto measures that have been
10 proposed for --

11 MS. GORHAM: So although my slide says
12 opportunity for public comment and break, we are
13 moving ahead of schedule, so we'll skip this and
14 come back to break and public comment a little
15 later. Next slide.

16 Okay, so measure by measure review,
17 potential gap filling measures for addition. If
18 you all remember, a number of you submitted task
19 force recommendations for measures to fill gaps,
20 so we'll review the gap areas we went over during
21 the web meeting, and then we'll get into the
22 actual staff recommendation or staff pick, if you

1 will, and then task force recommendations or
2 picks. Next slide.

3 So before you, you have the
4 recommendations for high priority gap areas. So
5 at the end of each meeting, we'll ask for gap
6 areas, ask whether or not you think a gap area
7 should be removed because we have addressed it,
8 or if there are additional recommendations for
9 gap areas.

10 The MAP recommended that the measure
11 set be strengthened over a long term by the
12 addition of measures in the key areas that you
13 see before you. Gap areas are identified from
14 state feedback, review of the 2014 reporting, and
15 data on prevalent conditions affecting the adult
16 Medicaid population.

17 Again, some areas recommended in 2015
18 as well as 2014 are on your slides, and that
19 asterisk denotes the newly identified gap areas.
20 Next slide? So this is a continuation of that
21 list. So as you can see, MAP identified quite a
22 few gap areas over 2014 and 2015. Next slide?

1 Again, just to remind you before we
2 get into voting your decision categories. So the
3 decision categories that we will mainly focus on
4 are support and conditional support.

5 Okay, so in your very, very huge Excel
6 spreadsheet that I sent you all, we identified
7 measures in the particular gap areas, so
8 perinatal and maternity care which we will
9 discuss tomorrow, health related quality of life,
10 we identified eight measures, behavioral health
11 and substance use, we identified 24 measures,
12 home and community-based services, we identified
13 one measure, and engagement and activation of
14 care, we identified two measures, and then
15 finally work force, we identified one measure.
16 Next slide?

17 Okay, so the staff pick or our
18 recommendation for strengthening the Adult Core
19 Set was Measure 2152, preventive care and
20 screening, unhealthy alcohol use screening and
21 brief counseling, and of course that would
22 address the behavioral health and substance use

1 gap area.

2 Feel free to open up your Excel sheet
3 if you want to get more information about the
4 measures. I'll give you a brief overview and
5 just highlight some areas, but if you want to get
6 a full look at the measure, you can definitely
7 access your Excel sheet.

8 So this measure addresses the
9 substance abuse gap area. The measure steward is
10 AMA PCPI. It is an NQF endorsed measure. This
11 measure includes patients who are screened at
12 least once within the last 24 months for
13 unhealthy alcohol use using a systematic
14 screening method, and who received brief
15 counseling if identified as an unhealthy alcohol
16 user.

17 It is a process clinical level
18 measure. The data source is electronic clinical
19 data. There are a number of definitions included
20 in the numerator statement that are not included
21 on your slide because we couldn't fit them, but
22 they are in the Excel spreadsheet.

1 And the rationale for this staff pick
2 is to foster the principles of care coordination
3 through screening and then counseling. So
4 screening without follow up services such as
5 counseling is not as beneficial since it defeats
6 the purpose of identifying those at risk. This
7 measure also looks at access as well as covers
8 behavioral health. So that is one measure for
9 your consideration.

10 MS. MUKHERJEE: The yellow one is the
11 staff pick?

12 MS. GORHAM: Yes, on your Excel sheet,
13 yes, the yellow. The measure highlighted in
14 yellow are staff pick - is a staff pick.

15 MS. MUKHERJEE: Is there just one
16 staff pick in each area?

17 MS. GORHAM: We only chose one staff
18 pick total. No, just total, exactly.

19 MS. MUKHERJEE: On each tab, is there
20 one?

21 MS. GORHAM: No, so the only staff
22 pick for the Adult Core Set -

1 MS. MUKHERJEE: Is this one?

2 MS. GORHAM: - is that one, and that
3 falls under behavioral health and substance
4 abuse.

5 CHAIR PINCUS: There are others that
6 have been recommended by members.

7 MS. MUKHERJEE: Right.

8 MS. GORHAM: Yes.

9 MS. MUKHERJEE: Also in that Excel
10 tab, there are colors which say that in 2014, and
11 '15, they were also recommended, so this Excel
12 not only has our staff pick this year as well as
13 our committee picks, but also recommendations
14 from previous MAP work.

15 MS. GORHAM: And we'll get to that a
16 little later as we go through.

17 DR. LILLIE-BLANTON: Can you tell us
18 more about the decision making for why - how one
19 measure versus - for that one area? So for
20 example, long term services and supports is one
21 of the gap areas, so how was the decision made
22 that a measure was not recommended for that area?

1 MS. GORHAM: So what we wanted to do,
2 we wanted to one, pick the measure or measures,
3 if you will, that we thought was a good fit based
4 on the measure selection criteria, and we didn't
5 want to overwhelm with a lot of measures. I
6 think last year we maybe did two staff picks. So
7 we try not to choose too many measures, and
8 because behavioral health and substance use was a
9 huge topic last year, we chose that measure
10 versus another area.

11 But not to say that measures in the
12 other areas are not as important, but we wanted
13 to focus our choices, narrow them down, follow
14 the measure selection criteria, and then just
15 give one staff pick knowing that the task force
16 members also had the opportunity to recommend,
17 and we received five recommendations from staff
18 from the task force members in other areas as
19 well.

20 MS. MUKHERJEE: Also for the long term
21 care, we know the HCDS project is looking at a
22 lot of those measures, and we wanted to sort of

1 wait for that project to sort of bring so that we
2 can tie into other NQF efforts and really use
3 their knowledge and what they find to inform
4 future MAP work.

5 DR. SULLIVAN: Yeah, I think that last
6 year there was a lot of talk about the substance
7 use indicators, measures, and I think the opioid
8 one was the one that went forward, but I think
9 there was a lot of discussion about the
10 importance of looking at alcohol.

11 And just especially I think in the
12 Medicaid population where it can be a very big
13 issue both on the medical side as well as the
14 behavioral health side, lots of medical problems
15 are caused by chronic alcoholism.

16 So I think this in particular is one
17 that is particularly good because it requires not
18 just that you screen, but that you go to the next
19 step which I think is important because a lot of
20 our measures are screening measures and then you
21 don't know what happens.

22 So this one, I think, is better

1 because it's screening plus that you get some
2 kind of outcome. And certainly the actual
3 detection of alcohol use is extremely low. I
4 mean, they kind of know it's there, but it's not
5 screened for. It's not detected, and the long
6 term consequences are bad.

7 So I think that was a lot of the
8 discussion last year about the importance of this
9 kind of measures, which is probably, I'm
10 assuming, why the staff and some put it on for
11 this year. You didn't want to overload with
12 substance abuse last year.

13 MS. MUKHERJEE: Exactly, well said.

14 CHAIR PINCUS: I was wondering, Lisa,
15 do you have any comments? I know that you've
16 looked at these kinds of measures, and if you -
17 from SAMHSA's point of view?

18 DR. PATTON: Yeah, 2052 has been a
19 core measure for SAMHSA with our National
20 Behavioral Health Quality Framework since at
21 least 2013, and we have really worked to, you
22 know, get word out to the field and educate

1 around the use of this measure, and we've had a
2 lot of interest in it from broad stakeholders,
3 and a lot of support from CMS and others around
4 using this.

5 And so I think it is a measure that
6 is, it's utilized a lot, and I think it's also,
7 you know, when we kind of talk about, you know,
8 more palatable for a wider audience, this one
9 seems to hit all of the marks for that. People
10 feel comfortable, I think, implementing it more
11 so than some of the other measures that we've
12 looked at in substance abuse and behavioral
13 health.

14 CHAIR PINCUS: Marsha?

15 DR. LILLIE-BLANTON: So I see that
16 it's - the data source is electronic clinical
17 data. Can you give us any information on
18 reporting using the electronic clinical data
19 sources?

20 DR. PATTON: Yeah, I'm not familiar
21 with where the reporting is on that. I know
22 that, you know, we're constantly looking at the

1 measure. We're working with AMA PCPI on that
2 measure ensuring that it stays updated and that
3 it is more broadly implemented with the e-specs
4 and so forth. So I know my colleagues at the
5 Center for Substance Abuse Treatment are in
6 frequent communication with AMA around that and
7 other similar measures.

8 CHAIR PINCUS: Other comments,
9 Michael?

10 MEMBER SHA: You know, I don't doubt
11 the importance, value, in fact, probably broad
12 acceptance of this type of measure. I suspect
13 it's going to probably fall in the same line as
14 the depression screening. The data is not going
15 to be available in claims databases, therefore
16 it's not going to be widely reported.

17 You know, having said that, you know,
18 I'm not necessarily opposed to supported this
19 measure because of its importance. You know, at
20 some point in the future, we may be able to
21 develop data sources to have this measure
22 reported, but I suspect it's probably going to

1 follow the same line as the clinical depression
2 screening.

3 CHAIR PINCUS: I have a comment or
4 two. One is that I think, if I'm not mistaken,
5 this has been part of meaningful use so that
6 there has been -

7 DR. PATTON: Yes, that's right.

8 CHAIR PINCUS: - that capacity. And
9 also, can one file a claim for providing the
10 screening and counseling?

11 DR. PATTON: Yeah, now we can. Yeah,
12 now the providers can.

13 CHAIR PINCUS: So there is the ability
14 to do that I think now. The other thing that, I
15 mean, just to speak in favor of it, is that, you
16 know, there already is the initiation and
17 engagement measure, and that is a reasonable
18 measure because it basically is looking at
19 whether people who once identified with an
20 alcohol or substance abuse problem, whether they
21 get - sort of initiated and engaged in care,
22 meaning that they've had one or two follow ups

1 over a sort of specified period of time.

2 The problem with that measure is that
3 depending upon whether you do screening or not,
4 the performance of that measure is highly
5 sensitive to how people are identified. So in
6 places where you're not screened, the people that
7 come in tend to be highly motivated, and those
8 places get - that population basically, you know,
9 has higher performance as compared to a place
10 where people are screened and get identified, and
11 they may be less highly motivated, and therefore
12 they're less likely to follow up.

13 So it kind of, you know, doesn't quite
14 disincentivize, but it, you know, if you screen,
15 you do worse on the initiation and engagement
16 measure. This would sort of level the playing
17 field, you know, by having it as a screening
18 measure. So in some ways, in addition to being a
19 performance measure, it's also a balancing
20 measure.

21 MEMBER DUNN: This is Katie. If I
22 may, although there are mandatory, and of course

1 optional Medicaid benefits that the state
2 Medicaid program has to provide, there is no
3 mandatory list of codes or billing codes that
4 must be turned on within any one state's Medicaid
5 program.

6 And although it might make total sense
7 to all of you sitting around the table that the
8 appropriate code for a screening for substance
9 use would be a code that was active and was
10 paying within a Medicaid program, I don't think
11 we can assume that that in fact is the case
12 because it is left up to the individual states.

13 The other part is states are being,
14 state Medicaid programs are being asked to move
15 into different alternative payment methodologies.
16 There are a lot of questions coming up from
17 providers that are saying, "Well, if you're going
18 to pay me a bundled rate, then why do I still
19 have to submit to you the individual billing
20 codes?" And we are trying to explain why they
21 still need to do it, but we are meeting some
22 resistance to it.

1 MEMBER CALMUS: I just wanted to, you
2 know, obviously this one is very important to
3 rural areas. We're seeing, you know, decreased
4 life expectancy as a result of alcohol use,
5 particularly in rural women. I guess my question
6 is the brief counseling and how much that
7 entails, and how much that then gets intertwined
8 with access issues?

9 Because we know that while there's a
10 lot of substance abuse problems in rural, there's
11 not a lot of resources for that follow up care.
12 So I guess my question is how do we, you know,
13 separate those issues without having to
14 necessarily separate those issues and make sure
15 that it's not just a box checking exercise?
16 Which, you know, the depression screen was kind
17 of talked about in the same -

18 CHAIR PINCUS: Lisa?

19 DR. PATTON: Yes, so I think that's a
20 very good point, and one of the activities that
21 we are undertaking at SAMHSA and have been for a
22 while, but more so now, is to really provide that

1 kind of technical assistance and training so that
2 there is that linkage between screening and brief
3 counseling and what's appropriate.

4 We're also looking at the behavioral
5 health workforce shortages and how that impacts
6 on the ability to provide any needed referrals,
7 where those shortages are, and, you know,
8 different ways to approach that with telehealth
9 and so forth.

10 So we're really trying to look at the
11 big picture of how these measures get implemented
12 and actually used in the field, and including the
13 reimbursement issues that were raised by Katie.
14 So, you know, we're working with CMS on that,
15 really looking at ensuring that those codes do
16 get turned on and that they are - that we see the
17 measure, you know, particular core measures
18 across programming where possible.

19 There's also an HHS wide effort
20 looking at core measures among different
21 programs, NCMS, SAMHSA, HRSA, and so forth, and
22 more information will be available about that

1 going forward, but it also includes 2152 as a key
2 measure for that effort.

3 CHAIR PINCUS: Other comments for or
4 against? Okay, so I guess we're ready to vote.
5 We're not?

6 MS. GORHAM: No, so we'll go through
7 all of the measures including the task force
8 recommendations, and then we'll vote.

9 I think they're going to be on the
10 screen, yes.

11 CHAIR PINCUS: Oh, so we're not voting
12 after each one?

13 MS. GORHAM: No.

14 CHAIR PINCUS: Okay.

15 MS. GORHAM: So the next slide? Okay,
16 so the measures you have before you are those the
17 task force members recommended. So there are
18 five measures and we'll go through them
19 individually, so the first measure 0055
20 comprehensive diabetes care eye exam performed.

21 This measure includes patients 18 to
22 75 with diabetes type 1 or type 2 who have had an

1 eye exam performed. The measure steward is NCQA.
2 It is an NQF endorsed measure. It is a process
3 measure.

4 The data source is administrative
5 claims, electronic clinical data, paper medical
6 records, electronic clinical data pharmacy. So
7 the task force member recommended this measure
8 because it is a composite measure for diabetes.
9 The measure can facilitate the interpretation of
10 quality data.

11 The task force member acknowledges
12 that diabetes may not be an ideal specific
13 ambulatory condition to consider for a composite
14 measure given the need for lab data which may not
15 be available for many Medicaid programs, but
16 there are a few ambulatory clinical conditions
17 with available NQF composite measures.

18 And I'm representing or I'm speaking
19 for a task force member as they emailed me their
20 comments, but feel free to weigh in as I go
21 through the measures if I misstate something.

22 Okay, so our next -

1 CHAIR PINCUS: Yes, I think we should
2 have questions or, you know, people speaking in
3 favor or against as we discuss each measure.

4 MS. MUKHERJEE: And I would say the
5 task force member or whoever has submitted,
6 please feel free to chime in and sort of provide
7 more elaboration. I'm looking at Dr. Shaw, but,
8 you know.

9 MEMBER SHA: Yeah, so there are a few
10 ambulatory chronic care conditions that have
11 composite measures. There are only a few
12 ambulatory chronic ambulatory conditions that
13 have composite measures. Diabetes is one of
14 them. Currently two of the other measures that
15 are part of the composite measures are a part of
16 the adult care core set. This would be in
17 addition to it.

18 I think there may be further
19 alignment, particularly with the IOM's vital
20 signs report since the diabetes composite care
21 measure is one of - part of their evidence-based
22 domain. So I think if we could gradually add in

1 more items of the composite measures, we could
2 probably eventually get to the point where we can
3 actually report out the diabetes composite
4 measure.

5 CHAIR PINCUS: Other comments or
6 questions? Julia?

7 DR. LOGAN: Yeah, so, excuse me, as
8 part of our external accountability sets or the
9 measures that we hold our plans accountable to,
10 we have this measure, and we have, I think, about
11 four measures that we require them around
12 diabetes, and the eye exam measure very closely
13 correlates with the other diabetes measures, so
14 the - especially the core set measures and the
15 hemoglobin A1c poor control measure.

16 So some of us in our department think
17 it may be a little bit duplicative because if
18 you're already doing quality improvement around
19 diabetes and control, that it may be kind of an
20 extra burden that's unnecessary.

21 CHAIR PINCUS: Other comments? Cindy?

22 MEMBER PELLEGRINI: So I'm not going

1 to pretend I know much about diabetes outside of
2 the fact that it's really important, but could
3 you explain a little bit more about what the
4 value added is beyond the four diabetes related
5 measures?

6 I understand the composite and I think
7 that is important, the composite aspect, but are
8 there other settings or other providers here that
9 we're measuring that we're not getting with the
10 other measures or something of that nature?

11 MEMBER SHA: So I think if you're
12 talking about a particular type of providers that
13 we're not actually currently capturing with the
14 core sets, I mean, for example, we are not
15 assessing, for example, ophthalmologists or
16 ophthalmology.

17 There are no core sets that address
18 eye care within the core sets, and, you know, I
19 think it's going to be hard to develop that
20 composite measure without using all - eventually
21 giving all of the components of the composite
22 within the core set.

1 CHAIR PINCUS: Other comments,
2 questions? Okay, so why don't we move onto the
3 next member recommended measure?

4 MS. GORHAM: Okay, Measure 0541,
5 proportion of days covered, PDC, three rates by
6 therapeutic category. This measure includes the
7 percentage of patients 18 years and older who met
8 the proportion of days covered the threshold of
9 80 percent during the measurement year.

10 A performance rate is calculated
11 separately for the following medication
12 categories, RAS antagonists, diabetes medications
13 and statins. A high score indicates better
14 quality. It's a process measure. The data
15 source is administrative claims. It is an NQF
16 endorsed measure. And I do not have a rationale
17 for this measure if the task force member who
18 recommended it would like to speak up.

19 MEMBER SCHLAIFER: So I think the
20 reasons for recommending this measure - and there
21 is also an asthma measure on medication
22 adherence. I think right now it's widely

1 accepted that one of the biggest issues we have
2 in healthcare right now is patients not being
3 adherent to their medications, and I think as we
4 discussed a year ago, the attempt to try and add
5 a medication adherence measure to the quality
6 measurement set to provide more attention to that
7 area.

8 I think some of these measures may be
9 more natural and easy in a MCO or a Medicaid
10 managed care setting, but the data, the
11 prescription drug data is available in both
12 Medicaid managed care setting and in the fee for
13 service side equally.

14 So the attempt on this was to get some
15 awareness with - you know, after we consistently
16 talk about the issues of medication adherence
17 measures, there are no medication, true
18 medication management measures in the current
19 set.

20 There is the anti-depressant
21 medication management, but that's a physician
22 follow up measure. It's not really a mediation -

1 it's not a true medication, "Are you taking your
2 medications" appropriate measure, so this was an
3 attempt to get that type of measure into the set.

4 And like I said, there is also, from
5 what was recommended last year, there's the
6 asthma measure, the 1799. So, you know, that one
7 - I can see either one, not both. That one would
8 go across both child and adult. So I could argue
9 for this one or argue for that one, but I do
10 think that we need to get Medicaid managed care
11 plans paying more attention to medication
12 adherence.

13 CHAIR PINCUS: So are you suggesting
14 that if this was added, you would remove the
15 asthma one?

16 MEMBER SCHLAIFER: The asthma one was
17 recommended last year, but not moved forward, so
18 I could go with either one. I think partly
19 because the asthma one wasn't moved forward last
20 year, the assumption might have been that maybe
21 there are other - because there are other asthma
22 measures, that this might be better. I can also

1 say that I think asthma in the Medicaid setting
2 may be a better recommendation.

3 So not knowing exactly why the asthma
4 measure didn't move forward, this is kind of an
5 attempt to put two out there to see which one -

6 MS. MUKHERJEE: So, we will revisit
7 asthma this year. And more measures.

8 The Coordinating Committee wanted us
9 to sort of consider some other measures. And
10 there wasn't enough time.

11 So, there are a couple of asthma
12 measures we will discuss tomorrow. And at that
13 point, it's going to be the Joint Adult/Child.

14 So, everybody will --

15 MEMBER SCHLAIFER: Okay.

16 MS. MUKHERJEE: Get to voice their
17 opinion about asthma. So, whichever one --

18 MEMBER SCHLAIFER: So, I guess my
19 suggestion, which people may or may not agree
20 with, is in not knowing what direction the asthma
21 measures will go, I would recommend that this
22 move forward.

1 MS. GORHAM: Just a note for process.
2 Today we'll vote on the measures. And then we'll
3 rank the measures.

4 But, tomorrow we'll also look at
5 maternity care as well as asthma care. And then
6 you have the opportunity to vote and re-rank the
7 measures.

8 So, if you like this measure, you vote
9 on it today. No worries, you'll vote tomorrow
10 asthma. If you like that better, then you can
11 re-rank.

12 MEMBER SCHLAIFER: Okay.

13 MS. GORHAM: And then that will be
14 fine.

15 CHAIR PINCUS: Okay. Other comments?
16 George?

17 MEMBER ANDREWS: Yes. I will agree
18 with including this measure with Marissa. Even
19 if -- for a number of reasons.

20 The ease of capturing the data. This
21 is administrative unlike what we have seen with
22 the data challenges on the hybrid measures.

1 Additionally, even though this
2 reflects a process kind of measure for various
3 disease conditions, cardiovascular, diabetes and
4 blood pressure, and also renal protection for
5 diabetes with the RAS antagonists, these are
6 medications that essentially improve outcomes.

7 So, indirectly helps support the
8 outcome that we want to see. So, for all of
9 those reasons, I think this is an excellent
10 measure to incorporate.

11 CHAIR PINCUS: Other comments for or
12 against the measure? Cindy?

13 MEMBER PELLEGRINI: Sorry, I'm
14 probably the only person in the whole room that
15 doesn't know the answer to this question. But,
16 can you tell me exactly what proportion of days
17 covered means?

18 MEMBER SCHLAIFER: Yes. Yes. I can
19 -- if I can get exactly right. So, the
20 proportion of days covered, it's gotten to be
21 accepted, and even though clinically this
22 probably isn't entirely true.

1 That if someone takes 80 percent of
2 their medications, that that is considered being
3 adherent to their medications. Obviously, we
4 would prefer that people take 100 percent of the
5 medications.

6 So, proportion of days covered looks
7 at in 100 day period, what percentage of days did
8 that person take the medication. The way it's
9 determined is you look at over a one year period
10 where you would have 365 days.

11 You know, how many days of tablets
12 were dispensed in that period. So, it's
13 calculated based on pharmacy data, pharmacy
14 refills.

15 We do know, and it's, you know,
16 obviously while accepted that just because you
17 get a prescription filled, doesn't mean you take
18 it. But, if you don't get a prescription filled,
19 then you obviously don't take it.

20 So, you know, it's not the perfect
21 esti -- you know, it's not an outcome's measure.
22 We don't know someone actually swallowed the

1 tablet.

2 But, it's as close as we can get. And
3 a lot of works been done over the last six or
4 seven years at trying to get to the perfect
5 medication adherence measures.

6 And this is accepted as close as we're
7 getting it. It is included in the Medicare Star
8 measures for Medicare Part D plans.

9 CHAIR PINCUS: Yes, this -- I mean,
10 actually a number of years ago I chaired -- co-
11 chaired the Medication Management NQF Endorsement
12 Committee.

13 And there were a lot of different ways
14 by which adherence was being measured at the
15 time. And the Committee recommended this
16 standardized way of doing it.

17 MEMBER SCHLAIFER: Yes. At the time
18 that that meeting was held, there was debate
19 between kind of two -- there was two different
20 factions.

21 There was the MPR group, the
22 medication physician ratio, and the proportion of

1 days covered that kind of debated it out in NQF.
2 While I think more people at that time were using
3 MPR, NQF went with proportion of days covered.

4 And that's become the standard.

5 CHAIR PINCUS: Any other comments?

6 (No response.)

7 CHAIR PINCUS: Okay. We'll have the
8 next one.

9 MS. GORHAM: Okay. Measure 0027,
10 Medical Assistance with Smoking and Tobacco Use
11 Cessation. This measure addresses the behavioral
12 health gap area.

13 The measure steward is NCQA. It is an
14 NQF endorsed measure. And it is -- the detailed
15 description of the measure is in your Excel
16 sheet.

17 But, I will read it, because it's not
18 on the screen. So, this measure assesses
19 different facets of providing medical assistance
20 with smoking and tobacco use cessation.

21 Advising smokers and tobacco users to
22 quit. A rolling average represents the

1 percentage of patients 18 years of age and older
2 who are current smokers or tobacco users and who
3 receive advice to quit during the measurement
4 year.

5 Discussing cessation medication. A
6 rolling average represents the percentage of
7 patients 18 years of age and older who are
8 current smokers and tobacco users, and who
9 discussed or were recommended cessation
10 medications during the measurement year.

11 And now I'll finish discussing
12 cessation strategies. A rolling average
13 represents the percentage of patients 18 years of
14 age and older who were current smokers or tobacco
15 users, and who discussed or were provided
16 cessation methods or strategies during the
17 measurement year.

18 This is a process measure. A health
19 plan/patient reported measure. The Task Force
20 Member rationale for including this measure, but
21 this -- it went past me.

22 We -- this measure's actually already

1 in the core set. But, -- right? And it totally
2 -- I totally just had a brain fart I guess.

3 But, I'll also read the Task Force
4 Member rationale. It could be reported for those
5 with a serious mental illness as well as the
6 general population.

7 But, it is already in the core set.
8 So, we can move onto the next measure. I guess
9 so. So, --

10 CHAIR PINCUS: Well, but this actually
11 raises a question. Do we -- does recommending
12 kind of a stratification, does that constitute
13 sort of a separate recommendation that we would
14 need to vote on?

15 Or does that -- or is that something
16 that is sort of -- we don't need to vote on since
17 it's already, you know, collected data?

18 DR. LILLIE-BLANTON: You're asking me?

19 CHAIR PINCUS: I'm not sure what the
20 recommendation was. Was it adding that -- so,
21 it's already part of the core set.

22 But, if we -- if that's being

1 nominated to be stratified by severe mental
2 illness or schizophrenia, does that require an
3 additional recommendation?

4 DR. SULLIVAN: I did this.

5 CHAIRMAN PINCUS: Yes.

6 DR. SULLIVAN: Just to say -- I mean,
7 I would just suggest, I don't know what that
8 means relative to what this group should decide
9 on.

10 And so I think it was just a
11 suggestion perhaps. Or should we think about
12 stratifying it for the seriously mentally ill?

13 Because we know that the smoking rate
14 amongst the seriously mentally ill is so much
15 higher. And it's so much more difficult to get
16 them to stop.

17 So, I don't know if that would be a
18 recommendation to look at for the future or a
19 gap? Or if that was something that could be
20 stratified into the measures.

21 So, that's why I've kind of put it
22 there. More for discussion than saying there was

1 an actual measure that had been codified. If you
2 know what I mean.

3 CHAIR PINCUS: Yes. This came up
4 actually several times before. Not so much in
5 the, you know, in the contested element process.

6 And so like last time, you know,
7 measure 1932 was added. Which is an existing
8 measure.

9 But, it was sort of added as an
10 additional measure, you know, the diabetes
11 screening for people with severe mental illness
12 it was, you know, it was a stratified measure.

13 And so the question is, does it --
14 since we're not -- it sounds like Ann that you're
15 not -- you weren't recommending it be an
16 additional measure. But, it would be stratified.

17 DR. SULLIVAN: No. I was just
18 recommending stratifying it so that you could
19 also pull out those with serious mental
20 illnesses.

21 As long as you were kind of doing it,
22 you know, to pull out those with serious mental

1 illness, bipolar, schizophrenia, and measure
2 their -- whether they're getting the same thing.

3 You know what I'm saying?

4 DR. LILLIE-BLANTON: I wouldn't say
5 that we would add a separate measure unless it
6 was a -- we would add a different measure unless
7 it really is a different measure.

8 CHAIR PINCUS: Um-hum.

9 DR. LILLIE-BLANTON: This is the same
10 measure. And all we have to do is ask and
11 encourage our State partners to stratify.

12 Whereas the other measure was actually
13 a separate measure --

14 CHAIR PINCUS: Right.

15 DR. LILLIE-BLANTON: With a separate
16 number. A separate methodology for collecting it
17 and technical specifications.

18 So, I would -- you know, I think this
19 would just be an encouragement to state -- our
20 State partners to stratify.

21 CHAIR PINCUS: Okay. Or you can just
22 use one of these.

1 DR. LIU: So, we're talking about
2 whether there's a separate measure on tobacco
3 screening and the brief counseling for people
4 with serious mental illness.

5 There is a measure that's NQF
6 endorsed. I can get you the number in a minute,
7 the NQF number.

8 So, there is a separate measure of
9 tobacco screening and the brief counseling about
10 people with serious mental illness. So that if
11 you are considering another measure for this sub-
12 population, so that's an option.

13 CHAIR PINCUS: Lisa?

14 DR. PATTON: Yes. I was going to say,
15 I think that one came up for discussion with the
16 previous meeting of this group. It was part of
17 the portfolio of 11 that included the SMI and
18 diabetes measure 1932.

19 It was part of that portfolio. So, I
20 think it may have been discussed at a previous
21 meeting.

22 But, I don't have the number either.

1 But yes, it is available.

2 CHAIR PINCUS: Okay. This sounds like
3 it was discussed the last time. And it was not
4 endorsed or not supported.

5 DR. PATTON: That's right. I think
6 the cardiovascular and the diabetes Screening
7 went forth. But, that one did not. Yes.

8 DR. LIU: So then, the NQF number for
9 that is 2600.

10 CHAIR PINCUS: Okay. So Ann, are you
11 proposing that measure or -- formally or not?

12 DR. SULLIVAN: I think, you know, in
13 terms of keeping things not too many, I think it
14 would be -- I'd be -- personally it would be okay
15 with me if we could suggest the stratification of
16 this measure rather than adding the other
17 measure.

18 If that would work. I mean, that's a
19 fine measure, I'm not saying. But, I think in
20 terms of just the numbers of measures, that that
21 might make sense with that.

22 CHAIR PINCUS: Okay. So what -- any

1 other comments on this?

2 (No response.)

3 CHAIR PINCUS: Okay. Let's move onto
4 the next one. No, let's go back.

5 MS. GORHAM: Okay. So, Measure 2111,
6 Antipsychotic Use in Persons with Dementia.

7 This measure recently underwent
8 maintenance review in our Neurology Project. And
9 the Standing Committee recommended continued
10 endorsement for this measure.

11 This measure includes the number of
12 patients in the denominator who had at least one
13 prescription and greater than 30 days' supply of
14 an antipsychotic medication during the
15 measurement period. And do not have a diagnosis
16 of schizophrenia, bipolar disorder, Huntington's
17 Disease, or Tourette Syndrome.

18 It is a process health plan measure.
19 Data source is administrative claim. The Task
20 Force Members recommended the measure.

21 The measure access is appropriate
22 treatment for Dementia, which is a gap area. The

1 measure attempts to at least track and bring to
2 the attention of providers if there is a high and
3 chronic use of these medications in these
4 patients.

5 DR. SULLIVAN: I put this one out as
6 well. I think there's the simplicity in
7 gathering this information, much like the other
8 pharmacy one.

9 This is pharmacy administrative claims
10 data. So, I think it falls to whether or not the
11 Committee feels that looking at this particular
12 issue is important enough.

13 And I think that theirs could be some
14 different thinking about that. But, I thought it
15 was worth at least mentioning.

16 Because I do think this is a gap area.
17 And we need maybe to discuss. And maybe there
18 could be other measures in the future if
19 necessary.

20 But that it is important to think
21 about this growing population of dementia. And
22 this is a -- this particular one is tricky

1 because it's a harmed induced thing to some
2 extent.

3 It's like doing the wrong thing. And
4 you want to make sure that too many people --
5 that people aren't doing the wrong thing by over
6 prescribing.

7 So, I brought it forwards partly to
8 bring up the issue of the gap measure. And then
9 I think it's just a decision on the group's part
10 as to whether you would think at this point in
11 time this was important enough as a con -- as an
12 issue to bring forward.

13 Certainly there's an overuse of this.
14 Certainly there's a growing population of
15 dementia.

16 Certainly in the Medicaid population
17 where a lot of people, especially in nursing
18 homes, et cetera. This is not an unusual
19 problem.

20 And this would give you the ability to
21 track and look at it. And it's easy to do.

22 So, I just wanted it open for, you

1 know, for discussion.

2 CHAIR PINCUS: Comments?

3 MEMBER DUNN: Again, this is Katie if
4 I may?

5 CHAIR PINCUS: Uh-huh.

6 MEMBER DUNN: Thank you. So,
7 following up on what was just said, if this is a
8 measure that is indicative of a wrong scope of
9 practice, then it raises the question, what
10 immediate response -- or what response does a
11 State Medicaid program have to take with this
12 data?

13 The other thing I would mention, I
14 think it's, you know, I understand the importance
15 of the measure. But, when we've tried to work
16 with different providers, particularly those with
17 a specialty in prescribing antipsychotics, we
18 often get a lot of push back about off label use
19 of certain drugs.

20 So, to the extent that that could be
21 an issue with individuals diagnosed with
22 dementia, that might be something to consider.

1 I'm not an expert in this area.

2 So, I'm just putting that out there.

3 CHAIR PINCUS: Other comments? Oh,
4 Marissa?

5 MEMBER SCHLAIFER: I was going to say,
6 I have not been directly involved with the
7 Pharmacy Quality Alliance, or PQA for several
8 years. But, this was -- when it was brought up,
9 it was brought up as a recognized gap area.

10 And an area that needed to be
11 addressed. And PQA was asked to create this
12 measure. I don't have the details.

13 I mean, I could easily get them. But,
14 not before we vote probably. But, I know that
15 off label utilization was discussed a lot as this
16 measure was being created.

17 I could try and see if I could contact
18 someone and get information on it. But I don't
19 have that now.

20 But, I do know that that was something
21 that was addressed. And felt like this was --
22 that these medications should not be used in

1 these things.

2 But you can probably state too far
3 better than I can.

4 CHAIR PINCUS: Well, let's let other
5 people comment. So, Julia, George, Michael.

6 DR. LOGAN: So, a couple of things
7 about this measure. The measure -- the
8 population age is over 65.

9 So, it may not be completely
10 appropriate for the Medicaid population and the
11 issue with the duals and not counting dually
12 eligible individuals. It may also be difficult.

13 And also, I don't have very much
14 experience in this area. But I'm pretty sure
15 that dementia can be under diagnosed.

16 So, we may be missing the boat with
17 this measure. Because people who actually have
18 dementia may be not diagnosed and then vice
19 versa.

20 CHAIR PINCUS: George?

21 MEMBER ANDREWS: Yes. The comment
22 that I want to make here is this particular

1 measure, the way I see it, impacts patient
2 safety.

3 Prescribing a medication that is not
4 for a specific and correct disorder,
5 antipsychotics have effects on the cardiovascular
6 system. Particularly the -- what is called the
7 electricity as a system of the heart, the AV
8 node.

9 Which can result in heart block and a
10 need for pacemakers, et cetera. So it could be a
11 patient falling, et cetera.

12 So, it is something that to me, if not
13 appropriately used, it can have a negative health
14 result.

15 CHAIR PINCUS: Michael? Then Kim.

16 MEMBER SHA: Well, as the Geriatrician
17 in the room. I think there are a lot of good
18 points being made here.

19 I would just sort of caution everyone
20 that I think what we're talking about here is
21 routine use of anti -- of a likely inappropriate
22 medication.

1 I think there are situations of which
2 it can be appropriate to use an antipsychotic in
3 a patient with dementia. So, I would just ask
4 everyone to sort of perhaps moderate some of
5 their perspectives on this issue.

6 CHAIR PINCUS: Kim?

7 DR. ELLIOT: And I was just going to
8 say that because at 65 and older, there will be a
9 lot of Medicare claims involved. And I know that
10 there have been initiatives with quality
11 improvement organizations for Medicare to work
12 with Medicaid on this particular topic.

13 And the data had to come from multiple
14 sources. It wasn't strictly Medicaid. So, it
15 would be a more challenging measure for a
16 Medicaid program to measure.

17 CHAIR PINCUS: Ann?

18 DR. SULLIVAN: I think that the Duals
19 Group is considering? Do we know anything like
20 this? The dual eligibles?

21 MS. MUKHERJEE: So, they looked at --
22 they did look at dementia. And I'm not sure if

1 they specifically addressed this.

2 But, they did look at mental
3 behavioral health and connections. And sort of
4 connections across.

5 And I will check to see if this
6 specific measure was recommended. But, I know
7 they do have measures related to dementia and
8 patients with dementia and treating them.

9 So, the Duals are looking at that.
10 They're really looking at connections to
11 community, connections of clinical and behavioral
12 health.

13 And they tried to sort of see what
14 measures they could find or what's sort of the
15 gap area in this.

16 DR. SULLIVAN: Would it be appropriate
17 -- have they seen this one? I mean, would it be
18 appropriate for us to suggest that they --

19 MS. MUKHERJEE: So, their meeting
20 happened a month before. The report is about to
21 go to public commenting soon.

22 So, you can definitely public comment

1 on the report. And I will let you know quickly.
2 Let me look at that about dementia.

3 DR. SULLIVAN: Okay. Because I was
4 just wondering if there might be a route to ask
5 them to look at it. If not right now, at a
6 future date if they're going to continue
7 something like that.

8 MS. MUKHERJEE: Well, definitely
9 comment on it when the report comes out. And it
10 should be early June.

11 DR. SULLIVAN: Great.

12 CHAIR PINCUS: I want to make -- let
13 me step out of as the Chair while I make a
14 comment on this one. I kind of agree with
15 George.

16 And I think I agree with Michael as
17 well. In that this measure is talking about
18 continued use.

19 So, it's, you know, it's 60 day -- you
20 know, more than 60 days in a year. So, you know,
21 which sets sort of a threshold beyond sort of
22 very short term use.

1 You know, there is a black box warning
2 for these drugs indicating that they can produce
3 death. Which is a bad thing.

4 And I also think that, you know, State
5 Medicaid programs do, even though they may, you
6 know, for people that are in nursing homes that
7 may be duals, they do have a responsibility to
8 those people as well as the Medicare programs.

9 And so I would speak in favor of this.
10 Other comments?

11 MS. MUKHERJEE: So yes, it is in the
12 Duals family of measures. And also their starter
13 set, which is sort of a subset of their family.

14 Which is the place where we would like
15 people to start when looking for measures for the
16 Duals population.

17 CHAIR PINCUS: So, this goes along
18 with alignment? Okay.

19 Julia, did you have another comment?

20 DR. LOGAN: No.

21 CHAIR PINCUS: Okay. And any other
22 comments on this?

1 (No response.)

2 CHAIR PINCUS: Okay. Let's move to
3 the next one.

4 MS. GORHAM: It's 2607, Diabetes Care
5 for People with Serious Mental Illness,
6 Hemoglobin AC -- A1C, poor control.

7 This is an NQF endorsed measure. This
8 measure includes the percentage of patients 18 to
9 75 years of age with a serious mental illness and
10 Diabetes Type 1 and Type 2, who's most recent
11 HBA1C level during the measurement year is less
12 than 9.0 percent.

13 And this is an outcome measure. The
14 Task Force Members recommended this measure
15 because it complements 0059 already in the core
16 set.

17 This measure would require those with
18 serious mental illness be reported separately.
19 The purpose would be to look at disparities in
20 the treatment of individuals with serious mental
21 illness compared to the general population.

22 If there are disparities then there

1 would need to be a targeted strategy within this
2 population.

3 DR. SULLIVAN: I put forward this one
4 too. This is the same one I think that we
5 recommended last year. But it wasn't accepted.

6 And my -- after hearing from
7 California, I think it is interesting how you,
8 you know, if you're doing a whole State
9 population, it would probably be easy to do. It
10 might be harder if you're doing samples.

11 But, you could also sample a group of
12 individuals who have a diagnosis of
13 schizophrenia. I think the point of this is
14 again to begin to try to look at disparities.

15 And I think when you have a diagnosis
16 that you know can end up with disparity by having
17 a diagnosis of schizophrenia or bipolar disorder.
18 But, that pushes you into the world of just
19 seeing if they're getting the same level of care.

20 And this one's particularly nice
21 because it would show you if they're not. If
22 they're getting a -- if their Hemoglobin and A1C

1 is high. And if that rate was higher with this
2 group, then the other group.

3 So, it's getting again to that
4 question of look at and comparing the groups.
5 And trying to pull out segments that might show a
6 problem.

7 And we kind of know that control and
8 -- amongst individuals with serious mental
9 illness is not as good. So, this would then
10 highlight that to the Medicaid providers, and the
11 importance of focusing on that group.

12 So, I was just going to put this for
13 -- I was suggesting we put this one forward
14 possibly. Again, it was presented -- it was sent
15 forward last year.

16 CHAIR PINCUS: Sue?

17 MEMBER KENDIG: You know, it strikes
18 me that this also gets to some of the quality
19 issues being addressed in emerging integrated
20 primary care, behavioral health, medical homes.

21 So, it's -- it really does call out
22 some of those unique issues that might be able to

1 give a quality picture of those types of clinical
2 integration models.

3 CHAIR PINCUS: Lisa?

4 DR. PATTON: Yes. The real intent of
5 this measure along with the health disparities
6 aspect was to get at that care coordination --
7 piece. It's really a proxy for that, so.

8 CHAIR PINCUS: Other comments? Cindy?

9 MEMBER PELLEGRINI: I'm finding myself
10 just a little ambivalent here. Clearly a really
11 important issue.

12 But, I think I'm feeling the tension
13 between wanting to create a core measure set that
14 is generally applicable to the entire Medicaid
15 adult population. And the desire to pull out
16 some of those disparities in sub-populations.

17 CHAIR PINCUS: Sue?

18 MEMBER KENDIG: But I think it also --
19 and I understand that point Cindy. But, I think
20 it does also go too really looking at populations
21 that are driving poor outcomes, higher costs,
22 looking at -- that sometimes gets lost in a more

1 generic measure.

2 And again, when we're looking at
3 emerging clinical integration models. I think
4 that's really where some of this can be really,
5 really important for us to think about in a way
6 that maybe we didn't in prior years.

7 CHAIR PINCUS: So, let me step out of
8 the chair's role and make a comment on this.

9 So, I think this is kind of a three-
10 for. And going beyond a two-for.

11 Where number one, it's the amount of
12 effort to do this -- is not much more since we
13 already have sort of an overall population
14 comprehensive diabetes measure for hemoglobin A1C
15 performance.

16 And this simply is a pulling out a
17 stratum. So, that's sort of one, it's not a lot
18 of effort.

19 Number two, is that it kind of
20 reinforces the notion of shared accountability
21 and integration and linkage between behavioral
22 health.

1 Because it indicates that whoever's
2 responsible for the diabetes care and for the
3 schizophrenia care are mutually responsible for
4 getting this kind of outcome. So, it reinforces
5 that notion of integration and shared
6 accountability.

7 And number three, it's focused on a,
8 you know, clearly a population that is
9 significantly at risk for dying early. And in
10 many cases because of diabetes or other similar
11 metabolic consequences.

12 So, I would speak in favor of it.

13 Diane?

14 MEMBER CALMUS: I guess I would just
15 follow onto what Cindy was asking. If we're
16 using this as a proxy to demonstrate the
17 connection between the behavioral health and the
18 physical health side.

19 I guess I -- my question, and I have
20 no idea, is this better than the diabetes
21 screening metric? Or is that not showing that
22 same -- same --

1 CHAIR PINCUS: I would say it's
2 complementary to it. So, number one, are you
3 able to identify them?

4 And number two, once identified, are
5 you getting good outcomes? Because actually, if
6 you don't identify them, they wouldn't be in this
7 denominator.

8 MEMBER CALMUS: No. Yes, I absolutely
9 understand.

10 CHAIR PINCUS: And so they're kind of
11 complementary.

12 MEMBER CALMUS: Yes.

13 CHAIR PINCUS: It kind of goes along
14 the -- sort of the logic trail that Charles
15 presented earlier today. You know, it's sort of
16 the -- you know, it sort of makes sense.

17 MEMBER KENDIG: And I would take that
18 even a step further to the clinical integration
19 piece. Because, you can identify them, you can
20 even treat them.

21 But, if you don't have that care
22 coordination, you will not meet the metric or

1 come close. And I think that's what this is
2 telling me.

3 That it's more than just identifying
4 them and treating them. But, it's also
5 recognized the -- recognizing the whole person
6 and the importance of that coordination piece.

7 So, I would speak in favor.

8 CHAIR PINCUS: Julia?

9 DR. LOGAN: Yes. So, I think it might
10 be more of a heavier lift than the diabetes
11 Screening for people with schizophrenia or
12 bipolar. Because that includes serious mental
13 illness. Which is also severe depression.

14 And so, you have to look at inpatient
15 claims for an inpatient visit for major
16 depression. So, that would be an extra, you
17 know, looking at the hospital claims as well.
18 Just a consideration.

19 CHAIR PINCUS: Cindy?

20 MEMBER PELLEGRINI: Does anyone -- can
21 anyone in the room give us even a very rough
22 estimate of what percentage of adults on Medicaid

1 have both diabetes and serious mental illness?

2 I don't have a good idea of how big
3 this population is.

4 CHAIR PINCUS: There's a substantial
5 comorbidity between people with schizophrenia and
6 -- so, looking at the denominator of people with
7 schizophrenia, there's a substantial comorbidity
8 with diabetes.

9 In part because of poor self-care,
10 obesity. In part because of the secondary side
11 effects of antipsychotic medications.

12 MEMBER PELLEGRINI: Sure. But are we
13 talking about tens of thousands? Hundreds of
14 thousands of people? Millions of people?

15 CHAIR PINCUS: Lisa?

16 DR. PATTON: I think Junqing can speak
17 to that.

18 DR. LIU: So, when we developed in the
19 measures looking at diabetes care for people with
20 serious mental illness, we did look into heart
21 problems and also disparities in care.

22 We found that the prevalence rate of

1 diabetes among people with serious mental illness
2 is doubling the rate among the general
3 population. So, it's showing it's a higher
4 prevalence.

5 And we know in Medicaid especially
6 there's a high concentration of people with
7 comorbid medical and behavioral health
8 conditions.

9 DR. LOGAN: So, I'm just trying to get
10 again the size of the pop -- if the proportion
11 maybe very high. But if the starting population
12 is modest, then the subset of that is going to be
13 small.

14 So, does that make sense?

15 MEMBER SHA: Right. So, the
16 prevalence of diabetes in the general population
17 is about 67 percent. So, if you're talking about
18 double, you're talking about 12 to 14 percent.

19 CHAIR PINCUS: Other comments? Lisa?

20 DR. PATTON: So, this may not be the
21 time. But, I'll just mention again, 2152 really
22 cuts right across the broad swath of the Medicaid

1 population.

2 The alcohol screening and brief
3 counseling, and one of the ways that we look at
4 it is really the impact on care management for a
5 lot of these conditions.

6 So, if we were looking at a measure
7 that really gets a lot of bang for the buck,
8 that's certainly one of them.

9 CHAIR PINCUS: Other comments?
10 Negative or positive?

11 (No response.)

12 CHAIR PINCUS: Okay. Let's move onto
13 the next one.

14 MS. GORHAM: Okay. So --

15 CHAIR PINCUS: And then we vote.

16 MS. GORHAM: That is actually our last
17 Task Force recommendation. And I just want to
18 clarify, 2607 although we discussed and you all
19 voted on that measure, when we prioritized, it
20 didn't actually make the cut.

21 So, that wasn't actually a 2015
22 recommendation. But, we did discuss it and voted

1 on that measure.

2 So, now you have before you the
3 measures that we will vote on. And we'll go
4 individually and vote on each measure.

5 Again, we have upgraded here at NQF.
6 And so you will use your blue clicker. And
7 Katie, if you would chat me your vote, then I
8 will vote for you. I have your clicker in my
9 hand.

10 And before we start, I think Michael
11 has a question.

12 MEMBER PELLEGRINI: A process
13 question?

14 CHAIR PINCUS: Yes?

15 MEMBER PELLEGRINI: I know we're going
16 to have a chance to re-prioritize and vote on
17 other measures tomorrow. Not knowing what those
18 other measures are, I'm just -- I'm thinking
19 about a specific one that I expected to see on
20 this list.

21 Not because I nominated it. But
22 because I thought it would show up there anyway.

1 So, will there be a chance at some
2 point to nominate additional measures? Or was
3 that it?

4 MS. GORHAM: So, now is the chance.
5 So, if you have other measures that you did not
6 send to us earlier, then we can consider those
7 now.

8 We can pull up the specs for them real
9 quick. And we'll consider those before we
10 actually vote on individual measures.

11 So, now would be the chance to do
12 that.

13 MEMBER PELLEGRINI: Well, could you
14 tell me if tomorrow we will end up voting on any
15 of the contraceptive measures?

16 MS. GORHAM: Yes. So, tomorrow --

17 MEMBER PELLEGRINI: That's all I
18 wanted to know.

19 MS. GORHAM: We'll discuss the
20 maternity care as well as the asthma measures.
21 So, we just broke the days up. We wanted --

22 CHAIR PINCUS: So, the contraceptive

1 and maternity?

2 MS. GORHAM: Yes.

3 CHAIR PINCUS: Okay.

4 MS. GORHAM: Yes.

5 CHAIR PINCUS: Because if you have
6 contraceptive care you don't get maternity.

7 MS. GORHAM: Exactly.

8 (Laughter.)

9 MS. GORHAM: Yes. We wanted to do the
10 measures that cut across both Task Forces on the
11 days that we had both Task Forces here.

12 But, if you have other measures that
13 apply only to the Adult Core Set, now would be
14 the time for us to pull up that information if
15 you want to put that forward.

16 CHAIR PINCUS: Michael?

17 MEMBER SHA: So, if we are going to
18 talk about measures that were recommended in the
19 last cycle that were not adopted by -- for the
20 current set of core measures, then I might
21 suggest 1927.

22 CHAIR PINCUS: Say what that is.

1 MEMBER SHA: Cardiovascular Health
2 Screening for People with Schizophrenia or
3 Bipolar Disorder Who Are Prescribed Antipsychotic
4 Medications.

5 MS. GORHAM: So, I can pull up the
6 specs for that real fast. Let me see if we can
7 get that on the screen.

8 Yes, it should be in the spreadsheet.
9 If you go to your Tab that says 2015
10 Recommendations, it should be there. I'm pulling
11 mine up as we speak.

12 Okay. So, if you're on the Tab 2015
13 Recommendations, I pulled that one up first. If
14 you're on line four of that Tab, then 1927 is the
15 measure that Michael put forward.

16 And that is Cardiovascular Health
17 Screening for People with Schizophrenia or
18 Bipolar Disorder who are Prescribed Antipsychotic
19 Medications. That is NQF endorsed.

20 It is a process measure.
21 Administrative claims, electronic clinical data,
22 electronic clinical data pharmacy.

1 It's a health plan level measure. The
2 care setting is ambulatory care, clinical office,
3 clinical behavioral health, psychiatric
4 outpatient and other.

5 And the steward is National Committee,
6 NCQF.

7 MEMBER SHA: I think this measure
8 addresses one of the identified gaps. I think
9 it's a bridge between two different disciplines.

10 You know, we sort of focused on the
11 risk that patients with, you know, serious
12 medical -- mental health conditions have
13 regarding diabetes. I think there are those high
14 risks for cardiovascular disease.

15 So, I think it's worthwhile for the
16 Committee to reconsider or re-nominate this
17 measure.

18 CHAIR PINCUS: Charles?

19 DR. GALLIA: So, the question about
20 the prevalence in the Medicaid population. I was
21 in the back because one of the performance
22 improvement projects that we did through the

1 Adult Quality Grand was related to diabetes care
2 among people with schizophrenia.

3 That was our first attempt. But, we
4 had to include bipolar disorder in order to have
5 sufficient numbers in order to make it -- and I
6 hate to use the word actionable again without a
7 definition.

8 But, you get the population
9 prevalence. So, with the combination of both
10 bipolar or schizophrenia, it represents about 3.6
11 percent of the population, of the adult
12 population in the Medicaid programs.

13 But, we did have -- it was a
14 sufficient number to do a whole performance
15 improvement project around that when we -- even
16 stratifying it by the number of coordinated care
17 organizations.

18 And they were able to demonstrate
19 improvement. So, I'm saying that it was
20 worthwhile. We implemented it.

21 The population while small, was still
22 sufficient in order to take action on. And we

1 were able to demonstrate results using a
2 modification of the measure.

3 CHAIR PINCUS: Thank you. Other
4 comments on this measure?

5 (No response.)

6 CHAIR PINCUS: So, we should add it to
7 the list. Okay.

8 So, are we ready to vote?

9 MS. GORHAM: No more recommendations?

10 CHAIR PINCUS: Um-um.

11 MS. GORHAM: Okay. Yes?

12 CHAIR PINCUS: Yes. Okay. So, let's
13 go over, what button do we press for what? I
14 can't see that far.

15 MS. GORHAM: And so let me just make
16 a statement for the record. So, only Task Force
17 Members are voting on the measures. Federal
18 Representatives are not voting members.

19 And so we will state each measure
20 number and measure title. And you will point
21 towards Alexandra over here against the wall.
22 And we will record.

1 And when we have greater than 60
2 percent, then that is a vote to include the
3 measure into the core set and recommend.

4 MS. MUKHERJEE: So, once we're set up,
5 we'll read out what one means and two means. And
6 then we'll do a test run.

7 So, right now we're just setting up.
8 So, if you bear with us one minute. Thank you.

9 MS. GORHAM: So, while they're setting
10 up voting, I think we have one comment on the
11 last measure recommendation.

12 DR. LIU: Oh, thanks for reconsidering
13 the Cardiovascular Health Screening Measure. I
14 would like to make several notes here.

15 Actually, I would recommend that the
16 Task Force to consider another measure. I wonder
17 whether that's the measure the second gentleman
18 over there was referring to.

19 There is a Cardiovascular House
20 Monitoring Measure for People with Cardiovascular
21 Disease and Schizophrenia or Bipolar. It's also
22 NQF endorsed. I can find the number in a minute.

1 So, the reason for recommending the
2 monitoring measure rather than the screening
3 measure is mostly because of the new guidelines
4 by ACHC and American Heart Association.

5 Their new guideline is not
6 recommending annual LDLC Screening for patients
7 who do not have established cardiovascular
8 conditions. Therefore, we are thinking the
9 Screening measure maybe not the most appropriate.

10 Rather the cardiovascular monitoring
11 measure, which is addressing patients who already
12 have established cardiovascular conditions as
13 well as schizophrenia and bipolar. Thank you.

14 MS. GORHAM: So, hearing that, do we
15 still want to put that forward as a
16 recommendation? Or do we want to -- how do --
17 okay.

18 MEMBER ANDREWS: Is the Screening for
19 cardiovascular meant to be for people with
20 established cardiovascular disease? Or is it
21 meant to be for individuals with behavioral
22 conditions that you're screening for

1 cardiovascular?

2 DR. LIU: That's a distinction between
3 the two measures. The monitoring measure is
4 intended for people who have established
5 cardiovascular conditions as well as the serious
6 mental illness.

7 In the screening measure, it does not
8 require the denominator has a cardiovascular
9 condition. So, that's the purpose of the
10 Screening measure.

11 So, that is the correct NQF number you
12 were referring to.

13 MS. GORHAM: And that number is 1933.

14 MEMBER SHA: So, I think the other
15 difference between 1927, which is last year's
16 recommendation, is that that measure covers
17 patients with bipolar disorder as well as
18 schizophrenia.

19 And 1933 only covers patients with
20 schizophrenia. Which I mean, I'm just mentioning
21 this primarily for informational purpose.

22 MS. GORHAM: So, Michael would you

1 like to -- cut your mic on.

2 MEMBER SHA: I would probably accept
3 the recommendation for us to consider 1933.

4 CHAIR PINCUS: And not the other one?

5 MEMBER SHA: Correct.

6 CHAIR PINCUS: Okay. Are we ready to

7 --

8 MS. GORHAM: Let me pull the title of
9 1933 then. Because we don't have that.

10 Well you can -- we're going to go
11 through all of them and you're going to vote.
12 And then we're going to --

13 MEMBER SHA: But no, I meant we vote
14 -- we all vote for every --

15 MS. GORHAM: So, we're going to go
16 through each measure, vote. And see which
17 measures we get more than 60 percent Task Force
18 support.

19 And then those measures left are the
20 measures that we'll actually rank. So, for
21 example, say that all five measures receive
22 support of 60 percent.

1 So, then we'll take those five
2 measures. And you all can pick your top three.
3 And that's how we'll rank the measures.

4 And then tomorrow we'll add in the
5 asthma and the maternity measures to rank.

6 MEMBER SHA: So, we should try to be
7 selective? Or --

8 MS. GORHAM: You definitely want to be
9 selective when we get to the ranking part. But,
10 right now you just want to vote on all of the
11 measures that you think would be a good fit.

12 Because we need at least 60 percent or
13 greater in order to actually make that a Task
14 Force Recommendation.

15 CHAIR PINCUS: So for this vote,
16 people vote each measure independently. It's not
17 a comparative thing.

18 Each measure is rated on its own
19 merits.

20 MS. GORHAM: Okay. So, the measure
21 that is being recommended is 1933, Cardiovascular
22 Monitoring for People with Cardiovascular Disease

1 and Schizophrenia.

2 CHAIR PINCUS: Okay.

3 MS. GORHAM: So, give us one minute so
4 that we can upload the measures.

5 So, I want to make sure, because we
6 did not have this measure on the Excel sheet.
7 Did you all want me to pull up the
8 specifications?

9 And do you want to walk through the
10 measure? Or are you okay with the measure?

11 CHAIR PINCUS: I think we'll be good
12 to go.

13 MS. GORHAM: Okay. You're good.
14 Okay. Catch a Michael at --

15 MEMBER ANDREWS: Yes, look at the
16 specs.

17 MS. GORHAM: Okay.

18 CHAIR PINCUS: If you want to see the
19 specs, we should -- yes.

20 MS. GORHAM: Okay. So, let's take a
21 five minute break. Let me pull up the specs real
22 fast. And we'll put it on the screen.

1 Okay. Well, she has the specs. All
2 right.

3 MS. MUKHERJEE: Okay. Too many mics
4 on. Okay.

5 So, Measure 1933, Cardiovascular
6 Monitoring for People with Cardiovascular Disease
7 and Schizophrenia.

8 So, the measure description is
9 percentage of patients 18 to 64 years of age with
10 schizophrenia and cardiovascular disease who had
11 an LDLC test during the measurement year.

12 So, the numerator has one or more LDLC
13 test performed during the measurement year. The
14 denominator is patients 18 to 64 years as the end
15 of the measurement cycle, December 31, with a
16 diagnosis of schizophrenia and cardiovascular
17 disease.

18 No exclusions. Not applicable. Risk
19 adjustment, no. It's a process measure. It's a
20 population health measure.

21 And the conditions it covers is mental
22 health, cardiovascular disease, serious mental

1 illness. It's ambulatory care, clinician's
2 office setting.

3 Administrative claims, electronic
4 clinical data, electronic clinical data
5 laboratory. And then level of analysis is health
6 plan integrated delivery system.

7 And then, let's see, and it's an NCQA
8 measure. Yes, any other information one would
9 like?

10 MS. GORHAM: Okay. I think we're
11 ready to vote. We are missing one person.

12 Okay. So, the first measure that
13 we're going to vote for potential addition to the
14 core set is 2152. You just want them to bring
15 the slide up? Okay.

16 All right. So, the first measure
17 again that we're voting on, and again, we need
18 greater than 60 percent of votes. One is yes and
19 two is no.

20 Again, Katie, if you chat me your
21 vote, I will vote for you. And for those in the
22 room, if you point at Alexandra.

1 (Voting.)

2 MEMBER DUNN: Hi, it's Katie. I sent
3 my vote. Just so that you're -- you know it's
4 coming through.

5 MS. GORHAM: I got it. Thank you.

6 CHAIR PINCUS: So, do we -- what's the
7 number we're aiming at?

8 MS. GORHAM: Nine, ten. We have nine
9 in the room and one on the phone, so ten.

10 MS. OGUNGBEMI: We had a bit of
11 technical difficulties. Could we vote again,
12 please?

13 CHAIR PINCUS: Tell us when. Why
14 don't we just raise hands?

15 Should we be pressing the button now
16 or? Okay.

17 MS. GORHAM: So, I might have
18 misstated. We might have to go back to the old
19 ways everybody.

20 MS. OGUNGBEMI: One more time. Go
21 ahead and vote, please.

22 (Voting.)

1 MS. GORHAM: So, the measure passes.
2 Seventy percent of the Task Force voted yes to
3 support this measure.

4 We'll move to the next measure. 0055,
5 Comprehensive Diabetes Care, Eye Exam Performed.

6 CHAIR PINCUS: When do we press?

7 MS. OGUNGBEMI: Voting is open.

8 (Voting.)

9 MS. GORHAM: Katie, please send your
10 vote to me, please? Via chat. Yes, I got it.

11 MEMBER DUNN: Okay. Great.

12 MS. GORHAM: Okay. They're having
13 technical difficulties with the voting system.
14 Let's take a five minute break and then come back
15 and vote.

16 (Whereupon, the above-entitled matter
17 went off the record at 3:07 p.m. and resumed at
18 3:13 p.m.)

19 CHAIR PINCUS: We're ready to redo it,
20 so if everybody could come back to their seats,
21 or at least be in range of the -- whatever it is
22 we have to be in range of.

1 (Pause.)

2 CHAIR PINCUS: Yes, we're missing some
3 people.

4 (Pause.)

5 CHAIR PINCUS: Okay. So I think we're
6 all here.

7 Okay. Okay. Right.

8 (Pause.)

9 MS. OGUNGBEMI: Okay. We are now
10 voting on whether Measure 0055 should be added to
11 the Core Set. Voting is open.

12 (Pause.)

13 CHAIR PINCUS: Has everybody voted or
14 attempted to vote?

15 MS. OGUNGBEMI: We need one more vote,
16 just one. He is not included, yes, thank you,
17 okay.

18 Results are 60 percent yes, 40 percent
19 no for whether 0055 should be added to the Core
20 Set.

21 CHAIR PINCUS: We had 60 --

22 MS. OGUNGBEMI: It has to have been --

1 it has to be greater than 60 percent.

2 Yes. So the votes have to be greater
3 than 60 percent, so greater than 60 percent is
4 required in order for the measure to pass, if you
5 will, for recommendation for addition to the Core
6 Set.

7 CHAIR PINCUS: So that means 7 out of
8 10 people have to vote.

9 (Pause.)

10 MS. OGUNGBEMI: We are now voting on
11 whether Measure 0541 should be included in the
12 Core Set. Voting is open.

13 CHAIR PINCUS: Say again what the name
14 of it is so everybody hears that.

15 MS. MUKHERJEE: It is 0541, Proportion
16 of Days Covered: 3 Rates by Therapeutic Category.

17 (Pause.)

18 MS. OGUNGBEMI: The results are for
19 Measure 0541 80 percent yes and 20 percent no.
20 This measure is going to be added to the Core Set
21 -- recommended to be added to the Core Set, not
22 certainly.

1 We are now voting on whether Measure
2 2607, which is Diabetes Care for People with
3 Serious Mental Illness: Hemoglobin A1c Poor
4 Control is going to be -- or is recommended to be
5 added to the Core Set. Voting is open.

6 (Pause.)

7 MS. OGUNGBEMI: Results are 70 percent
8 yes and 30 percent no. This measure is
9 recommended to be added to the Core Set.

10 We are now voting on whether Measure
11 2111, Antipsychotic Use in Persons with Dementia,
12 should be recommended to be added to the Adult
13 Core Set. Voting is open.

14 (Pause.)

15 MS. OGUNGBEMI: Results are 60 percent
16 yes and 40 percent no. Because we did not reach
17 61 percent, the measure will not be recommended
18 to be added to the Core Set.

19 We are now voting on whether Measure
20 1933 should be added to the Core Set. I cannot
21 recall the title -- and the -- the -- Measure
22 1933, Cardiovascular Monitoring for People with

1 Cardiovascular Disease and Schizophrenia.

2 (Pause.)

3 MS. OGUNGBEMI: Results are 60 percent
4 yes and 40 percent no. The measure will not be
5 recommended to be added to the Core Set.

6 MS. GORHAM: So those are the measures
7 that we wanted to look at individually and vote
8 on individually. Our thought was that we were
9 actually going to prioritize today, but I think
10 -- they'll pull up the results of the voting, but
11 I think we only have support for three measures,
12 and that being the case, I'll put it before the
13 task force, do you want to prioritize those three
14 measures, or do you want to hold onto those
15 measures, vote on the asthma/maternity measures,
16 and then prioritize after all of the measures are
17 voted on?

18 (Pause.)

19 MS. GORHAM: Okay. So we had a motion
20 and a second to just prioritize tomorrow after we
21 vote on the asthma and the maternity measures and
22 contraceptive measures, because you can't have --

1 (Laughter.)

2 MS. GORHAM: So -- so we'll do that.
3 And just for the record, Alexandra, can you state
4 the measures that the task force supported?

5 MS. OGUNGBEMI: Yes. The task force
6 supported Measure 2152, Preventative Care and
7 Screening: Unhealthy Alcohol; Measure 0541,
8 Proportion of Days Covered: 3 Rates by
9 Therapeutic Category; and Measure 2607, Diabetes
10 Care for People with Serious Mental Illness:
11 Hemoglobin A1c Poor Control.

12 MS. GORHAM: Thank you. Okay. So
13 we'll hold onto these measures. We'll discuss
14 asthma, maternity, and contraceptive tomorrow,
15 and we will then prioritize after that.

16 CHAIR PINCUS: Do you want to do
17 public -- public comments?

18 OPERATOR: At this time, if you would
19 like to make a comment, please press star, then
20 the number one.

21 (No response.)

22 OPERATOR: There are no public

1 comments from the phone line.

2 CHAIR PINCUS: Any public comments in
3 the room?

4 DR. LIU: Can you hear me? Sorry I
5 have not introduced myself. I am Junqing Liu,
6 Research Scientist at NCQA.

7 So I'd like to make several comments
8 regarding three measures. The first is the eye
9 exam for people with diabetes. That measure
10 actually shows the largest performance room for
11 improvement among the diabetes measure set. Of
12 all kinds of indicators, that indicator had the
13 lowest rate. That's showing room for
14 improvement.

15 And we did see correlations among the
16 ten indicators. However, each of them is
17 addressing a different aspect of care for people
18 with diabetes, and that particular measure had
19 the lowest rate.

20 So my second comment is about follow-
21 up after emergency department visit for mental
22 illness and alcohol and other drug dependence.

1 That's NQF number 2605. I believe that measure
2 was discussed last year by the task force, but it
3 was not recommended. I just wanted to give some
4 update of the new developments since last year
5 for that measure.

6 So that measure is now approved and
7 included in HEDIS's 2017 measure set. So
8 Medicaid, Medicare and commercial plans will
9 start reporting that measure using 2016 calendar
10 year data. That's just something for your
11 consideration.

12 And also, that measure is used by CMS
13 Medicaid Innovation Accelerator Programs. There
14 were about a dozen states participating in that
15 program, and they used Medicaid fee-for-service
16 and managed care plan data to report that measure
17 because they think that's an important measure
18 because mental health and substance abuse issues
19 are the top-ten conditions among Medicaid
20 beneficiaries for ED visits, and there is also
21 evidence showing that those who receive follow-up
22 care -- who do not receive follow-up care are six

1 times more likely to be readmitted to the ED.

2 And that measure is a pure claims-based measure,
3 so that's more feasible to report.

4 So I would encourage the task force to
5 consider that measure given the new developments
6 and the evidence in support.

7 Another measure I would like to
8 recommend is the NQF 2601. That is BMI Screening
9 and Follow-Up Care for People with Serious Mental
10 Illness.

11 I think we are all aware that
12 metabolic risks are higher among this population,
13 and our evidence find that there is higher
14 prevalence of obesity and overweight for people
15 with SMI, and that they receive lower quality of
16 care. Our testing results showed that the
17 performance rates on BMI screening and follow-up
18 for people with SMI is half the rate for the
19 general population. So 27 percent for the SMI,
20 and a 54 percent for the general population. So
21 it is definitely showing disparities in care.

22 So those are the three measures that

1 I would encourage the task force to consider.
2 That's the follow-up after ED measure and the BMI
3 measure, and also I made a note about the eye
4 exam for people with diabetes.

5 CHAIR PINCUS: So I am -- actually, I
6 have a question for NQF staff, just it's unclear
7 to me why we have the voting before the public
8 comments. It seems to me that you -- one would
9 want to have public comments to inform the
10 voting.

11 MS. GORHAM: We can -- so we can. We
12 can --

13 CHAIR PINCUS: Just as a general rule.
14 It's just --

15 MS. GORHAM: Right.

16 CHAIR PINCUS: -- I am curious to
17 understand how that --

18 MS. GORHAM: So that's --

19 CHAIR PINCUS: -- process --

20 MS. GORHAM: -- definitely good
21 feedback, so we can definitely make sure we do
22 that, and we'll do that tomorrow as well as Day

1 3. But because I am assuming you -- you like
2 some of the measures, and we can definitely put
3 those back --

4 CHAIR PINCUS: I am just wondering
5 whether --

6 MS. GORHAM: -- for consideration.

7 CHAIR PINCUS: -- you know, that
8 information, you know, would influence people's
9 thoughts about whether to reconsider or add some
10 additional measures for consideration. So let me
11 sort of open that up for nominations from people,
12 having heard the comments from Junqing, are there
13 any members of the committee that would like to
14 reconsider any of the measures, or consider,
15 because some of them weren't considered, measures
16 again? Ann?

17 DR. SULLIVAN: The ED follow-up
18 measure, where -- I mean, is that something that
19 we could consider, or where is that measure --
20 has that been NQF-endorsed, the ED follow-up
21 measure? Yes.

22 And it's being -- I mean, in terms of

1 the concept of alignment and doing things that to
2 some extent kind of make sense, I don't remember
3 that one actually from last year, but --

4 CHAIR PINCUS: It's a recently
5 endorsed measure.

6 DR. SULLIVAN: Recently. So I would
7 propose perhaps that that be considered. Is that
8 possible, that we could add it?

9 CHAIR PINCUS: I think it's possible.

10 DR. SULLIVAN: I don't know if people
11 are interested or not, but.

12 CHAIR PINCUS: George?

13 MEMBER ANDREWS: Yes, I know NCQA
14 already has follow-up after hospital discharge,
15 seven days and 30 days, and I know the results on
16 those measures, or the performance on those
17 measures, is pitiful in terms of the level of
18 follow-up percent-wise, okay?

19 Emergency room is even tougher because
20 a lot of the population that we're talking about
21 uses emergency room as the primary care setting.
22 So to get a follow-up post-emergency-room visit,

1 the access becomes a major and a critical issue,
2 and -- and I know access, and I think we
3 mentioned it earlier, is an issue.

4 Now, having said all of that, do I
5 think it is important? Absolutely, definitely
6 so. I think that, you know, addressing those
7 patients that have had a visit to the emergency
8 room, whether you are being followed by PCP or
9 not, is a must, so I'm not sure what message I am
10 saying, but I -- I do -- I guess overall, what I
11 am saying is it's a tough one to manage because
12 it encompasses again that access issue that I
13 think is a critical one.

14 CHAIR PINCUS: So does that mean
15 you're speaking in favor of it?

16 MEMBER ANDREWS: Yes.

17 CHAIR PINCUS: Okay. Other comments?
18 And this is specifically on the follow-up after
19 emergency room visit.

20 MEMBER SHA: So I think it's Measure
21 2605.

22 CHAIR PINCUS: So Ann, are you putting

1 that before us to vote?

2 DR. SULLIVAN: Yes, I'd like to
3 propose that we consider Measure 2605.

4 CHAIR PINCUS: Can -- can we hear the
5 specifications for that?

6 MS. GORHAM: Sure. The measure
7 description, the percentage of discharges for
8 patients 18 years of age and older who had a
9 visit to the emergency department with a primary
10 diagnosis of mental health or alcohol or other
11 drug dependency during the measurement year and
12 who had a follow-up visit with any provider with
13 a corresponding primary diagnosis of mental
14 health or alcohol or other drug dependence within
15 seven and 30 days of discharge.

16 It is an NQF-endorsed measure. The
17 numerator statement, the numerator for each
18 denominator population consists of two rates,
19 mental health and alcohol or other drug
20 dependence. There are -- the denominator
21 statement, patients who were treated in discharge
22 from an emergency department with a primary

1 diagnosis of mental health or other alcohol or
2 drug dependence on or between January 1st and
3 December 1st of the measurement year.

4 This is a process measure. The care
5 settings: ambulatory care, clinical office,
6 clinic, behavioral health, psychiatric,
7 outpatient, hospital, acute care facility. The
8 data source is administrative claims. The level
9 of analysis is health plan, population, state.
10 And it is an NCQA measure.

11 DR. PATTON: Harold?

12 CHAIR PINCUS: Yes, Lisa.

13 DR. PATTON: Yes, so I think the meat
14 of the discussion the last go-round was about the
15 mental health or substance use being the primary
16 diagnosis, and so there was some concern from the
17 panel about -- about how the diagnosis would be
18 categorized, that it might be secondary, or it
19 might be coded as secondary, and so that would --
20 those numbers would be lost in the -- in the
21 measure, in capturing it.

22 CHAIR PINCUS: Yes, so but I guess

1 this measure is designed to be less sensitive and
2 more specific.

3 DR. PATTON: I just recall that as
4 part of the reason it didn't go forward before.

5 CHAIR PINCUS: Other comments about
6 this measure? Kim?

7 DR. ELLIOTT: I just want to voice
8 some concern about the challenges in identifying
9 those Medicaid members that are in the ED. There
10 is no requirement under federal law now for
11 hospitals to let a health plan or a primary care
12 doctor know when a patient has entered the ED,
13 like inpatient, so for them to be able to impact
14 and get that follow-up care initiated is going to
15 be extremely challenging. Sometimes they may not
16 find out until those claims come in 30 days
17 later, so the follow-up after discharge within
18 seven days, the accountability and responsibility
19 is going to be extremely challenging to apply to
20 a health plan, a managed care organization or to
21 a primary care doc.

22 CHAIR PINCUS: Other comments? Ann?

1 DR. SULLIVAN: I -- I absolutely agree
2 on kind of how challenging it is. I think that
3 it's very difficult. But I also -- it's a major
4 I think failure of our system that we don't have
5 more follow-up out of EDs, and I think when you
6 talk about the opioid epidemic and you talk about
7 the drugs, I mean, I think that one of the
8 biggest areas for catching those individuals is
9 when they're in the emergency departments, and we
10 just don't pay enough attention to that. That is
11 a big group of the Medicaid population.

12 So I -- while I -- I think what it
13 would do is shine the light on the problem. I
14 think it would be difficult to fix, but I don't
15 know that that's a bad thing. I don't think any
16 state would come out of this looking very good if
17 they decided to run these numbers, but we talked
18 -- we thought about access, et cetera, if there
19 isn't access in the emergency rooms, and that's
20 an issue, if people aren't getting the follow-up,
21 it's an issue.

22 So I think it's the kind of thing

1 where you're not going to expect good numbers at
2 all, but if you shine the light on it, I would
3 hope that people might think a little bit more
4 about what has to be in those emergency rooms to
5 change this tide of phenomena that -- we keep
6 saying too many people are going to emergency
7 rooms, but we don't kind of emphasize enough what
8 has to happen there.

9 So I would just -- so I would think
10 it's an important measure.

11 CHAIR PINCUS: Diane?

12 MEMBER CALMUS: That was very similar
13 to what I was going to say. I mean, this one
14 seems like one of the measures that might be
15 helpful from a policy perspective of providing
16 information and really just getting -- getting
17 that message to people who could actually, you
18 know, change some of these issues and -- and make
19 that follow-up possible, so for that reason, I
20 think it's an important measure.

21 CHAIR PINCUS: Julia?

22 DR. LOGAN: Yes, I think it -- I think

1 it's definitely a very important issue,
2 obviously. I think it would fall into the
3 category of very few states reporting because of
4 the difficulty with obtaining mental health data
5 because they can -- the person can follow up with
6 a mental health provider, so that would be very
7 difficult for states to obtain.

8 CHAIR PINCUS: Explain a little bit
9 why it would be difficult. If they put in for a
10 claim, for an encounter, for a -- for a visit,
11 for an outpatient visit, why wouldn't it be
12 captured in claims?

13 DR. LOGAN: Well, it would be
14 difficult for managed care plans to obtain. They
15 can't obtain it. The state, the overall state
16 program could obtain it, but the mental health
17 claims for the managed care plans are very
18 difficult to get.

19 CHAIR PINCUS: I am not sure I
20 understand. Why is it different from other
21 claims?

22 DR. LOGAN: It --

1 CHAIR PINCUS: Is it carved?

2 DR. LOGAN: -- is carved out, yes.

3 DR. LIU: If I could offer some notes
4 here. So the measures we recommended for HEDIS
5 Health Plan reporting do require corresponding
6 benefit for the follow-up after ED for mental
7 illness. It requires mental health benefits.
8 And the follow-up after an ED visit for an
9 alcohol or other drug dependence requires
10 chemical-dependence benefit.

11 So those were carved out. The
12 behavioral health benefit would not be required
13 to report the measures.

14 The other note is that, when we
15 develop a measure, we discuss with the -- our
16 measurement advisory panels, they noted that
17 there may be challenges in sharing that
18 information between ED visit and seven and 30
19 days follow-up, but they thought that this
20 measure, when it's out there, it would encourage
21 providers between the EDs and outpatient to
22 coordinate and communicate that information

1 sharing.

2 So they thought there is a gap in
3 care, and that this measure would help to address
4 the care coordination follow-up for this
5 vulnerable population.

6 CHAIR PINCUS: So let me step back of
7 being Chair and just comment on this.

8 So I -- I agree very much with Diane
9 that this is kind of a broad-based policy issue
10 that can push the needle, I think. Number one, I
11 don't think that, you know, if there's a carve-
12 out, they should get a pass, that actually, that
13 states should be encouraged to require that, if
14 they're going to have carve-outs, that that
15 information should be shared and available and
16 that's not insuperable. It happens in a number
17 of states. And so that can be done.

18 And number two, it also encourages
19 hospital EDs to develop a network of outpatient
20 providers that they have sort of ready
21 connections and access to, to be able to get
22 follow-up. So I think at a policy level, I agree

1 with Ann, it's not going to look good initially,
2 but it is something that shines a light on it and
3 can encourage, you know -- you know, a bad
4 situation to get better.

5 MEMBER DUNN: So this is Katie. I
6 agree that the -- I am sure the measure will
7 shine a light on the issue, but there's a huge
8 feasibility issue here.

9 My experience, and I would think that
10 experience of other Medicaid directors, is that
11 the hospitals and their emergency departments are
12 not the place for this type of system
13 development. I venture that we could not pay
14 them enough to do this sort of work when we can't
15 even get them to have a dentist in their
16 emergency room.

17 May I make a recommendation that this
18 particular measure, if it's not included this
19 year, that it go out to the Medicaid directors
20 and actually do an assessment of what the
21 feasibility is? I think between cooperation from
22 the emergency departments as well as issues of

1 privacy and concerns about sharing mental health
2 and SUD diagnoses, you would see a tunneling and
3 a lack of coding of those -- of those diagnoses.
4 Thank you.

5 CHAIR PINCUS: Other comments?

6 DR. LIU: Actually, I would like to
7 share our testing results of the two measures.
8 We tested the measures in Medicaid claims data,
9 and the results, the performance results is 60
10 percent for seven-day follow-up and 80 percent
11 for the 30-day follow-up. Actually, the rates
12 are a little bit higher than the follow-up after
13 hospitalization for mental illness. We discussed
14 with our measurement advisory panels, they
15 thought this makes sense because the ED
16 population is different from the hospitalized
17 population.

18 So, and for the AOD, our testing also,
19 alcohol and other drug dependence population, our
20 testing results show that there is sufficient
21 denominator for that ED visit for alcohol and
22 other drug conditions.

1 MS. RANEY: And in terms of testing,
2 this measure is part of the Certified Community
3 Behavioral Health Clinic Demonstration Pilot.
4 It's one of the required measures that are going
5 to be part of that pilot going forward, so while
6 all the states have not yet been collecting that
7 measure, it is part of that -- that measure set
8 for -- for attempted collection and reporting.

9 CHAIR PINCUS: And 24 states had
10 planning grants --

11 MS. RANEY: Twenty-four states had
12 planning grants, and I think eight or so will be
13 selected in January of 2017.

14 CHAIR PINCUS: Any other comments?

15 (No response.)

16 CHAIR PINCUS: So are we prepared to
17 vote on this?

18 (No audible response.)

19 CHAIR PINCUS: Okay.

20 MS. OGUNGBEMI: We are now voting on
21 whether Measure 2605 should be added to the Adult
22 Core Set. The title is Follow-Up After Discharge

1 from the Emergency Department for Mental Health
2 or Alcohol or Other Drug Dependence. Voting is
3 open.

4 I am not sure the system was capturing
5 responses, so you -- could you please vote?

6 For those listening on the phone,
7 we're having some technical difficulties that
8 we're trying to resolve.

9 Let's go to a manual vote, please.
10 Okay. So we are voting on Measure 2605, Follow-
11 Up After Discharge from the Emergency Department
12 for Mental Health or Alcohol or Other Drug
13 Dependence. We have nine voters. Katie, I have
14 your vote. Raise your hand if you support the
15 measure.

16 (A show of hands.)

17 Six, yes. So we had six members vote
18 in support of the measure. And can we have hands
19 raised high for those who do not support the
20 measure?

21 (A show of hands.)

22 Three. Okay.

1 So for the record purposes, we have
2 six task force members in support of Measure
3 2605, and we have three task force members that
4 do not support the measure. So that is 67
5 percent in support of the measure, so this
6 measure we will vote later after we vote on
7 asthma as well as maternity, whether this measure
8 will be included into the Core Set as a
9 recommendation to CMS.

10 CHAIR PINCUS: So are any -- is there
11 anybody else proposing any other measures?

12 (No response.)

13 CHAIR PINCUS: Okay. So why don't we
14 move on to --

15 MS. OGUNGBEMI: Gaps.

16 CHAIR PINCUS: -- gaps.

17 MS. MUKHERJEE: So the last section of
18 the day is a discussion about the gaps, the gaps
19 that we have identified so far and any additional
20 gap areas that have come up today.

21 One that was mentioned was
22 stratification, but this is the -- the MAP gap

1 list as it stands right now, and the elements are
2 beneficiary-reported outcomes; access to primary,
3 specialty, and behavioral health care; care
4 coordination; and some of these have some sub-
5 points like quality of life; integration of
6 services, especially medical and psychosocial;
7 primary care and behavioral health integration;
8 cultural competency of providers; efficiency, and
9 by efficiency, misuse, overuse, inappropriate
10 emergency department utilization; promotion of
11 wellness; work force and chronic opiate use;
12 polypharmacy; engagement and activation in health
13 care; trauma-informed care; treatment outcomes
14 for behavioral health conditions and substance
15 use disorders; maternal health, which we will
16 deal with tomorrow and look at all the measures;
17 and then long-term supports and services.

18 And just a note that the HCBS, the
19 Home- and Community-Based Services project is
20 still ongoing, and they are looking at sort of
21 the universe of HCBS and measures and everything
22 there.

1 And then the one extra point we
2 discussed today that's not on this list is
3 stratification within a measure based on severity
4 based on type of mental illness, and -- and now,
5 I turn it over to Harold for a discussion of
6 these questions and addition of any gap areas to
7 this list.

8 CHAIR PINCUS: So, I mean, we should
9 probably go back, but I -- I guess the -- go back
10 to keeping that in front of us, the list.

11 So looking at this list, do people
12 think that, with our recommendations that we have
13 made so far -- and actually, could we just remind
14 everybody about what those recommendations were,
15 specifically? Because I guess the ones that
16 we've formally recommended are -- I think there
17 were four measures that were officially
18 recommended?

19 MS. GORHAM: So I can tell you quickly
20 the numbers. I have to -- it would take me some
21 time to get the title of all the measures. But
22 2152, 0541 --

1 CHAIR PINCUS: We -- you've got to
2 tell us what they are --

3 MS. GORHAM: Okay. Give me a --

4 CHAIR PINCUS: -- and not just the
5 number. It's hard to keep a spreadsheet in our
6 heads.

7 MS. GORHAM: Okay. 2152, Preventive
8 Care and Screening: Unhealthy Alcohol Use
9 Screening and Brief Counseling was one measure
10 recommendation. 0541, Proportion of Days
11 Covered: 3 Rates by Therapeutic Category was
12 another recommendation.

13 2607, Diabetes Care for People with
14 Serious Mental Illness: Hemoglobin A1c Poor
15 Control was the fourth recommendation. And 2605,
16 ED visit, was another recommendation. 1933 did
17 not pass.

18 CHAIR PINCUS: So just looking at
19 that, it seems that there was two that relate to
20 behavioral health, although it's not specifically
21 with regard to access. And screening for -- yes,
22 it's alcohol, and also the one for, yes, for

1 diabetes, so it was three that relate to
2 behavioral health, so they are not specifically
3 for access.

4 One of them is partly related to
5 outcomes in terms of the diabetes one, although
6 it's -- it's outcomes in relationship to a
7 comorbid chronic illness. And it's not clear
8 whether the fourth one, which is the -- the days
9 covered --

10 MS. GORHAM: We'll put them on the
11 screen --

12 CHAIR PINCUS: Yes.

13 MS. GORHAM: -- so that you can see
14 them.

15 CHAIR PINCUS: -- is specific to any
16 of the gaps mentioned. So the -- it's not clear.
17 That would be a leap because you -- I mean,
18 people think of wellness as something that's more
19 preventative, not for people that have, you know,
20 a chronic disease and seeing whether they're
21 taking their medication.

22 MEMBER SHA: So would the diabetes

1 care of patients with serious medical illness
2 address the primary care and behavioral health
3 integration?

4 CHAIR PINCUS: Yes, that would be one
5 that does.

6 So I mean, do -- do people have any
7 suggestions, given what we just voted on, that we
8 should remove any of these gaps? Any proposals
9 to remove gaps?

10 (No response.)

11 CHAIR PINCUS: Can you maybe go back
12 to the gaps list? Marissa?

13 MEMBER SCHLAIFER: The only thing I
14 thought was worth mentioning, and I don't -- I
15 don't think it addresses it, you can just take it
16 off, with the opioid use. I think they're
17 completely different, but I just thought I would
18 throw that out there.

19 CHAIR PINCUS: Okay. No, that's a
20 good point.

21 MEMBER SCHLAIFER: I think they are
22 different, but --

1 CHAIR PINCUS: Yes, but the question
2 is is that -- do people think that there's
3 sufficient coverage given some of the new
4 measures that have been proposed to eliminate any
5 of these gaps?

6 MEMBER SCHLAIFER: And I would say no,
7 but --

8 CHAIR PINCUS: Okay. So anybody,
9 going once, going twice, going three times?

10 (No response.)

11 CHAIR PINCUS: So no gaps are being
12 removed. Are there any gaps that people feel
13 should be added based upon the review of what we
14 just looked at both in terms of what has been
15 proposed and what has -- and what is currently in
16 the measure set? Oh, Kim, did you just put your
17 thing up?

18 DR. ELLIOTT: It -- it doesn't really
19 fit into any of those buckets, but I continue to
20 be concerned about access to care on the
21 behavioral health side, and there really aren't
22 good measures to capture that.

1 And I think everybody that provides
2 care and services on the behavioral health side
3 is extremely important to the system, but every
4 measure that I've looked at over the last several
5 years doesn't focus on the assessed need of that
6 individual and getting them in to a behavioral
7 health professional. It really focuses on many
8 of the supportive types of providers, which are
9 critical in the system but may not be addressing
10 the fundamental need of that individual from an
11 access to care perspective.

12 So I just want to throw it on the
13 table that we really need to start looking at
14 developing a measure, if there isn't one being
15 developed, related to addressing the access to
16 care to behavioral health professionals.

17 CHAIR PINCUS: I should say that a few
18 colleagues and myself actually have proposed
19 developing such a measure in a grant proposal to
20 NIMH that was not funded, yes, essentially
21 developing at a -- at a health-plan level an
22 accessibility to -- to behavioral health care

1 index.

2 DR. ELLIOTT: Well having managed the
3 quality of care and adverse outcomes for the
4 Medicaid program for many years, I just see the
5 adverse outcomes that have occurred as a result
6 of -- and we all know that there's a lack of
7 providers available, but if you're not measuring
8 it, there is not much you can really do to
9 address that issue.

10 CHAIR PINCUS: Yes. So yes, so it's
11 -- basically, you're putting sort of added
12 emphasis onto that category and added urgency.

13 Any other comments, suggestions for
14 things that are left out?

15 (No response.)

16 CHAIR PINCUS: Okay. So let's
17 continue with this gap and hopefully that we can
18 encourage -- and one of the issues is who is it
19 that we should be encouraging to develop these
20 measures? I -- I think that one group that we
21 should certainly as an audience for this, is NQF
22 itself, as they, you know, develop some of their

1 new procedures in terms of thinking about the,
2 you know, measurement -- measure incubator
3 process and those kind of things, so I think that
4 would be an audience that I think is worth, you
5 know, really specifying. Also CMS, which still
6 has, I think, a load of resources for measure
7 development.

8 DR. MATSUOKA: Less so on the Medicaid
9 side --

10 CHAIR PINCUS: Yes.

11 DR. MATSUOKA: -- yes.

12 CHAIR PINCUS: And obviously NCQA as
13 well.

14 Okay. So any other final comments?

15 (No response.)

16 CHAIR PINCUS: Do we have public --
17 any reports from the public at the end?

18 MS. GORHAM: So we moved public
19 comment up.

20 Operator, if you can open the line for
21 public comment please?

22 OPERATOR: Okay. At this time, if you

1 would like to make a comment, please press star
2 and then the number 1.

3 There are no public comments from the
4 phone lines.

5 CHAIR PINCUS: Any public comments
6 from the room?

7 DR. LIU: So I noticed one gap area
8 that this task force identified is access to
9 care, so we -- NCQA has two relevant access to
10 care measures I would like to mention.

11 One is Adults' Access to Preventive or
12 Ambulatory Health Services. I can search to see
13 if that one is NQF-endorsed. If so, we can find
14 the number.

15 The second measure is Use of First-
16 Line Psychosocial Care for Children, Adolescents
17 on Antipsychotics. That measure, I believe, is
18 NQF-endorsed. I know there will be a Joint Child
19 and Adult Task Force meeting tomorrow, so the
20 idea of that measure is to promote use and access
21 to psychosocial care around the prescription of
22 antipsychotic medications.

1 CHAIR PINCUS: So -- and I think
2 that's actually a good point that I think is
3 worth putting on the agenda for tomorrow's
4 discussion, or tomorrow and/or on Thursday,
5 because last time, there was a recommendation
6 from the Child Task Force for multiple
7 antipsychotic use which was not -- which was
8 actually proposed for endorsement but was not
9 endorsed by NQF.

10 DR. LIU: Actually, the use of -- the
11 first-line -- use of first-line --

12 CHAIR PINCUS: Right, but the -- but
13 the one for multiple -- multiple antipsychotic
14 medication was not endorsed, and so it -- and
15 that was the one that was recommended for the
16 child Medicaid set.

17 MS. GORHAM: Yes, and the Child Task
18 Force will have that conversation on Day 3.

19 CHAIR PINCUS: Okay, so we make sure
20 that goes. Okay. Thank you.

21 So it has been a -- a busy day,
22 intense, and thank you, all. I want to thank all

1 the members of the task force. We have another
2 busy day tomorrow.

3 I especially want to thank NQF staff.
4 You know, it's a lot of work to prepare for this,
5 so we really appreciate it. So I will see
6 everybody tomorrow.

7 MS. GORHAM: Yes, and I definitely
8 want to thank you all for your patience with our
9 voting problems, but we hope to have all of the
10 technical issues straightened out for tomorrow.
11 I know that a few members are going to dinner, so
12 if you all would like to all go together for
13 dinner, then definitely let us know. Thank you.

14 (Whereupon, the above-entitled matter
15 went off the record at 4:02 p.m.)
16
17
18
19
20
21
22

A		
a.m 1:9 4:2 109:13,14	309:21 315:2 317:21	23:2,3,5,7 27:1 29:1
A1c 123:17 233:15	318:3 320:20 321:11	31:1 38:4 68:5 77:4
262:6 263:22 266:14	321:15 324:8,9,11,20	135:18 138:4 153:16
292:3 294:11 317:14	accessibility 93:1	155:3,13 234:4
AAP 52:10 198:10	321:22	237:14 247:7,9
abbreviated 49:14	accessible 193:8	290:10,19 291:20,21
ability 14:17 69:12 74:2	accessing 96:14	292:5,9,12,18,20
76:2 88:6 105:15	accountability 79:3	293:5 312:21 320:13
114:19 139:11 141:16	80:4,14 84:2 94:15	322:11,12
145:5 148:14 170:1	119:15 121:21 122:3	adding 15:3,7 53:16
180:11 181:5,18	122:22 123:10 124:7	245:20 250:16
185:14 225:13 229:6	158:18 162:16 233:8	addition 16:9 29:2 81:1
253:20	266:20 267:6 304:18	151:21 185:8 187:14
able 19:10 37:6 42:11	accountable 78:22	214:17 215:12 226:18
50:8 66:15 69:14	105:13 233:9	232:17 287:13 291:5
70:15 72:1,7 73:9	accuracy 156:17	316:6
76:20 93:16 97:20	accurate 121:15 128:5	additional 9:13 47:2
98:4 102:22 110:9	accurately 13:2	106:14 123:21 181:21
117:19 127:9 130:12	ACHC 281:4	198:21 215:8 246:3
131:21,22 135:16	achieve 19:8	247:10,16 274:2
136:11 142:8 146:11	achieving 120:20	299:10 314:19
154:16 158:20 159:7	acknowledges 231:11	Additionally 129:15
160:8 166:6,9 168:19	ACO 57:3,4 82:14	240:1
172:6 175:10 178:13	ACOs 57:2	address 66:14 83:4
182:6 194:5 200:8	acquisition 69:3	120:14 121:11 134:1
209:14,19 210:1,2	act 131:10	155:8 164:22 168:19
211:3,7 212:7 224:20	acted 35:19	170:15 178:18 185:1
264:22 268:3 278:18	action 22:19 102:18	186:3 187:21 190:21
279:1 304:13 309:21	278:22	216:22 234:17 309:3
abnormal 117:6	actionability 163:5	319:2 322:9
above-entitled 109:12	164:8	addressed 67:6,19
183:1 289:16 326:14	actionable 145:2 153:7	113:18 188:4 215:7
absolute 151:16 184:19	162:11,12,17 163:12	255:11,21 259:1
absolutely 203:9 268:8	163:16 164:15 169:14	264:19
301:5 305:1	187:2 278:6	addresses 40:21
abstain 14:2	actions 145:16 185:17	117:10 217:8 243:11
abstinence 76:16	activated 93:14 106:13	277:8 319:15
abuse 2:6 217:9 219:4	106:16	addressing 92:22
222:12 223:12 224:5	activating 92:17	281:11 295:17 301:6
225:20 228:10 296:18	activation 216:13	321:9,15
AC 262:6	315:12	adds 45:16
ACA 21:13	active 163:9 227:9	adequately 117:2 186:3
Academy 10:6 18:3	actively 25:21,21	adherence 117:8
131:4 213:19	activities 228:20	235:22 236:5,16
Accelerator 296:13	activity 39:13 49:9	237:12 242:5,14
accept 56:6 283:2	108:6	adherent 236:3 241:3
acceptable 182:5	actual 65:11 76:18	Adjourn 3:21
acceptance 224:12	214:22 222:2 247:1	adjustment 67:20,21
accepted 236:1 240:21	acute 118:13 303:7	286:19
241:16 242:6 263:5	adaptable 155:14	administer 117:20
access 36:12 37:13	adapted 189:17	210:11
45:12 55:5,6,16,19	add 23:15,15 36:19	Administration 2:6
56:2 60:1 86:21 87:12	53:3 77:13 158:11	administrative 75:16
87:14 127:10 131:19	180:5 232:22 236:4	108:5 123:3,5 127:3,5
150:8 172:6 217:7	248:5,6 279:6 284:4	136:4,8 143:6 164:3
218:7 228:8 251:21	299:9 300:8	164:18,19 174:1,6
301:1,2,12 305:18,19	add-on 161:18	182:3 185:14 231:4
	added 5:15 22:7,21	235:15 239:21 251:19
		252:9 276:21 287:3
		303:8
		administratively 159:3
		admissions 123:14
		admittedly 119:14
		Adolescents 324:16
		adopted 81:8 129:16
		275:19
		adoption 178:3 190:2
		adult 1:3 3:10,15 4:10
		4:18,21 5:15 7:15
		14:13 16:17 17:1,19
		20:4,14,18 21:1,15
		22:8 24:10 26:3 31:21
		33:12 49:11,19 50:11
		58:6,7,10 65:8 74:15
		91:15 93:6 98:3 121:4
		122:1,5 123:9,13
		126:12,16 127:21
		133:2 134:8,20 135:1
		138:14 142:10 146:15
		148:21 175:15 189:17
		190:14 192:8,20,22
		215:15 216:18 218:22
		232:16 237:8 265:15
		275:13 278:1,11
		292:12 312:21 324:19
		Adult/Child 238:13
		adults 21:1,6,6 29:5
		91:8 137:1 155:12
		157:11 269:22
		Adults' 324:11
		advance 31:3 209:18
		209:18 210:1
		advanced 124:16 125:4
		125:6,7
		adverse 204:20 322:3,5
		advice 139:13 244:3
		advisable 29:20
		Advising 243:21
		Advisor 5:22 6:1 7:8
		advisory 2:2 11:3 24:9
		135:7 308:16 311:14
		advocates 166:19
		affairs 84:9
		affect 67:16
		affinity 120:17 201:6,17
		201:19
		affordability 93:1
		African-American
		113:1
		afternoon 110:4 183:5
		age 35:5 65:6 74:20
		99:7 125:11 143:10
		189:18 244:1,7,14
		256:8 262:9 286:9
		302:8
		agencies 87:7 103:20

agency-type 103:12	88:15,21 91:6 92:2,3	207:2 211:19 240:15	20:19 57:20
agenda 4:11 5:6 43:8	111:11 114:8 172:18	antagonists 235:12	area 12:17 13:15 43:16
325:3	186:13 198:11 232:19	240:5	76:15 103:11 111:12
ages 192:9,10	261:18 300:1	antenatal 127:12 205:8	120:21 130:2 132:1,4
aggregate 63:22 176:9	all-cost 123:13	anti 257:21	144:8 147:1 149:21
aggregating 176:15	Alliance 255:7	anti-depressant 236:20	155:4,21 156:2
aggregation 138:18	allow 103:17 123:1,2,6	anti-psychotic 22:12	169:21 185:17 197:20
198:4,14	allowable 190:2	antibiotic 116:17	201:17 215:6 217:1,9
aggregator 54:19	allowed 31:16 61:5	anticipate 169:2	218:16 219:19,22
ago 41:15 56:3 171:2	126:19 142:18	anticipated 151:12	220:10 236:7 243:12
236:4 242:10	allowing 181:9	155:21	251:22 252:16 255:1
agree 106:1 107:2	allows 29:2 115:9	anticipates 157:5	255:9,10 256:14
167:16 169:11 202:16	alternative 115:10	antidepressant 33:18	259:15 324:7
203:14 238:19 239:17	227:15	126:5	areas 3:17 14:18 16:13
260:14,16 305:1	alternatives 135:21	antipsychotic 201:18	17:20 18:13 64:8 67:4
309:8,22 310:6	AMA 217:10 224:1,6	251:6,14 258:2	86:21 87:1 112:1
agreement 117:15	ambitious 4:11 5:6	270:11 276:3,18	113:15 119:20,21
142:1 206:18	23:12 43:19	292:11 324:22 325:7	120:3,6,7 122:7 125:3
agreements 181:6	ambitiousness 43:22	325:13	131:1,12,15 134:20
ahead 9:3 51:4 57:13	ambivalent 265:10	antipsychotics 254:17	138:2 140:1 146:5
139:18 210:8 214:13	ambulatory 75:20	257:5 324:17	147:13 151:18,21
288:21	145:3 231:13,16	anxiety 143:22 175:22	156:9 157:2 162:21
AHIP 52:9 198:10	232:10,12,12 277:2	anybody 13:9 101:8	170:3 177:22 197:11
AHRQ 59:14 134:11	287:1 303:5 324:12	182:19 209:3 314:11	214:20 215:4,6,9,12
135:7	America's 1:17 10:11	320:8	215:13,17,19,22
aim 111:10 117:21	American 1:15 10:20	anybody's 100:14	216:7 217:5 219:21
120:21	105:7 213:19 281:4	anyway 15:14 167:11	220:12,18 228:3
aiming 288:7	amount 34:7 102:19	273:22	305:8 314:20 316:6
aims 186:4	104:20 135:11 266:11	AOD 311:18	arena 63:14 175:8
Alaska 37:21 133:13	analysis 20:16 50:21	Aparna 10:12	argue 237:8,9
alcohol 33:16 216:20	59:2 69:4 148:7	apologies 71:8	Arizona 11:6
217:13,15 221:10	160:16 213:13 287:5	apologize 49:2	array 16:11
222:3 225:20 228:4	303:9	apparent 65:15	article 145:12
272:2 294:7 295:22	Analyst 2:10 8:4	apparently 125:12	articles 43:12 173:20
302:10,14,19 303:1	analytic 77:19 81:16	appear 100:13 184:2	Articulating 175:5
308:9 311:19,21	82:11,20 162:14	applaud 171:15	artifact 78:7
313:2,12 317:8,22	analyze 147:16	applicable 151:22	Asian 112:22
alcoholism 221:15	and/or 29:5 61:4 65:7	265:14 286:18	asked 13:21 31:18
alert 163:20	70:21 325:4	APPLICATION 1:3	32:10 46:7 50:15 71:9
Alexandra 2:10 20:3	Andrews 1:12 11:7,8	applied 35:18 94:16	109:17 155:19 156:8
31:3 279:21 287:22	35:15 37:14 38:3	95:11	227:14 255:11
294:3	72:20 106:1 196:7,15	apply 275:13 304:19	asking 47:4 87:7 158:2
align 18:16 56:10 57:3	198:15 239:17 256:21	appreciate 6:17 132:14	183:8 245:18 267:15
60:15 62:11,16 82:13	281:18 285:15 300:13	326:5	asks 201:14
122:10 169:19	301:16	approach 229:8	aspect 234:7 265:6
aligned 18:18 185:21	angst 175:14	approached 66:6	295:17
193:3	Ann 2:2 10:16 47:14	approaches 96:5	aspects 79:10 84:21
aligning 56:22 60:6,13	52:17 98:1 99:10	appropriate 51:10	206:22
60:13,15 63:17 64:3	200:11 203:15 247:14	58:16 78:2 126:8	aspiration 157:1
67:17 113:6	250:10 258:17 299:16	186:7 187:22 204:10	assess 24:12 90:16
alignment 3:7 5:12 15:8	301:22 304:22 310:1	227:8 229:3 237:2	117:2 203:6
18:22 19:1,9 25:13	Ann's 94:21	251:21 256:10 258:2	assessed 95:21 203:10
51:14,15 58:14,17	annotation 69:2	259:16,18 281:9	321:5
60:5,9,10,11,11,18	annual 20:13,14 21:20	appropriately 257:13	assesses 243:18
61:3,8,19,20 62:6	22:1 123:14 281:6	approval 115:4	assessing 95:22
63:4,6,8,12,12 64:1	annually 119:18	approved 115:3 296:6	149:17 163:1 234:15
64:14 65:19,20 67:5	answer 166:9 170:9	approximately 20:22	assessment 42:22
68:20 69:1,1,2 72:10	172:15 173:11 201:13	April 5:7 9:13 19:15	45:16 76:1 162:20

310:20
assessments 150:18
assist 184:14
assistance 31:18,18
 34:19 53:6 138:14
 200:16 201:5,9,12,14
 229:1 243:10,19
assistive 145:2
Associate 71:15
associated 80:19 129:9
 184:15
Association 1:13,15
 11:19 71:18 105:8
 281:4
assume 36:16 227:11
assumed 135:5
assuming 222:10 299:1
assumption 237:20
assumptions 69:15
Assurance 2:14
asterisk 31:2 215:19
asthma 23:4 59:7
 235:21 237:6,15,16
 237:19,21 238:1,3,7
 238:11,17,20 239:5
 239:10 274:20 284:5
 293:21 294:14 314:7
asthma/maternity
 293:15
attempt 236:4,14 237:3
 238:5 278:3
attempted 290:14 312:8
attempts 252:1
attention 33:8 75:6 90:5
 137:6,21 236:6
 237:11 252:2 305:10
attorney 213:18
attribute 73:21
audacious 113:12
audible 312:18
audience 13:7 147:9,10
 165:18 166:8,15,16
 166:17 223:8 322:21
 323:4
audiences 167:10
August 17:9,17
auspice 96:20
Authority 2:12
authorization 208:15
automatic 174:8 208:12
AV 257:7
availability 35:10 43:20
 92:22 149:18
available 37:10,11
 84:20 129:3 130:1
 150:8 190:7 191:5
 192:5 194:12 195:1
 205:5 224:15 229:22

231:15,17 236:11
 250:1 309:15 322:7
avenues 27:8
average 74:6 152:15
 243:22 244:6,12
avoid 94:17
aware 297:11
awareness 88:14
 236:15

B

B 169:6
babies 120:12
baby 204:7
back 8:7 9:20,21 12:10
 22:21 30:3,6 40:5,14
 79:20 83:17 84:1,6
 85:18 87:17 94:3,8,11
 94:21 103:6 108:11
 108:20 109:10 132:1
 141:9 148:1,14
 154:11,20,20 157:8
 161:18 162:9,12
 165:4 166:10 173:3
 177:15 182:21 209:2
 214:14 251:4 254:18
 277:21 288:18 289:14
 289:20 299:3 309:6
 316:9,9 319:11
background 133:6
bad 141:13,13 142:3
 179:22 222:6 261:3
 305:15 310:3
balance 26:13 66:12
 166:4 204:16
balancing 64:21 131:10
 226:19
ball 53:20 54:4 88:9,20
bang 272:7
bank 157:7
bar 80:17 119:14
barrier 194:4 206:3,4
barriers 70:20 164:18
 164:19 181:21
base 145:18
based 14:20 16:1 73:1
 97:5 127:3,6 142:12
 148:5 166:15 184:7
 190:15 192:21 193:11
 207:10 220:3 241:13
 316:3,4 320:13
baselines 122:14
basic 41:13 68:15
 198:18
basically 15:14 65:21
 91:8 202:14 225:18
 226:8 322:11
basis 15:4 22:1 121:8

142:12 145:11 193:19
 193:20 201:1
bear 138:11 280:8
beauties 48:2
beauty 48:5
bedevil 19:10
beginning 165:11
beginnings 113:16
begins 21:9
begun 19:20
behalf 11:16
behavior 114:21
behavioral 38:8,13,16
 39:7,16 43:4,9 44:15
 47:21 55:4,5,8,10,17
 55:19,20 58:18 59:7
 92:1 97:1,6 118:3,13
 124:8 125:3 126:3,10
 131:18 146:17 147:2
 175:7,16 213:14
 216:10,22 218:8
 219:3 220:8 221:14
 222:20 223:12 229:4
 243:11 259:3,11
 264:20 266:21 267:17
 271:7 277:3 281:21
 303:6 308:12 312:3
 315:3,7,14 317:20
 318:2 319:2 320:21
 321:2,6,16,22
believe 23:20 196:8
 296:1 324:17
benchmark 78:2 137:18
 152:14,16
benchmarks 35:10
 122:15
beneficial 107:21 218:5
beneficiaries 104:11
 112:6,21 118:4 128:6
 170:17 296:20
beneficiary 170:15
beneficiary's 118:19
beneficiary-reported
 315:2
benefit 8:16 308:6,10
 308:12
benefits 63:11,12
 114:11,13 118:20
 130:8 152:19 168:6
 227:1 308:7
best 51:10 76:9 105:11
 106:5 150:20 170:18
 202:15,17
best-performing
 152:18
better 27:3 39:22 72:7
 78:10,17 81:20 89:18
 152:17 179:1 181:3

221:22 235:13 237:22
 238:2 239:10 256:3
 267:20 310:4
beverages 13:14
beyond 43:18 68:10
 105:15 158:14 206:21
 234:4 260:21 266:10
big 48:18 54:7 60:1,9
 75:17 87:12 89:8
 90:19 93:18 95:20
 99:18,22 100:19
 101:11 114:21 120:20
 124:9,15 125:17
 128:19 197:14 201:11
 221:12 229:11 270:2
 305:11
bigger 50:20 64:1
biggest 53:3 68:17
 146:13 169:22 171:17
 181:4 236:1 305:8
bill 85:17
billing 227:3,19
bipolar 22:12 23:7 38:5
 248:1 251:16 263:17
 269:12 276:3,18
 278:4,10 280:21
 281:13 282:17
birth 205:9,10
births 120:19,20
bit 9:16 14:9 16:16
 17:15 23:11 41:9
 42:19 49:20,22 51:6
 54:21,22 70:19 79:12
 81:19 82:5 85:22 89:4
 110:5,7 111:9 112:4
 114:3 115:19 133:20
 140:3 141:12 146:18
 154:8 158:15 169:17
 190:17 207:10 233:17
 234:3 288:10 306:3
 307:8 311:12
bitty 19:9
black 85:6 261:1
block 257:9
blocks 19:8
blood 23:8 40:10 45:13
 62:17 124:2 158:5,7
 158:10 159:10,19,21
 160:6 176:8 196:9,12
 240:4
blue 93:18 273:6
BMI 297:8,17 298:2
board 107:14 199:18
boat 256:16
body 27:14 33:12
bold 32:13 113:11
born 204:7
bottom 21:11 31:6

93:20 137:12 208:20
box 147:21 228:15
 261:1
boy 172:14
brain 245:2
break 109:7 164:4
 182:21 214:12,14
 285:21 289:14
breakfast 13:11
bridge 277:9
brief 111:7 216:21
 217:4,14 228:6 229:2
 249:3,9 272:2 317:9
briefly 8:15 123:8 124:6
 186:1
bring 15:11 56:9 59:17
 137:6 142:6 206:7
 221:1 252:1 253:8,12
 287:14
Brittany 85:19
broad 16:11 48:8
 185:15 223:2 224:11
 271:22
broad-based 309:9
broader 5:11 57:19
 193:11
broadly 224:3
broke 274:21
brought 75:6 87:10
 157:18 253:7 255:8,9
Brown 113:7
bubble 39:13 93:18
buck 272:7
bucket 78:14
bucketed 32:16
buckets 63:7 320:19
budgetary 70:16 84:18
build 89:20 92:1 97:12
 177:2 203:15
building 86:19 89:16
 199:16
built 134:9 176:21
bulletins 177:1
bullets 20:21 84:15
bundled 227:18
burden 23:13 28:13
 50:16 51:17 59:15
 60:5,6 63:15 123:6,22
 147:6 148:3 149:7
 167:18 198:20 199:20
 233:20
business 145:20 177:6
 177:7,8,11
busy 12:15 325:21
 326:2
button 9:18 279:13
 288:15

C

C 114:7
C-section 208:4
CAHPS 6:9 130:11,21
 146:1 150:20 154:5
Cal 111:6 114:2 128:6
calculate 168:1
calculated 235:10
 241:13
calculation 191:22
calculus 167:21
calendar 296:9
California 2:15 11:16
 36:20 98:14 109:16
 110:14 111:3,10,11
 111:20 112:1 113:4,9
 113:10,21 114:9,10
 114:12,19 115:4
 116:2 117:22 120:19
 121:2 122:11 158:9
 159:6 263:7
California's 110:21
call 5:7 12:16 57:21
 74:1 111:5 115:7
 137:1 264:21
called 18:3 81:3 97:2
 132:3 257:6
calling 116:21
Calmus 1:13 11:18,18
 56:8 86:18 197:5
 228:1 267:14 268:8
 268:12 306:12
CalPERS 114:11
cancer 22:15 116:15
 123:15 129:20
candidates 5:14 130:9
capability 147:18
capacity 37:2,4 47:1
 49:21 59:16 203:16
 209:18 210:9 225:8
Capitol 85:17
capture 66:15 91:18,19
 93:7 97:16 102:21
 105:16 158:10 210:2
 320:22
captured 76:10 155:5
 307:12
captures 185:15
capturing 48:9 105:18
 106:3 140:11 158:16
 234:13 239:20 303:21
 313:4
cardiac 107:6
cardiologist 11:8
cardiovascular 23:6
 240:3 250:6 257:5
 276:1,16 277:14
 280:13,19,20 281:7

281:10,12,19,20
 282:1,5,8 284:21,22
 286:5,6,10,16,22
 292:22 293:1
cards 12:19
care 2:15 3:6 6:10 10:7
 18:11 26:20,21 27:2,3
 27:4,5,7,9,12 28:16
 29:4 32:2,3 34:12
 36:3,4,11 37:8 38:7
 39:8,17 41:21 42:1,2
 42:3,7,18 43:5,10
 46:4,13 47:22 52:1,5
 52:12 53:21 55:5,6,15
 55:16,21 56:19 57:8
 58:16 59:20,22 60:1
 65:9 66:4,7 72:12
 73:13,17,22 74:2,4,11
 87:8 88:12 89:3,6,14
 89:15,18 90:2,17 91:7
 91:8,10,12,14,16,19
 91:21 92:21 93:16
 94:6 97:2,3,8 103:5,9
 103:13 105:4,6,9,10
 105:13 106:6,12
 107:1,2,20 108:2,17
 111:14 112:8,9,14,17
 113:20 115:7,10,10
 116:5 117:22 118:1,8
 118:14,15,16,18
 119:3,3,5,12,22 121:4
 121:20 123:1,4,9,11
 123:20 124:4,10,15
 124:16,19 125:1,4,6,6
 125:7 127:4,7 128:9
 131:4,19 137:2
 138:17 139:20 140:15
 140:20 145:2,3,13
 146:4,10 147:2 148:9
 149:22 150:3,7,11,18
 152:6 153:18 154:10
 154:11 155:5 158:19
 159:8 160:2 171:19
 178:5 180:7,9,10,14
 186:9 190:21 191:12
 191:13,14 195:1
 197:13 204:8,9,12
 205:1 216:8,14,19
 218:2 220:21 225:21
 228:11 230:20 232:10
 232:16,20 234:18
 236:10,12 237:10
 239:5,5 262:4 263:19
 264:20 265:6 267:2,3
 268:21 270:19,21
 272:4 274:20 275:6
 277:2,2 278:1,16
 287:1 289:5 292:2

294:6,10 295:17
 296:16,22,22 297:9
 297:16,21 300:21
 303:4,5,7 304:11,14
 304:20,21 307:14,17
 309:3,4 315:3,3,7,13
 315:13 317:8,13
 319:1,2 320:20 321:2
 321:11,16,22 322:3
 324:9,10,16,21
carefully 195:5
caregiver 106:19
CARTS 35:5
carve- 309:11
carve-outs 309:14
carved 308:1,2,11
case 73:5 89:16,21 97:2
 104:7 108:2,17
 161:17 177:7,7,8,11
 187:19 193:21 195:10
 227:11 293:12
cases 47:8 79:13
 267:10
catalyst 114:6
catalyze 185:16
Catch 285:14
catching 305:8
categories 77:17 79:11
 187:4,7,18 216:2,3
 235:12
categorized 303:18
category 187:14,22
 194:17 235:6 291:16
 294:9 307:3 317:11
 322:12
caused 125:12 221:15
causes 64:10
caution 90:17 141:11
 209:7 257:19
caveat 61:2
CCSQ 52:8 198:10
CDC 178:5
cell 12:14
center 103:10,11
 213:13 224:5
centered 186:9
centers 2:13,16,17
 104:6,9,12,18 135:9
 210:9
central 184:22 209:3
certain 35:17 95:4 97:7
 98:7 99:6 108:16
 124:6 158:21 175:20
 209:11,13 254:19
certainly 45:22 46:19
 74:4,10 75:3 80:16
 83:13 222:2 253:13
 253:14,16 272:8

291:22 322:21
certificate 205:10,10
Certified 312:2
cervical 123:15 129:19
cessation 163:20
 243:11,20 244:5,9,12
 244:16
cetera 103:21 107:11
 253:18 257:10,11
 305:18
chair 1:9,11 4:3,5 5:5
 6:19,22 9:11,21 14:8
 22:20 23:16 28:1
 32:19 37:16 38:2 41:3
 42:14 46:15 47:13
 48:20 49:5 53:11
 54:21 55:22 57:16
 62:5 65:18 71:3,6,11
 71:20 72:19 76:22
 77:14 83:21 84:5
 86:17 87:16 90:10
 92:5 94:5 99:10
 101:19 104:22 105:22
 107:18 109:5,15
 132:15 151:2,7
 157:17 158:11 161:2
 161:8,17 162:2
 163:14 164:11 165:1
 166:11 167:15 169:1
 170:5,22 172:2,10,12
 173:17 174:2,16
 175:11 176:1 178:17
 180:16 182:12,19
 183:4 188:22 189:3
 193:17 195:7,15
 196:13,17 200:11
 204:1 205:2 206:6
 207:7,21 209:2 211:9
 212:17,20 213:21
 214:8 219:5 222:14
 223:14 224:8 225:3,8
 225:13 228:18 230:3
 230:11,14 232:1
 233:5,21 235:1
 237:13 239:15 240:11
 242:9 243:5,7 245:10
 245:19 247:3 248:8
 248:14,21 249:13
 250:2,10,22 251:3
 254:2,5 255:3 256:4
 256:20 257:15 258:6
 258:17 260:12,13
 261:17,21 262:2
 264:16 265:3,8,17
 266:7 268:1,10,13
 269:8,19 270:4,15
 271:19 272:9,12,15
 273:14 274:22 275:3

275:5,16,22 277:18
 279:3,6,10,12 283:4,6
 284:15 285:2,11,18
 288:6,13 289:6,19
 290:2,5,13,21 291:7
 291:13 294:16 295:2
 298:5,13,16,19 299:4
 299:7 300:4,9,12
 301:14,17,22 302:4
 303:12,22 304:5,22
 306:11,21 307:8,19
 308:1 309:6,7 311:5
 312:9,14,16,19
 314:10,13,16 316:8
 317:1,4,18 318:12,15
 319:4,11,19 320:1,8
 320:11 321:17 322:10
 322:16 323:10,12,16
 324:5 325:1,12,19
chair's 266:8
chaired 242:10,11
CHAIRMAN 246:5
chairs 12:18
challenge 64:11 121:9
 121:11 129:8 153:4,4
 160:5,11
challenged 26:8 179:16
challenges 43:17 54:17
 63:11 64:2 84:11
 102:13 109:20 111:12
 111:21 114:16 121:10
 156:12 181:21 239:22
 304:8 308:17
challenging 41:20
 84:21 126:13 128:2
 129:20 130:4,12
 146:18 154:12 166:21
 177:4,17,18 258:15
 304:15,19 305:2
Chan 8:2,3
chance 9:4 273:16
 274:1,4,11
change 30:2 45:16
 53:17 57:1 77:6 78:18
 78:20 86:16 91:5
 120:5 131:6 135:17
 136:20 141:5 155:7
 159:13,13,14 166:15
 171:22 180:11 187:1
 306:5,18
changed 122:8 125:11
 178:21 188:4
changes 23:12 24:12
 30:1,2 64:6 89:2
 109:22 135:11 139:11
 146:9 157:6 166:16
 166:18 168:10
characteristics 140:11

141:3 144:14,20
 184:14
characterize 143:8
charge 15:15,19 174:20
Charles 2:12 37:18
 132:17 162:3 165:10
 167:1,15 170:22
 207:7 209:12 268:14
 277:18
Charles's 177:6
chart 20:15 32:12 33:21
 37:6 42:12 68:16
 75:14 84:20 99:19
 158:20 159:7 182:4
 191:22 204:4,17
chat 13:9,10 273:7
 287:20 289:10
check 136:18 141:16
 259:5
checked 12:17
checking 117:12
 228:15
chemical-dependence
 308:10
Chief 6:4,7 11:9 110:13
child 4:18,21 16:18,21
 17:2,2,19 20:14 49:12
 50:9 52:9 58:7,10
 65:7 74:14,15,16,19
 76:12 82:6 138:15
 237:8 324:18 325:6
 325:16,17
child's 50:7 163:22
childhood 120:1
children 74:16 91:2
 112:15 115:13 134:15
 154:22 155:12 324:16
children's 134:22
chime 232:6
CHIP 138:12 143:14
CHIPRA 50:6 132:20
 133:12 134:5 136:1
 143:12 173:21
chlamydia 33:13
choice 88:5 136:14
 139:6 161:22 185:10
choices 220:13
choose 24:21 88:6
 139:7 179:13 220:7
chooses 201:4
choosing 28:14 114:5
 131:17
chose 28:18,19 184:10
 184:10 218:17 220:9
chronic 28:16 90:22
 91:9 106:11 113:17
 117:10,14,15 152:2
 154:21 157:12 221:15

232:10,12 252:3
 315:11 318:7,20
Cindy 11:12 41:3 84:7
 194:9 205:2 233:21
 240:12 265:8,19
 267:15 269:19
Cindy's 197:7
circle 9:19
city 96:18,21 97:11
CLABSI 210:13 211:5
claim 128:3 161:3
 196:11 225:9 251:19
 307:10
claims 41:10,12 42:7,17
 68:10,15,17 75:11
 128:4,10 141:9,12,20
 142:14,22 158:9,14
 195:6,9 202:14
 206:10 224:15 231:5
 235:15 252:9 258:9
 269:15,17 276:21
 287:3 303:8 304:16
 307:12,17,21 311:8
claims-based 28:3
 297:2
clarification 35:6
 189:22
clarify 23:19 46:2
 272:18
clarity 70:12
clear 18:17 187:13
 318:7,16
clearly 265:10 267:8
click 13:18
clicker 273:6,8
clients 104:11
climate 30:1
climbing 133:14
clinic 51:22 303:6 312:3
clinic-level 174:5,12
clinical 30:2 34:15
 58:19 92:15,16 93:21
 119:19 129:3,5 172:7
 173:6,16 177:7 187:1
 192:12,14 196:22,22
 197:3 217:17,18
 223:16,18 225:1
 231:5,6,16 259:11
 265:1 266:3 268:18
 276:21,22 277:2,3
 287:4,4 303:5
clinical-level 174:1
clinically 126:8 240:21
clinician 146:1
clinician's 287:1
clinics 145:9 164:6
close 26:2 133:18
 174:14 242:2,6 269:1

closely 15:16 115:20
121:22 233:12
closer 54:22 174:2
206:6,7
CMMI 120:15
CMS 3:5 6:1 7:4 15:5
17:9 20:10 21:22 22:4
23:12 24:8 28:11 29:2
29:11 31:1,10 32:5
39:1 46:2 49:8 52:6
59:14 101:1 103:20
103:20 105:19 111:22
117:17,18 118:7
120:18 126:17 128:1
134:11 165:11 166:8
166:20 167:12 168:1
171:5,14 188:5,11,12
188:14 193:4 194:13
223:3 229:14 296:12
314:9 323:5
CMS's 20:4 29:16 48:21
192:21
co- 44:10 242:10
co-chairing 16:19
co-morbidities 45:8
code 105:19 227:8,9
coded 303:19
codes 189:21 196:8
227:3,3,20 229:15
codified 247:1
coding 311:3
coffee 4:4
collaboration 106:18
collaborative 171:8
collated 62:3
colleague 85:18
colleagues 7:4 41:7
46:2 144:16 164:20
224:4 321:18
collect 26:5 28:4 36:14
76:3 97:10 196:16
212:12
collected 34:10 36:17
78:8 174:19 198:5
245:17
collecting 36:1,6 46:22
47:1 81:2 248:16
312:6
collection 60:3,22
68:10 69:4,5,9 70:13
72:4,17 76:18 86:20
91:6 156:12 312:8
collections 72:8
collectively 85:21
College 10:20
colors 219:10
Columbia 4:6 9:12
combination 136:11

145:15 278:9
combine 8:9,17 58:10
combined 46:5,8,11,13
208:4
combining 118:19
208:2,6
come 8:20 19:17 43:15
43:18 53:7 62:19
83:22 90:4 109:10
163:20 178:20 182:21
195:9 214:14 226:7
258:13 269:1 289:14
289:20 304:16 305:16
314:20
comes 47:5 79:20
81:16 82:7 83:17
89:11 150:13 156:15
166:2 260:9
comfortable 206:20
223:10
coming 6:5 22:17 69:20
128:12 182:7 209:2
227:16 288:4
comment 3:9,12,19
41:5 72:4 73:15 77:3
79:20 94:8 95:12
103:5 104:1 157:20
166:12 182:13,15,17
182:20 214:12,14
225:3 256:5,21
259:22 260:9,14
261:19 266:8 280:10
294:19 295:20 309:7
323:19,21 324:1
commented 13:9
commenting 13:6
259:21
comments 54:13 57:16
71:3 76:22 77:16
83:21 84:6 92:4 94:10
94:21 106:2 162:2
165:1 169:8 172:2
180:16 182:18 222:15
224:8 230:3 231:20
233:5,21 235:1
239:15 240:11 243:5
251:1 254:2 255:3
261:10,22 265:8
271:19 272:9 279:4
294:17 295:1,2,7
298:8,9 299:12
301:17 304:5,22
311:5 312:14 322:13
323:14 324:3,5
commercial 64:3 67:8
296:8
Commission 10:17
Commission's 185:22

Commissioner 71:15
commitment 113:5
168:14,18
committee 2:14 8:8,9
9:2,7 12:1 13:3 60:20
122:4 219:13 238:8
242:12,15 251:9
252:11 277:5,16
299:13
committees 189:6
common 107:2 118:22
170:13 190:7 191:4
192:4 193:7
Commonwealth 43:8
communicate 85:2
308:22
communicating 195:12
communication 224:6
communities 102:11
113:19 139:22
community 3:6 58:14
58:17,19 91:22 92:10
92:11,15 93:2,4,13,13
93:14 94:1,7 95:14,18
96:12 97:3,19 100:2
100:20 101:18,22
102:14,18,21 103:9
106:6,19 111:15
169:16,19 210:9
259:11 312:2
community- 97:4
community-based
99:15 124:18 216:12
315:19
community-related
58:20
comorbid 271:7 318:7
comorbidity 270:5,7
comparability 61:1
63:13 65:10,11
comparative 39:3 50:21
80:17 138:3,8 142:19
211:8 284:17
comparatively 39:21
compare 44:18 51:2
70:4
compared 34:12 226:9
262:21
compares 32:12
comparing 264:4
comparison 63:16
173:22 174:5
compelling 61:4 85:14
86:1,15 145:22
competency 186:12
315:8
competing 185:2
complementary 268:2

268:11
complements 262:15
completely 15:11 98:10
256:9 319:17
completeness 70:14
complex 69:19 91:2
163:8
compliance 106:4
compliant 155:9
complicated 45:10,17
85:5 99:17 127:15
206:13 207:17,19
208:7
complicating 181:15
component 14:14 97:2
208:2
components 67:18
134:9 144:2 163:15
234:21
composite 231:8,13,17
232:11,13,15,20
233:1,3 234:6,7,20,21
composites 69:20
comprehensive 140:22
162:19 230:20 266:14
289:5
comprehensively
157:9
comprehensiveness
68:22
con 253:11
conceivable 36:5
concentration 271:6
concept 19:6 60:11
61:13,19,20,21 62:10
64:14 66:6,18 149:7
300:1
concepts 19:11 134:7
conceptual 62:10
conceptually 62:11,16
concern 94:10 125:17
126:6 139:10 155:8
179:19 303:16 304:8
concerned 86:5 95:7
320:20
concerns 105:10 311:1
concert 146:4
concerted 201:8,15
conclude 164:2
condition 91:9 143:15
188:7 231:13 282:9
conditional 187:8,22
188:12 216:4
conditions 75:21 90:22
91:1 152:2 154:22
157:12 215:15 231:16
232:10,12 240:3
271:8 272:5 277:12

281:8,12,22 282:5
 286:21 296:19 311:22
 315:14
conference 1:8 57:21
confidence 79:6 185:13
confirm 188:5
conflicts 214:5
conforms 15:16
confusion 125:13
conjunction 52:9
connect 101:4
connection 95:19
 164:10 267:17
connections 97:3 259:3
 259:4,10,11 309:21
Consensus 19:18
consequences 222:6
 267:11
consider 16:5 19:21
 50:15 140:9 153:15
 174:11 183:11 189:12
 231:13 238:9 254:22
 274:6,9 280:16 283:3
 297:5 298:1 299:14
 299:19 302:3
considerable 79:6
 135:10
consideration 49:18
 50:20 68:6 75:1
 186:11 218:9 269:18
 296:11 299:6,10
considerations 3:6
 52:20 53:8 62:21 65:5
 90:15
considered 15:10 25:1
 142:11,13 165:14
 182:3,3,4 183:10
 241:2 299:15 300:7
considering 15:2
 122:21 186:18,20
 249:11 258:19
considers 208:22
consistency 187:13
consistent 28:5 123:12
 138:21 141:2,6
 184:17
consistently 186:21
 236:15
consists 302:18
constantly 223:22
constituents 89:22
constitute 245:12
constructs 69:18
contact 255:17
contains 116:11,20
CONTENTS 3:1
contested 247:5
continual 204:22

continually 51:8 57:11
continuation 215:20
continue 3:14 6:11 74:7
 90:11 129:5 139:8
 154:9 167:4 171:16
 207:5 260:6 320:19
 322:17
continued 251:9 260:18
continuing 121:7
 127:19 148:18
continuity 26:19 164:7
continuous 139:1
 143:4 163:11 190:1
continuously 141:7
contraceptive 22:22
 23:1 274:15,22 275:6
 293:22 294:14
contract 112:16 205:1
 212:16
contracting 127:15
contracts 114:20
 127:13,19
contractually 119:13
contrast 134:2
contrasts 136:3
contributing 132:10
control 45:9 62:17
 114:18 123:17 159:22
 196:12 233:15,19
 262:6 264:7 292:4
 294:11 317:15
controlled 159:20
 196:3,9,9
controlling 23:8 124:2
 131:16 158:5 159:10
 170:20
controls 15:13 175:9
convening 43:14
conversation 325:18
convert 146:16 153:6
convey 153:3
cooperation 310:21
coordinate 118:12
 308:22
coordinated 118:16,18
 137:2 152:6 278:16
Coordinating 60:20
 238:8
coordination 3:6 27:2,3
 27:9,13 38:7 58:14,16
 60:1 65:9 91:7,8,10
 91:12,14,17,19,21
 94:6 95:13 103:6,13
 105:4,10 107:20
 108:2,17 111:15
 118:3 119:3 124:10
 218:2 265:6 268:22
 269:6 309:4 315:4

Coordinator 2:5 213:8
core 3:4,10,15 5:15
 14:13 17:19 19:15,22
 20:4,6,8,10,12,16
 22:8,8 23:13 29:8
 30:22 31:1,21 35:7,8
 38:20 39:2 49:19 50:9
 50:11 51:10 52:6,7,8
 58:6,13 65:6,8 81:7
 82:11 91:18 109:22
 111:22 113:18 121:6
 122:1,5,6 123:13
 124:3 125:2,5,16
 126:4,20 128:1
 135:11,13 167:3,8,21
 167:22 186:17,19
 189:18 190:12,14
 192:8,20,22 193:4
 198:11 199:10 201:20
 216:18 218:22 222:19
 229:17,20 232:16
 233:14 234:14,17,18
 234:22 245:1,7,21
 262:15 265:13 275:13
 275:20 280:3 287:14
 290:11,19 291:5,12
 291:20,21 292:5,9,13
 292:18,20 293:5
 312:22 314:8
Corporate 11:9
correct 24:2 257:4
 282:11 283:5
correctly 33:5
correlates 233:13
correlations 295:15
correspond 22:18
corresponding 302:13
 308:5
corticosteroids 205:8
cost 86:20 90:2 113:20
 114:6 169:3,3
costly 89:15
costs 44:13 90:8 168:2
 169:4 170:20,20
 265:21
Council 135:7
counseling 216:21
 217:15 218:3,5
 225:10 228:6 229:3
 249:3,9 272:3 317:9
counterparts 87:3
counties 118:9,10,17
 124:12
counting 256:11
country 102:15 104:9
 156:21
county-based 118:2
couple 8:12 25:8,10

32:1,18 43:12 49:15
 52:18 62:2 64:13
 67:10 75:10 85:16
 104:13 136:2 154:18
 202:22 212:6 238:11
 256:6
course 22:18 71:14
 83:17 124:4 125:5
 127:8 146:14 161:4
 176:17 182:10 194:22
 204:10 216:21 226:22
cover 145:1 175:1,2
coverage 20:22 21:6,9
 141:5 149:20 150:7,8
 163:1,6,11 164:4
 179:7,8,15,20 180:2,4
 180:13 320:3
covered 42:7 114:10,18
 235:5,8 240:17,20
 241:6 243:1,3 291:16
 294:8 317:11 318:9
covering 9:16 59:6
 149:15
covers 218:7 282:16,19
 286:21
CPE 1:12
create 149:11 175:21
 255:11 265:13
created 133:4 171:4,14
 255:16
creates 147:14 175:14
 181:21
creating 93:18 113:19
credit 21:8 153:9
criminal 96:11
criteria 53:14 139:1
 142:16 143:4 151:19
 184:13 185:4,9
 187:10 190:2 192:1
 220:4,14
critical 42:22 51:16
 99:17 106:7 148:10
 169:7 177:17 197:10
 197:20 198:12 210:2
 301:1,13 321:9
cross 17:1
crossover 197:8
crosswalked 205:13
crux 152:13
cultural 130:18 186:12
 206:4,17 315:8
culture 146:20
cultures 130:20 150:4
cumulative 162:22
curious 29:13 177:20
 178:7,8 198:15 210:5
 298:16
current 19:15 24:1 93:7

117:1 236:18 244:2,8
244:14 275:20
currently 27:10 186:19
193:12 232:14 234:13
320:15
cut 140:5 272:20
275:10 283:1
cuts 271:22
CVS 1:19 10:7
cycle 120:3 275:19
286:15
cycles 137:7 160:16
CYNTHIA 1:16

D

D 242:8
D.C 1:9
daily 145:11
dampens 102:5
data 6:9 18:16 20:11,12
20:16 21:22 26:6
27:10,11 28:4 36:1,6
36:14 37:10,10,12
41:10,11,12,14 42:5,8
43:20 45:12,19,19
46:8 47:1 51:6 59:10
59:16 60:2,5,6,22
63:22 65:15 68:2,9,10
68:12,15,16,17 69:3,3
69:5,9,10,14,21 70:4
70:5,7,13,14,15 72:4
72:7,16 73:22 74:9
75:11,16 76:3,18 77:8
78:8 86:20 91:6,7
98:14,18 99:1 126:11
126:14,14 127:4,6,10
127:14,18 128:7,8,8
128:10,12,16,18,20
128:21 129:3,4,5,7,9
129:13,14,18 130:5
136:4,8 138:11
141:13 142:14 151:14
152:22 154:13 156:12
156:22 158:9,16,20
158:22 159:2 160:4,6
160:13 167:11 172:7
173:6 174:1,1,5,6,12
174:18 175:12 176:4
176:8,14,15,20,21
177:9,12,21 178:14
178:16 181:3,9,12,18
182:2,4,4,6 185:14
190:7 191:5 192:4,6
193:7,14,22 194:11
194:20 195:1,19
196:22,22 197:4,22
198:17,22 199:6,6,9
199:12 200:4,8,9,9,10

200:10 205:4,5,11,18
205:22 206:2,9,18,19
206:19,22 208:2,6,13
209:14 210:3,10,12
210:16,18,19,20
212:2,4,9,12 215:15
217:18,19 223:16,17
223:18 224:14,21
231:4,5,6,10,14
235:14 236:10,11
239:20,22 241:13
245:17 251:19 252:10
254:12 258:13 276:21
276:22 287:4,4
296:10,16 303:8
307:4 311:8
data's 195:8
databases 129:15
224:15
date 50:3 100:15 260:6
David 2:5 213:3,7
day 9:17 13:5,17 14:1
41:2 51:14 53:13
93:20 165:21,22
166:1 241:7 260:19
298:22 314:18 325:18
325:21 326:2
day-to-day 145:16
days 108:16 235:5,8
240:16,20 241:6,7,10
241:11 243:1,3
260:20 274:21 275:11
291:16 294:8 300:15
300:15 302:15 304:16
304:18 308:19 317:10
318:8
days' 251:13
de- 176:9
de-identified 175:12
deadline 35:9
deal 315:16
dealing 109:18
death 261:3
debate 242:18
debated 123:19 243:1
Debjani 2:10 4:19 12:10
57:17 62:5 87:17
90:11
decades 44:8
December 115:3
188:19 286:15 303:3
decently 74:14
decide 246:8
decided 26:16 305:17
decides 111:20
decision 17:10 24:19
165:6 187:4,7,10,14
187:16 207:10 216:2

216:3 219:18,21
253:9
decision-making 155:4
155:11 171:9
decisions 17:12 20:17
75:5 83:2 163:10
184:21 187:12
deck 34:18
decreased 34:4 191:8
228:3
dedicated 208:8
deeper 39:22 189:10
defeats 218:5
define 18:22 108:7
defined 60:20 108:4
definitely 102:9 104:14
114:15 117:17 131:10
159:3 182:7 198:3
201:4 217:6 259:22
260:8 284:8 297:21
298:20,21 299:2
301:5 307:1 326:7,13
definition 60:18 61:7,7
61:12 63:2 103:13
105:3 107:20 189:22
278:7
definitions 60:14
217:19
definitive 107:20
degree 72:21 73:1 79:6
96:10 178:21
delay 49:2
delays 127:17
deleting 15:3
deliberate 83:6
deliberately 80:2 82:8
82:19
deliberations 13:2
deliver 106:5
delivered 140:14
deliverer 107:1
deliveries 194:20
205:15
delivering 42:3
delivery 36:3 39:11
112:7 116:6 127:12
177:10,15 204:9,13
208:3 287:6
Delphi 43:14
demand 149:5
dementia 251:6,22
252:21 253:15 254:22
256:15,18 258:3,22
259:7,8 260:2 292:11
demographics 111:10
112:5
demonstrate 97:20
267:16 278:18 279:1

demonstration 50:7
132:21 133:12 134:6
173:22 312:3
denominator 72:9
191:22 251:12 268:7
270:6 282:8 286:14
302:18,20 311:21
denotes 215:19
dental 115:10,12
dentist 310:15
department 1:14 2:15
4:6 11:16 37:11 75:20
111:3 114:9 117:19
122:21 123:2 127:1
233:16 295:21 302:9
302:22 313:1,11
315:10
departments 305:9
310:11,22
dependence 295:22
302:14,20 303:2
308:9 311:19 313:2
313:13
dependencies 33:16
dependency 302:11
dependent 104:7,7
depending 103:8 226:3
depends 107:22 201:3
211:11
depression 34:15
117:13 126:9 136:22
192:13,15 207:16
224:14 225:1 228:16
269:13,16
derived 42:16
describe 121:1 133:20
described 158:14
161:19 162:5,13
describing 151:15
description 243:15
286:8 302:7
descriptive 77:19
design 67:14,15 69:17
designated 116:1
185:19
designed 48:4 138:16
153:21 304:1
desirable 211:6
desire 210:14 265:15
desired 168:4
despite 44:11
detail 47:2
detailed 32:4 37:22
46:10 183:18 243:14
details 19:9 25:6 209:1
255:12
detected 222:5
detection 222:3

determined 99:20,21
 241:9
determining 204:21
develop 43:8 134:12
 139:10,16 144:9
 146:12 157:4 165:16
 177:9 194:5 224:21
 234:19 308:15 309:19
 322:19,22
developed 52:8 96:17
 96:18 184:13 270:18
 321:15
developers 135:9
developing 50:8 51:8
 69:7 321:14,19,21
development 16:3
 19:18 81:9 105:12,12
 118:11 310:13 323:7
developmental 91:12
 103:11 136:21 202:3
developments 296:4
 297:5
DHCS 121:6
diabetes 22:10 32:3
 38:5,10 48:8 59:7
 66:7 100:8 107:5
 120:1 123:16,18,18
 230:20,22 231:8,12
 232:13,20 233:3,12
 233:13,19 234:1,4
 235:12 240:3,5
 247:10 249:18 250:6
 262:4,10 266:14
 267:2,10,20 269:10
 270:1,8,19 271:1,16
 277:13 278:1 289:5
 292:2 294:9 295:9,11
 295:18 298:4 317:13
 318:1,5,22
diagnosed 254:21
 256:15,18
diagnoses 311:2,3
diagnosis 160:20
 251:15 263:12,15,17
 286:16 302:10,13
 303:1,16,17
diagram 94:3
diagrams 93:10
dialogue 171:21
Diane 1:13 11:18 56:7
 86:17 267:13 306:11
 309:8
die 44:8
difference 55:15 62:8
 78:7,17 114:21
 133:19 152:10 196:19
 282:15
differences 137:11

146:19,20 151:16
 152:8,11
different 19:12 24:11
 27:4,8 30:11 36:22
 39:10,12 41:4 57:15
 60:7,16 61:22 66:11
 68:12 76:15 77:17
 80:13 83:3 87:22
 88:13 94:2 95:10
 96:19 98:11 103:13
 114:17,17,22 127:9
 130:20,20,21 134:2
 142:10 146:22 150:3
 151:21 162:7 163:15
 163:16 167:10 170:3
 174:13 189:3 194:16
 206:14 227:15 229:8
 229:20 242:13,19
 243:19 248:6,7
 252:14 254:16 277:9
 295:17 307:20 311:16
 319:17,22
difficult 28:4 85:2,15
 100:13 104:17 143:9
 158:3 159:20 197:3
 200:3 246:15 256:12
 305:3,14 307:7,9,14
 307:18
difficulties 98:13
 288:11 289:13 313:7
difficulty 101:5 193:22
 307:4
Dimes 1:16 11:12 86:5
dinner 326:11,13
dipstick 211:13
direct 44:12 115:11
direction 6:18 13:18,19
 42:11 179:15 187:13
 238:20
directives 147:19
directly 40:21 212:13
 255:6
director 2:10 4:7,20 6:3
 7:18 71:16 103:18
 213:12
directors 71:19 72:5
 105:7 310:10,19
dis-aggregate 141:19
dis-enrollments 143:6
disabilities 103:11
 112:16 142:15
disability 91:11 142:11
 152:1 160:22
disappears 148:3
discharge 108:16,20
 300:14 302:15,21
 304:17 312:22 313:11
discharges 302:7

disciplines 277:9
disclose 8:22 9:5 10:8
 10:13 11:2,10,20
disclosing 214:1
disclosure 8:11,13,15
 214:5
disclosures 5:3 8:10,18
 8:19 9:13 11:13,22
discuss 19:7 30:15
 115:8 216:9 232:3
 238:12 252:17 272:22
 274:19 294:13 308:15
discussed 185:10
 236:4 244:9,15
 249:20 250:3 255:15
 272:18 296:2 311:13
 316:2
discussing 111:17
 244:5,11
discussion 6:16 27:16
 27:17 28:6 58:3 63:3
 63:9 70:19 74:22 94:4
 94:6 109:6 132:16
 151:9 157:19,20
 183:5,18 193:16,19
 210:4 221:9 222:8
 246:22 249:15 254:1
 303:14 314:18 316:5
 325:4
discussions 14:2 17:21
 18:21 92:4
disease 113:17 240:3
 251:17 277:14 280:21
 281:20 284:22 286:6
 286:10,17,22 293:1
 318:20
diseases 28:16
disincentivize 226:14
disorder 22:12 23:7
 38:5 251:16 257:4
 263:17 276:3,18
 278:4 282:17
disorders 29:5,6
 315:15
disparaging 175:19
disparities 44:6,7 48:10
 90:16,16 94:19 98:3,7
 149:12,17 150:12,14
 153:11,22 160:15
 162:5,22 163:1
 186:11 262:19,22
 263:14 265:5,16
 270:21 297:21
disparity 48:6 160:19
 185:18 263:16
dispensed 241:12
disservice 200:6
distinct 112:7 113:14

distinction 65:14,19
 282:2
distinctions 140:8
district 101:1,4 116:3
dive 39:22 189:10
diverse 112:19 130:19
diverting 87:8
divides 32:14,22
division 6:3 7:9,19 8:1
 213:12
doable 212:18,19
doc 103:9 304:21
docs 145:14
doctor 304:12
documented 130:17
DOI 214:2
doing 4:13 18:10,11
 30:10 38:14 39:22
 40:1,2 43:11 45:17
 57:3 66:2,19 71:2
 73:3 74:14 76:13 78:6
 78:6,9,20 80:11 82:18
 83:20 85:19 98:13
 121:16 133:13 135:5
 137:16 138:8 142:17
 149:11 152:5,17
 159:21 160:1 161:22
 169:3,5,5,15 170:4
 200:6,21 233:18
 242:16 247:21 253:3
 253:5 263:8,10 300:1
dollars 76:12 86:7
 176:18 177:2
domain 28:10 59:6 66:1
 116:11 232:22
domains 116:5
door 154:16
dosage 22:14,15
double 271:18
doubling 271:2
doubt 224:10
downscale 213:10
dozen 296:14
Dr 4:22 5:20,21 6:20 7:1
 7:7 8:6 9:14 10:14,16
 11:1,14,21 12:7 24:3
 28:21 29:9,17 35:20
 36:21 37:17 38:17
 46:7,18 47:15 49:1,7
 54:14 55:1 73:10 77:2
 79:19 84:3 89:1 98:2
 98:21 99:3,5,6,11
 107:19 110:16 132:18
 151:4,10 158:17
 159:16 160:2,10,12
 160:20 161:5,10,12
 161:14,21 162:18
 163:17 164:16 166:13

167:16 169:10 170:6 171:1 172:8,11,14 173:15,20 174:4 175:5,13 176:11 179:2 180:5,21 194:18 195:8 196:19 198:2 200:12 201:3 202:6 204:2 205:21 206:8 207:8 208:1 210:5 211:21 212:19 213:11 214:3 219:17 221:5 222:18 223:15 223:20 225:7,11 228:19 232:7 233:7 245:18 246:4,6 247:17 248:4,9,15 249:1,14 250:5,8,12 252:5 256:6 258:7,18 259:16 260:3,11 261:20 263:3 265:4 269:9 270:16,18 271:9,20 277:19 280:12 282:2 295:4 299:17 300:6,10 302:2 303:11,13 304:3,7 305:1 306:22 307:13,22 308:2,3 311:6 320:18 322:2 323:8,11 324:7 325:10 dramatic 85:11 133:17 133:19 136:20 dramatically 137:14 draw 33:8 206:18 drive 20:9 53:17 77:6 81:10 83:12 86:15 111:17 170:19 driven 119:7 drives 106:4 driving 72:16 126:21 265:21 drop 143:1 dropped 135:18 136:1 150:6 DrPH 2:13 drug 33:16 117:12 236:11 295:22 302:11 302:14,19 303:2 308:9 311:19,22 313:2,12 drugs 254:19 261:2 305:7 dual 105:14 118:18 258:20 dually 128:1,6 130:4 256:11 duals 157:11 256:11 258:18 259:9 261:7	261:12,16 due 68:18 163:22 191:5 dump 138:11 212:4 Dunn 1:14 71:4,5,7,13 71:15,22 75:8 101:21 165:3 180:19 202:20 226:21 254:3,6 288:2 289:11 310:5 duplicating 51:17 duplication 18:15 duplicative 60:22 233:17 dying 267:9 <hr/> E <hr/> e-specs 224:3 EA 174:20 earlier 57:20 62:6 79:20 94:22 110:7 113:2 150:1 162:13 180:8 185:11 189:8 197:7 210:6 268:15 274:6 301:3 early 81:12 127:11 194:19 202:7 205:15 208:3 260:10 267:9 earn 21:7 ease 122:14 239:20 easier 42:13 81:19 144:22 159:22 197:4 212:11 easiest 105:18 easily 60:15 62:16 100:14 159:8 193:8 255:13 easy 85:10 170:10 202:15 207:15 236:9 253:21 263:9 echo 47:15 105:2 ECL 198:6 ED 77:9 89:16 296:20 297:1 298:2 299:17 299:20 304:9,12 308:6,8,18 311:15,21 317:16 EDs 305:5 308:21 309:19 educate 222:22 effect 42:22 170:2 effective 96:8 168:22 effectively 148:1 157:13 effects 134:2 257:5 270:11 efficiency 116:9 315:8 315:9 efficient 42:12 effort 6:12 18:15 40:12	105:18 148:4,18 166:3 168:5 196:2 198:10 229:19 230:2 266:12,18 efforts 61:11 148:15,16 163:7 207:5 221:2 EHR 173:2 181:1,3 EHRs 42:11 69:16 172:7 181:17 182:10 eight 34:21 199:12,15 216:10 312:12 either 15:3 30:16 36:20 39:18 67:16 81:8 82:6 143:5 150:16 161:22 166:11 184:16 188:1 188:4 237:7,18 249:22 elaboration 232:7 elderly 66:14 elected 85:3 194:20 elective 127:12 205:15 208:3 electricity 257:7 electronic 30:14 45:19 176:6 217:18 223:16 223:18 231:5,6 276:21,22 287:3,4 element 247:5 elements 91:16 92:9 106:15 127:10 315:1 elevators 14:7 Eleven 127:3 eligibility 21:4 142:7,12 142:16 eligible 128:2,6 130:4,8 256:12 eligibles 105:14 118:18 258:20 eliminate 320:4 eliminating 144:1 Elliot 11:1,1 54:14 55:1 89:1 107:19 169:10 180:21 204:2 211:21 212:19 258:7 ELLIOTT 2:2 304:7 320:18 322:2 emailed 231:19 eMeasure 174:9 eMeasures 156:15 emergency 75:19 295:21 300:19,21 301:7,19 302:9,22 305:9,19 306:4,6 310:11,16,22 313:1 313:11 315:10 emerging 264:19 266:3 empathy 133:21 emphasis 154:1 322:12	emphasize 80:15 306:7 emphasized 154:19 employed 10:7 employees 114:12,14 empowered 92:18 EMR 197:1,2 EMRs 69:16 emulate 138:8 enables 186:8 enacting 39:11 encompasses 301:12 encounter 128:7,8,12 128:16 141:13 307:10 encourage 10:1 248:11 297:4 298:1 308:20 310:3 322:18 encouraged 13:22 147:15 309:13 encouragement 248:19 encourages 106:9 309:18 encouraging 143:20 322:19 end-of-life 125:5 131:4 endeavor 7:12 ended 50:13 188:8 endorsed 22:16 116:21 122:12 125:22 185:12 172:10 231:2 235:16 243:14 249:6 250:4 262:7 276:19 280:22 300:5 325:9,14 endorsement 19:17 84:2 126:1 188:2,3,16 242:11 251:10 325:8 endpoint 150:19 167:20 ends 84:14 137:11 enemy 174:22 energy 144:9 engage 164:5 engaged 59:19 106:15 106:17 107:13 156:8 225:21 engagement 33:15 92:10,11 216:13 225:17 226:15 315:12 enhance 60:22 enrollee 170:15 enrollment 98:16 129:22 139:1 141:5,7 143:4 160:13 163:8 190:1 ensuring 117:7 131:19 224:2 229:15 entails 228:7 enter 127:13 entered 304:12 entire 265:14
--	---	--	---

entirely 240:22
entities 102:15
entity 9:1 36:12
entrenched 197:15
environment 70:16
 84:18 144:11 147:15
environments 93:19
Epic 173:3
epidemic 131:17 305:6
EPSDT 143:15
EQR 89:7
EQRO 75:15 121:17
equal 19:5 55:9
equally 236:13
equity 149:12,20
 151:11
especially 58:18 63:20
 68:18 85:3 96:3
 111:14 120:10 221:11
 233:14 253:17 271:5
 315:6 326:3
essential 91:16 129:10
 148:17 162:6 168:10
essentially 139:17
 142:12 147:19 174:15
 176:19 240:6 321:20
establish 21:15 113:8
established 281:7,12
 281:20 282:4
establishes 115:14
establishing 72:8 174:9
esti 241:21
estimate 134:14 269:22
et 103:20 107:11 253:18
 257:10,11 305:18
etcetera 198:21
ethical 107:16
ethnicity 98:17 99:7
 151:22 152:11 153:6
 157:12 160:14
evaluate 126:19
evaluating 185:5
evaluation 38:11
 213:12
event 150:2
eventually 137:15
 233:2 234:20
everybody 4:9 10:10
 103:12 238:14 288:19
 289:20 290:13 291:14
 316:14 321:1 326:6
Everybody's 4:4
evidence 30:2 64:9,9
 187:1 296:21 297:6
 297:13
evidence-based 64:7
 96:5 97:7 232:21
evolution 16:3 64:9

 76:5,17 156:14
exact 60:13 61:14
exactly 36:21 63:2 83:5
 83:7 134:10 198:21
 206:10 218:18 222:13
 238:3 240:16,19
 275:7
exam 230:20 231:1
 233:12 289:5 295:9
 298:4
example 28:14 39:5
 42:6 44:22 65:10
 74:13 75:21 76:12
 80:19 100:5 102:17
 104:8,10 116:10
 129:11 152:4 158:15
 159:18 164:8 179:11
 194:19 204:6 219:20
 234:14,15 283:21
examples 116:13 117:4
 117:11 136:2
Excel 216:5 217:2,7,22
 218:12 219:9,11
 243:15 285:6
Excellence 135:9
excellent 165:9 212:11
 240:9
exception 34:3
exchange 114:11 173:7
 173:13 181:7,8,8
 182:2
exchanges 172:19
excited 110:20
exclusion 192:1
exclusions 62:19 67:19
 69:17 286:18
exclusively 86:7
excuse 202:21 233:7
execute 166:7 208:8
executive 113:8
exercise 228:15
exist 138:16 141:17
 150:14 152:11 156:13
existing 44:19 147:20
 247:7
exists 143:18 147:11
 164:7
expand 29:3
expanded 21:4 106:11
 179:3,5,17 180:4
expansion 106:14
 178:22
expect 98:8 306:1
expectancy 228:4
expectation 38:13,15
expectations 43:20
 119:10 166:7
expected 46:4 134:22

 273:19
expensive 42:13
experience 62:15
 110:21 133:22 134:3
 147:1 155:5 193:14
 198:17 205:22 206:16
 256:14 310:9,10
experiences 14:12
 15:22 16:2 126:17
 135:2
experiencing 152:20
experimental 79:14
expert 10:18 255:1
expertise 16:13
experts 2:1 13:21
expire 163:22
explain 115:19 207:14
 207:15 227:20 234:3
 307:8
explaining 203:19
explanations 37:22
exploratory 208:16
explore 77:22 120:15
 147:15
express 146:11 188:7
expressed 209:8
extension 86:2
extent 6:12 75:22 95:20
 95:22 210:10 253:2
 254:20 300:2
external 11:3 74:1
 119:15 121:21 122:3
 123:9 124:7 127:14
 158:6,18 233:8
extra 76:11,14 233:20
 269:16 316:1
extrapolate 160:19
extremely 107:3 124:11
 138:9 155:12 175:6
 222:3 304:15,19
 321:3
eye 230:20 231:1
 233:12 234:18 289:5
 295:8 298:3
eyes 31:4

F

FAANP 1:15
FACC 1:12
face 109:20 121:9
 135:20 136:10,16
faced 135:12 139:6
facet 168:13
facets 243:19
facilitate 21:18 69:5
 152:13 155:7 156:10
 171:15,22 231:9
facilitates 144:12

facilitating 63:16
 146:14 168:9
facilities 129:17
facility 27:6,7 303:7
FACP 1:12,20
fact 24:15,16 25:1
 35:16,18 38:6 42:2,21
 44:11 97:16 107:4
 163:17 164:14 193:20
 198:18 224:11 227:11
 234:2
factions 242:20
factor 25:18 181:15
factors 24:18,22 70:10
 77:4 169:13 185:9
failure 305:4
fairly 4:11 96:4 199:10
 206:12,13
fall 87:22 224:13 307:2
falling 67:22 257:11
falls 87:21 219:3 252:10
familiar 20:20 25:5
 197:12 223:20
families 114:14
family 186:9 261:12,13
family-centered 59:20
far 62:20 68:11,22
 72:14 90:15 133:18
 256:2 279:14 314:19
 316:13
fared 131:21
fart 245:2
farther 176:12
farthest 177:5
fascinating 101:16
fast 276:6 285:22
favor 185:12 225:15
 232:3 261:9 267:12
 269:7 301:15
FCCP 1:12
fear 171:12
feasibility 68:9,18,21
 70:13 71:10 72:4
 84:19 91:6 188:6
 310:8,21
feasible 65:3 68:11
 69:6 297:3
federal 2:4 13:22 53:4
 86:8,10 103:15,19
 117:16 138:5 143:12
 143:16 144:16 152:5
 170:12 177:21 178:12
 279:17 304:10
federally-qualified
 103:10 104:8,12
federated 174:19
feds 138:14
fee 236:12

fee- 140:15	137:13 148:22 149:16	309:4,22 311:10,11	191:16 192:19 194:16
fee-for- 73:17,18	177:8 179:6 230:19	311:12 312:22	199:9,13 233:11
fee-for-service 37:7	276:13 278:3 287:12	follow-ups 92:19	234:4 276:14 316:17
46:3 66:4 72:6 73:14	287:16 295:8	followed 92:21 301:8	fourth 21:20 74:17
75:2,7,11 88:11 112:8	First- 324:15	following 47:22 67:22	76:13 317:15 318:8
121:3 128:10 296:15	first-line 325:11,11	77:3 92:21 235:11	Fox 7:7,8
feedback 86:14 110:1	fiscal 50:12 108:22	254:7	FQHCs 163:19 178:4
139:22 146:3,12	190:3 192:19	follows 137:22	211:15
148:8,17 149:4 165:5	fit 184:6 217:21 220:3	for-service 140:16	fragment 170:11
215:14 298:21	284:11 320:19	forays 91:21	181:19
feeding 52:10,12	fit-for- 53:18	force 1:3,8 4:10,21	frail 66:15
feeds 208:13	fit-for-use 53:18	11:15 15:19 16:11,17	frame 16:16 17:5 189:4
feel 15:11 74:5,11 92:19	fitting 79:13	16:18,21 23:20 30:16	framework 103:16
109:19 157:21 217:2	five 34:11,21 85:12	113:9,13 157:20	149:13,16 157:4,15
223:10 231:20 232:6	151:8 189:9 190:20	166:5 214:19 215:1	162:5,19 163:4 171:2
320:12	191:8 192:16 220:17	216:15 220:15,18	222:20
feeling 102:9 265:12	230:18 283:21 284:1	230:7,17 231:7,11,19	frankly 171:10
feels 29:20 252:11	285:21 289:14	232:5 235:17 244:19	fraught 127:16
feet 209:17	fix 109:9 206:12 305:14	245:3 251:20 262:14	free 15:11 217:2 231:20
felt 26:2,12 255:21	fixating 205:4	272:17 279:16 280:16	232:6
female 99:7	fixed 208:14	283:17 284:14 289:2	frequent 224:6
fewer 34:11	flag 49:15	293:13 294:4,5 296:2	frequently 32:1 63:1
fewest 34:8	flaws 78:22	297:4 298:1 314:2,3	143:7 196:1
field 18:1,6 222:22	flexibility 64:22 65:1,2	315:11 324:8,19	front 22:6 72:15 164:1
226:17 229:12	flood 131:9	325:6,18 326:1	187:5 316:10
fifth 74:17 76:13	floor 1:8 194:7	forces 4:18 47:20 49:12	fruit 177:19
figure 138:7 148:14	flow 103:15	184:18 187:12 275:10	frustrated 107:4
152:7 198:13 202:8	flux 156:14	275:11	full 69:1 161:22 188:6
file 34:18 225:9	focal 145:22	forefront 144:7	217:6
files 32:7,8	focus 73:19 76:15 87:4	foreseeable 86:16	full-blown 49:8,10
fill 98:15 214:19	114:18 118:2 123:1	formally 250:11 316:16	full-scope 112:17
filled 15:1 241:17,18	132:6 134:21 146:7	forms 98:16	function 81:17,17 82:21
filling 214:17	157:2 181:5 183:4	forth 28:13 31:19 32:11	83:1
final 17:9 89:2,6 106:21	184:22 197:14 201:11	65:1,4 66:9 173:3	functional 69:22 89:19
323:14	201:17 216:3 220:13	188:17 224:4 229:9	93:21
finally 13:8 70:5 96:16	321:5	229:21 250:7	functioning 183:13,19
100:10 111:22 150:15	focused 32:2 96:22	forthcoming 157:6	184:3
216:15	113:14 125:21 133:2	Forum 1:1,8	functions 82:18
financial 25:7 26:5	267:7 277:10	forward 6:15 16:6 50:4	Fund 43:8
89:17 143:16	focuses 321:7	50:20 56:13 96:10	fundamental 41:13
find 13:14 36:8 124:21	focusing 55:2 89:12	135:10 188:11,12	321:10
139:14 141:21 195:19	170:3 264:11	208:17 221:8 230:1	fundamentally 135:16
221:3 259:14 280:22	follow 70:7,15 87:18	237:17,19 238:4,22	fundamentals 157:8
297:13 304:16 324:13	130:14 138:19 197:6	253:12 263:3 264:13	funded 176:18 321:20
finding 54:6 73:21	208:9 218:4 220:13	264:15 275:15 276:15	funding 50:2,13 52:19
102:1 146:18 265:9	225:1,22 226:12	281:15 304:4 312:5	86:8,13 87:8 102:18
findings 73:20	228:11 236:22 267:15	forwards 253:7	103:22 143:11 203:13
fine 63:1 65:14 160:8	307:5	foster 16:19 218:2	funds 103:15,17 167:14
189:13 239:14 250:19	follow- 295:20 313:10	found 45:4 72:5 73:11	further 10:12 11:13
finish 17:6 151:7	follow-up 34:15 73:14	73:15 74:8 98:6 103:7	106:14 180:17 232:18
244:11	108:15,20 109:3,4	130:16,19 145:21	268:18
firm 107:19	117:7 129:12 192:13	148:21 149:5 164:8	future 86:16 159:4
firmly 108:4	192:15 296:21,22	212:1 270:22	221:4 224:20 246:18
first 9:8 13:7 24:3 25:8	297:9,17 298:2	foundation 113:22	252:18 260:6
25:9 30:4 34:10 41:17	299:17,20 300:14,18	115:14	FY 34:10 190:13,13
60:9,19 96:3,6 100:6	300:22 301:18 302:12	four 33:9 115:4 117:20	191:8,9
110:12 116:5 121:2	304:14,17 305:5,20	119:19 127:4 178:6,9	
124:8 135:4 136:5	306:19 308:6,8,19	178:10 189:8,20	

G

gained 133:22	147:5 148:17 149:20	8:17 12:13 14:22 16:6	32:22 183:22 189:7
Gallia 2:12 37:17,18	164:17,19 178:15	16:20,21 17:22 19:13	214:11 218:12,17,21
132:18 151:4,10	189:6 193:22 199:17	26:14 37:19 42:5	219:2,8,15 220:1
162:18 163:17 164:16	211:14 234:9 242:7	43:21 48:21 49:4,8,10	230:6,13,15 235:4
167:16 171:1 173:15	248:2 263:19,22	49:13 51:13,15 52:2	239:1,13 243:9 251:5
173:20 174:4 175:5	264:3 267:4 268:5	53:2,16 54:8,9 55:14	262:4 272:14,16
175:13 207:8 208:1	305:20 306:16,16	57:17 68:3 72:3 76:15	274:4,16,19 275:2,4,7
277:19	321:6	78:1 81:14 83:16	275:9 276:5 279:9,11
game 79:18 144:19	Gigi 2:17 7:13	86:11 87:6 88:11 89:3	279:15 280:9 281:14
210:8	give 16:6 27:18,21 31:8	94:21 96:9 99:12	282:13,22 283:8,15
gap 3:17 17:20 21:7	42:17 111:7,9 133:6	101:4 102:12 103:3	284:8,20 285:3,13,17
56:1 181:17 187:21	145:5 152:3 153:9	105:17 106:17 109:7	285:20 287:10 288:5
214:17,20 215:4,5,6,9	190:16 193:9 199:8	109:15 110:3,12	288:8,17 289:1,9,12
215:13,19,22 216:7	199:11 200:18,19	127:19 132:18,22	293:6,19 294:2,12
217:1,9 219:21	202:18 217:4 220:15	133:8,20 135:3 137:3	298:11,15,18,20
243:12 246:19 251:22	223:17 253:20 265:1	138:10,10 140:2	299:6 302:6 316:19
252:16 253:8 255:9	269:21 285:3 296:3	143:17,21 147:12,14	317:3,7 318:10,13
259:15 309:2 314:20	317:3	149:2,9 150:22	323:18 325:17 326:7
314:22 316:6 322:17	given 30:17 34:19 50:1	151:14,18 152:16	gotten 4:4 178:22
324:7	50:16,20 51:11 52:18	153:13,14 154:16	240:20
gaps 5:12 14:19 15:1,1	64:19 65:3,10 69:19	155:7,7,16 156:7,9,10	government 2:4 84:9
15:22 19:19 59:12	88:6 153:19 154:1,3	156:12,15,18,19	181:13
98:18 122:6 124:7	231:14 297:5 319:7	157:8 162:12 165:21	governor 113:7,7
156:18 190:2 214:19	320:3	165:22 166:1 167:2	governor's 166:1
277:8 314:15,16,18	giver 206:19	168:5,10,17,20	graders 76:13
314:18 318:16 319:8	gives 17:4 141:16	169:10,22 175:21	gradually 232:22
319:9,12 320:5,11,12	giving 152:18 184:9	177:16 181:3,12	Grand 278:1
garner 188:6	200:7 234:21	183:5,6,7,8 184:3	grant 1:17 10:10 43:7
gather 199:5 209:14	glad 213:15	188:1 198:5 200:18	98:4 120:14,15 121:5
gathering 18:15 252:7	Global 115:8	201:21 202:11 203:7	121:5 126:13,16,18
gender 152:1	go 9:3,8 12:13 13:6	203:17 204:4,7 207:9	127:8,22 128:15,20
general 16:22 43:10	14:8 19:13 20:2,20	207:13 209:5 211:11	133:12 134:6,20
44:9,10,14,20 144:21	22:20 30:6 53:13	212:21 224:13,14,16	142:10 144:4 146:16
144:22 184:20 245:6	59:13 62:21 66:9 71:2	224:22 227:17 230:1	148:21 163:18 173:22
262:21 271:2,16	83:14 90:14 94:8 96:8	230:9 233:22 234:19	175:16 201:11 321:19
297:19,20 298:13	103:3,16 104:5	238:13 249:14 255:5	granted 75:12
generalized 211:18	108:11 149:9 150:3	258:7 260:6 264:12	Grantees 24:10 26:4
generally 54:1 73:12	158:14,20 161:18	266:10 271:12 273:15	grants 7:16 50:7 171:5
104:5 265:14	162:6 164:9 189:13	275:17 283:10,11,12	178:9 201:10 312:10
generate 210:10 212:13	195:18 202:14,18	283:15 287:13 291:20	312:12
generating 148:6	203:20 204:17 208:17	292:4 293:9 304:14	granular 41:14 42:5
generative 145:18	209:8 219:16 221:18	304:19 306:1,6,13	68:16
generic 266:1	230:6,18 231:20	309:14 310:1 312:4,5	granular-level 145:7
gentleman 76:4 280:17	237:8,18 238:21	320:9,9,9 326:11	granularity 59:10 69:9
geography 90:21	251:4 259:21 265:20	good 5:7 7:7,13,17 8:2	graphs 80:17
George 1:12 11:7 38:2	273:3 276:9 279:13	10:9 11:7,11,14 33:5	grassroots 102:16
72:19 101:20 105:22	283:10,15 285:12	48:9,14 53:12 66:2	gray 85:6
150:1 239:16 256:5	288:18,20 304:4	67:14 71:4,7,14 78:16	great 6:19 8:6 9:14
256:20 260:15 300:12	310:19 313:9 316:9,9	122:9 130:9 145:12	54:11 135:14 139:14
Georgia 26:1	319:11 326:12	169:1 174:22 184:6	158:17 170:4 260:11
geriatrician 10:21	go-round 303:14	212:1 220:3 221:17	289:11
257:16	goal 20:4 60:21 64:21	228:20 257:17 264:9	greater 44:13 154:1
gestalt 70:22	106:21 107:3,10	268:5 270:2 284:11	179:7,8 251:13 280:1
Gesten 16:19	goals 186:5	285:11,13 298:20	284:13 287:18 291:1
getting 45:5,5 55:13,18	goes 69:1 94:11 104:21	305:16 306:1 310:1	291:2,3
74:18,19 88:2 92:12	137:14 202:16 261:17	319:20 320:22 325:2	green 188:10
93:16 96:1 99:1	268:13 325:20	Gorham 2:9 4:16,17	grossly 154:7
105:15 126:1 127:18	going 4:12,15 7:3 8:9	20:1 22:22 28:22 30:9	ground 146:9 168:11

groundbreaking

117:20

group 2:2 11:3 24:9

48:10 67:12 71:1 82:6

91:14 152:18 194:15

201:18,19 242:21

246:8 249:16 258:19

263:11 264:2,2,11

305:11 322:20

group's 253:9**groups** 29:4 81:4 95:2,4

114:1 120:18 142:8

146:2 152:12 164:6

184:18 189:19 201:6

264:4

growing 252:21 253:14**grown** 112:9,12**growth** 33:9**guess** 54:18 105:20

172:15 173:11 197:14

228:5,12 230:4

238:18 245:2,8

267:14,19 301:10

303:22 316:9,15

guests 41:8**guidance** 6:17 184:20**guideline** 62:15 281:5**guidelines** 281:3**guys** 176:3 213:4**gymnastics** 66:10**H****half** 120:19 297:18**hallway** 14:7**Hampshire** 71:16 75:10

104:10

hand 66:12 79:16

202:16 273:9 313:14

handed 174:13**handful** 81:10**handoff** 174:7**handout** 32:9 34:18,22

35:12 187:5

hands 30:12 288:14

313:16,18,21

happen 101:12 173:14

200:22 201:1 203:17

208:19 306:8

happened 29:18 42:4

43:6 108:18 134:19

259:20

happening 26:22 40:16

51:22 56:18 82:13

84:15 173:1

happens 29:9,15 75:2

108:13 144:7 173:13

201:16 221:21 309:16

happy 72:2**hard** 80:5 97:9 143:8

234:19 317:5

harder 57:12 263:10**harmed** 253:1**harmonization** 62:7,18

63:6 65:20 66:20,21

72:10

harmonize 18:14 62:13**harmonizing** 67:16**Harold** 1:9,11 4:5 5:4

9:9 20:1 47:16 58:2

83:5 99:12 106:8

110:21 131:8 183:22

193:15 303:11 316:5

Harold's 81:11**hate** 278:6**HBA1C** 62:12 262:11**HCBS** 315:18,21**HCDS** 220:21**HCVS-type** 69:22**headed** 83:14 134:8**heads** 101:8 317:6**headway** 207:5**health** 1:13,14,17,19

2:2,3,5,6,12,15 6:3

7:8,9,14,19 8:1 10:7

10:11,18,18 11:2,19

17:2 20:14,15 21:14

23:6 29:6 37:12 39:5

39:7,16 43:4,9 47:21

55:4,5,7,8,10,11,17

55:19,20 56:12,21

57:9,14 58:18 59:7

63:21 69:13 77:10

81:5,6 87:11 88:12,14

88:17 91:9 92:12,13

93:12,21 96:7,7 97:1

97:6 103:10,11 104:6

104:8,12,18 106:10

106:22 107:10 112:17

112:18 113:5,14

114:10,19 118:3,3,7

124:9 125:3 126:4,10

126:11 129:17 131:18

132:9 140:14,17

146:2,8,17 147:2

150:16,17 151:11,16

170:16 172:19 173:2

175:7,16 176:3,18

178:3 181:7 185:19

191:13 193:4 197:2

201:6 202:3,5 204:10

208:10 210:9,11

212:14 213:8,14,17

216:9,10,22 218:8

219:3 220:8 221:14

222:20 223:13 229:5

243:12 244:18 251:18

257:13 259:3,12

264:20 265:5 266:22

267:17,18 271:7

276:1,16 277:1,3,12

280:13 286:20,22

287:5 296:18 302:10

302:14,19 303:1,6,9

303:15 304:11,20

307:4,6,16 308:5,7,12

311:1 312:3 313:1,12

315:3,7,12,14,15

317:20 318:2 319:2

320:21 321:2,7,16,22

324:12

health-based 56:15**health-plan** 321:21**healthcare** 11:17 21:15

21:17 32:4 44:13,14

44:15 59:22 61:1

99:19 111:3 112:5,7

112:14 113:19 114:9

117:19 118:13,20

119:4,10 129:17

132:6,7 134:14,15

149:18 152:1 153:11

154:22 156:21 157:11

158:21 176:10 186:11

236:2

healthiest 113:10**healthy** 59:19 113:9,15

113:19,21 178:4

hear 9:17 14:11 37:16

51:13 59:9 81:4 82:5

109:10 110:8,12

111:5 125:10,13

126:1 132:16,22

144:3 177:20 182:13

295:4 302:4

heard 8:16 25:19,19

26:9,10,15 74:22

139:3 140:4 143:22

173:9 185:11 299:12

hearing 109:16 176:2

201:7 202:4 263:6

281:14

hears 291:14**heart** 125:20 257:7,9

270:20 281:4

Hearts 116:14 120:17**heavier** 269:10**heavily** 25:18**heavy** 103:2 143:21**HEDIS** 122:13 185:21

308:4

HEDIS's 296:7**heed** 144:17**held** 34:2 242:18**help** 13:14 27:12,14

36:12 40:18,18 42:10

50:11 56:17 73:6 80:7

80:9 83:4,16 102:7

107:13,17 142:10,14

152:22 170:18,19

194:13 196:18 198:3

202:1 206:8 309:3

helped 153:12**helpful** 24:4 53:9

122:13 211:7 306:15

helping 56:18 77:8

81:16 171:15

helplessness 168:21**helps** 54:5 89:20 98:9

240:7

hemoglobin 123:17

233:15 262:6 263:22

266:14 292:3 294:11

317:14

hep 114:7**Hernandez** 85:19**heroic** 85:19**hey** 85:11**HHS** 21:21 70:21

103:21 187:13 229:19

Hi 4:16,19,22 7:17 8:2

10:5 202:20 213:16

288:2

HIE 181:3**Higgins** 10:12**high** 22:14,15 23:8

32:17 35:1 38:19 54:8

118:5 120:11 124:2

124:11,12 137:7

185:1 186:21 196:21

215:4 235:13 252:2

264:1 271:6,11

277:13 313:19

high- 114:5**high-cost** 77:11 116:7

116:17

high-level 40:5**high-performers** 78:5,5

78:9 80:10,11

high-quality 112:2,3

131:2,13

high-risk 116:7 118:13**high-utilizers** 118:14

119:5 124:10

higher 78:17 81:20

198:14 226:9 246:15

264:1 265:21 271:3

297:12,13 311:12

highest 124:13**highlight** 217:5 264:10**highlighted** 92:9

123:12 136:2,6

218:13

highlighting 137:5
highly 226:4,7,11
hill 85:18 88:9,20
hire 195:18
Hispanic 112:21
historically 23:14
history 27:19
hit 149:19 152:14
 154:14 199:19 223:9
HIV 34:8 127:10 177:22
 178:5 189:16 190:11
 208:1 210:6
hold 78:21 158:19
 188:15 233:9 293:14
 294:13
holding 209:21
home 70:4 138:15
 150:9 175:16 193:4
 216:12
Home- 315:19
homes 39:5 118:7
 253:18 261:6 264:20
homework 5:9 57:18
 61:18
honor 110:17
hope 14:9 39:12,20
 49:17 58:22 306:3
 326:9
hopefully 63:8 81:15
 131:22 322:17
hoping 39:2 41:7
horizon 143:18
hospital 4:9 27:5,6
 105:6 115:5 116:12
 130:5 191:1 194:22
 195:2 197:2 205:16
 269:17 300:14 303:7
 309:19
hospitalization 129:13
 311:13
hospitalized 311:16
hospitals 116:2,3 140:3
 159:6 173:6 176:14
 304:11 310:11
House 280:19
housekeeping 9:17
 12:13 14:3
housing 95:19,22 96:1
 96:3,6 100:5,6,11
HR 178:15
HRSA 178:2,5 210:7,7
 210:18,19 229:21
HRSA's 190:15
huge 55:14 86:21,22
 87:13 90:2 126:20
 181:17 216:5 220:9
 310:7
Human 1:14 21:14

Humana 1:12 11:9
Humana's 11:9
hundreds 86:7 270:13
Hunt 2:5 213:6,7
Huntington's 251:16
HVL 190:2
hybrid 36:7 75:13 123:2
 123:5 127:5,6 136:11
 159:2 239:22
hypertension 45:9,10
 119:21,22 176:8
 196:4,9,20
hypothesis 209:22

I

ice 133:14
idea 41:10 72:13 111:9
 167:19 175:8 205:4
 267:20 270:2 324:20
ideal 184:15 231:12
ideas 67:11
identified 16:1 19:19
 43:2 56:1 112:1 124:8
 176:10 177:6 193:13
 215:13,19,21 216:6
 216:10,11,12,14,15
 217:15 225:19 226:5
 226:10 268:4 277:8
 314:19 324:8
identifier 129:16
identify 5:13 54:5 73:6
 73:20 138:1 142:15
 146:5,11 152:22
 170:18 187:21 268:3
 268:6,19
identifying 69:6 95:9
 162:20 184:14 218:6
 269:3 304:8
IDIQ 8:3
ignore 139:7
ill 28:17 246:12,14
illness 23:9 44:5,12
 45:9 91:2 95:3 96:15
 129:13 245:5 246:2
 247:11 248:1 249:4
 249:10 262:5,9,18,21
 264:9 269:13 270:1
 270:20 271:1 282:6
 287:1 292:3 294:10
 295:22 297:10 308:7
 311:13 316:4 317:14
 318:7 319:1
illnesses 95:15 247:20
illuminate 104:15
illuminated 94:18
illuminates 104:15
illuminating 95:8
illustration 32:16

imagine 152:4,5
imaging 116:17
immediate 187:8,20
 254:10
immunization 59:6
immunizations 120:1,9
 120:10
impact 97:10 108:22,22
 133:17 163:6 272:4
 304:13
impacts 139:10 140:10
 229:5 257:1
impediment 208:21
implement 124:20
 151:18 168:22 199:5
 199:7
implementation 61:15
 64:22 118:9 124:18
 124:22 168:7
implemented 24:1
 52:21 64:17 190:20
 224:3 229:11 278:20
implementing 63:2
 114:4 131:17,18,18
 167:19 168:3 175:15
 223:10
importance 25:15
 70:16 87:21 113:3
 221:10 222:8 224:11
 224:19 254:14 264:11
 269:6
important 13:4 14:5,14
 18:8 26:10,19 34:9
 38:10,18 40:15,22
 42:20 48:12 50:4 56:1
 56:11 57:2 62:20 67:2
 72:18,18 82:11 84:2,4
 84:17 90:20 98:20
 102:12 120:22 124:2
 124:21 129:8 131:8
 132:8 140:8,21 145:8
 155:2,13 157:1 163:3
 165:14 166:6 169:12
 171:22 172:21 180:14
 181:5 203:2,9,19
 220:12 221:19 228:2
 234:2,7 252:12,20
 253:11 265:11 266:5
 296:17 301:5 306:10
 306:20 307:1 321:3
importantly 108:8
improve 27:9 77:8 80:8
 80:22 84:18,19 97:21
 107:5 116:13 117:21
 138:2 170:16 211:18
 240:6
improved 53:21 85:11
 106:22 107:10 108:19

 179:5
improvement 8:5 20:9
 21:19 31:21 39:14,19
 40:19 53:6 55:21
 78:15 80:22 81:10,17
 81:22 82:22 83:12
 87:6 97:13 110:19
 119:18 122:4 126:21
 126:22 128:16 144:12
 146:5 151:18 152:13
 160:17 162:15 170:19
 181:10 185:17 204:15
 233:18 258:11 277:22
 278:15,19 295:11,14
improvements 69:13
 69:16 89:14 139:11
 150:17 168:15
improving 77:10 87:14
 90:1 113:5 119:3
 124:1 132:6,9
in-depth 58:8
inappropriate 257:21
 315:9
incentive 116:1 181:1
incentives 25:7 115:6
 115:12 120:15 181:16
incentivize 107:15
 152:8
incidences 117:1
include 37:7 116:13
 117:5 190:5 191:22
 278:4 280:2
included 34:22 35:4
 136:16 154:21 189:21
 217:19,20 242:7
 249:17 290:16 291:11
 296:7 310:18 314:8
includes 30:22 186:6
 186:10 217:11 230:1
 230:21 235:6 251:11
 262:8 269:12
including 5:12 20:13
 55:16 69:7 120:10
 134:15 229:12 230:7
 239:18 244:20
inclusion 35:7
incorporate 240:10
incorporated 106:15
 129:14
increase 20:5,6,8 137:3
increased 34:2
increases 198:20
increasingly 99:16
incremental 23:12
 135:17 159:14
incrementally 86:11
incubator 323:2
incumbent 167:22

independently 284:16
index 33:12 149:12
 151:11 153:1 162:18
 322:1
Indiana 1:20 10:21
Indianapolis 10:22
indicate 196:11
indicates 235:13 267:1
indicating 261:2
indication 35:17
indicative 254:8
indicator 130:10 295:12
indicators 113:14 221:7
 295:12,16
indirectly 240:7
individual 75:19 93:16
 107:12 108:13 109:1
 141:22 183:5 203:12
 203:12 227:12,19
 274:10 321:6,10
individual- 175:8
individually 230:19
 273:4 293:7,8
individuals 89:19 90:21
 90:22 91:10 92:13
 95:21 179:6 254:21
 256:12 262:20 263:12
 264:8 281:21 305:8
induced 253:1
infant 81:5 202:3
infinity 81:4
influence 110:2 114:19
 114:20 163:10 165:6
 171:20 185:10 299:8
influencing 70:10 77:5
inform 15:5 17:21 20:17
 136:17 221:3 298:9
information 2:5 14:18
 14:20,21 26:20 27:21
 31:14 32:7,8 38:15
 39:3 42:17 46:16 47:5
 47:8,11 52:4 54:10
 58:1 61:2 73:6,9,16
 76:11 78:16 80:18
 97:10 98:9 102:9,22
 104:18 106:3 130:1
 130:22 138:4,5,9
 141:8,15,20 142:1,19
 142:22 145:19 147:10
 148:1,6,18 154:6
 155:22 156:17 157:5
 157:21 172:19 175:9
 175:18 176:5,9 182:9
 187:3 190:17 193:10
 195:2 198:1,19
 200:20 205:9 211:8
 212:6,14 217:3
 223:17 229:22 252:7

255:18 275:14 287:8
 299:8 306:16 308:18
 308:22 309:15
informational 176:22
 282:21
informed 106:13,16
 132:22
infrastructure 26:7
 50:8 51:7,12 57:6
 59:16 60:4 75:13
 103:1 139:19 147:20
 176:21 177:10,13,15
 197:22 199:17,20
inherent 152:19
inhibitor 54:18
initial 54:12
initially 133:11 310:1
initiated 225:21 304:14
initiation 33:15 225:16
 226:15
initiative 39:6 81:6,6
 82:7 115:11 116:15
 118:2,16 120:17
 156:3
initiatives 40:15,19
 81:5 83:3 114:1 115:5
 119:8 120:9 122:11
 178:6 201:7 258:10
innovation 64:4,7 101:1
 296:13
innovations 97:15,21
innovative 97:18
 115:17 116:22,22
 117:4,11 158:13
 159:5 161:19
inpatient 25:2,4 89:16
 191:20 269:14,15
 304:13
input 6:16 24:6,7,8,10
 167:7
inquiries 205:18
instances 103:14
Institute 18:2 179:21
instructive 18:9
insufficient 139:8
insuperable 309:16
insurance 1:17 7:14
 10:11 56:5 141:4
 149:18 163:21,22
insurmountable 160:5
integrate 118:12
integrated 45:18
 264:19 287:6
integrating 57:22
integration 39:7 111:15
 119:3 265:2 266:3,21
 267:5 268:18 315:5,7
 319:3

intended 282:4
intends 121:6
intense 325:22
intensive 166:4
intent 265:4
intercede 90:9
interest 8:11 9:1 147:4
 165:11 170:9,13,13
 170:14 214:5 223:2
interested 176:2 300:11
interesting 39:1 64:19
 65:14 67:13 69:19
 75:9 96:17 104:2
 115:16 179:18 263:7
interestingly 64:15
interests 8:21 170:11
interface 43:9
interim 19:14
interlock 90:9
internal 122:4,21
internally 36:2 121:13
 121:14 207:11
internist 10:21
interoperability 69:16
interpretation 148:7
 231:9
interrelatedness 92:11
intertwined 84:16 228:7
interweaves 108:3
introduce 4:14 5:19 7:2
 7:6 12:2 71:12 132:18
 137:13 213:3,5
introduced 9:11 295:5
introduction 12:9
introductions 3:2 4:13
 5:3 8:10,18 9:4,10
invest 135:10
invested 76:11
investigation 204:8
investigator 132:20
investment 50:6,10
 76:14 103:3
investments 94:20
 139:19
involved 255:6 258:9
IOM 58:4,13 63:5
IOM's 232:19
IQR 205:16,17
Island 112:22
issue 18:5 38:18 39:7,9
 40:5 41:4 43:2 51:13
 64:1 72:10 73:11,13
 86:22 87:13 94:12
 95:17 96:3 100:2
 108:18 124:9,15
 125:18,20,22 128:1,7
 128:19 129:2 155:8
 158:2 176:2 177:14

178:19 180:4 198:3,4
 198:8,18 204:21
 206:10 209:10 221:13
 252:12 253:8,12
 254:21 256:11 258:5
 265:11 301:1,3,12
 305:20,21 307:1
 309:9 310:7,8 322:9
issues 5:8,10,12,12
 14:16 15:8,9,12 16:22
 17:1,3 30:1 39:4 41:1
 42:6 49:3,21 56:9
 57:18,20 58:12 59:21
 65:9 67:5,15 68:2,2
 71:8 75:17 76:16 79:8
 84:10 90:12 95:18,19
 100:18 103:22 104:15
 109:7,19 113:18
 128:14,14 130:18
 139:4 144:15 151:12
 157:18 194:16,19
 203:2,19 204:12
 205:11 228:8,13,14
 229:13 236:1,16
 264:19,22 296:18
 306:18 310:22 322:18
 326:10
items 12:13 233:1

J

jails 96:12
JAMA 56:3
January 303:2 312:13
JD 1:13,15
Jerry 113:7
job 72:7
joined 7:10 9:7 12:5
 16:18 213:4
joining 6:14
joins 12:9
Joint 185:21 238:13
 324:18
joy 135:3
judge 150:20
Julia 2:15 11:15 98:1,21
 110:13,15 158:5
 166:14 169:17 177:20
 196:17 233:6 256:5
 261:19 269:8 306:21
jumping 149:13
June 260:10
Junqing 2:14 270:16
 295:5 299:12
justice 96:11

K

Kaiser 158:22
Karen 2:16 6:5,11 48:21

79:12 172:4 197:6
210:4
Kathleen 1:14 12:3,5,8
Kathy's 73:14
Katie 71:5,6,11,15 75:8
101:20 165:2 166:13
180:17 202:20,21
226:21 229:13 254:3
273:7 287:20 288:2
289:9 310:5 313:13
Katie's 77:3 105:2
170:7
keep 12:14 30:5 40:6
41:1 51:3,9 124:2
180:15 306:5 317:5
keeping 250:13 316:10
Kendig 1:15 213:16,16
264:17 265:18 268:17
kept 166:10
Kevin 213:10
key 3:3 18:13 19:14
95:2 96:2 103:19
113:13,22 114:1
119:1 134:7,9 152:13
195:3 215:12 230:1
keypad 182:16
keys 169:18
kicked 201:19
kids 81:14 201:18
Kim 2:2 11:1 87:17
107:18 169:9 180:18
204:1 209:10 211:20
257:15 258:6 304:6
320:16
Kimberly 7:21
kind 15:9,18 17:1 23:13
25:10 27:12 28:9
29:12 30:6 31:8,17
32:16 41:14 42:5,21
43:22 44:1,6,16,17
47:17,20 50:21 53:19
56:8,13,16 57:13
58:15 63:16 76:17
78:11,12 79:9,14
81:21 84:22 86:18
87:10,11,21 93:11
97:12 100:7,15 101:8
109:17 110:18 113:11
119:1 135:12 137:13
138:11,13 141:9
144:11,15 145:7
154:3 164:10 171:12
173:7 174:22 181:10
186:1 194:14,16
196:2 197:5,7,10
200:16 201:17 202:7
205:19 210:1,2 211:8
211:13 213:9 222:2,4

222:9 223:7 226:13
228:16 229:1 233:19
238:4 240:2 242:19
243:1 245:12 246:21
247:21 260:14 264:7
266:9,19 267:4
268:10,13 300:2
305:2,22 306:7 309:9
323:3
kinds 17:3 39:4 42:6
48:19 52:17 66:9
101:14 145:8 222:16
295:12
kinks 128:22
knew 23:10 26:14
142:17 151:13
know 6:2,15 12:2,15
13:11 15:10,11,14,17
15:19 16:10 18:10
24:4 26:6,18,18,22
27:14 28:3,8,12,14
32:6 36:9,18,19 37:2
38:19,22 39:8,15 40:8
40:20 42:4 43:12 44:6
44:8 45:4,5,12,13,14
47:9 48:13 49:4,10
50:5,14,19 51:6 52:14
52:18 53:13,17,22
54:11 55:12 56:2,9
57:7 61:13 72:22,22
72:22 74:10,14 76:7
76:19 80:8,9 81:11
88:3 91:20 93:11
97:11 98:22 99:18
101:12 102:7 105:6
108:11 110:5 133:1,7
140:4 144:17 147:12
147:13,14 148:22
150:14 151:12 152:12
153:21 154:13,13
156:4 157:14 159:13
161:3 162:12 165:11
166:16 169:17 172:16
174:12,21 176:5,6,18
177:22 178:4,19
179:11 180:1,3,12
183:14 193:18 195:16
195:17 197:1,13,15
197:16 199:20 200:17
203:3,8 205:8,10
206:19,20 207:6
209:11,11,15,20
210:19 211:12,19
220:21 221:21 222:4
222:15,22 223:7,7,21
223:22 224:4,10,17
224:17,19 225:16
226:8,13,14,17 228:2

228:3,9,12,16 229:7
229:14,17 232:2,8
234:1,18 236:15
237:6 240:15 241:11
241:15,15,20,21,22
245:17 246:7,13,17
247:2,5,6,10,12,22
248:3,18 250:12
254:1,14 255:14,20
258:9,19 259:6 260:1
260:19,20,20 261:1,4
261:6 263:8,16 264:7
264:17 267:8 268:15
268:16 269:17 271:5
273:15 274:18 277:10
277:11 288:3 299:7,8
300:10,13,15 301:2,6
304:12 305:15 306:18
309:11 310:3,3
318:19 322:6,22
323:2,5 324:18 326:4
326:11,13
knowing 80:9 142:9
157:7 158:7 220:15
238:3,20 273:17
knowledge 85:7 221:3
knowledgeable 173:10

L

lab 128:19,21 231:14
label 254:18 255:15
labeled 207:18
laboratory 287:5
labs 212:13,13
lack 105:3 129:7 311:3
322:6
lacking 129:18 172:20
lag 205:11
landscape 52:19
language 126:22
160:18
large 100:14 114:8,16
largely 6:8 146:21
195:2
larger 171:20
largest 295:10
Larsen 213:10
lastly 20:16 122:20
late 127:18 213:6
latest 17:18
Laughter 275:8 294:1
launched 81:13
law 134:11 304:10
lay 166:18
layered 163:3
layering 153:17
layperson 85:8
LCSW 2:17

LDLC 281:6 286:11,12
lead 7:20 113:22
leap 318:17
learn 184:5
learned 16:2 40:3 78:9
78:13 126:12 127:21
128:20 144:4 171:13
learning 171:6,7,8
leave 9:20 132:2 200:19
leaving 21:6
led 118:8,14
left 227:12 283:19
322:14
legislature 122:18
167:12
legislatures 75:19 85:4
lens 84:11
lessons 40:3 127:21
133:3
let's 9:3 14:8 30:3 37:16
54:7 113:8,21 130:3
151:4 251:3,4 256:4
262:2 272:12 279:12
285:20 287:7 289:14
313:9 322:16
level 38:19 39:14 40:17
49:22 51:7,20,22 52:1
52:5,11,13,14,16,22
53:4 55:13 69:14
81:11 82:1,14,14,15
82:17,18,19,21 83:13
83:18 86:10 93:16
103:18 104:4 137:18
137:20 138:5 139:15
141:4,17,22 144:17
145:18 146:9 152:5
153:18,20 154:11
155:6,15 156:17
165:19 170:12 171:9
173:16 175:9 176:16
178:12 185:20 191:1
191:20 193:3 195:20
198:5,6,6,7,12 203:10
203:12,13 204:13
208:16 209:13 211:7
217:17 226:16 262:11
263:19 277:1 287:5
300:17 303:8 309:22
321:21
levels 21:4 62:12 63:17
82:9 83:19 137:8,10
138:18 162:6 183:12
184:4 186:21 198:14
leveraging 143:17
life 6:2 40:10 74:17
113:17 132:11 137:7
216:9 228:4 315:5
lift 143:21 269:10

lifted 134:10	133:6,20 134:10	200:4 204:5,5 206:9	258:9 266:17 272:5,7
light 188:10,13 305:13	140:3 141:12 146:18	210:21 211:21 217:6	300:20 326:4
306:2 310:2,7	154:8 158:15 169:17	229:10 239:4 241:9	lots 25:20 135:14
Lillie-Blanton 2:13 5:21	185:11 188:15 189:10	246:18 253:21 258:22	221:14
5:22 6:20 7:1 24:3	190:16 202:7,18	259:2 260:2,5 262:19	Louis 213:18
28:21 29:17 35:20	206:17 207:9 214:14	263:14 264:4 269:14	low 32:17 47:18 54:9
46:7,18 73:10 77:2	219:16 233:17 234:3	270:20 272:3 285:15	119:14 130:15 183:12
170:6 179:2 194:18	265:10 306:3 307:8	293:7 310:1 315:16	184:4 185:17 186:22
195:8 219:17 223:15	311:12	look-back 129:19,22	222:3
245:18 248:4,9,15	Liu 2:14 249:1 250:8	looked 17:19 19:16,18	low-hanging 177:19
limit 68:18 151:1	270:18 280:12 282:2	44:3 126:4 180:6	low-performers 78:6
limitation 195:20	295:4,5 308:3 311:6	186:17 222:16 223:12	lower 60:6 297:15
limitations 42:15 65:4	324:7 325:10	258:21 320:14 321:4	lowering 63:15 113:20
68:20	living 113:16	looking 6:15 17:22	lowest 295:13,19
limited 181:19 204:17	load 34:8 127:11 178:1	26:17 28:15 39:6,9	lunch 13:11 147:5
limited-scope 130:7	178:10 189:16 190:11	44:21 45:9 55:13,16	182:21
limits 107:16	197:12 204:19 208:1	56:10,13,16,20 57:2	
line 32:14,20,22 35:8	210:6 211:2 323:6	57:13 58:5,6 62:12	M
208:20 224:13 225:1	local 78:19 102:11	63:4,14,21 65:6,7,13	Macro 46:21
276:14 295:1 323:20	located 21:10	65:15 66:18 67:18	main 96:13 170:14
324:16	Logan 2:15 11:14,15	69:21 75:11,16 86:9	183:4
lines 145:20 324:4	36:21 98:2 99:3,6	87:12 88:8 90:21	maintenance 251:8
link 97:5	110:13,16 158:17	108:18 124:6 135:22	major 85:20 101:2
linkage 3:6 58:14 59:21	160:2,12 161:5,10,14	137:17 142:14 169:13	115:5 119:8 269:15
91:22 92:14 93:4,10	161:21 166:13 172:8	169:14,15 181:2	301:1 305:3
94:1,2,7 97:19 101:18	172:11,14 180:5	182:1 195:5 203:11	majority 56:6 183:16
102:21 178:5 192:6	196:19 233:7 256:6	203:18 204:20 208:22	184:2
206:1,2,9,22 229:2	261:20 269:9 271:9	211:12 220:21 221:10	making 5:16 42:12
266:21	306:22 307:13,22	223:22 225:18 229:4	56:12 57:10,12 85:14
linkages 58:19 95:14	308:2	229:15,20 232:7	87:4,5,9 135:11 164:6
95:18 99:15 100:2	logic 268:14	252:11 259:9,10	168:14 177:14 184:20
102:1 181:2	long 9:17 54:16 68:1	261:15 265:20,22	199:18 206:22 207:4
linked 177:15	72:1 110:22 137:10	266:2 269:17 270:6	207:11 219:18
linking 91:22 92:15	172:9,13 173:11,15	270:19 272:6 305:16	male 99:7
96:10,22 106:8	173:17 180:6,11	315:20 316:11 317:18	manage 158:9 301:11
108:20 211:22 212:2	199:4 200:2 209:9	321:13	managed 6:10 10:6
212:9	215:11 219:20 220:20	looks 218:7 241:6	27:5 36:4,11 37:8
Lisa 2:6 213:4,11	222:5 247:21	loop 148:17	46:4,12 52:1,5,12
222:14 228:18 249:13	long-term 27:7 86:8	loops 86:14	57:8 66:4 72:12 73:13
265:3 270:15 271:19	315:17	lost 265:22 303:20	73:17,21 74:2,4,10
303:12	longer 122:7 140:19	lot 18:15 27:15 37:1,3	88:12 89:2,6 112:7,9
list 29:10 64:18 68:5	151:2 179:9	40:12 41:18 44:15	112:14,17 118:8,15
77:4,13 84:16 110:22	longer-term 15:4	49:9 50:21 51:13 52:4	119:10,12 121:4,20
123:10 131:12 215:21	longitudinal 200:9	54:15 55:3 59:5 64:8	123:1,4,9,11,20 127:4
227:3 273:20 279:7	longitudinally 70:15	64:10 75:2 78:3 83:9	127:6 128:9 138:17
315:1 316:2,7,10,11	look 13:8 30:4,7 31:8	84:12 85:7 89:9 98:17	139:20 140:15 146:4
319:12	44:16 45:7 47:17 48:8	100:22 105:8 106:1	146:10 148:9 150:18
listed 22:5 30:17 33:7	48:13 53:5 54:6 59:13	108:12 127:17 129:18	153:18 154:10,10
35:3 154:6 186:17	62:17 74:3 78:3,4	130:18 146:22 157:17	158:19 159:8 160:2
listening 171:21 313:6	84:10 86:19 88:2	157:18 158:8 164:13	171:19 180:7,9,10,14
lists 205:7	93:11 94:22 95:1 98:4	172:19 175:14,21	205:1 236:10,12
little 9:16 14:9 16:16	98:9,20 100:2 104:9	176:20 179:19 181:1	237:10 296:16 304:20
17:15 19:9 30:11 41:9	106:11 108:8,15	202:11 204:12 220:5	307:14,17 322:2
42:19 49:20,22 51:6	110:3 122:5,7 125:2	220:22 221:6,9,19	management 2:9 23:4
54:21,22 70:19 79:12	125:16 136:5 138:3	222:7 223:2,3,6	32:3 33:18 91:9 97:8
81:19 82:5 85:22 89:4	148:14 149:2,17	227:16 228:10,11	107:6 108:3,17 120:1
102:16 110:5,7 111:9	159:4,18 160:8,18	242:3,13 253:17	124:11 125:4,16
112:4 114:3 115:19	184:3 186:14 189:16	254:18 255:15 257:17	126:6 208:9 236:18

236:21 242:11 272:4
Manager 2:9 4:17
manages 114:13
managing 104:4 113:17
 170:20
mandate 64:15,15,16
 65:1 144:1 167:3
mandated 122:18 167:4
mandatory 226:22
 227:3
manpower 37:4
manual 174:7 313:9
MAP 22:9 29:20 60:19
 70:21 184:14,18
 187:10 188:7 189:1
 215:10,21 219:14
 221:4 314:22
MAP's 21:20 22:18
mapped 203:4
March 1:16 11:12 86:4
Marcia 2:8 4:22 8:8
marginalized 144:6
MARIE 2:2
Marissa 1:19 9:15 10:4
 10:5 87:16 239:18
 255:4 319:12
marketplace 21:9
 179:10
marks 223:9
Marsha 2:13 5:18,21
 34:14 36:21 37:5 77:1
 79:12 137:7 147:8
 169:8 170:5 171:15
 172:4 205:21 223:14
Maryland 176:13 178:7
mass 33:12 197:10,20
 198:12 210:2
match 177:1
matched 205:13
material 85:13
materials 3:3 110:3
maternal 17:2 81:5
 202:2 315:15
maternity 216:8 239:5
 274:20 275:1,6 284:5
 293:21 294:14 314:7
Matsuoka 2:16 6:5
 38:17 49:1,7 79:19
 84:3 176:11 198:2
 201:3 205:21 206:8
 210:5 323:8,11
matter 2:1 13:21 14:10
 64:5 106:19 109:2,12
 137:18 140:13 143:8
 156:13 183:1 289:16
 326:14
matters 108:6
maturity 76:17

maximize 70:3
Mayor's 96:19
MBA 1:12 2:8
MCO 72:16 236:9
MD 1:11,12,20 2:2,15
MDS 70:4
mean 18:22 19:1 24:20
 26:17 27:21 30:1
 35:22 40:9 52:14
 60:12 61:18 66:16
 73:18 74:18 92:14
 99:3 100:3 101:13
 111:6 140:20 143:18
 151:1 152:4 156:13
 156:18 159:18 160:21
 162:12 164:10 165:18
 168:6,8 170:16
 174:16 175:20 180:1
 189:14 194:14 195:5
 198:17 200:14,18,22
 200:22 202:15 208:3
 211:9 212:17 222:4
 225:15 234:14 241:17
 242:9 246:6 247:2
 250:18 255:13 259:17
 282:20 299:18,22
 301:14 305:7 306:13
 316:8 318:17 319:6
meaning 225:22
meaningful 105:12
 146:12 176:17 185:22
 225:5
means 19:3 62:13 71:1
 103:14 140:18 156:7
 207:19 208:15 209:1
 240:17 246:8 280:5,5
 291:7
meant 51:21 80:18
 82:20,22 83:18
 184:19 281:19,21
 283:13
measurable 87:5
 159:12
measure 1:3 3:17 15:5
 15:22 16:3 18:1 19:2
 19:5 22:10,16 24:17
 25:3,9,15 26:3,13,17
 26:18 27:10,15,16
 28:3 31:16 33:19
 34:10 35:18,22 38:4,9
 39:14,17,18,20 43:5
 47:7,17 48:8,17 50:16
 50:17 53:19 54:4 55:9
 55:12 60:13 61:14
 64:15 65:2 66:16,21
 67:18 69:17,18 70:12
 70:17 73:2 74:8,13,15
 74:16,18 75:1 77:6,20

77:22 79:1,7 81:1,18
 81:21 82:18 85:12
 87:14 98:7,10 100:3
 100:12 110:9 111:19
 114:8 122:5,8,9 124:3
 124:22 125:5,7,9,11
 125:16 126:6 127:11
 127:12 131:6 134:12
 136:12 137:13,22
 139:2,9 140:19
 141:18,19 150:16
 152:7 153:1,2,5,21
 154:5,6 156:11 157:7
 158:3,5 159:11,17
 167:19,20 168:3,5,12
 168:15 169:14 170:1
 178:1,2,11 182:1,5
 183:7,7,15,18 184:1,1
 184:13,15,20 185:4,7
 185:8 186:2,4,6,7,8
 186:10,12 188:4,12
 188:14 189:11,14
 190:5,6,11,12,14,17
 190:19,21 191:2,3,4,8
 191:10,15,17,19
 192:2,4,7,12,15,17,20
 193:1,3,5,7 194:14
 196:5,20 198:7 201:9
 201:12,14,22 202:1,5
 204:14,22 210:6,7,13
 210:17 214:16,16
 215:10 216:13,15,19
 217:6,8,9,10,11,18
 218:7,8,13 219:19,22
 220:2,4,9,14 222:19
 223:1,5 224:1,2,12,19
 224:21 225:17,18
 226:2,4,16,18,19,20
 229:17 230:2,19,21
 231:1,2,3,7,8,9,14
 232:3,21 233:4,10,12
 233:15 234:20 235:3
 235:4,6,14,16,17,20
 235:21 236:5,22
 237:2,3,6 238:4 239:8
 239:18 240:2,10,12
 241:21 243:9,11,13
 243:14,15,18 244:18
 244:19,20 245:8
 247:1,7,8,10,12,16
 248:1,5,6,7,10,12,13
 249:2,5,8,11,18
 250:11,16,17,19
 251:5,7,10,11,18,20
 251:21 252:1 253:8
 254:8,15 255:12,16
 256:7,7,17 257:1
 258:15,16 259:6

260:17 262:7,8,13,14
 262:17 265:5,13
 266:1,14 272:6,19
 273:1,4 276:15,20
 277:1,7,17 279:2,4,19
 279:20 280:3,11,13
 280:16,17,20 281:2,3
 281:9,11 282:3,7,10
 282:16 283:16 284:16
 284:18,20 285:6,10
 285:10 286:5,8,19,20
 287:8,12,16 289:1,3,4
 290:10 291:4,11,19
 291:20 292:1,8,10,17
 292:19,21 293:4
 294:6,7,9 295:9,11,18
 296:1,5,6,7,9,12,16
 296:17 297:2,2,5,7
 298:2,3 299:18,19,21
 300:5 301:20 302:3,6
 302:16 303:4,10,21
 304:1,6 306:10,20
 308:15,20 309:3
 310:6,18 312:2,7,7,21
 313:10,15,18,20
 314:2,4,5,6,7 316:3
 317:9 320:16 321:4
 321:14,19 323:2,6
 324:15,17,20
measure's 244:22
Measure-Specific 3:10
 3:14
measured 18:18 61:21
 61:22 89:9 101:9
 105:11 242:14
measurement 5:2 7:20
 18:11,19 21:16,17
 29:3 43:9 52:11,13
 60:5,12 63:17 64:21
 68:22 82:9,13 83:19
 85:1,17 111:16,21
 115:20 128:4 131:5
 135:8 144:10 148:19
 165:13 172:6 186:9
 190:1 212:8 235:9
 236:6 244:3,10,17
 251:15 262:11 286:11
 286:13,15 302:11
 303:3 308:16 311:14
 323:2
measures 5:14 15:3,7
 16:8,9 18:7,8,14,20
 19:4,16 20:6,7,8
 21:19 22:3,4,7,9 23:1
 23:2,3,11,14 24:1
 27:11 28:9,15,19 29:1
 29:2,8 30:15,22 31:2
 31:5,13,14 32:2,14,17

33:1,3,6,9,11,22 34:1
34:6,20 35:2,7,12,17
36:7,8,8,9 37:2,3,5,7
38:20 39:2 40:7,7,9
40:13,14,17 41:16,18
41:20 42:16 43:13
44:19 45:6 48:2,19
49:18 50:9,12 51:1,10
51:11,19 52:6,7,8,15
53:1,10,16 55:4,10
56:10,15 59:5,9,14
60:21 61:5,10 63:3
66:14 67:14 69:7,20
75:13 76:5 77:17,18
79:21 80:16,20 81:2,3
81:8 82:5,11,20,21
83:7,12,18 84:13 85:1
87:9 88:7,8,15,16,21
88:22 89:5,8,12 91:18
93:7 94:13 98:5,5
99:14,15 101:3,13,15
110:6 111:20 112:2,3
115:18 116:12 121:2
121:7,12,13,15,18,22
122:11,12,13,16
123:2,3,7,11,12,16,19
123:21 126:5,20
127:3,9 129:4,10
130:3 131:2,9,11,13
131:15,21 132:7,7,8
135:14 136:1,22
137:1,6,9,17 138:12
140:9 141:1 143:3,13
143:14 144:5,21
145:3,8,9,15 148:16
150:5,13 153:10,15
155:18 156:22 157:3
157:10 158:13 159:2
161:19 162:15 165:7
165:16 166:7,17
168:22 170:18 178:15
180:15 183:6,9,11
184:2,4,6,8,11,12
185:1,10,12,16,18,20
186:18,20,21 187:2
187:20 188:1 189:9
189:10,13 190:20
193:10,12,18 194:3,8
195:4,6 196:1 197:8
198:11 199:1,3 200:1
202:3 203:1,4,4,7,8
203:21 204:5 205:6
207:9,12 209:4,6,15
211:5 213:1,2 214:9
214:17,19 215:12
216:7,10,11,14 217:4
220:2,5,7,11,22 221:7
221:20,20 222:9,16

223:11 224:7 229:11
229:17,20 230:7,16
230:18 231:17,21
232:11,13,14,15
233:1,9,11,13,14
234:5,10 236:8,17,18
237:22 238:7,9,12,21
239:2,3,7,22 242:5,8
246:20 250:20 252:18
259:7,14 261:12,15
270:19 273:3,17,18
274:2,5,10,15,20
275:10,12,18,20
279:17 282:3 283:17
283:19,20,21 284:2,3
284:5,11 285:4 293:6
293:11,14,15,15,16
293:21,22 294:4,13
295:8 297:22 299:2
299:10,14,15 300:16
300:17 306:14 308:4
308:13 311:7,8 312:4
314:11 315:16,21
316:17,21 320:4,22
322:20 324:10
measuring 39:10 63:18
63:19 65:11,12,22
66:8 101:6 109:2
127:22 156:20 161:6
234:9 322:7
meat 303:13
mechanisms 111:19
121:1 146:12
Medi- 111:5 114:1
128:5
Medi-Cal 98:14 111:5
111:13,18 112:5,9,17
115:2,6 118:4,19
119:7 120:18 123:9
124:19 132:3
media 137:19
median 192:9,10
mediation 236:22
Medicaid 1:3 2:13,16
2:17 4:10,18,21 6:10
11:4,6 16:4,14 20:12
20:18,21 21:2,4,8,18
29:4 52:1,5,7,12
53:22 54:15 56:6 66:3
66:4,5 67:3,6,21
71:16,18 72:5,14
82:15 86:22 87:7
88:11 90:1 91:8,15
93:6 97:13,17,22 98:3
98:14 103:18,20
104:11 107:21 108:14
110:14 111:4 121:4
125:8 126:12,16

127:22 138:12 140:7
140:16 141:3 142:21
145:20 146:15 149:19
154:20 157:11 169:20
176:7 178:20,22
179:9 180:22 185:16
210:15 211:3 212:4
215:16 221:12 227:1
227:2,4,10,14 231:15
236:9,12 237:10
238:1 253:16 254:11
256:10 258:12,14,16
261:5 264:10 265:14
269:22 271:5,22
277:20 278:12 296:8
296:13,15,19 304:9
305:11 310:10,19
311:8 322:4 323:8
325:16
medical 7:8 36:9,13
38:8,13,16 43:10
44:10 91:2 92:1
100:14,19 105:7
138:15 150:9 190:8
191:6 192:5 194:1
195:16,18 197:1
198:19 202:10 221:13
221:14 231:5 243:10
243:19 264:20 271:7
277:12 315:6 319:1
Medicare 2:13,16,17
25:3,4,14 26:15 27:1
57:4 66:5,13 67:8
82:16 103:20 118:19
125:9 128:4 130:6
197:14,16 205:17
242:7,8 258:9,11
261:8 296:8
medication 23:4 33:18
81:14 126:5,7 235:11
235:21 236:5,16,17
236:18,21 237:1,11
241:8 242:5,11,22
244:5 251:14 257:3
257:22 318:21 325:14
medications 22:13
114:7 117:8 123:15
126:7 155:10 235:12
236:3 237:2 240:6
241:2,3,5 244:10
252:3 255:22 270:11
276:4,19 324:22
Medicine 1:21 18:3
105:7 131:4
medium 32:17
meet 188:19 268:22
meeting 3:2,3 6:15
14:15 15:17 16:20

17:16,17 20:19 41:16
59:12 71:17 131:3
214:21 215:5 227:21
242:18 249:16,21
259:19 324:19
meetings 17:6
Megan 7:18
member 10:5,9,19 11:7
11:11,18 23:18 35:15
37:14 38:3 41:6 56:8
71:4,7,13,22 72:20
75:8 84:8 86:18 87:18
101:21 105:2 106:1
108:14 157:22 165:3
180:19 188:18 189:2
189:5 194:10 195:10
196:7,15 197:5
198:15 202:20 205:3
213:16 224:10 226:21
228:1 231:7,11,19
232:5,9 233:22
234:11 235:3,17,19
237:16 238:15,18
239:12,17 240:13,18
242:17 244:20 245:4
254:3,6 255:5 256:21
257:16 264:17 265:9
265:18 267:14 268:8
268:12,17 269:20
270:12 271:15 273:12
273:15 274:13,17
275:17 276:1 277:7
281:18 282:14 283:2
283:5,13 284:6
285:15 288:2 289:11
300:13 301:16,20
306:12 310:5 318:22
319:13,21 320:6
members 1:10 2:4
13:12,13 16:10,18
30:16 112:11,12
130:7 161:7 165:18
166:19 180:8,10
219:6 220:16,18
230:17 251:20 262:14
279:17,18 299:13
304:9 313:17 314:2,3
326:1,11
mental 2:3,6 10:17,18
23:9 29:5 44:5,12
45:8 91:1,11 95:3,15
96:7,15 103:10
126:11 129:13 197:2
245:5 246:1 247:11
247:19,22 249:4,10
259:2 262:5,9,18,20
264:8 269:12 270:1
270:20 271:1 277:12

282:6 286:21,22
 292:3 294:10 295:21
 296:18 297:9 302:10
 302:13,19 303:1,15
 307:4,6,16 308:6,7
 311:1,13 313:1,12
 316:4 317:14
mentally 28:16 246:12
 246:14
mention 122:20 179:19
 254:13 271:21 324:10
mentioned 5:6 52:17
 70:20 80:14 106:8
 110:22 111:2 121:21
 129:2 130:6 131:8,14
 133:10 137:7 142:20
 144:13 147:7 164:14
 165:10 167:18 180:7
 210:6 301:3 314:21
 318:16
mentioning 252:15
 282:20 319:14
merits 284:19
message 90:3 104:21
 301:9 306:17
messaging 104:16
met 1:8 235:7
metabolic 267:11
 297:12
method 141:14 217:14
methodologies 194:6
 227:15
methodology 64:16
 72:8 248:16
methods 244:16
metric 267:21 268:22
metrics 57:12 115:21
 116:20,22,22 117:2,5
 117:6,11 119:15,16
 126:10 159:5
mic 104:22 174:3 206:7
 283:1
Michael 1:20 10:19
 101:20 104:22 157:21
 224:9 256:5 257:15
 260:16 273:10 275:16
 276:15 282:22 285:14
microphone 5:20 12:21
 12:21,22 172:14
microphones 9:18 10:3
 12:20
mics 286:3
middle 84:15
midway 31:6
mike 9:20
mikes 9:19,21
mild 126:9
million 20:22 50:5,10

112:6,11,12 114:14
 116:14 120:16
millions 86:7 270:14
mind 40:6 41:2 51:3,9
 53:14 54:10 202:22
 214:1
mindful 168:16
minds 166:10
mine 276:11
minority 95:4
minute 144:5 249:6
 280:8,22 285:3,21
 289:14
minutes 109:8,8 151:8
MIPS 197:18
mirrors 122:1
missed 67:12 68:5
missing 128:19 130:1
 143:9 151:14 256:16
 287:11 290:2
misstate 231:21
misstated 288:18
mistaken 225:4
misuse 114:4 120:12
 315:9
mix 104:7 186:7
mixed 127:4 189:6
MMIS 141:20
mobility 142:20
mode 144:11
model 106:12 159:4
 173:8
modeling 67:20
models 63:20 91:22
 115:10 265:2 266:3
moderate 126:9 258:4
modest 271:12
modification 138:13
 279:2
modified 125:10
modify 154:8
money 18:10 100:22
 101:2 181:16
monitor 139:9 203:5
monitored 203:20
monitoring 117:12
 123:14 280:20 281:2
 281:10 282:3 284:22
 286:6 292:22
month 180:12 259:20
months 124:21 180:2
 217:12
morbidity 44:11
morning 7:7,13,17 8:2
 10:9 11:7,11,14 49:3
 71:4,7,14 213:7
motion 30:19 209:4
 293:19

motivated 77:12 226:7
 226:11
move 9:21 41:12 42:11
 45:18 56:11,14 57:9
 76:15 78:18 99:14
 140:18 155:16 168:5
 179:9 188:11,12
 202:15 213:1 214:9
 227:14 235:2 238:4
 238:22 245:8 251:3
 262:2 272:12 289:4
 314:14
moved 237:17,19
 323:18
movement 96:4 100:19
 101:18
moving 50:4,20 68:10
 87:10 92:2 168:3
 174:9 179:14 214:13
MPH 1:14 2:10
MPR 242:21 243:3
MSN 1:15
MSSP 193:4
MSW 2:14
Mukherjee 2:10 4:19,20
 7:3 12:12 58:2 62:9
 67:9 90:13 92:7 199:2
 214:1 218:10,15,19
 219:1,7,9 220:20
 222:13 232:4 238:6
 238:16 258:21 259:19
 260:8 261:11 280:4
 286:3 291:15 314:17
multi- 133:22
multiple 22:14 24:7
 60:14 61:4 90:22
 116:10 119:6 138:17
 165:19 186:22 194:19
 195:11 258:13 325:6
 325:13,13
mutually 267:3

N

N 139:8
N's 125:17 161:8,10
N.W 1:9
name 4:16 8:2,8 11:14
 37:17 71:14 291:13
narrow 220:13
narrowly-focused 61:5
nation 113:11
national 1:1,8,13 2:5,14
 11:19 18:3 71:18
 88:12,13,18 131:3
 133:21 135:7 152:15
 155:6 171:8 185:2
 186:3 213:8 222:19
 277:5

nationally 190:20
nationwide 6:9 56:5
natural 236:9
nature 64:3 67:21 68:19
 206:21 234:10
NCMS 229:21
NCQA 122:13 125:7
 138:21 231:1 243:13
 287:7 295:6 300:13
 303:10 323:12 324:9
NCQF 277:6
Nearly 138:11
necessarily 19:1 40:20
 51:21 52:15 55:7
 60:12 78:15,20 83:6
 160:14 174:17 175:1
 176:20 178:15 204:11
 211:3 224:18 228:14
necessary 64:8 139:19
 208:10 252:19
need 8:13,22 12:16
 29:21,22 42:9,10
 56:16,20 67:6 78:15
 80:3 85:21 86:9 87:13
 88:20 94:20 95:9
 102:5,7,19 106:22
 107:10 112:2 124:20
 131:2 136:18 137:21
 141:22 155:21 156:1
 164:2 165:6 167:14
 172:18 173:19 175:1
 180:15 183:17 188:15
 197:19 198:18 203:17
 203:19 205:12 206:6
 227:21 231:14 237:10
 245:14,16 252:17
 257:10 263:1 284:12
 287:17 290:15 321:5
 321:10,13
needed 102:10 185:3
 188:16 193:15 194:21
 195:11 198:17,22
 199:1 212:7 229:6
 255:10
needle 309:10
needs 16:4 17:8 91:3
 134:16,17 142:9
 145:17 152:1 155:1
 166:4,10 167:22
 173:14 188:3
needy 54:1
negative 104:19 257:13
 272:10
neonatal 76:16
nervous 175:7
net 90:18 94:11 104:2,5
 168:6
network 118:11 309:19

Neurology 251:8
never 42:5 80:18,19
 156:19
new 2:2 4:8 6:6 10:17
 23:19 25:9 38:22
 46:19,22 52:20,20
 71:16 75:10 94:20
 96:17,21 97:18
 100:22 101:12 102:20
 104:10 114:7 199:10
 213:9 281:3,5 296:4
 297:5 320:3 323:1
newly 15:20 215:19
news 145:11
NH 1:14
nice 263:20
NIMH 321:20
nine 22:3 23:11 288:8,8
 313:13
node 257:8
nominate 274:2
nominated 194:8 246:1
 273:21
nominations 194:7
 299:11
non-malignant 117:10
 117:14
non-measure-specific
 35:1,3
non-Medicaid 211:4
non-medical 102:14
NON-VOTING 2:4
norm 49:6
note 34:9 209:7 239:1
 298:3 308:14 315:18
noted 70:2 308:16
notes 280:14 308:3
noticed 324:7
notion 44:4 175:20
 266:20 267:5
novelty 137:20
nowadays 49:6
NPI 129:9,16
NQF 2:7 4:14 8:3 13:13
 14:21 19:17 22:16
 70:6 84:2 91:3 116:21
 122:12 125:22 126:1
 135:5 153:9,10
 184:10 188:2,16
 217:10 221:2 231:2
 231:17 235:15 242:11
 243:1,3,14 249:5,7
 250:8 262:7 273:5
 276:19 280:22 282:11
 296:1 297:8 298:6
 322:21 325:9 326:3
NQF's 30:9
NQF-endorsed 299:20

302:16 324:13,18
nuances 62:18
number 5:15 20:5,6,8
 32:12 34:1,3 41:17
 76:7 81:19,20 108:16
 112:12 129:10 137:3
 150:5 158:13 163:19
 183:8 190:10 191:7
 191:14 192:13 206:13
 210:8 214:18 217:19
 239:19 242:10 248:16
 249:6,7,22 250:8
 251:11 266:11,19
 267:7 268:2,4 278:14
 278:16 279:20 280:22
 282:11,13 288:7
 294:20 296:1 309:10
 309:16,18 317:5
 324:2,14
numbers 55:17 129:9
 136:6 139:5 151:13
 186:22 250:20 278:5
 303:20 305:17 306:1
 316:20
numerator 72:9 129:12
 189:22 217:20 286:12
 302:17,17
nurse 1:15 213:17,19
nursing 27:6 70:4
 253:17 261:6

O

obese 136:9
obesity 82:1 116:14
 120:13 270:10 297:14
objective 168:4
objectives 3:2 15:17
obligated 160:3 172:15
obligations 12:16
 107:16
obtain 20:11 197:3,4
 307:7,14,15,16
obtaining 37:2 141:14
 307:4
obvious 27:20 136:13
 152:9,10
obviously 44:7 86:21
 95:18 124:5,9 228:2
 241:3,16,19 307:2
 323:12
occur 74:9 136:3 143:6
 146:9 153:17
occurred 75:5 134:3
 135:1 322:5
occurring 73:16 75:7
occurs 73:13
offer 72:3 105:21 308:3
offered 126:20

office 2:2,5 10:17 164:2
 166:2 213:8 277:2
 287:2 303:5
Officer 6:4,7 7:15
 110:13
officially 316:17
officials 85:4
offline 125:14
oftentimes 44:9 73:22
 105:5 108:1
OGUNGBEMI 2:10
 288:10,20 289:7
 290:9,15,22 291:10
 291:18 292:7,15
 293:3 294:5 312:20
 314:15
oh 6:20 23:17 26:21
 37:17 47:13 71:13
 84:7 92:7 164:16
 165:2 169:9,9 172:11
 172:14 180:18 197:21
 213:2 230:11 255:3
 280:12 320:16
okay 7:2 12:7 17:14
 28:22 31:7,20 32:11
 33:4 34:17 41:4 49:7
 54:6 68:6 71:6 72:19
 76:11 78:4 92:7 94:5
 109:8 119:6 123:8
 126:15 127:20 131:1
 143:20 151:6 164:11
 172:11 175:18 188:17
 189:5,7 190:17
 191:11 193:9 195:14
 199:9,14 200:5 209:5
 210:18 213:1 214:8
 214:16 216:5,17
 230:4,14,15 231:22
 235:2,4 238:15
 239:12,15 243:7,9
 248:21 250:2,10,14
 250:22 251:3,5 260:3
 261:18,21 262:2
 272:12,14 275:3
 276:12 279:7,11,12
 281:17 283:6 284:20
 285:2,10,13,14,17,20
 286:1,3,4 287:10,12
 287:15 288:16 289:11
 289:12 290:5,7,7,9,17
 293:19 294:12 300:18
 301:17 312:19 313:10
 313:22 314:13 317:3
 317:7 319:19 320:8
 322:16 323:14,22
 325:19,20
old 31:4 288:18
older 87:2 189:19

192:10 235:7 244:1,7
 244:14 258:8 302:8
once 17:5 43:1 45:3
 58:17 62:17 99:14
 102:6 150:10 191:10
 191:18 192:18 217:12
 225:19 268:4 280:4
 320:9
one's 263:20
one-size-fits-all 72:14
ones 22:21 29:14 41:19
 53:2,3 70:20 81:8,9
 135:14,19 144:22
 145:11 153:19 183:19
 316:15
ongoing 120:8 315:20
open 94:6 141:6 157:19
 188:7 217:2 253:22
 289:7 290:11 291:12
 292:5,13 299:11
 313:3 323:20
operate 17:5
operational 19:8
operationalization
 66:22
operationalize 61:19
 64:14
operationalized 67:1
operationalizing 67:16
operator 12:5,8 182:14
 294:18,22 323:20,22
ophthalmologists
 234:15
ophthalmology 234:16
opiate 315:11
opinion 238:17
opioid 22:15 23:3 28:19
 117:9,15 120:12
 124:11,12 125:3,15
 131:16 221:7 305:6
 319:16
opioids 22:13
opportunities 59:11
 115:17 141:5 179:7
 179:10,12
opportunity 3:9,12,19
 7:2,6 17:7 42:2
 126:18,21 164:5
 169:4 171:7,20 199:5
 200:7 214:12 220:16
 239:6
opposed 82:1 149:6
 224:18
optimized 91:15 93:5,5
option 249:12
optional 227:1
options 30:17
oral 81:6 202:5

order 113:8 162:19
168:10 278:4,5,22
284:13 291:4
Oregon 2:12 36:20
37:16,18 109:16
125:10 132:17,19
134:4 136:7,20 139:3
147:9 149:11 152:6
Oregon's 37:20
organic 157:4
organization 8:21 11:4
12:3 27:5 121:17
205:1 304:20
organizational 8:19
13:20 146:19 168:18
organizations 72:13
88:19 97:5,6 99:16
102:16 105:13 137:2
139:20,21 140:15
146:4,10 148:9 149:4
150:4,19 152:6
158:21 169:15,20
171:19 175:6,17
258:11 278:17
organized 116:4
originally 190:22
191:19 193:2
Oscars 110:18
ought 66:1,2,7,19
outcome 58:21 59:9
101:4,13 108:9,19,21
109:4 132:8 148:20
150:16 175:5 178:14
203:5 222:2 240:8
262:13 267:4
outcome's 241:21
outcomes 4:8 6:4 7:9
7:19 8:1 44:7 53:21
69:7,8,8 70:1 77:21
89:13,18,22 90:8
93:21,21 97:21 98:10
102:22 106:22 108:11
108:12 113:5 146:8
151:17 170:2 202:10
204:20 240:6 265:21
268:5 315:2,13 318:5
318:6 322:3,5
outlined 113:13 119:20
outpatient 116:5
131:16 277:4 303:7
307:11 308:21 309:19
outreach 163:7 201:16
206:1
outside 10:2 103:16
110:10 147:21 234:1
over- 161:14
overall 15:15,19 31:21
92:12 94:22 98:19

130:16 134:14 149:18
188:22 211:12 266:13
301:10 307:15
overarching 3:6 15:9
overdose 124:13,14
overlap 210:15
overload 222:11
overuse 114:4 120:12
126:7 253:13 315:9
overview 3:3 20:2 31:9
59:3 111:8 217:4
overweight 136:9
297:14
overwhelm 220:5
overwhelmed 157:21
owners 182:5

P

p 206:17
P-R-O-C-E-E-D-I-N-G-S
4:1
p.m 183:2,3 289:17,18
326:15
P4P 115:22
pacemakers 257:10
Pacific 112:22
pack 20:15 72:15
pagars 31:11,13,14
pain 117:10,14,14
painting 164:12
pairs 60:16 63:13 64:4
palatable 223:8
palliative 124:15,19
125:1 131:19
panel 3:8 41:16 43:14
303:17
panels 308:16 311:14
paper 56:3 231:5
paperwork 164:3
parallel 136:21
parameters 90:20
parents 21:5
parse 210:21 211:3
parsimonious 18:8
157:13
parsimony 63:6,9
186:13
part 6:11 18:12 19:17
25:2 63:9 73:18 80:8
101:11 105:9 120:2
133:10 134:16 137:4
140:14 141:14,15
142:1,6 146:14 148:5
150:12 160:16 166:6
168:8 190:12,19
197:17 205:16 207:13
225:5 227:13 232:15
232:15,21 233:8

242:8 245:21 249:16
249:19 253:9 270:9
270:10 284:9 304:4
312:2,5,7
partial 69:1
partially 136:16
participants 176:7,19
participate 14:1 88:6
119:18 126:18 143:21
participated 41:15
participating 4:15
13:12 14:12 15:20
88:3,22 109:20
296:14
participation 31:22
70:11 77:5 143:16
particular 16:13 18:1
28:10 49:14 51:1
65:22 67:5,7 73:2
95:8,17 140:1 153:21
156:9 165:5 187:17
216:7 221:16 229:17
234:12 252:11,22
256:22 258:12 295:18
310:18
particularly 17:2 24:21
36:7 53:21 56:11
95:14 96:12,22
104:17 105:13 106:15
115:18 175:7 221:17
228:5 232:19 254:16
257:6 263:20
partly 160:12 202:8
237:18 253:7 318:4
partner 88:17 96:11
partners 53:4 93:13
210:11 248:11,20
partnership 1:3 117:17
170:12
partnerships 208:11
parts 92:3
pass 291:4 309:12
317:17
passed 124:17
passes 289:1
passive 163:9
patience 326:8
patient 59:20 62:19
69:14 87:8 92:17,18
93:15 106:4,13,16
107:7,17 108:14
117:5 155:9 205:13
257:1,11 258:3
304:12
patient's 158:7
patient- 69:22
patient-centered 150:9
patient-centric 92:18

patient-reported 69:8
patients 25:5 78:12
107:6 117:15 123:14
140:5 147:1 159:19
217:11 230:21 235:7
236:2 244:1,7,13
251:12 252:4 259:8
262:8 277:11 281:6
281:11 282:17,19
286:9,14 301:7 302:8
302:21 319:1
pattern 30:3
patterns 31:17
Patton 2:6 213:11,11
222:18 223:20 225:7
225:11 228:19 249:14
250:5 265:4 270:16
271:20 303:11,13
304:3
pause 67:10 68:4 290:1
290:4,8,12 291:9,17
292:6,14 293:2,18
pausing 70:18
pay 90:4 105:20 137:21
227:18 305:10 310:13
pay-for-performance
115:22
payer 130:6 142:3
154:19
payers 66:8 86:10
113:6 114:17 115:1
146:12 154:21
paying 227:10 237:11
payment 8:5 25:7 63:20
80:19 115:8,9 177:8
177:16 184:16 227:15
pays 120:18
PBMs 88:13,18
PC-01 34:3,4
PC-03 34:11 190:19
191:8
PCORI 163:18
PCP 55:17 301:8
PCPI 217:10 224:1
PDC 235:5
PDSA 120:3 160:16
pediatric 122:17 136:7
pediatrician 7:10
Pellegrini 1:16 11:11,12
41:6 84:8 188:18
189:2,5 194:10
195:10 205:3 233:22
240:13 265:9 269:20
270:12 273:12,15
274:13,17
penalize 90:18
penalizing 94:10 95:7
penalties 25:8,12 94:16

pending 188:2
Pennsylvania 26:1
people 5:9,13,16 7:2
 8:13 10:1 13:7 15:10
 18:5 22:11 23:4,6,9
 42:14 44:5,9 45:8,13
 59:19,20 63:18 66:15
 78:8 95:14 96:14
 98:15 104:4 117:13
 130:17,20 131:5
 132:10,12 140:17
 144:8 145:22 152:2
 154:21 157:20 160:8
 161:3 163:11 164:20
 171:10 173:9 177:11
 179:22 180:6 183:8
 211:14 223:9 225:19
 226:5,6,10 232:2
 238:19 241:4 243:2
 247:11 249:3,10
 253:4,5,17 256:5,17
 261:6,8,15 262:5
 269:11 270:5,6,14,14
 270:19 271:1,6 276:2
 276:17 278:2 280:20
 281:19 282:4 284:16
 284:22 286:6 290:3
 291:8 292:2,22
 294:10 295:9,17
 297:9,14,18 298:4
 299:11 300:10 305:20
 306:3,6,17 316:11
 317:13 318:18,19
 319:6 320:2,12
people's 299:8
Perault 7:21,21
perceive 14:18
perceived 70:16 84:17
 87:21 148:5 149:8
 155:20
percent 21:5,10 56:4
 85:12 112:20,21,22
 113:1 116:20,21
 121:14 130:16 136:8
 137:4,4 145:13
 154:15 180:8,9 235:9
 241:1,4 262:12
 271:17,18 278:11
 280:2 283:17,22
 284:12 287:18 289:2
 290:18,18 291:1,3,3
 291:19,19 292:7,8,15
 292:16,17 293:3,4
 297:19,20 311:10,10
 314:5
percent-wise 300:18
percentage 235:7 241:7
 244:1,6,13 262:8

 269:22 286:9 302:7
percentile 74:6,19
 119:14 120:4
perception 148:3
perfect 54:3 82:4
 156:20 174:22 211:2
 241:20 242:4
perform 78:19 119:13
performance 7:20
 44:19 61:9 66:7 73:2
 74:3,5 75:17 77:9
 80:20 97:17 119:9,18
 122:9 128:5 137:8,10
 137:18 152:10 160:17
 185:18 186:22 204:14
 204:14,22 226:4,9,19
 235:10 266:15 277:21
 278:14 295:10 297:17
 300:16 311:9
performed 230:20
 231:1 286:13 289:5
performer 138:6
performers 54:8,9
performing 95:2,5
 120:3
perinatal 41:16,18 59:7
 85:17 116:16 190:21
 205:6 216:8
period 35:6 70:6 148:14
 180:11 190:1 226:1
 241:7,9,12 251:15
periods 13:6
permit 136:14
persistent 91:1 95:15
 123:15
person 7:11 9:7,9 12:1
 102:8 115:7 117:22
 150:21 186:9 240:14
 241:8 269:5 287:11
 307:5
person's 163:21
personal 170:2
personally 250:14
persons 22:15 112:16
 251:6 292:11
perspective 30:10
 37:21 54:15 63:22
 72:6 91:5 108:11
 133:1,11,15,18,21
 135:13 165:14 167:7
 169:16 181:13 204:2
 211:10 306:15 321:11
perspectives 3:8 134:1
 158:1 258:5
pertain 133:3 145:4
pertinent 49:16
pertussis 120:12
pervasive 207:6

pessimistic 164:12
pharmaceuticals 114:6
pharmacy 10:7 125:19
 231:6 241:13,13
 252:8,9 255:7 276:22
PhD 2:2,6,8,12,14,15,16
phenomena 306:5
philosophy 88:4
phone 9:7,9 10:1 12:1,4
 12:10 13:8 17:16,17
 288:9 295:1 313:6
 324:4
phones 12:14
phrase 134:10
physical 55:7,11 91:11
 267:18
physician 236:21
 242:22
Physicians 10:20 107:3
Picarillo 1:17 10:9,10
pick 29:11 30:7 53:2
 214:22 216:17 218:1
 218:11,14,14,16,18
 218:22 219:12 220:2
 220:15 284:2
picked 28:11 30:16,19
 63:8
picking 101:21
picks 184:11 202:17
 215:2 219:13 220:6
picture 17:4 87:12
 164:13 175:4 193:11
 229:11 265:1
pie 99:18
piece 51:15 80:5 86:22
 201:20 265:7 268:19
 269:6
pieces 106:22 212:6
pilot 118:1,17 312:3,5
pilots 115:7 163:13
Pincus 1:9,11 4:3,5 5:5
 6:19,22 9:11 14:8
 22:20 23:16 28:1
 32:19 37:16 38:2 41:3
 42:14 46:15 47:13
 48:20 49:5 53:11
 54:21 55:22 57:16
 62:5 65:18 71:3,6,11
 71:20 72:19 76:22
 77:14 83:21 84:5
 86:17 87:16 90:10
 92:5 94:5 99:10
 101:19 104:22 105:22
 107:18 109:5,15
 132:15 151:2,7
 157:17 158:11 161:2
 161:8,17 162:2
 163:14 164:11 165:1

 166:11 167:15 169:1
 170:5,22 172:2,10,12
 173:17 174:2,16
 175:11 176:1 178:17
 180:16 182:12,19
 183:4 188:22 189:3
 193:17 195:7,15
 196:13,17 200:11
 204:1 205:2 206:6
 207:7,21 209:2 211:9
 212:17,20 213:21
 214:8 219:5 222:14
 223:14 224:8 225:3,8
 225:13 228:18 230:3
 230:11,14 232:1
 233:5,21 235:1
 237:13 239:15 240:11
 242:9 243:5,7 245:10
 245:19 246:5 247:3
 248:8,14,21 249:13
 250:2,10,22 251:3
 254:2,5 255:3 256:4
 256:20 257:15 258:6
 258:17 260:12 261:17
 261:21 262:2 264:16
 265:3,8,17 266:7
 268:1,10,13 269:8,19
 270:4,15 271:19
 272:9,12,15 273:14
 274:22 275:3,5,16,22
 277:18 279:3,6,10,12
 283:4,6 284:15 285:2
 285:11,18 288:6,13
 289:6,19 290:2,5,13
 290:21 291:7,13
 294:16 295:2 298:5
 298:13,16,19 299:4,7
 300:4,9,12 301:14,17
 301:22 302:4 303:12
 303:22 304:5,22
 306:11,21 307:8,19
 308:1 309:6 311:5
 312:9,14,16,19
 314:10,13,16 316:8
 317:1,4,18 318:12,15
 319:4,11,19 320:1,8
 320:11 321:17 322:10
 322:16 323:10,12,16
 324:5 325:1,12,19
pipe 100:21
pitiful 300:17
place 30:19 57:6 76:21
 97:15 173:19 181:17
 187:6 226:9 261:14
 310:12
placed 19:16
places 85:16 88:1 96:14
 100:15 197:9 226:6,8

- plaguing** 18:5
plan 10:11 52:1,4,13
 82:15 86:9 114:20
 118:20 119:19 127:4
 139:18 146:2 180:10
 180:15 185:19 192:13
 192:15 251:18 277:1
 287:6 296:16 303:9
 304:11,20 308:5
plan/patient 244:19
planning 124:16 125:4
 125:6,7 312:10,12
plans 1:18 74:2,5,11
 88:12,14,17 112:17
 112:18 118:8,15
 119:11,12 121:20
 123:1,4,11,20 127:7
 128:9,13,21 130:13
 158:19 159:8 160:3,7
 160:17 180:7,9,14
 181:7 204:10 212:14
 233:9 237:11 242:8
 296:8 307:14,17
play 129:9 156:15
playing 226:16
please 5:20 12:2,14,19
 12:20 13:17 16:15
 20:3,10 21:13 58:3
 59:1,18 61:6,17 62:1
 64:12 65:16 68:8,14
 69:11 70:9 90:14 91:4
 92:8 93:5,8 182:15
 232:6 288:12,21
 289:9,10 294:19
 313:5,9 323:21 324:1
pleased 5:16
plus 222:1
PMP 2:9
point 13:17 24:19,20
 25:17 45:1 48:6,17,22
 50:17 53:12 67:2 68:3
 70:18 81:12 82:9 98:2
 99:13 105:3 122:17
 140:21 145:22 147:5
 150:1 162:9 166:22
 169:2 177:6 185:5
 199:14 208:20 222:17
 224:20 228:20 233:2
 238:13 253:10 263:13
 265:19 274:2 279:20
 287:22 316:1 319:20
 325:2
pointing 18:1 23:16
 28:7
points 3:3 19:14 38:18
 40:4 61:14 95:16
 155:17 162:21 165:5
 186:2 193:14 198:17
 198:22 200:8,9
 257:18 315:5
policies 143:11 163:6
policy 3:6 5:11 6:1 7:8
 15:9 16:22 20:17
 57:19 58:9 75:18
 93:18 199:19 306:15
 309:9,22
policymakers 84:14,17
 85:3,15 86:1 102:10
 107:11 165:22
political 70:17 87:22
 89:21 90:3 147:11
 206:17,17
politicians 90:3
polypharmacy 315:12
poor 21:6 123:17
 233:15 262:6 265:21
 270:9 292:3 294:11
 317:14
poorer 87:2
pop 271:10
populated 174:8
population 20:18 28:17
 29:4 35:7 42:21 44:6
 44:9,18,20 45:7 46:17
 47:6 48:14 54:20
 56:12,15,21 57:5,8,9
 57:14,15 62:19 63:21
 66:17 67:22 72:9 87:6
 87:11 91:15,17 92:13
 93:6,20 95:1 106:9
 107:10,22 112:19
 125:8,9 130:19 136:9
 139:7 140:7,11,14,17
 141:2 142:9,21 143:2
 143:9 144:14,14
 145:1 152:19 160:22
 161:22 163:2 175:2,3
 178:20 185:16,20
 203:10 204:13,20
 211:13,14 215:16
 221:12 226:8 245:6
 249:12 252:21 253:14
 253:16 256:8,10
 261:16 262:21 263:2
 263:9 265:15 266:13
 267:8 270:3 271:3,11
 271:16 272:1 277:20
 278:8,11,12,21
 286:20 297:12,19,20
 300:20 302:18 303:9
 305:11 309:5 311:16
 311:17,19
population-level 69:13
 69:15
populations 20:13 37:8
 53:22 68:13 95:9
 97:22 114:16 116:8
 145:5 152:16,21
 210:15 265:20
portfolio 249:17,19
portion 128:3 175:3
pose 172:3
positive 76:9 102:8
 104:19 144:10 272:10
possibilities 157:18
 200:17
possibility 102:3
possible 50:22 61:3
 65:3 156:3 164:21
 165:16 176:12 185:12
 229:18 300:8,9
 306:19
possibly 161:1 264:14
post-emergency-room
 300:22
post-incarceration
 116:16
postpartum 32:2 41:21
 119:22 124:4
potential 5:13,14 42:22
 109:21 165:18 168:2
 186:16,20 193:13
 214:17 287:13
potentially 140:19
 177:22 183:14
PowerPoint 165:20
PowerPoints 166:15
PQA 255:7,11
PQI 130:3
PQIs 207:16
PQMP 59:14 82:7
PQRS 193:4
practical 131:2
practice 80:1 141:17
 153:18 154:12,14
 155:15 206:13 254:9
practice-level 146:3
practices 76:9 146:1,13
 148:8 164:6 168:9
 175:17
practitioner 213:17
Practitioners 1:15
 213:19
precipitated 137:19
precipitates 38:1
precipitating 150:2
precise 105:3
prefer 122:12 167:8
 241:4
preference 152:18
pregnant 112:15
 179:12
preliminary 5:8
premature 25:16 204:7
prenatal 41:21 120:10
 204:6 212:8
prepare 326:4
prepared 312:16
Presbyterian 4:8
Prescribed 276:3,18
prescribers 125:19
prescribing 253:6
 254:17 257:3
prescription 117:8,12
 236:11 241:17,18
 251:13 324:21
present 1:10 2:1,4,11
 2:22 62:2 159:2
presentation 58:9
 133:4 165:20
presentations 41:10
 165:9
presented 20:12 42:3
 134:6 264:14 268:15
presenting 11:16 48:21
 158:1
President 2:8 5:1
presiding 1:9
press 85:13 137:19
 182:15 279:13 289:6
 294:19 324:1
pressing 176:1 288:15
pressure 23:8 45:14
 62:17 124:3 158:6,8
 158:10 159:11,20,22
 160:6 176:8 196:10
 196:12 240:4
presumably 176:5
presume 27:17
pretend 234:1
pretty 27:20 48:8 78:16
 103:2 109:6 137:12
 159:1 183:19 256:14
prevailing 155:22
prevalence 270:22
 271:4,16 277:20
 278:9 297:14
prevalent 215:15
prevent 64:6
preventative 294:6
 318:19
preventing 113:16
prevention 116:6,14,15
 120:14 125:21 130:10
preventive 32:4 42:7
 115:13 130:8 216:19
 317:7 324:11
previous 76:3 144:4
 219:14 249:16,20
previously 19:19 87:11
 118:6
primarily 7:11 36:11

150:19 193:18,19
282:21
primary 39:8,17 43:5
47:22 103:9 118:12
125:21 130:6 140:12
145:13 150:15 160:18
264:20 300:21 302:9
302:13,22 303:15
304:11,21 315:2,7
319:2
prime 53:14 115:7,18
115:19,22 116:19
117:9 118:21 119:7
131:20 173:5
principal 132:20
principally 133:2
155:18
principles 218:2
prior 6:2 11:5 201:10
266:6
priorities 14:19 43:16
114:22 185:3
prioritization 139:22
prioritize 293:9,13,16
293:20 294:15
prioritized 153:9
272:19
Prioritizing 3:17
priority 119:19,21
153:19 154:3 196:21
199:18 215:4
prisons 96:13
privacy 311:1
private 61:10 64:4
86:10
privilege 110:17
proactive 201:15
probably 24:4 31:4 37:9
54:16 87:22 100:4,16
105:20 146:13 151:5
167:13 171:17 212:11
222:9 224:11,13,22
233:2 240:14,22
255:14 256:2 263:9
283:2 316:9
problem 26:13 38:7
120:13 225:20 226:2
253:19 264:6 305:13
problematic 27:15
36:10
problems 14:16 25:20
54:5 95:8 98:12,18
138:2 156:16 162:10
221:14 228:10 270:21
326:9
procedures 323:1
proceeding 15:6
process 15:6,12 16:12

19:18 24:5 37:6 42:16
43:11,14,19 80:6
89:13 90:7 132:7
136:17 142:16 146:21
165:6 188:2,19 192:1
217:17 231:2 235:14
239:1 240:2 244:18
247:5 251:18 273:12
276:20 286:19 298:19
303:4 323:3
process-oriented 146:6
processes 105:14
163:8 173:18 211:19
produce 136:12,15
145:1 153:4 261:2
produced 136:7 140:9
143:22 173:21
producing 151:11
168:12
production 144:10
168:8
productive 17:16 93:14
professional 55:20
321:7
professionals 191:13
321:16
Professor 4:5
program 11:6 14:13
16:5,14 19:2 20:17
21:16 25:3,14 26:14
40:11,11 50:1,3 64:20
65:21 66:3,13 67:3,8
67:8 68:1 79:8,14,17
95:6 96:17 97:12
102:18,20 108:1
109:21 110:10,11,14
111:4 112:8,9 115:6,9
115:18 116:1,19
118:7,8,17 119:8
124:19,20 125:1
131:20 142:7 143:12
143:17 149:19 169:20
173:5 180:22 181:1
184:6 185:6 186:2,4,5
186:6,8,10,12 201:11
203:12 210:12 212:4
227:2,5,10 254:11
258:16 296:15 307:16
322:4
program-wide 121:3
programmatic 142:15
programming 229:18
programs 8:5 11:4
21:18 52:20 60:7,14
61:14,22 63:20 65:21
67:17 96:20 97:19
107:22 117:13,20
119:1 143:13 152:9

184:16 185:21 227:14
229:21 231:15 261:5
261:8 278:12 296:13
Progress 85:10
progresses 41:2
project 2:9,10 4:17 7:15
22:17 70:6 91:3
116:11,16,16 117:9
117:11 128:17 132:21
164:21 204:15 208:9
208:14 220:21 221:1
251:8 278:15 315:19
project's 117:1
projects 116:11,13,18
117:6 120:8 133:13
277:22
proliferation 18:6
promote 324:20
promotes 118:17
186:13
promoting 85:16
131:15
promotion 315:10
prompt 139:20 164:1
prompts 150:2
promulgated 200:14
properties 185:13
proportion 46:16 47:6
235:5,8 240:16,20
241:6 242:22 243:3
271:10 291:15 294:8
317:10
proposal 321:19
proposals 319:8
propose 300:7 302:3
proposed 139:18 213:2
214:10 320:4,15
321:18 325:8
proposing 250:11
314:11
protection 240:4
proud 159:12,15
proved 135:21
provide 6:18 37:22
46:15 47:2 53:5 59:2
86:13,13 93:10 102:9
115:12 146:3 148:1
167:13 184:20 187:2
187:13 201:5,8,15
227:2 228:22 229:6
232:6 236:6
provided 13:12 31:10
31:12 55:15 92:21
138:6,14 148:8 149:3
160:7 206:1 244:15
provider 39:18 52:11
55:8 82:14,21 99:20
105:4 106:5,18

114:21 129:7,8,11
139:21 141:17,21
164:1 179:13 191:20
193:3 196:10 198:1,5
198:12 302:12 307:6
provider-reporting
70:3
providers 22:14 39:16
56:19 66:8 73:19
90:18 92:16,17 94:11
100:18 103:8 104:2,5
115:12 118:12 126:11
129:17 142:2 145:19
148:2 171:19 175:6
181:6,20 182:10
196:16 198:21 199:18
225:12 227:17 234:8
234:12 252:2 254:16
264:10 308:21 309:20
315:8 321:8 322:7
provides 20:22 112:5
112:14 115:11,17
321:1
providing 56:19 92:20
96:5,6 97:4,7 187:15
225:9 243:19 306:15
proxy 199:6 200:10
265:7 267:16
psych 25:4
psychiatric 25:2 277:3
303:6
psychiatrists 56:5
Psychiatry 4:6,7 56:4
psychosocial 315:6
324:16,21
psychotropic 81:13
public 3:9,12,19 13:5
13:13 35:10 37:12
61:10 79:4 86:2 92:13
93:17 114:12,14
115:5 116:2 134:11
159:6 165:21 166:18
182:13,15,17,18,20
184:16 208:10 210:11
214:12,14 259:21,22
294:17,17,22 295:2
298:7,9 323:16,17,18
323:21 324:3,5
publicly-reported 33:2
published 43:12 56:3
145:12
pull 161:4 162:7 247:19
247:22 264:5 265:15
274:8 275:14 276:5
283:8 285:7,21
293:10
pulled 276:13
pulling 266:16 276:10

purchase 21:9
purchasers 114:8
purchasing 79:5
 115:15
pure 297:2
purely 127:6
purpose 38:20 53:19
 68:21 79:22 82:12
 94:12 211:11 218:6
 262:19 282:9,21
purposes 18:18,19
 32:16 71:17 77:19,19
 79:4 95:6 162:14,15
 162:16 163:16 172:6
 181:10 314:1
pursue 207:12
push 9:18 48:2,12
 53:17 88:19 101:2
 254:18 309:10
pushed 197:17
pushes 263:18
put 17:6,12 65:1,4 89:3
 97:15 101:7 104:18
 135:10 173:19 176:22
 181:9,17 204:3,22
 212:15 222:10 238:5
 246:21 252:5 263:3
 264:12,13 275:15
 276:15 281:15 285:22
 293:12 299:2 307:9
 318:10 320:16
puts 73:5
putting 102:20 194:17
 255:2 301:22 322:11
 325:3
puzzle 87:1 107:1

Q

QI 120:8
QIP 193:4
qualifies 179:9
qualify 21:7
qualifying 143:3
quality 1:1,8 2:9,14 4:7
 5:1 6:3,4,7 7:9,15,19
 8:1,4 11:3,9 18:1 20:9
 20:11,14,15 21:15,17
 21:19 24:9,10 26:3
 29:3 40:18 42:1,3,19
 52:2 53:6 55:15,21
 59:5 63:14 74:1 83:13
 85:1,1,17 98:3 108:22
 110:10,13,19 111:16
 111:18 116:12 119:7
 119:20 121:5,22
 122:2,4 126:13,16,21
 126:22 127:22 128:12
 128:17 130:10 132:11

134:14 139:16 142:10
 144:12 146:16 148:21
 150:10 156:21 165:13
 168:22 172:6 173:21
 175:15 181:10 185:1
 185:2,17 186:3 204:8
 213:13,14 216:9
 222:20 231:10 233:18
 235:14 236:5 255:7
 258:10 264:18 265:1
 278:1 297:15 315:5
 322:3

quantity 42:2,18
question 29:9 35:16
 37:15 38:4,6,12,18
 40:21 46:1 47:10,12
 51:18 62:6 70:20 71:9
 71:21 77:15,16 83:15
 84:4 100:1,7,8,10
 102:6,12 156:16
 158:4 161:18 162:3
 170:7,8 172:3 173:11
 188:19 194:2,11
 195:22 196:7 197:7
 197:15,19 200:12
 209:3 211:16 228:5
 228:12 240:15 245:11
 247:13 254:9 264:4
 267:19 273:11,13
 277:19 298:6 320:1

questions 14:4 35:8,14
 47:3,13 48:20 54:13
 57:17 61:16,17 68:7,9
 71:3 73:9 75:18 77:1
 83:4,22 84:6 91:5,13
 93:4 102:2 109:17
 155:3 158:17 162:3,4
 165:2,4 169:8 172:3
 178:18 180:17 227:16
 232:2 233:6 235:2
 316:6

quick 12:13 50:18 59:3
 60:18 85:10 188:18
 274:9

quickly 81:22 139:5
 260:1 316:19

quickly-enlarging
 129:21

quit 120:16 243:22
 244:3

quite 28:12 95:2 107:7
 197:16 215:21 226:13

quote 69:17

quotes 67:13

R

race 98:16 99:6 151:21
 152:11 153:6 157:12

160:14
raise 77:16 288:14
 313:14
raised 30:12 162:10
 209:10 229:13 313:19
raises 77:14 245:11
 254:9

raising 40:22
rally 144:9

ran 145:9
Raney 2:17 7:13,14
 312:1,11

range 65:13 96:19
 179:6 289:21,22

ranged 34:20

ranges 62:14,20 65:6

rank 239:3 283:20
 284:3,5

ranking 284:9

rapid 137:3

RAS 235:12 240:5

rate 46:13 47:18 130:15

154:15 192:9,10
 227:18 235:10 246:13

264:1 270:22 271:2

295:13,19 297:18

rated 284:18

rates 82:2 120:11

124:11,12,13 178:3

235:5 291:16 294:8

297:17 302:18 311:11

317:11

ratio 242:22

rationale 19:3 187:16

199:22 218:1 235:16

244:20 245:4

re- 123:13

re-make 29:22

re-nominate 277:16

re-prioritize 273:16

re-rank 239:6,11

re-recommended 29:12

reach 30:3 156:19

197:10,20 209:14

210:1 292:16

reached 199:13

reaction 141:12

reactive 139:17

read 8:15 186:1 243:17

245:3 280:5

readmitted 297:1

ready 5:2 187:20 230:4

279:8 283:6 287:11

289:19 309:20

real 90:8 100:1,17

150:12 211:16 265:4

274:8 276:6 285:21

real-time 174:11

realign 56:19
reality 101:3,10
realize 68:14

really 5:18 14:15 18:13

21:12,12 36:10 40:10

40:14 41:13 48:14

49:1,3 52:22 53:11

54:17,20 55:1,14

56:10 57:2,10 73:8,20

75:9,14 77:18 78:7,11

80:6,21 81:9 82:20,22

85:9,14 88:19 89:3,21

90:1 94:15 98:19

101:7,17 102:11

104:17 105:10,17

107:2,21 108:4,6,7,12

108:13 109:3 110:17

110:20 113:4 114:4

115:16 123:20 124:14

125:20,20 126:19

129:9 130:9 131:13

132:8,9,10,13 135:15

139:5 140:7,17 143:9

143:21 144:2 145:7

146:8 147:21 148:9

149:1,2 154:7,12

156:9 157:9 159:12

161:10 165:9 166:8

167:18 168:7,16

169:12,12,14,18

170:1,10 171:22

172:17,17,20,21

173:12,13 181:4,14

183:17 184:1 186:14

194:16 197:17 203:15

203:18 204:3 205:3

207:15 208:2 212:5

221:2 222:21 228:22

229:10,15 234:2

236:22 248:7 259:10

264:21 265:7,10,20

266:4,4,5 271:21

272:4,7 306:16

320:18,21 321:7,13

322:8 323:5 326:5

reason 37:9 61:4 66:2

74:7 134:16 137:4

142:6 149:12 190:7

191:4 192:4 193:7

195:13 281:1 304:4

306:19

reasonable 175:4

185:15 225:17

reasons 28:5 34:19,21

34:22 35:4,11,19,21

36:15,22 37:20 44:16

67:3 155:19 186:16

186:17 190:4,6 191:2

191:3 192:2,3 193:5,6
206:14 235:20 239:19
240:9
recall 75:22 99:9
292:21 304:3
recap 60:18
receive 31:15 32:6
127:14 244:3 283:21
296:21,22 297:15
received 35:13 62:4
102:17 115:4 140:21
217:14 220:17
receiver 107:2 206:20
receiving 35:2
receptive 147:10
recognition 25:14
recognize 185:18
recognized 255:9 269:5
recognizing 269:5
recommend 183:14
188:11 220:16 238:21
280:3,15 297:8
recommendation 24:22
29:10,21,22 198:16
214:22 216:18 238:2
245:13,20 246:3,18
272:17,22 280:11
281:16 282:16 283:3
284:14 291:5 310:17
314:9 317:10,12,15
317:16 325:5
recommendations 3:10
3:14 15:2 16:7 21:20
24:6,13 28:9 29:11
30:4,6,18 43:15 70:22
183:9 188:20 214:19
215:1,4,8 219:13
220:17 230:8 276:10
276:13 279:9 316:12
316:14
recommended 22:3,4
22:10 23:11,21 29:15
30:15 215:10,17
219:6,11,22 230:17
231:7 235:3,18 237:5
237:17 242:15 244:9
251:9,20 259:6
262:14 263:5 275:18
284:21 291:21 292:4
292:9,12,17 293:5
296:3 308:4 316:16
316:18 325:15
recommending 209:6
212:22 235:20 245:11
247:15,18 281:1,6
reconsider 29:21
277:16 299:9,14
reconsidering 280:12

reconvene 109:9
record 36:9 100:14
109:13 183:2 190:8
191:6,12,15 192:5
194:1 195:16,19
198:19 279:16,22
289:17 294:3 314:1
326:15
recording 9:22 197:21
recordings 13:1
records 23:22 34:13
36:13 194:21 202:10
205:14 208:5 231:6
red 9:19 12:21 32:13,20
32:22
Redesign 115:5
redesigning 113:18
redo 289:19
reduce 23:13 60:22
reduced 45:13 70:21
reducing 77:9 90:2
reduction 153:22
reductions 89:14
refer 94:3
reference 72:20 185:5
referral 92:19,20
referrals 229:6
referred 100:9
referring 280:18 282:12
refills 241:14
refine 15:22
refinement 19:22
reflect 13:2
Reflecting 165:4
reflection 128:5 153:20
reflects 157:10 240:2
reform 177:8,10,16,16
reforms 39:11
regard 16:8 79:6 143:5
210:15 317:21
regarding 105:8,10
158:5 277:13 295:8
Regardless 39:15
regs 89:3,6
regular 201:1
regulations 52:20
reimbursement 229:13
reinforced 209:12
reinforces 266:20
267:4
reinventing 57:11
reiterate 20:3
relate 317:19 318:1
related 9:2 38:15 55:10
56:9 60:21 79:10
142:7 155:3 216:9
234:4 259:7 278:1
318:4 321:15

relates 38:4,6 111:14
115:20
relating 106:2
relationship 77:21
171:3,4 318:6
relationships 93:14
relative 80:10 83:19
149:7 151:16 178:21
185:6 246:8
relatively 81:22 178:4
184:7
release 35:8 85:13
114:7
relevant 16:14 44:20
45:15 122:8 133:3
145:15 149:14,14
324:9
reliability 79:7 128:14
reliable 121:15 130:22
207:1
remain 191:16 192:15
remained 34:14,16
remaining 3:17 8:10
remarks 5:4
remember 214:18
300:2
remind 216:1 316:13
reminder 13:20
reminds 132:5
removal 16:8 23:22
186:16,20 189:13
193:13 200:5 209:21
212:22
remove 194:3 209:4
237:14 319:8,9
removed 194:8 199:1
215:7 320:12
removing 23:21 183:14
209:6
renal 240:4
Renee 7:7
renewed 115:2
repercussions 171:12
replace 12:22 51:22
report 13:3 14:17 17:7
17:8,10 18:2,3 23:20
24:17 26:6 35:22
36:14 37:1 40:13 46:4
46:8,10,11 47:4 50:9
50:11,17 58:5,13
60:20 63:5 73:3,4
74:7 80:16 88:16 89:5
92:10 111:20 119:17
121:1,6,13 122:18
123:3,4,7 127:9 129:6
130:12,13 131:22
136:12 139:9 153:10
154:19,20 160:4

168:13 176:9 201:9
201:22 232:20 233:3
259:20 260:1,9
296:16 297:3 308:13
reported 20:7 25:12
31:12 32:2,14 33:1,10
33:13,14,17,19 34:11
36:17 41:19 46:12,13
47:7 70:1 73:22 121:7
127:2 174:20 178:10
184:7 189:18 190:5
190:13 191:3,10,17
192:3,17,20 193:6,13
196:2,14 205:16
224:16,22 244:19
245:4 262:18
reporting 14:13 20:5
25:2,4,10 26:2,14
28:13 31:8,15 32:13
33:6,22 34:1,4,8 35:4
35:6,9,16 36:6 38:1,9
39:17,18 46:22 51:1
51:17 52:2 56:17 60:3
63:15,15 64:3,18
68:19 70:11 73:1 74:9
74:12 75:4 77:5 79:4
79:17 81:2 89:7,10
111:19,21 121:3,19
121:20 127:5,22
138:21 142:22 144:8
165:17 166:17 167:20
169:3 176:4 181:20
183:12 184:5,16
187:1 189:9 190:3,4,6
190:10,22 191:2,4,7
191:14,16,20 192:2,3
192:7,14,16 193:2,5,6
193:20 194:6,22
195:21 196:5 200:14
201:12 215:14 223:18
223:21 296:9 307:3
308:5 312:8
reports 20:14,15 74:1
89:7 323:17
repository 37:12
represent 10:6 11:8
16:11 203:1
representatives 8:20
13:22 279:18
represented 46:17
130:5
representing 8:20
10:10,19 71:18
213:18 231:18
represents 33:21 189:8
243:22 244:6,13
278:10
reproductive 21:2

request 32:10 139:14
requested 14:2 155:20
requests 32:5,9 34:20
 34:21 35:1,2,4,5
 189:20 191:1,21
require 36:9 75:14 89:5
 89:7 98:15 119:16
 120:4 126:11 129:5
 138:12 161:16 174:17
 196:2,4 202:11
 233:11 246:2 262:17
 282:8 308:5 309:13
required 21:14 25:3
 119:13,17 120:2
 121:19 127:10 129:11
 129:19 143:13,15
 155:19 156:7 160:3
 160:16 167:8,12
 168:17 192:6 197:9
 208:18 209:13 291:4
 308:12 312:4
requirement 25:11
 144:8 186:6 190:8
 191:6 304:10
requirements 27:1
 212:15
requires 45:11 106:14
 158:7 164:17,18
 195:17 208:7,14
 221:17 308:7,9
requiring 144:5
Research 4:8 8:4 295:6
Researcher 7:22
residents 87:1
resistance 227:22
resistant 149:6
resolve 313:8
resonant 59:19
resonated 58:12
resource 49:21 59:16
 60:2,4 65:3 68:2,20
 116:8 204:17
resource- 166:3
resource-intensive
 167:1,9
resources 26:5,7 40:12
 84:20 92:15,16 93:1
 95:10 97:4 102:4
 106:6,9,20 168:19
 171:17 204:4 209:13
 228:11 323:6
respond 47:11 102:4
 130:20 147:18
responds 155:9
response 130:15
 154:15 243:6 251:2
 254:10,10 262:1
 272:11 279:5 294:21

312:15,18 314:12
 319:10 320:10 322:15
 323:15
responses 62:4 63:11
 313:5
responsibility 47:19
 100:21 135:5 140:13
 261:7 304:18
responsible 43:3 45:2
 176:4 180:22 267:2,3
responsive 66:17 186:5
rest 5:3
restaurants 13:14
restrictions 147:19
restrooms 14:5
restructure 86:12
result 46:5 53:20 83:8
 108:19 128:15 146:15
 228:4 257:9,14 322:5
results 70:7 76:9,18
 77:10 117:7 140:10
 148:13 158:3 279:1
 290:18 291:18 292:7
 292:15 293:3,10
 297:16 300:15 311:7
 311:9,9,20
resumed 109:13 183:2
 289:17
retained 194:4
retire 24:19 25:16 26:16
 27:19 210:17
retirement 114:12
retiring 182:11
retrieve 198:19
return 170:7
review 3:2,4 11:3 17:7
 17:10 36:10,13 37:6
 42:12 74:1 75:14
 84:21 110:2 122:3,5
 125:6 135:3,4 158:6
 158:20 159:7 183:7
 184:1 187:17 190:9
 191:6,22 192:5
 193:12 204:4 214:16
 214:20 215:14 251:8
 320:13
reviewed 24:5
reviewing 15:21 43:13
reviews 137:16 204:18
revisit 59:12 238:6
rich 154:6
right 4:12 14:7 28:21
 29:19 36:22 45:21
 76:14,19 80:1 83:5
 85:3,13,18 86:5 89:4
 89:10 99:1 104:5
 118:10 121:11 123:4
 160:3,21 161:5,16

163:17 167:17 170:8
 179:14 188:20 189:2
 195:7 198:9 205:13
 219:7 225:7 235:22
 236:2 240:19 245:1
 248:14 250:5 260:5
 271:15,22 280:7
 284:10 286:2 287:16
 290:7 298:15 315:1
 325:12
rise 204:11
risen 72:15
risk 67:19,20 181:11
 218:6 267:9 277:11
 286:18
risk-adjusted 79:1
risks 277:14 297:12
RN 1:14
road 19:8 103:4
robust 109:6 202:11
rock 88:9
role 129:10 266:8
roles 6:8
roll 39:13 82:15,16
 198:7,13
rolled 52:15
rolling 53:20 54:4 88:9
 243:22 244:6,12
rollout 6:10
room 1:8 7:5 9:8 13:6
 31:20 85:19 182:19
 240:14 257:17 269:21
 287:22 288:9 295:3
 295:10,13 300:19,21
 301:8,19 310:16
 324:6
rooms 305:19 306:4,7
rooted 143:11
rough 269:21
route 260:4
routine 149:3 257:21
routinely 73:17 155:6
RPh 1:19
rule 27:1 52:2,12
 298:13
rules 89:4 184:19
run 37:5 119:1 121:13
 206:11 280:6 305:17
running 37:3 72:11
 213:6
rural 1:13 11:19 86:21
 87:1 99:7 102:1
 124:12 228:3,5,10
Ryan 210:12,20 212:10

S

sadly 121:5
safety 90:18 94:11

104:2,5 117:5 131:16
 257:2
SAMHSA 103:20
 213:11 222:19 228:21
 229:21
SAMHSA's 222:17
sample 161:6,7,15,15
 161:20 162:1 263:11
sampled 161:12
samples 263:10
sauce 78:10,13
savings 89:17
saw 41:17 60:2 64:18
 136:20 137:2 144:1
 188:17 189:7 204:12
saying 47:16 56:14
 62:16 65:11 82:10
 83:7 103:7 111:5
 131:6 140:6 150:21
 174:17 203:22 227:17
 246:22 248:3 250:19
 278:19 301:10,11
 306:6
says 134:11 137:20
 163:21 214:11 276:9
SBIR 137:1
scale 120:5
schedule 214:13
scheduled 118:9,10
schizophrenia 22:11
 23:7 38:5 47:19 48:11
 159:19 160:9,22
 161:3 246:2 248:1
 251:16 263:13,17
 267:3 269:11 270:5,7
 276:2,17 278:2,10
 280:21 281:13 282:18
 282:20 285:1 286:7
 286:10,16 293:1
Schlaifer 1:19 10:5,6
 87:18 235:19 237:16
 238:15,18 239:12
 240:18 242:17 255:5
 319:13,21 320:6
School 1:20
Science 7:22
scientific 185:13
Scientist 295:6
scope 212:15 254:8
score 235:13
screen 21:11 22:5 35:3
 163:21 221:18 226:14
 228:16 230:10 243:18
 276:7 285:22 318:11
screened 217:11 222:5
 226:6,10
screening 22:11 23:6
 33:14 34:15 59:6

117:13 123:16 129:20 136:21,22 192:12,14 207:16 216:20,20 217:14 218:3,4 221:20 222:1 224:14 225:2,10 226:3,17 227:8 229:2 247:11 249:3,9 250:6 267:21 269:11 272:2 276:2 276:17 280:13 281:2 281:6,9,18,22 282:7 282:10 294:7 297:8 297:17 317:8,9,21	176:12 197:10 239:21 259:17 segment 44:18 45:7 141:1 142:8 185:15 segmentation 28:15 44:4 143:10 segments 264:5 select 40:18 150:5 155:18 163:18 selected 193:18 201:13 312:13 selecting 40:14 selection 19:4 184:13 184:21 185:1,4,9 220:4,14 selective 28:12 78:11 284:7,9 self-care 270:9 self-manage 93:17 self-reported 150:16,17 send 274:6 289:9 sending 128:21 138:5 168:12 Senior 2:8,9,10 4:17,20 5:1,22,22 seniors 112:15 sense 94:14,18 145:10 164:13 195:16 203:22 227:6 250:21 268:16 271:14 300:2 311:15 sensitive 24:15,16 75:20 148:15,16 153:11,22 226:5 304:1 sensitivity 104:20 sent 32:9 216:6 264:14 288:2 separate 46:5 52:7 63:7 128:9 228:13,14 245:13 248:5,13,15 248:16 249:2,8 separately 235:11 262:18 September 7:10 112:20 series 81:3 serious 23:9 245:5 247:19,22 249:4,10 262:5,9,18,20 264:8 269:12 270:1,20 271:1 277:11 282:5 286:22 292:3 294:10 297:9 317:14 319:1 seriously 26:17 246:12 246:14 serve 82:11,20,22 88:13 112:19 132:10 132:12 145:19 170:10 170:17	served 6:2 90:1 107:22 108:14 109:1 112:11 210:16 service 58:21 73:18,19 92:16 97:5 108:5,21 204:9,13 236:13 services 1:14 2:2,6,13 2:15,16 11:2,17 21:15 58:19 59:22 77:11 96:1,7,14,22 97:1,7,8 111:3 112:6,15 114:10 115:13 117:19 118:4 119:4 129:12 130:9 131:19 186:10 216:12 218:4 219:20 315:6,17,19 321:2 324:12 serving 89:20 session 49:15 sessions 135:4,4 set 3:4,10,15 5:15 14:13 15:6 16:8 18:8 19:15 19:22 20:4,6,8,11,12 20:16 21:20 22:8,8 27:10,12 29:8 30:4,5 30:22 31:1,21 35:7,8 49:19 50:9,12 51:11 64:12 65:7 68:8 71:9 78:16 91:18 109:22 111:22 113:9 116:12 117:2 119:15,16 121:6,21,22 122:1,4,5 122:6,6,22 123:10,13 124:3,7 125:2,5,16 126:4,14,20 128:1 130:10 134:13 135:12 135:13 136:7 138:14 138:15,15 145:14 146:21 148:19 157:13 158:7,18,21 165:16 167:3,9,21,22 168:20 169:14 171:2 180:19 182:5 183:15 184:15 185:7 186:4,6,8,10,12 186:17,19 189:18 190:13,14,19 192:8 192:20 193:1,4 198:11 208:2 210:19 210:20 215:11 216:19 218:22 232:16 233:14 234:22 236:6,19 237:3 245:1,7,21 261:13 262:16 265:13 275:13,20 280:3,4 287:14 290:11,20 291:6,12,20,21 292:5 292:9,13,18,20 293:5 295:11 296:7 312:7	312:22 314:8 320:16 325:16 sets 17:19 23:13 55:12 58:6,13 65:8 72:16 156:22 186:2 199:10 205:5,18 208:6 210:17 233:8 234:14 234:17,18 260:21 setting 26:21 36:3,4 73:22 146:17 147:2 171:16 236:10,12 238:1 277:2 280:7,9 287:2 300:21 settings 19:11,12 27:4 39:8 150:10 234:8 303:5 seven 33:14,16 118:17 186:2,14 192:17 242:4 300:15 302:15 304:18 308:18 seven-day 311:10 Seventy 289:2 severe 44:5,12 45:8 95:3,15 96:15 246:1 247:11 269:13 severely 28:16 severity 316:3 Sha 1:20 10:19,19 23:18 105:2 157:22 224:10 232:9 234:11 257:16 271:15 275:17 276:1 277:7 282:14 283:2,5,13 284:6 301:20 318:22 Shaconna 2:9 4:14,16 19:13 22:20 183:20 214:8 shades 85:6 shaming 80:6 share 110:20 173:3,6 206:5 212:5 311:7 shared 76:10 155:4,11 171:9 266:20 267:5 309:15 sharing 173:1,4 175:9 175:18 176:14 308:17 309:1 311:1 Shaw 232:7 sheet 217:2,7 218:12 243:16 285:6 Sheila's 13:19 shift 89:4,8 90:7 100:17 shine 305:13 306:2 310:7 shines 310:2 short 207:2 260:22 shortages 229:5,7 shortly 126:2
--	--	--	---

show 90:8 97:13 123:8
133:14 137:5 263:21
264:5 273:22 311:20
313:16,21
showed 33:9 34:6
297:16
showing 56:4 108:21
267:21 271:3 295:13
296:21 297:21
shows 99:19 295:10
sicker 87:2 140:6
side 42:22 44:14,15
52:9 55:7,10,11,19
56:12 128:11 133:2
134:22 135:1 197:14
197:16 198:1 200:3
212:8 221:13,14
236:13 267:18 270:10
320:21 321:2 323:9
sides 208:10
signaling 188:10,14
signed 113:7
significant 109:20
significantly 267:9
signs 18:4 58:5 92:10
232:20
silent 12:15
silos 103:22
similar 19:11,11 61:9
66:8,18,19 142:18
170:13 210:10 211:4
224:7 267:10 306:12
similarly 56:22 61:4
205:15
simple 55:4 57:7
108:15 163:8
simplicity 252:6
simplified 142:16
simplify 69:18
simplifying 63:14
simply 43:6 89:17
135:19 266:16
single 138:16 156:20
156:22
sit 9:21
sitting 10:11 176:20
177:21 227:7
situation 73:5 132:17
310:4
situations 258:1
six 33:10,18 112:11
118:10 124:21 189:20
191:9,17 242:3
296:22 313:17,17
314:2
size 204:20 271:10
skilled 27:6
skin 79:18

skip 153:14 214:13
slack 140:5
slew 32:7
slide 15:13,15 16:15
17:14 20:3,10 21:3,13
22:2,6 29:7 31:3,7,20
33:4,5,7,21 34:6,7,17
35:14 58:3 59:1,2,18
60:8,17 61:6,17 62:1
62:6 64:12 65:16 68:8
68:14 69:11 70:9
72:21 90:13,14 91:4
92:7,8,14 93:5,8,8
94:9 113:15 115:8
132:2 136:1 184:8
186:15,18 187:3
188:17 189:8,15
190:18 191:11 192:11
193:8 214:11,15
215:2,20,22 216:16
217:21 230:15 287:15
slides 15:14 32:1,18
62:2 64:13,13 67:10
109:10 215:18
slog 85:20
small 21:12 48:9 78:19
93:11 99:20 102:18
120:5 125:18 137:12
139:5 151:13 159:13
161:9,11 181:19
271:13 278:21
smaller 102:14
SMI 249:17 297:15,18
297:19
smokers 243:21 244:2
244:8,14
smoking 120:16 163:20
243:10,20 246:13
SNAC 147:7
snapshot 20:11 174:13
snapshots 31:11,11
SNOMED 189:21
so-called 78:5
social 7:22 58:20 92:16
96:22 97:5 118:4
society 105:6 107:11
sociodemographic
106:3
socioeconomic 95:4
software 102:20
solution 107:8
somebody 38:10 78:21
100:9 150:2 195:17
195:18 207:14,20
somewhat 38:22 66:11
95:6 181:18
soon 12:9 22:17 259:21
sooner 44:8

Sophia 8:3
sorry 37:15 71:13,22
113:6 189:6,14 213:6
240:13 295:4
sort 4:12 5:11 16:3
17:17,22 19:7 28:15
43:22 44:4 53:17,18
53:19 54:4,5,9 57:19
66:14 67:15 68:16,21
69:5 70:14,19,22
77:16,18 86:13 91:5
92:1,2,2 93:15 94:2,3
94:12,14,15,20 95:7
95:13,19 96:3,4,11,12
96:13 105:15 158:11
160:19 161:18 162:10
166:2 174:21 176:1,3
176:9 177:6 199:17
199:21,21 201:15
209:14 220:22 221:1
225:21 226:1,16
232:6 238:9 245:13
245:16 247:9 257:19
258:4 259:3,13,14
260:21,21 261:13
266:13,17 268:14,15
268:16 277:10 299:11
309:20 310:14 315:20
322:11
sought 140:12
sound 140:2 151:20
sounds 193:21 209:5
212:17 247:14 250:2
source 156:22 182:9
195:9 203:13 210:18
217:18 223:16 231:4
235:15 251:19 303:8
sources 16:13 21:10
212:2,9 223:19
224:21 258:14
SP104 124:17
space 83:11
speak 10:2 12:20 54:21
58:7 162:8 165:12
225:15 235:18 261:9
267:12 269:7 270:16
276:11
speaker 76:4 101:22
speakers 165:7
speaking 38:22 231:18
232:2 301:15
speaks 113:1 118:5
special 70:10 134:15
152:1 154:22
Specialist 7:14
specialty 112:18
254:17 315:3
specific 16:6,12 47:3

47:10 91:1 92:3 120:6
121:11,17 125:3
141:21 147:13 165:7
186:5 200:9 208:14
231:12 257:4 259:6
273:19 304:2 318:15
specifically 47:4 97:4
114:20 120:13 122:1
161:15 186:19 206:9
259:1 301:18 316:15
317:20 318:2
specifications 35:9
70:12 136:14 138:20
138:22 174:10 182:2
190:15,16 192:8,21
192:22 193:1 248:17
285:8 302:5
specificity 62:11
specified 43:5 190:22
191:19 193:2 226:1
specify 98:16
specifying 323:5
specs 274:8 276:6
285:16,19,21 286:1
spectrum 24:11
speculate 207:9
spend 37:19 84:8 181:1
spending 18:10
spent 84:12 86:4
spirit 25:13 80:12
spoke 34:14,17 76:4
118:21 119:9
spread 40:2 200:20
spreadsheet 216:6
217:22 276:8 317:5
SSI 99:7
St 213:18
stability 95:20,21 141:4
178:19,21 179:5,15
179:20 180:2,13
stable 96:1 100:5,6,9
100:11
staff 2:7 3:4 4:14 7:11
13:13 14:21 17:6
19:15 30:16 184:11
186:17 193:11 198:22
200:3 208:7 214:22
214:22 216:17 218:1
218:11,14,14,16,17
218:21 219:12 220:6
220:15,17 222:10
298:6 326:3
staff's 198:16
stages 81:12 162:7
stake 120:20
stakeholder 169:16
stakeholders 16:12
24:7,8,11 127:14

156:9 166:19 223:2
standard 117:2 243:4
standardize 21:16
 64:16
standardized 61:9
 242:16
standardizing 60:14
Standing 251:9
standpoint 105:5,19
stands 212:21 315:1
star 182:15,16 242:7
 294:19 324:1
start 4:13 9:10 39:21
 40:2 47:20 51:2 53:20
 81:22 82:13,19 85:8
 88:9 89:12 100:18
 134:5 144:5 157:15
 169:22 184:9 202:13
 203:18 261:15 273:10
 296:9 321:13
started 4:4 51:5 58:4
 76:8 102:15 128:15
 128:16 149:15 155:17
starter 261:12
starting 271:11
state 2:2 3:8 10:17 20:7
 21:17 25:20 26:11
 35:16,21 36:1,5,11
 38:8 39:14 40:16
 46:11 47:11 49:21
 51:7,11,20 52:14,16
 52:22 53:4 70:11
 71:16 74:9 75:4,19
 77:5,12 81:11 82:1,17
 82:17,19 83:13,18
 85:4 86:9 90:4 97:11
 98:4 100:22 104:3
 110:14 113:10 122:17
 124:17 127:15 132:19
 134:1 138:12 139:3
 139:15 140:6,18
 141:16 153:17 155:14
 156:4 165:19 166:6
 167:7,12 170:12
 171:18 172:18 173:1
 173:4,10 174:10,18
 174:21 176:16,18
 181:8 191:21 195:20
 198:7 200:7 201:2,4
 204:2 208:22 210:21
 210:22 211:7 215:14
 227:1,14 248:11,19
 248:20 254:11 256:2
 261:4 263:8 279:19
 294:3 303:9 305:16
 307:15,15
state's 50:17 73:1 111:4
 115:2 227:4

state-level 53:1 54:19
 129:15
state-wide 178:6
statement 187:15
 194:12 217:20 279:16
 302:17,21
states 14:12,17 20:5,8
 21:3,21 23:14 24:17
 25:19,21 26:1,4,6,9
 26:15 29:3 31:9,10,12
 31:15,18 32:10,13,15
 33:2,6,10,12,14,17,19
 33:22 34:1,3,4,5,8,11
 35:12 36:10,18,19
 37:1 39:3,6,9,21 40:1
 40:10 41:8 42:10
 45:22 46:3 47:3 50:8
 50:11,22 51:2,17 52:3
 53:5 54:6 63:13 73:7
 73:12,15 75:10,12
 76:7,10,20 77:7 79:15
 80:7 81:10 83:16 88:3
 88:4,5,21 89:5,10
 102:2 103:2,3 104:13
 109:11,16 110:1,6
 134:2 136:14 138:6
 138:20 139:16 141:6
 141:7,10 142:17
 143:7,20 147:17,22
 148:2 154:9 156:4
 158:2 165:6,12,15
 168:1 171:5,13 172:5
 176:12,19 177:5
 178:6,9,10 179:3,4,16
 180:3 184:7 187:1
 189:9,20 190:5,10,13
 191:3,7,8,9,14,16
 191:17 192:3,7,14,16
 192:17,19,22 193:6
 193:20 194:5 196:5
 196:21 199:4,9,13
 200:13,15,21,21
 201:14,16,21 202:7
 203:5,22 205:19
 206:2,8,11 207:3,4
 209:16 211:17,22
 227:12,13 296:14
 307:3,7 309:13,17
 312:6,9,11
states' 15:21 16:2 31:16
 76:1 102:5 140:12
 163:5
statewide 111:18 114:3
 114:5
statins 235:13
statistically 151:20
statistics 211:22
 213:14

status 69:22 89:19 99:7
 99:8 150:17,18
stay 29:13 179:13
 180:10
staying 159:16 180:6
stays 224:2
steady 34:2
step 54:12 57:13
 208:14 221:19 260:13
 266:7 268:18 309:6
steps 78:19 146:20
 173:14 199:21
steroids 127:13
steward 188:5 217:9
 231:1 243:13 277:5
stewardship 116:17
stop 74:12 246:16
store 30:6
stories 104:16
story 72:1
straightened 326:10
straightforward 206:12
strangle 167:2
strategies 44:3 95:10
 139:16 244:12,16
strategy 119:20 122:2
 185:2 186:4 263:1
stratification 35:5 70:6
 70:7 90:15,20 91:7
 94:7,9,17 113:3
 134:21 142:11 144:13
 145:6 245:12 250:15
 314:22 316:3
stratifications 55:3
 98:13
stratified 160:4 189:18
 246:1,20 247:12,16
stratify 98:5,22 99:2,4
 139:2 153:5 159:17
 248:11,20
stratifying 68:12 90:18
 246:12 247:18 278:16
stratum 266:17
streamlining 69:3
streams 50:2 86:13
Street 1:9
strengthened 215:11
strengthening 3:10,15
 15:5 216:18
strengths 59:3,4 142:5
 171:11 185:6
stretched 91:19 93:7
strictly 195:4 258:14
strikes 264:17
strong 31:22 102:3
 113:4
strongly 26:12
structure 103:12

structures 173:18
struggle 165:15
struggling 73:4 99:13
studies 104:14 179:20
 179:22
sub- 42:20 68:12
 160:21 249:11 315:4
sub-populations 55:2
 265:16
subcommittee 135:6
subject 2:1 13:21 25:12
 137:18
subjects 175:20
submission 196:11
submit 227:19
submitted 17:8 22:17
 34:22 67:12 189:20
 191:1,21 199:9,12
 214:18 232:5
submitting 21:22
subsequent 163:2
subsequently 134:12
subset 261:13 271:12
subsidies 21:8
substance 2:6 29:5
 216:11,22 217:9
 219:3 220:8 221:6
 222:12 223:12 224:5
 225:20 227:8 228:10
 296:18 303:15 315:14
substantial 175:3 270:4
 270:7
substantive 135:21
substitute 157:3
success 83:10 104:15
 212:1
successes 110:8
 111:11 169:18 170:1
successful 117:3
SUD 311:2
Sue 1:15 213:3,16
 264:16 265:17
sufficient 278:5,14,22
 311:20 320:3
sufficiently 79:2
suggest 153:14 246:7
 250:15 259:18 275:21
suggested 17:20 22:18
 45:6
suggesting 209:21
 237:13 264:13
suggestion 70:8 238:19
 246:11
suggestions 5:16 19:21
 319:7 322:13
Sullivan 2:2 10:16,16
 29:9 47:15 99:11
 159:16 160:10,20

161:12 200:12 202:6
 221:5 246:4,6 247:17
 250:12 252:5 258:18
 259:16 260:3,11
 263:3 299:17 300:6
 300:10 302:2 305:1
summary 144:15 210:3
supply 158:2 251:13
supplying 177:12
support 6:11 26:5 50:6
 86:3 102:8,19 115:15
 147:11 148:18 177:10
 187:7,8,9,19,22 188:7
 188:10,13 216:4,4
 223:3 240:7 283:18
 283:22 289:3 293:11
 297:6 313:14,18,19
 314:2,4,5
supported 50:2 146:10
 147:22 224:18 250:4
 294:4,6
supporting 50:7
supportive 93:19 156:8
 321:8
supports 58:20,21
 59:22 118:11 122:2
 219:20 315:17
supposed 15:21 38:14
 134:12
suppression 34:9
 127:11 189:17 190:11
sure 6:22 7:1 12:21
 27:3 40:13,17 41:6
 49:1 53:2 56:13 57:10
 62:9 63:18 87:4,9,13
 87:20 90:13 97:12
 117:18 121:14 130:17
 143:4 150:22 151:10
 164:6 167:5 177:14
 178:18 183:22 196:5
 203:20 204:9 206:22
 228:14 245:19 253:4
 256:14 258:22 270:12
 285:5 298:21 301:9
 302:6 307:19 310:6
 313:4 325:19
surfaces 148:4
surprised 98:6
survey 6:9 69:21
 130:11,21 146:1
 154:5 155:13
surveys 69:22
suspect 224:12,22
suspects 59:15
sustainability 89:11,17
 90:6
sustainable 86:6
swallowed 241:22

swath 271:22
SWOT 59:2
syndrome 76:16 251:17
system 46:19,22 47:20
 52:3 56:14 69:13 86:6
 86:12 93:12 99:20
 113:19 114:12 116:6
 119:5 137:14,20
 138:17 142:3 153:20
 156:20 157:4 168:2
 168:20 171:20 174:7
 176:4,10 194:22
 198:20 212:5 257:6,7
 287:6 289:13 305:4
 310:12 313:4 321:3,9
system- 146:8
systematic 28:4 217:13
systems 45:19,20 48:3
 48:18 57:1 70:3 72:17
 112:7 138:17 140:16
 141:9 149:2 156:13
 173:2,2 174:14 176:6
 195:11,14 208:13

T

TA 32:4,9 34:20 35:2
 189:20 191:1,21
tab 218:19 219:10
 276:9,12,14
table 10:15 167:5,6
 171:14 227:7 321:13
tables 46:9,10
tablet 242:1
tablets 241:11
take 12:16,17 49:17
 56:5 109:7 122:9
 123:5 133:8 144:17
 157:10 163:3 168:5
 172:5,9,10 173:16,18
 194:6 241:4,8,17,19
 254:11 268:17 278:22
 284:1 285:20 289:14
 316:20 319:15
taken 60:19 134:13,20
takes 37:3 40:12 181:11
 241:1
talk 39:15 41:9 56:1
 59:12 62:14 105:5
 109:18 114:2 121:10
 126:15 127:20 131:1
 140:4 144:21 151:15
 154:16 158:15 171:10
 177:21 205:21 207:8
 221:6 223:7 236:16
 275:18 305:6,6
talked 5:11 46:20 49:22
 57:20 63:5 88:8 104:3
 110:7 158:8 228:17

305:17
talking 16:22 37:19
 42:15 55:3 57:17
 60:10,10 61:13 76:8
 86:4 94:1 103:18
 111:1,8,22 113:2
 118:6 119:2 133:7
 166:14 172:17 197:6
 234:12 249:1 257:20
 260:17 270:13 271:17
 271:18 300:20
talks 15:15 61:8 64:13
taper 137:15
targeted 116:7 263:1
task 1:3,8 4:10,18,21
 11:15 15:19 16:11,17
 16:18,21 23:20 30:16
 49:12 113:9,13
 157:20 158:3 166:5
 184:18 187:12 214:18
 215:1 220:15,18
 230:7,17 231:7,11,19
 232:5 235:17 244:19
 245:3 251:19 262:14
 272:17 275:10,11
 279:16 280:16 283:17
 284:13 289:2 293:13
 294:4,5 296:2 297:4
 298:1 314:2,3 324:8
 324:19 325:6,17
 326:1
tax 21:8
taxonomy 129:11
Tdap 120:11
team 7:20 164:20
technical 7:18 24:9
 31:17 34:19 61:7 71:8
 138:13,22 178:17
 200:16 201:5,8,11
 229:1 248:17 288:11
 289:13 313:7 326:10
technological 206:3,15
 209:18
technology 2:5 72:3
 157:6 206:21
teleconference 2:22
telehealth 229:8
telephone 182:16
tell 9:16 25:22 29:17
 41:22 42:1 81:19
 133:7 219:17 240:16
 274:14 288:13 316:19
 317:2
telling 269:2
templates 35:6
temporal 65:5
ten 33:6,12 109:8,8
 112:12 173:12 182:8

288:8,9 295:16
tend 73:19 75:18 84:10
 87:1 226:7
tendency 9:20
tends 23:12
tens 86:6 270:13
tension 265:12
tent 12:19
term 215:11 219:20
 220:20 222:6 260:22
termed 96:20
terms 5:10 14:17,19
 15:2,6,7 17:5,20
 19:10 24:14 26:19,20
 28:12 29:16 38:7 43:3
 43:19 44:7 45:19
 47:17 51:16 56:2
 57:22 62:22 66:6
 72:15 73:7 76:1 77:20
 78:7,11 95:17 96:9
 97:19 107:17 124:10
 141:4 158:12 163:5
 168:7 179:15 202:9
 206:17 210:8 250:13
 250:20 299:22 300:17
 312:1 318:5 320:14
 323:1
test 115:17 126:19
 157:13 280:6 286:11
 286:13
tested 311:8
testing 123:17 131:14
 173:8 297:16 311:7
 311:18,20 312:1
tests 120:5
thank 6:13 8:6 9:14
 10:14 11:21 12:7,10
 12:12 13:19 20:1 31:6
 33:3 41:8 54:12 58:2
 86:17 87:16 90:10
 101:21 104:21 109:5
 109:11 110:16 132:13
 132:15 157:17,22
 165:3,8 172:1 180:19
 182:21 189:5 213:20
 214:7 254:6 279:3
 280:8 281:13 288:5
 290:16 294:12 311:4
 325:20,22,22 326:3,8
 326:13
thankful 126:17
thanks 71:20 101:19
 105:22 182:12 213:21
 280:12
theirs 252:13
themed 63:11
themes 58:5,9,10 59:19
 62:3 63:10 68:17

69:12 70:12 113:22
118:22
theoretically 159:9
therapeutic 235:6
291:16 294:9 317:11
thing 6:21 8:22 26:22
28:7 44:21 45:11
53:19 78:11 83:22
86:3 98:20 100:16
115:16 121:16 133:5
136:19 149:16 153:20
163:15 165:19 172:20
173:4 181:14,22
194:14 195:3 202:2
225:14 248:2 253:1,3
253:5 254:13 261:3
284:17 305:15,22
319:13 320:17
things 14:11 15:18
18:17 19:4 28:2 39:1
41:17 46:20 48:4
49:16 50:14 52:17,19
53:12 55:5 56:12 59:8
60:7 63:5 66:8 76:2
79:16 80:14 81:3
84:20 85:4 87:19 89:1
99:6 100:21 101:9
108:15 109:1 110:22
130:14 132:21 133:17
144:3 145:21 147:22
149:10,10 153:8,13
154:4,8,18 155:2
162:11,13,14 164:14
165:15 172:22 174:4
175:1,15 178:13
181:4 186:14 189:11
202:9,21 204:15
206:21 250:13 256:1
256:6 300:1 322:14
323:3
think 5:5,7 8:11,16 9:6
11:21 14:22 15:4 18:5
18:13 19:20 23:18
25:6,8 27:11,13,20,22
28:1 29:20 30:1,8
36:15,16 38:17 39:12
39:20 40:4,6 41:1
42:14 43:17 44:16
45:4 47:16 48:1,5,6
48:12,16,18 49:16
51:5,8,9,12,14 53:11
53:12,15 54:2,14,17
55:22 56:9,22 62:22
63:3,18 65:19,20 67:1
73:12 74:10 75:2
76:19 77:3,11,12,16
78:3 79:19,22 80:5,11
80:13,15 81:1,11,14

81:18,21 82:3,4 83:5
83:8,11 84:3,11,12,14
85:8,21,22 86:18,19
87:18,20 88:7,10 89:2
89:3 90:6 94:21 95:16
96:2,9 97:14 98:8,19
99:8,16 100:1,4,17,18
100:20 101:5,7,17
102:5,11,13 104:5
105:9,14 106:2,6,7,8
106:12,21 107:8,11
107:19 109:5,22
124:1 131:7 132:5
135:15 144:15 145:16
149:13 151:4,17
153:15 156:18 157:1
157:8,15 158:2,4,6
160:12 165:10,14,18
166:9,16,17 167:1,18
167:22 168:7,21
169:1,6 170:4,7,10,21
172:16,16,20 177:3,4
177:13 178:1,2,12
179:14,16 180:1,3
188:9 194:2,18 198:2
198:9,9 199:2 200:3
201:13 202:6,13
203:14,14,16 206:3,4
206:11 209:7,10
211:10 212:20 213:9
215:6 220:6 221:5,7,8
221:11,16,19,22
222:7 223:5,6,10
225:4,14 227:10
228:19 230:9 232:1
232:18,22 233:10,16
234:6,11,19 235:19
235:22 236:3,8
237:10,18 238:1
240:9 243:2 246:10
246:11 248:18 249:15
249:20 250:5,12,13
250:19 252:6,10,13
252:16,20 253:9,10
254:14 257:17,20
258:1,18 260:16
261:4 263:4,7,13,15
265:12,18,19 266:3,5
266:9 269:1,9 270:16
273:10 277:7,8,13,15
280:10 282:14 284:11
285:11 287:10 290:5
293:9,11 296:17
297:11 300:9 301:2,5
301:6,13,20 303:13
305:2,4,5,7,12,14,15
305:22 306:3,9,20,22
306:22 307:2 309:10

309:11,22 310:9,21
312:12 316:12,16
318:18 319:15,16,21
320:2 321:1 322:20
323:3,4,6 325:1,2
thinking 5:10 15:8 40:7
44:5 47:21 51:3,14,18
53:10 95:17 97:18
107:9 108:10 110:2
147:21 157:9 158:12
162:17 199:2 202:9
205:5,20 211:10
252:14 273:18 281:8
323:1
third 74:17 76:13 116:8
126:3 181:22
Thomas 7:17,18
thought 17:15 25:15
26:10 27:7 53:9 64:19
71:1 120:22 134:7
145:14 148:10 160:1
167:17 193:14 198:22
220:3 252:14 273:22
293:8 305:18 308:19
309:2 311:15 319:14
319:17
thoughts 67:11 109:21
202:22 299:9
thousands 270:13,14
threats 59:15
three 9:19 20:7 21:1
41:15 63:5,7 77:17
79:10 80:13 82:18
84:15 112:10,13,18
113:13,14,18 114:8
114:16 115:1 116:4
125:3 127:9 130:13
154:9 155:19 186:4
187:7 190:12 191:9
235:5 267:7 284:2
293:11,13 295:8
297:22 313:22 314:3
318:1 320:9
three- 266:9
three-part 20:4
three-quarters 151:5
three-state 132:20
threshold 235:8 260:21
Thrive 96:21
throw 319:18 321:12
Thursday 16:20 325:4
tide 306:5
tie 40:14 58:15 221:2
tier 137:11,12
time 16:4,16 17:4 27:16
27:17 28:6 34:10 35:8
37:3,19 39:13,19
41:12 45:6,15,16

52:21 61:8 64:22 84:9
84:12 86:4,12 102:17
130:14 132:14 135:11
137:10 139:9,12
140:21 147:4 148:13
149:9 151:1,8 157:3
168:16 178:2 181:2
182:13,15 189:4
194:5 199:4,11,19
202:19 205:11 226:1
238:10 242:15,17
243:2 247:6 250:3
253:11 271:21 275:14
288:20 294:18 316:21
323:22 325:5
time-consuming
127:16 166:3
timeliness 128:14
timely 23:21 24:15
34:13 191:15
times 37:1 98:17
178:20 247:4 297:1
320:9
tipping 199:14
title 208:21 279:20
283:8 292:21 312:22
316:21
tobacco 243:10,20,21
244:2,8,14 249:2,9
today 8:14 9:6 10:12
14:9,15 16:16 49:14
53:8 55:13 58:7 59:12
60:9 63:4,8 82:6
110:18 111:8 119:2
135:13 166:9 239:2,9
268:15 293:9 314:20
316:2
today's 6:14 88:10
tomorrow 14:10 16:17
16:21 49:11 53:7 58:8
81:4 201:8 202:4
216:9 238:12 239:4,9
273:17 274:14,16
284:4 293:20 294:14
298:22 315:16 324:19
325:4 326:2,6,10
tomorrow's 325:3
tool 75:15 165:17
tools 13:16
top 137:11 138:6
199:10 284:2
top-performing 138:3
top-ten 296:19
topic 149:15 207:18
220:9 258:12
topics 60:9 175:21
189:21 191:21
total 116:18 143:2

163:4 218:18,18
227:6
totaled 116:19
totally 175:12 245:1,2
touch 51:6
touched 49:20 169:17
touches 106:9
touching 48:14 111:13
tough 101:17 144:2
301:11
tougher 300:19
Tourette 251:17
track 69:12 74:3 180:15
252:1 253:21
tracking 73:16
trade 74:11
traditional 101:14
112:8 197:1
trail 268:14
train 6:6
training 229:1
transcript 9:22
transcripts 13:1
transform 117:22
transformation 115:11
116:6 117:3
transient 67:21
transition 26:20 34:12
34:13 56:17 76:20
115:15 191:12,12,14
191:15 195:1 197:13
transitioned 46:21
transitions 105:5,9
translating 154:11
transmission 23:21
24:14,15 34:13
191:15
transmitted 191:13
transparency 61:1 80:7
transportation 49:3
trauma-informed
315:13
treat 268:20
treated 156:7 302:21
treating 259:8 269:4
treatment 224:5 251:22
262:20 315:13
tremendous 18:6
102:19 104:20
tremendously 112:10
trend 139:11
trending 148:12
trial 70:6
tricky 252:22
tried 18:4 24:11 80:5
85:15 176:22 254:15
259:13
trigger 162:21

triple 120:21
trouble 72:11 127:17
true 136:10 140:11
209:22 236:17 237:1
240:22
truly 140:7 167:21
try 18:7 40:6 54:7 70:2
78:4 101:8 122:10
133:20 143:8 165:12
170:8 196:15 199:6
200:7 212:12 220:7
236:4 255:17 263:14
284:6
trying 6:6 19:5,8 26:5
26:13 27:2,8 38:21
51:8 53:5 57:1 66:10
73:6 79:15 80:21 82:3
82:4,8 84:13 94:16
106:5 107:4,17 108:7
128:22 146:16 153:3
170:10,14,17,21
173:5 198:10,10
203:6 227:20 229:10
242:4 264:5 271:9
313:8
TUESDAY 1:5
tunneling 311:2
turn 8:7 9:9 12:20
193:15 316:5
turned 227:4 229:16
turning 141:18,19
turns 206:2,12,16
Twenty-five 33:3
Twenty-four 312:11
twice 320:9
two 20:6 21:1 22:7,9
23:1,3,14 25:19,21
26:1 29:1,2,4,14,19
29:19 31:5 44:8 50:10
56:9 76:2 81:4 89:1
94:9 95:15 106:22
109:16 112:6 122:3
123:16 136:5 171:5
187:17 189:18 190:13
191:10,18,21 192:18
192:22 195:14 208:13
216:14 220:6 225:4
225:22 232:14 238:5
242:19,19 266:19
268:4 277:9 280:5
282:3 287:19 302:18
309:18 311:7 317:19
324:9
two-for 266:10
two-step 198:8
two-way 173:7
type 102:21,21 108:1
224:12 230:22,22

234:12 237:3 262:10
262:10 310:12 316:4
types 41:11 89:15 94:2
95:10 96:7 186:7
265:1 321:8
typically 90:3 133:5
137:17 201:16

U

U.S 120:13
Uh-huh 254:5
ultimately 25:8,11
109:2 170:14,21
Um-hum 248:8
Um-um 279:10
uncertain 77:20
unchanged 191:16
192:16
unclear 78:2 298:6
uncompensated 115:9
unconsciously 154:2
under- 130:4
underneath 103:21
understand 27:12,19
54:7 78:1 85:9 94:18
94:19 131:7 157:2
160:10 167:16 169:12
194:13 198:16 234:6
254:14 265:19 268:9
298:17 307:20
understandable 28:10
84:13
understanding 18:17
23:19 203:1
undertaking 228:21
underutilized 154:7
underway 49:9 83:4
underwent 251:7
unfinished 134:17
unhealthy 216:20
217:13,15 294:7
317:8
unique 143:5 171:4
264:22
universe 315:21
University 1:20 4:6
10:21
unlock 178:14
unnecessary 233:20
unusual 253:18
unwillingness 103:15
update 49:8,11,14
50:18 296:4
updated 22:9 30:21
141:8 224:2
updates 3:5 22:18
upgraded 30:12 273:5
uphill 85:20

upload 285:4
upper 137:11
ups 225:22
uptake 31:9,17 34:7
207:10
urban 87:2 179:21
urgency 322:12
usable 86:15 148:3
151:20
USDA 120:14
use 10:2,2 12:19 13:1
14:18 18:19 19:2,11
21:18 22:13 28:19
29:5 42:11 53:15
54:10 61:9 77:6,9,10
79:15 80:22 81:14
82:5 83:12 86:15 88:7
88:15 94:13 97:20
99:2 105:12 117:15
120:11 131:13 142:14
143:3 145:11 147:6
148:7 150:19 151:18
152:15,17 153:8,12
159:17 176:17 177:1
181:9,18 182:6,6
185:14,19,22 187:8
187:18,20 189:21
205:18 206:18 208:4
210:7,18 211:12,14
211:18 216:11,20,22
217:13 220:8 221:2,7
222:3 223:1 225:5
227:9 228:4 243:10
243:20 248:22 251:6
252:3 254:18 257:21
258:2 260:18,22
273:6 278:6 292:11
303:15 315:11,15
317:8 319:16 324:15
324:20 325:7,10,11
useful 18:9 81:15 84:13
101:10 162:13,14,15

user 217:16
users 42:10 243:21
244:2,8,15
uses 20:10 187:10
300:21
usual 59:15
usually 46:9 78:19
174:13 187:15 188:19
196:16 208:11
utilization 75:20 116:8
255:15 315:10
utilize 57:5 181:3
utilized 223:6
utilizers 118:5

V

VA 10:22
vague 194:12
valid 136:13 207:1
validate 121:17 141:22
validation 121:12
validity 77:20 79:7
 136:10,16
valuable 48:16 75:15
 98:9 138:9
value 26:19 47:16 50:16
 53:3 54:11 62:13 77:7
 135:20 140:20 148:4
 149:7 153:16 203:7
 224:11 234:4
value-based 79:5
 115:15
values 48:19 138:4
 158:10
variable 128:13
variables 99:1
variation 54:7 64:5,10
 77:22 78:4
variations 82:12
varies 46:9,18
variety 44:10
various 34:21 36:15
 83:3 240:2
varying 82:8 83:9,9
venture 310:13
venues 150:11
verbal 214:4
versa 256:19
version 17:9,18 146:2
 213:10
versions 165:20
versus 33:17 41:11
 65:10,12 69:1 72:18
 73:3 78:6 89:13 148:4
 151:16 219:19 220:10
viable 86:8 182:8
vibrate 12:14
vice 2:8 4:5 5:1 256:18
view 24:12 29:16 48:22
 50:18 72:17,18 87:20
 170:11 222:17
viewpoint 133:15
viral 34:8 127:11
 177:22 178:10 189:16
 190:11 197:12 204:19
 208:1 210:6 211:1
Virginia 37:21 136:10
visit 41:21 42:7 55:17
 269:15 295:21 300:22
 301:7,19 302:9,12
 307:10,11 308:8,18
 311:21 317:16
visits 32:3 41:21 74:15
 74:16,20 76:12 137:8

143:14 296:20
vital 6:16 18:4 58:4 92:9
 194:21 208:4 211:22
 232:19
vitals 206:10
voice 10:2 92:19 238:16
 304:7
voluntarily 21:21
voluntary 40:11 50:1
 64:2,20 68:19 118:1
 144:2 167:4
vote 13:17,21 30:13,20
 53:15 230:4,8 239:2,6
 239:8,9 245:14,16
 255:14 272:15 273:3
 273:4,7,8,16 274:10
 279:8 280:2 283:11
 283:13,14,16 284:10
 284:15,16 287:11,13
 287:21,21 288:3,11
 288:21 289:10,15
 290:14,15 291:8
 293:7,15,21 302:1
 312:17 313:5,9,14,17
 314:6,6
voted 272:19,22 289:2
 290:13 293:17 319:7
voters 313:13
votes 287:18 291:2
voting 13:16,18 14:3
 16:7 30:11,14 40:7
 49:18 183:6 184:12
 209:16 216:2 230:11
 274:14 279:17,18
 280:10 287:17 288:1
 288:22 289:7,8,13
 290:10,11 291:10,12
 292:1,5,10,13,19
 293:10 298:7,10
 312:20 313:2,10
 326:9
vulnerable 309:5

W

wait 92:5 221:1
waiting 209:17
waiver 111:14 114:2
 115:3,14 117:16
 131:20
walk 14:6 154:16
 183:20 285:9
wall 279:21
want 4:14 5:19 6:13,14
 12:19 14:11,11,15,22
 15:10,12 27:21 30:20
 36:16,19 41:4 44:2
 51:19 52:14,22 53:14
 57:8,14 62:16 63:22

64:6 66:13 79:21 83:7
 83:14,22 84:6 88:7
 90:11 92:5 99:12
 104:18 107:13 110:5
 144:21 147:5,12,13
 166:11 170:16 183:13
 183:20 189:10 201:22
 201:22 203:15 207:3
 213:4 217:3,5 220:5
 222:11 240:8 253:4
 256:22 260:12 272:17
 275:15 281:15,16
 284:8,10 285:5,7,9,18
 287:14 293:13,14
 294:16 298:9 304:7
 321:12 325:22 326:3
 326:8
wanted 4:9 5:9 7:5
 17:21 18:12 27:18
 30:13 46:1 49:15
 93:22 95:12 97:11
 111:7 115:19 121:11
 122:20 123:8 126:15
 127:20 131:1 133:14
 151:22 153:9 170:6
 171:1 179:18 184:9
 187:6 193:9 207:8
 220:1,2,12,22 228:1
 238:8 253:22 274:18
 274:21 275:9 293:7
 296:3
wanting 265:13
warehouse 37:11 129:4
 129:15
warning 261:1
warranted 126:8
washed 142:3
Washington 1:9 26:12
 49:6
wasn't 47:9 175:19
 197:12 237:19 238:10
 258:14 263:5 272:21
way 19:6 28:5 39:18
 45:17 48:3,18 54:2
 61:21 63:10 64:16
 65:18 66:3,19 67:1,7
 82:4 83:16 88:8 96:8
 97:20 98:11 100:4
 105:18 107:9 121:19
 124:22 131:6 141:1
 141:18 151:5 156:8
 161:5 165:8 168:14
 168:22 174:19 176:10
 202:8 204:16 207:1
 207:17 210:21 211:1
 211:2,17,18 212:11
 212:11 241:8 242:16
 257:1 266:5

ways 39:10,12 44:17
 71:1 80:2 83:9 94:17
 97:20 119:6 130:21
 138:1,2,20 139:10
 142:14 148:2 171:9
 177:3,18 209:12,16
 209:17 226:18 229:8
 242:13 272:3 288:19
we'll 8:7 9:8,8 12:8,22
 13:5,6,7,8 16:7,17
 17:7 58:10 67:10 68:6
 109:8,9,10,10 131:20
 131:22 172:12 183:11
 184:1 189:13,16
 194:6 214:13,20,21
 215:5 219:15 230:6,8
 230:18 239:2,2,4
 243:7 273:3 274:9,19
 280:5,6 283:20 284:1
 284:3,4 285:11,22
 289:4 294:2,13,13
 298:22 318:10
we're 4:12 8:9,17 9:16
 15:21 16:21 19:5
 24:16 30:10 37:5 40:6
 40:14 42:4 43:10,14
 44:21 45:21 52:2 53:5
 54:6 55:3,12,13,16
 56:13 57:10 60:10,10
 62:12 63:4 67:17
 72:11 73:6 74:14
 76:15 79:14 80:21
 81:12 82:3,8,10 83:14
 83:20 85:16 87:11
 99:13 102:1,12 103:8
 104:6 109:7,15 110:3
 110:12 116:21 120:9
 120:16 121:14,16,16
 123:22 127:18 128:17
 128:22 129:18 130:12
 131:14 143:5 146:16
 146:18 147:15 149:11
 156:19 159:11,15
 163:19 167:11 168:20
 170:14,21 173:5,7
 174:9 179:4,4,14,16
 183:6,7 184:3 188:10
 188:13 194:17 197:21
 202:9 203:6,11 204:7
 204:19 207:4,13
 209:5,20,20 212:21
 223:22 224:1 228:3
 229:4,10,14 230:4,5
 230:11 234:9,9,13
 242:6 247:14 249:1
 257:20 266:2 267:15
 273:15 280:4,7
 283:10,12,15 287:10

287:13,17 288:7
 289:19 290:2,5
 300:20 313:7,8
we've 16:1 30:10,11,14
 30:17,17 43:11,11
 44:3 49:20,22 50:15
 51:5 74:22 75:10,15
 80:5 83:8 86:4 100:4
 103:1,18 104:3 109:6
 109:17 123:19 124:8
 124:14 128:16 130:16
 146:14 148:8 158:8
 176:22 205:22 211:4
 223:1,11 254:15
 316:16
weakness 185:6
weaknesses 48:17 59:4
 59:8 142:4 171:11
web 13:8,10 20:19
 214:21
webinar 8:12 9:5 214:4
website 132:3,4
weeks 41:15
weigh 204:3,15 231:20
weighed 24:18 25:18
weighted 185:3
weighting 154:1
welcome 3:2 4:9 6:14
 13:13 213:21
well-being 92:12
 132:11
well-child 137:8 143:14
well-developed 96:4
wellness 132:4 315:11
 318:18
Welltopia 132:3
went 5:8 17:18 20:19
 28:22 109:13 183:2
 214:20 221:8 243:3
 244:21 250:7 289:17
 326:15
weren't 22:21 212:5
 247:15 299:15
West 37:21 136:10
wheel 57:11
whichever 238:17
white 85:6 112:21
 210:12,20 212:10
WHNP-BC 1:15
who've 31:12
whoever's 267:1
wide 229:19
widely 224:16 235:22
wider 223:8
wife 96:19
willing 25:22 73:4
 164:21 212:3,5
willingness 102:6

206:5
Wilson 2:8 4:22,22 5:20
 8:6,8 9:14 10:14
 11:21 12:7 98:21 99:5
 214:3
windows 43:22
wisely 114:5 131:17
wish 64:17 131:12
 182:20 189:12
woman 179:12
women 21:1 33:14
 112:15 228:5
women's 32:3 213:17
wonder 79:11 280:16
wonderful 55:18
wondering 72:21
 194:13 222:14 260:4
 299:4
word 133:8 139:13
 147:6 222:22 278:6
words 61:11 144:1
 155:21 168:4
work 6:17 7:20 8:3 9:2
 11:2 46:6 48:1 57:8
 57:14,21 58:4 59:17
 85:20 88:18,19 105:8
 111:2 113:21 114:15
 126:12 128:22 134:8
 134:17 135:5,8
 139:21 145:16,17
 146:17,22 147:17
 164:21 165:12 166:5
 167:14 175:17 176:21
 181:5 184:18 187:11
 196:16 201:20 203:16
 216:15 219:14 221:4
 250:18 254:15 258:11
 310:14 315:11 326:4
worked 11:5 222:21
workforce 229:5
workgroup 13:12 114:3
 114:5
working 6:9 8:4 11:4
 25:22 57:4 73:7 81:9
 103:8 104:17 106:4
 120:9,16 128:17
 133:11 135:20 144:18
 149:5 168:8 169:21
 188:5 207:3 224:1
 229:14
works 139:15 242:3
world 62:15 75:7 84:9
 88:10 131:9 263:18
worried 164:12
worries 239:9
worse 81:20 178:22
 226:15
worth 23:16 28:7 97:17

148:13 252:15 319:14
 323:4 325:3
worthwhile 135:22
 148:11 277:15 278:20
wouldn't 47:10,11 48:9
 75:4 125:19 160:7
 204:11 248:4 268:6
 307:11
wrapped 108:2
write 13:3 165:19
wrong 136:1 253:3,5
 254:8

X

Y

yay 85:12
Yeah 198:15 212:17,19
 221:5 222:18 223:20
 225:11,11 232:9
 233:7
year 17:13 21:19 30:11
 30:12,13,18 40:8
 46:21 47:5 49:19 50:4
 50:12 53:10 56:3
 74:17 119:17,22
 120:20 188:20 190:3
 192:19 199:8,11
 219:12 220:6,9 221:6
 222:8,11,12 235:9
 236:4 237:5,17,20
 238:7 241:9 244:4,10
 244:17 260:20 262:11
 263:5 264:15 286:11
 286:13 296:2,4,10
 300:3 302:11 303:3
 310:19
year's 30:4 148:13
 282:15
year- 180:10
years 11:5 21:2 25:9,10
 29:19,19 50:10 52:3
 112:10,13 117:21
 122:3 130:13 131:22
 146:14 173:12 182:8
 186:22 191:11,18
 192:18 193:1 199:15
 235:7 242:4,10 244:1
 244:7,13 255:8 262:9
 266:6 286:9,14 302:8
 321:5 322:4
yellow 136:5 188:13
 218:10,13,14
yes/no 65:12
yesterday 131:3
YETUNDE 2:10
York 2:2 4:8 10:17
 96:17,21 100:22

101:12

Z

zero 21:5 189:9

0

0.4 136:8
0027 243:9
0055 230:19 289:4
 290:10,19
0059 262:15
0418 192:12
0541 235:4 291:11,15
 291:19 294:7 316:22
 317:10

1

1 182:15,16 230:22
 262:10 324:2
1.6 114:13
1:00 182:21
1:10 183:3
10 291:8
10,000 9:1
10:57 109:13
100 21:10 50:5 121:14
 241:4,7
1030 1:8
109 3:8
11 34:5 180:2 249:17
11:10 109:9
11:13 109:14
1115 111:14 114:2
 115:3
12 33:22 271:18
12:37 183:2
13 34:4 112:22
14 271:18
15 11:5 50:12 109:7
 130:15 154:15 219:11
15th 1:8
16 127:2 152:6
1799 237:6
18 125:12 137:3 189:19
 192:9 230:21 235:7
 244:1,7,13 262:8
 286:9,14 302:8
182 3:9
183 3:10
19 3:4
1927 275:21 276:14
 282:15
1932 22:10 247:7
 249:18
1933 282:13,19 283:3,9
 284:21 286:5 292:20
 292:22 317:16
1st 303:2,3

2	3.6 278:10	9:00 1:9
2 230:22 262:10	3:07 289:17	9:03 4:2
20 21:3 116:18,21	3:13 289:18	90 180:8
145:13 291:19	30 190:5 192:3 251:13	9010 177:1
2003 205:9	292:8 300:15 302:15	90th 74:6
2012 113:7	304:16 308:18	9th 1:8
2013 32:13 33:11,13,17	30-day 311:11	
33:20 34:2,4,12	30-percent 143:1	
112:10 190:13 191:9	30th 115:3	
191:17 192:16 222:21	31 179:4 191:3 286:15	
2014 31:8 32:13 33:11	314 3:17	
33:13,15,17,19 34:2,5	324 3:19	
34:11,12 190:3,11,13	365 241:10	
190:15 191:9,17		
192:8,17,19,21	4	
215:14,18,22 219:10	4 3:2	
2015 22:3,4 112:20	4:02 326:15	
115:4 121:7 127:2	40 56:4 116:4 290:18	
215:17,22 272:21	292:16 293:4	
276:9,12	40.5 192:10	
2016 1:6 22:8 29:8	411 161:7	
30:22 296:9	42 21:5 137:4	
2017 296:7 312:13	44 20:22	
2020 111:13 114:2	46 112:20	
115:2	49 3:5	
2022 113:11		
2052 222:18	5	
21 116:3	54 297:20	
2111 251:5 292:11	58 3:7 50:10 118:10	
2152 216:19 230:1	59.4 192:9	
271:21 287:14 294:6		
316:22 317:7	6	
22 112:21	60 260:19,20 280:1	
23 112:16 119:10	283:17,22 284:12	
24 1:6 33:22 216:11	287:18 290:18,21	
217:12 312:9	291:1,3,3 292:15	
24/7 150:8	293:3 311:9	
25 33:6 51:2	61 292:17	
250,000 120:19	64 189:19 192:9 286:9	
25th 119:14 120:4	286:14	
26 31:12,15 32:15 33:1	65 189:19 192:10 256:8	
127:2	258:8	
2600 250:9	67 271:17 314:4	
2601 297:8		
2605 296:1 301:21	7	
302:3 312:21 313:10	7 291:7	
314:3 317:15	70 180:9 292:7	
2607 262:4 272:18	75 116:20 230:22 262:9	
292:2 294:9 317:13		
27 297:19	8	
29 193:6	8 112:22	
294 3:12	80 116:20 235:9 241:1	
295 3:15	291:19 311:10	
	80th 74:19	
3		
3 291:16 294:8 299:1	9	
317:11 325:18	9 180:2	
3.1 112:6	9.0 262:12	

C E R T I F I C A T E

This is to certify that the foregoing transcript

In the matter of: Measure Application Partnership
Medicaid Adult Task Forces

Before: NQF

Date: 05-24-16

Place: Washington, DC

was duly recorded and accurately transcribed under
my direction; further, that said transcript is a
true and accurate record of the proceedings.



Court Reporter

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com